<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004839.pub3" GROUP_ID="CF" ID="891800092511044744" MERGED_FROM="" MODIFIED="2013-08-22 10:25:19 +0100" MODIFIED_BY="Nikki Jahnke" REVIEW_NO="0035" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2013-08-22 10:19:16 +0100" MODIFIED_BY="Nikki Jahnke">
<TITLE>Oral deferiprone for iron chelation in people with thalassaemia</TITLE>
<CONTACT>
<PERSON ID="8055" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Roberts</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Haematologist</POSITION>
<EMAIL_1>david.roberts@ndcls.ox.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Systematic Review Initiative</DEPARTMENT>
<ORGANISATION>NHS Blood and Transplant</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Oxford</CITY>
<ZIP>OX3 9BQ</ZIP>
<REGION>Oxon</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 447971</PHONE_1>
<PHONE_2>+44 1865 447913</PHONE_2>
<FAX_1>+44 1865 447915</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-08-22 10:17:07 +0100" MODIFIED_BY="Nikki Jahnke">
<PERSON ID="80220549376421696774101006130657" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sheila</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Fisher</LAST_NAME>
<SUFFIX/>
<POSITION>Research Officer</POSITION>
<EMAIL_1>sheila.fisher@nhsbt.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Systematic Review Initiative</DEPARTMENT>
<ORGANISATION>NHS Blood and Transplant</ORGANISATION>
<ADDRESS_1>Level 2, John Radcliffe Hospital</ADDRESS_1>
<ADDRESS_2>Headington</ADDRESS_2>
<CITY>Oxford</CITY>
<ZIP>OX3 9BQ</ZIP>
<REGION>Oxon</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>01865 387941</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11614" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Susan</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Brunskill</LAST_NAME>
<SUFFIX>MSc, BSc</SUFFIX>
<POSITION>Senior Information Scientist</POSITION>
<EMAIL_1>susan.brunskill@nhsbt.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Systematic Review Initiative</DEPARTMENT>
<ORGANISATION>NHS Blood and Transplant</ORGANISATION>
<ADDRESS_1>Level 2, John Radcliffe Hospital</ADDRESS_1>
<ADDRESS_2>Headington</ADDRESS_2>
<CITY>Oxford</CITY>
<ZIP>OX3 9BQ</ZIP>
<REGION>Oxon</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0)1865 387706</PHONE_1>
<PHONE_2>+44 (0)1865 857947</PHONE_2>
<FAX_1>+44 (0)1865 447915</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13392" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Carolyn</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Doree</LAST_NAME>
<SUFFIX/>
<POSITION>Information Specialist</POSITION>
<EMAIL_1>carolyn.doree@nhsbt.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Systematic Review Initiative</DEPARTMENT>
<ORGANISATION>NHS Blood and Transplant</ORGANISATION>
<ADDRESS_1>John Radcliffe Hospital</ADDRESS_1>
<ADDRESS_2/>
<CITY>Oxford</CITY>
<ZIP>OX3 9BQ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="30192264140104896771120111115304" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Onima</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chowdhury</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>onima.chowdhury@gtc.ox.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Haematopoietic Stem Cell Laboratory</DEPARTMENT>
<ORGANISATION>Weatherall Institute of Molecular Medicine</ORGANISATION>
<ADDRESS_1>John Radcliffe and Churchill Hospital</ADDRESS_1>
<ADDRESS_2/>
<CITY>Oxford</CITY>
<ZIP>OX3 9DS</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="44544553626777193465120111115645" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sarah</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gooding</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>sarahgooding@doctors.org.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Haematology</DEPARTMENT>
<ORGANISATION>John Radcliffe and Churchill Hospital</ORGANISATION>
<ADDRESS_1>Old Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Oxford</CITY>
<ZIP>OX3 7LJ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8055" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Roberts</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Haematologist</POSITION>
<EMAIL_1>david.roberts@ndcls.ox.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Systematic Review Initiative</DEPARTMENT>
<ORGANISATION>NHS Blood and Transplant</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Oxford</CITY>
<ZIP>OX3 9BQ</ZIP>
<REGION>Oxon</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 447971</PHONE_1>
<PHONE_2>+44 1865 447913</PHONE_2>
<FAX_1>+44 1865 447915</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2013-08-22 10:17:07 +0100" MODIFIED_BY="Nikki Jahnke">
<UP_TO_DATE>
<DATE DAY="7" MONTH="8" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="3" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="7" MONTH="8" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2013-08-22 10:17:53 +0100" MODIFIED_BY="Sheila A Worsley">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-08-22 10:17:53 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="22" MONTH="8" YEAR="2013"/>
<DESCRIPTION>
<P>Contact person changed and funding sources (internal and external) corrected.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-08-22 10:17:45 +0100" MODIFIED_BY="Tracey Remmington">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-08-22 10:17:42 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="7" MONTH="8" YEAR="2013"/>
<DESCRIPTION>
<P>Eight new trials have been included in the review update (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>).</P>
<P>One trial by Fassos previously included in the original review has now been confirmed as excluded in this update (<LINK REF="STD-Fassos-1994" TYPE="STUDY">Fassos 1994</LINK>).</P>
<P>All studies identified from the most recent search (March 2013) which appear to meet the eligibility criteria have been listed as '<LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>' for inclusion in the next update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-08-22 10:17:45 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="7" MONTH="8" YEAR="2013"/>
<DESCRIPTION>
<P>The adverse event analyses from the original review have been changed to calculate the risk associated with treatment (i.e. in all individuals) rather than only in individuals experiencing an adverse event.</P>
<P>Evidence of reduced end organ damage data have been added for all trials.</P>
<P>Minor data errors throughout the original review have been amended and data have been re-analysed where necessary.</P>
<P>The conclusion of the US Food and Drug Administration (FDA) who reviewed the evidence surrounding the efficacy and safety for an application for the licensing of deferiprone in the USA has been added to the <LINK TAG="BACKGROUND" TYPE="SECTION">Background</LINK> and <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> sections. The FDA only gave support for deferiprone to be used as a last resort treatment of iron overload in thalassemia, myelodysplasia and sickle cell disease.  </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-06-22 12:53:49 +0100" MODIFIED_BY="Tracey Remmington">
<DATE DAY="10" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-08-22 10:19:16 +0100" MODIFIED_BY="Nikki Jahnke">
<INTERNAL_SOURCES MODIFIED="2013-08-22 10:18:51 +0100" MODIFIED_BY="Nikki Jahnke">
<SOURCE MODIFIED="2013-08-22 10:18:51 +0100" MODIFIED_BY="Nikki Jahnke">
<NAME>NHS Blood and Transplant, Research and Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2013-08-22 10:19:16 +0100" MODIFIED_BY="Nikki Jahnke">
<SOURCE MODIFIED="2013-08-22 10:19:16 +0100" MODIFIED_BY="Nikki Jahnke">
<NAME>National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Programme (SF, CD) and the NIHR under its Programme Grant Scheme (NIHR-RP-PG-0310-1004, SF)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-08-22 10:21:10 +0100" MODIFIED_BY="Sheila A Worsley">
<SUMMARY MODIFIED="2013-08-07 11:25:12 +0100" MODIFIED_BY="Sheila A Worsley">
<TITLE MODIFIED="2012-04-12 13:47:30 +0100" MODIFIED_BY="Sheila A Worsley">The use of the iron chelator deferiprone in people with thalassaemia who are dependent on blood transfusions</TITLE>
<SUMMARY_BODY MODIFIED="2013-08-07 11:25:12 +0100" MODIFIED_BY="Sheila A Worsley">
<P>In thalassaemia sometimes the body cannot produce enough haemoglobin. Regular blood transfusions can manage this, but may lead to excess iron in the body, which, if not removed, may damage major organs. Iron chelation therapy removes excess iron; one common chelator is deferiprone. Questions exist about whether deferiprone is as good and safe as the most widely-used iron chelator, desferrioxamine. Desferrioxamine is administered by a needle under the skin or into a vein, and was the standard monotherapy for 20 years.</P>
<P>Seventeen randomised controlled trials compared deferiprone with desferrioxamine. They report little data on death or end organ damage, so we report the effects of therapy using mainly other markers.<B> </B>Removing excess iron was assessed by iron concentration in the blood and liver; heart function; and the amount of iron passed in urine. However, the amount of iron removed with either deferiprone or desferrioxamine was not consistent; one reason being that outcomes were measured differently. This makes it difficult to compare results between trials.</P>
<P>Adverse events included joint pain, nausea, stomach upsets and low white blood cell count with deferiprone and pain or skin reactions at the injection site and joint pain with desferrioxamine. In one trial, the risk of an adverse event with deferiprone was twice that of the risk with desferrioxamine. Two further trials showed a three-fold increased risk of an adverse event with combined deferiprone and desferrioxamine therapy compared with desferrioxamine alone.</P>
<P>We found no evidence to change current recommendations to treat iron overload in thalassaemia with deferiprone when desferrioxamine cannot be used or is inadequate. Intensified desferrioxamine treatment or use of other oral iron chelators (or both of these) remains the established treatment to reverse heart problems due to iron overload. Indeed, the US Food and Drug Administration (FDA) recently gave support for deferiprone only to be used as a last resort treatment in patients with thalassaemia, myelodysplasia and sickle cell disease. The danger of raised liver enzymes or a very low white blood cell count with deferiprone means that this treatment should not be used unless close monitoring of full blood counts and liver function is possible. Large trials of chelation therapy with standardised measures of iron stores and end organ damage are needed so valuable trial data can be compared and analysed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-08-07 10:39:45 +0100" MODIFIED_BY="Sheila A Worsley">
<ABS_BACKGROUND MODIFIED="2013-08-07 10:26:57 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Thalassaemia major is a genetic disease characterised by a reduced ability to produce haemoglobin. Management of the resulting anaemia is through red blood cell transfusions.</P>
<P>Repeated transfusions result in an excessive accumulation of iron in the body (iron overload), removal of which is achieved through iron chelation therapy. A commonly used iron chelator, deferiprone, has been found to be pharmacologically efficacious. However, important questions exist about the efficacy and safety of deferiprone compared to another iron chelator, desferrioxamine.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-08-07 10:28:22 +0100" MODIFIED_BY="[Empty name]">
<P>To summarise data from trials on the clinical efficacy and safety of deferiprone and to compare the clinical efficacy and safety of deferiprone with desferrioxamine for thalassaemia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-08-07 10:28:30 +0100" MODIFIED_BY="Sheila A Worsley">
<P>We searched the Cochrane Cystic fibrosis and Genetic Disorders Group's Haemoglobinopathies trials Register and MEDLINE, EMBASE, CENTRAL (<I>The Cochrane Library), </I>LILACS and other international medical databases, plus registers of ongoing trials and the Transfusion Evidence Library (www.transfusionevidencelibrary.com). We also contacted the manufacturers of deferiprone and desferrioxamine.</P>
<P>All searches were updated to 05 March 2013.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-05-09 14:01:17 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Randomised controlled trials comparing deferiprone with another iron chelator; or comparing two schedules or doses of deferiprone, in people with transfusion-dependent thalassaemia.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-03-15 11:04:51 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed trials for risk of bias and extracted data. Missing data were requested from the original investigators.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-08-07 10:36:18 +0100" MODIFIED_BY="Sheila A Worsley">
<P>A total of 17 trials involving 1061 participants (range 13 to 213 participants per trial) were included. Of these, 16 trials compared either deferiprone alone with desferrioxamine alone, or a combined therapy of deferiprone and desferrioxamine with either deferiprone alone or desferrioxamine alone; one compared different schedules of deferiprone. There was little consistency between outcomes and limited information to fully assess the risk of bias of most of the included trials.</P>
<P>Four trials reported mortality; each reported the death of one individual receiving deferiprone with or without desferrioxamine. One trial reported five further deaths in patients who withdrew from randomised treatment (deferiprone with or without desferrioxamine) and switched to desferrioxamine alone. Seven trials reported cardiac function or liver fibrosis as measures of end organ damage.</P>
<P>Earlier trials measuring the cardiac iron load indirectly by magnetic resonance imaging (MRI) T2* signal had suggested deferiprone may reduce cardiac iron more quickly than desferrioxamine. However, a meta-analysis of two trials suggested that left ventricular ejection fraction was significantly reduced in patients who received desferrioxamine alone compared with combination therapy.  </P>
<P>One trial, which planned five years of follow up, was stopped early due to the beneficial effects of combined treatment compared with deferiprone alone in terms of serum ferritin levels reduction.</P>
<P>The results of this and three other trials suggest an advantage of combined therapy over monotherapy to reduce iron stores as measured by serum ferritin. There is, however, no conclusive or consistent evidence for the improved efficacy of combined deferiprone and desferrioxamine therapy over monotherapy from direct or indirect measures of liver iron. Both deferiprone and desferrioxamine produce a significant reduction in iron stores in transfusion-dependent, iron-overloaded people. There is no evidence from randomised controlled trials to suggest that either has a greater reduction of clinically significant end organ damage.</P>
<P>Evidence of adverse events were observed in all treatment groups. Occurrence of any adverse event was significantly more likely with deferiprone than desferrioxamine in one trial, RR 2.24 (95% CI 1.19 to 4.23). Meta-analysis of a further two trials showed a significant increased risk of adverse events associated with combined deferiprone and desferrioxamine compared with desferrioxamine alone, RR 3.04 (95% CI 1.18 to 7.83). The most commonly reported adverse event was joint pain, which occurred significantly more frequently in patients receiving deferiprone than desferrioxamine, RR 2.64 (95% CI 1.21 to 5.77). Other common adverse events included gastrointestinal disturbances as well as neutropenia or leucopenia, or both.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-08-07 10:39:45 +0100" MODIFIED_BY="Sheila A Worsley">
<P>In the absence of data from randomised controlled trials, there is no evidence to suggest the need for a change in current treatment recommendations; namely that deferiprone is indicated for treating iron overload in people with thalassaemia major when desferrioxamine is contraindicated or inadequate. Intensified desferrioxamine treatment (by either subcutaneous or intravenous route) or use of other oral iron chelators, or both, remains the established treatment to reverse cardiac dysfunction due to iron overload. Indeed, the US Food and Drug Administration (FDA) recently only gave support for deferiprone to be used as a last resort for treating iron overload in thalassaemia, myelodysplasia and sickle cell disease. However, there is evidence that adverse events are increased in patients treated with deferiprone compared with desferrioxamine and in patients treated with combined deferiprone and desferrioxamine compared with desferrioxamine alone. There is an urgent need for adequately-powered, high-quality trials comparing the overall clinical efficacy and long-term outcome of deferiprone with desferrioxamine.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-08-22 10:21:10 +0100" MODIFIED_BY="Sheila A Worsley">
<BACKGROUND MODIFIED="2013-08-07 11:58:23 +0100" MODIFIED_BY="Sheila A Worsley">
<CONDITION MODIFIED="2013-08-07 11:56:03 +0100" MODIFIED_BY="[Empty name]">
<P>Iron overload constitutes a major health problem for all people who require regular blood transfusions, such as people with thalassaemia. Effective iron removal, known as chelation therapy, is essential to the survival and quality of life of iron overloaded people. Before iron chelation therapy was available, the prognosis for transfusion-dependent individuals was poor and less than 5% of children survived beyond 15 years of age. Control of iron load using desferrioxamine (DFO) showed that if the children's total body iron was controlled adequately, survival was increased and the frequency of cardiac deaths fell (<LINK REF="REF-Brittenham-1994" TYPE="REFERENCE">Brittenham 1994</LINK>; <LINK REF="REF-Olivieri-1994" TYPE="REFERENCE">Olivieri 1994</LINK>). The clinical effectiveness of DFO was confirmed in long-term follow-up studies, where the cohort born after 1970 shows that 68% of the individuals are alive at the age of 35 years (<LINK REF="REF-Borgna_x002d_Pignatti-1998" TYPE="REFERENCE">Borgna-Pignatti 1998</LINK>; <LINK REF="REF-Borgna_x002d_Pignatti-2004" TYPE="REFERENCE">Borgna-Pignatti 2004</LINK>).</P>
<P>In people with transfusion-dependent thalassaemia major, failure to control the iron load has been demonstrated to be the main cause of death (<LINK REF="REF-Olivieri-1994" TYPE="REFERENCE">Olivieri 1994</LINK>). In these people, where serum ferritin was maintained at less than 2500 mg/L, there was a survival rate without cardiac disease of 91% at 15 years, whereas in those whose serum ferritin levels were greater than 2500 mg/L there was a survival rate without cardiac disease of only 20% over the same period (<LINK REF="REF-Olivieri-1994" TYPE="REFERENCE">Olivieri 1994</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-08-07 11:56:57 +0100" MODIFIED_BY="[Empty name]">
<P>Currently, the iron chelator of first choice for clinical use is desferrioxamine (DFO). To be clinically effective, DFO must be administered as a subcutaneous infusion over 8 to 12 hours, 5 to 7 days a week. This regimen has been demonstrated to regulate iron balance, reduce the body iron load, prevent the onset of iron-induced complications, reverse some of the induced organ damage and increase survival as a result of iron excretion (<LINK REF="REF-Aldouri-1990" TYPE="REFERENCE">Aldouri 1990</LINK>; <LINK REF="REF-Borgna_x002d_Pignatti-1998" TYPE="REFERENCE">Borgna-Pignatti 1998</LINK>; <LINK REF="REF-Brittenham-1994" TYPE="REFERENCE">Brittenham 1994</LINK>; <LINK REF="REF-Ehlers-1991" TYPE="REFERENCE">Ehlers 1991</LINK>; <LINK REF="REF-Gabutti-1996" TYPE="REFERENCE">Gabutti 1996</LINK>; <LINK REF="REF-Modell-2000" TYPE="REFERENCE">Modell 2000</LINK>; <LINK REF="REF-Olivieri-1999" TYPE="REFERENCE">Olivieri 1999</LINK>; <LINK REF="REF-Pippard-1978" TYPE="REFERENCE">Pippard 1978</LINK>; <LINK REF="REF-Propper-1976" TYPE="REFERENCE">Propper 1976</LINK>; <LINK REF="REF-Propper-1977" TYPE="REFERENCE">Propper 1977</LINK>; <LINK REF="REF-Wolfe-1985" TYPE="REFERENCE">Wolfe 1985</LINK>).</P>
<P>Unfortunately, chronic therapy with DFO has had a number of problems, particularly the adherence to an arduous daily regimen of infusions (<LINK REF="REF-Olivieri-1997b" TYPE="REFERENCE">Olivieri 1997b</LINK>; <LINK REF="REF-Weatherall-2002" TYPE="REFERENCE">Weatherall 2002</LINK>) and adverse events due to DFO may cause renal impairment (<LINK REF="REF-Bacon-1983" TYPE="REFERENCE">Bacon 1983</LINK>; <LINK REF="REF-Richardson-1993" TYPE="REFERENCE">Richardson 1993</LINK>), local skin reactions (<LINK REF="REF-Kushner-2001" TYPE="REFERENCE">Kushner 2001</LINK>), growth retardation (<LINK REF="REF-Olivieri-1992" TYPE="REFERENCE">Olivieri 1992</LINK>; <LINK REF="REF-Piga-1988" TYPE="REFERENCE">Piga 1988</LINK>), increased susceptibility to Yersinia infections (<LINK REF="REF-Gallant-1986" TYPE="REFERENCE">Gallant 1986</LINK>), high frequency sensorineural hearing loss (<LINK REF="REF-Kontzogolou-1996" TYPE="REFERENCE">Kontzogolou 1996</LINK>; <LINK REF="REF-Olivieri-1986" TYPE="REFERENCE">Olivieri 1986</LINK>; <LINK REF="REF-Porter-1989b" TYPE="REFERENCE">Porter 1989b</LINK>) and retinal damage (<LINK REF="REF-Davies-1983" TYPE="REFERENCE">Davies 1983</LINK>; <LINK REF="REF-Olivieri-1986" TYPE="REFERENCE">Olivieri 1986</LINK>). However, reports of these adverse events, which appear frequently in the literature from the early years of DFO use, have declined in recent years as the relationship between toxicity and drug dose has been more clearly understood and managed (<LINK REF="REF-Porter-1989a" TYPE="REFERENCE">Porter 1989a</LINK>; <LINK REF="REF-Porter-2002" TYPE="REFERENCE">Porter 2002</LINK>). The principle problem with desferrioxamine remains the low rate of compliance - only 70% in some series of participants (<LINK REF="REF-Olivieri-1995b" TYPE="REFERENCE">Olivieri 1995b</LINK>). A Cochrane Review has examined the efficacy of different regimens of desferrioxamine in people with transfusion-dependent thalassaemia (Fisher 2013).</P>
<P>The introduction of a pharmacologically efficacious and well-tolerated oral iron chelator, which would negate some of the problems associated with DFO, has been widely seen as highly desirable. The drug 1,2-dimethyl-3-hydroxypyroid-4-one, or deferiprone (also known as L1, Kelfer or DMHP) has been the first oral iron chelator to be clinically evaluated. It was first synthesised in 1984 (<LINK REF="REF-Hider-1984" TYPE="REFERENCE">Hider 1984</LINK>) and was soon shown to be pharmacologically efficacious in achieving iron excretion (<LINK REF="REF-Agarwal-1992" TYPE="REFERENCE">Agarwal 1992</LINK>; <LINK REF="REF-Kontoghiorghes-1990" TYPE="REFERENCE">Kontoghiorghes 1990</LINK>; <LINK REF="REF-Tondury-1990" TYPE="REFERENCE">Tondury 1990</LINK>). Since these early studies, a large number of centres have reported their experience with deferiprone (<LINK REF="REF-Cohen-2003" TYPE="REFERENCE">Cohen 2003</LINK>; <LINK REF="REF-Del-Vecchio-2000" TYPE="REFERENCE">Del Vecchio 2000</LINK>; <LINK REF="REF-Fischer-2003" TYPE="REFERENCE">Fischer 2003</LINK>; <LINK REF="REF-Lucas-2002" TYPE="REFERENCE">Lucas 2002</LINK>; <LINK REF="REF-Olivieri-1995a" TYPE="REFERENCE">Olivieri 1995a</LINK>; <LINK REF="REF-Olivieri-1997a" TYPE="REFERENCE">Olivieri 1997a</LINK>; <LINK REF="REF-Rombos-2000" TYPE="REFERENCE">Rombos 2000</LINK>).</P>
<P>As with desferrioxamine, adverse events have been reported in people with thalassaemia taking deferiprone. These include gastrointestinal disturbances (<LINK REF="REF-Ceci-2002" TYPE="REFERENCE">Ceci 2002</LINK>; <LINK REF="REF-Cohen-2003" TYPE="REFERENCE">Cohen 2003</LINK>; <LINK REF="STD-Taher-2001" TYPE="STUDY">Taher 2001</LINK>), arthropathy (<LINK REF="REF-Cohen-2003" TYPE="REFERENCE">Cohen 2003</LINK>; <LINK REF="REF-Hoffbrand-1998" TYPE="REFERENCE">Hoffbrand 1998</LINK>; <LINK REF="REF-Lucas-2002" TYPE="REFERENCE">Lucas 2002</LINK>; <LINK REF="REF-Mazza-1998" TYPE="REFERENCE">Mazza 1998</LINK>; <LINK REF="STD-Taher-2001" TYPE="STUDY">Taher 2001</LINK>), raised liver enzymes (<LINK REF="REF-Ceci-2002" TYPE="REFERENCE">Ceci 2002</LINK>; <LINK REF="REF-Cohen-2003" TYPE="REFERENCE">Cohen 2003</LINK>), neutropenia and agranulocytosis (<LINK REF="REF-Cohen-2003" TYPE="REFERENCE">Cohen 2003</LINK>; <LINK REF="REF-Pati-1999" TYPE="REFERENCE">Pati 1999</LINK>). Progression of liver fibrosis during treatment with deferiprone has been cited by some studies (<LINK REF="REF-Berdoukas-2000" TYPE="REFERENCE">Berdoukas 2000</LINK>; <LINK REF="REF-Olivieri-1998" TYPE="REFERENCE">Olivieri 1998</LINK>; <LINK REF="REF-Tondury-1998" TYPE="REFERENCE">Tondury 1998</LINK>), but not others (<LINK REF="REF-Wanless-2002" TYPE="REFERENCE">Wanless 2002</LINK>); and ensuing correspondence (<LINK REF="REF-Brittenham-2003" TYPE="REFERENCE">Brittenham 2003</LINK>). Variation in the length of treatment (<LINK REF="REF-Berdoukas-2000" TYPE="REFERENCE">Berdoukas 2000</LINK>) and the failure to record baseline values of liver fibrosis (<LINK REF="REF-Hoffbrand-1998" TYPE="REFERENCE">Hoffbrand 1998</LINK>; <LINK REF="REF-Tondury-1998" TYPE="REFERENCE">Tondury 1998</LINK>) has made precise evaluation of the progression and significance of liver fibrosis on treatment difficult.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2013-08-07 11:58:18 +0100" MODIFIED_BY="[Empty name]">
<P>Different iron chelators may have variable ability to chelate iron from specific tissues although the side effects of the drugs in combination may also be, in some way, additive. Therefore, the benefits and safety profiles of the combination of iron chelators compared with monotherapy cannot be predicted but can only be determined in high-quality, adequately-powered, long-term, randomised controlled trials. Indeed any new treatment must be evaluated against the best available treatment by randomised clinical trials.</P>
<P>Comparisons of iron chelation regimens face a number of methodological problems, including accurately assessing the clinical efficacy and effectiveness of therapy, determining the consequences of underlying disease, attributing side effects to therapy and monitoring participants for a sufficient period of time to reach clinically useful endpoints. It is therefore essential for trials to carefully report baseline values, choose appropriate outcome measures and consider observed changes in outcome measures in the context of underlying conditions. Moreover, the relatively short period of clinical use of deferiprone to date limits long-term comparison of not only safety but also effectiveness with desferrioxamine, which has been available for clinical use since the 1970s.</P>
<P>The need for long-term trials cannot be overemphasised. Iron chelators in thalassaemia are rather different to many drug trials simply because of the time-scale involved. Iron accumulates slowly and the onset of complications again is very variable in its timing. Thus the only reliable way to learn more about the relative value of the two iron-chelating drugs would be a long-term, i.e. more than a 5-year and preferably a 10-year prospective trial, starting in early life before there is really significant iron loading and carried through to the critical period of adolescence and beyond.</P>
<P>The importance of long-term considerations validate the need for a systematic review of the clinical efficacy and safety profile of the iron chelator deferiprone to determine and analyse the available evidence regarding such treatment.</P>
<P>One early systematic review examining the use of deferiprone in thalassaemia was published prior to the completion of 12 of the 17 relevant trials included in the current review and considered only one outcome, namely reduction of hepatic iron overload<B> </B>(<LINK REF="REF-Caro-2002" TYPE="REFERENCE">Caro 2002</LINK>). Two reviews have examined the limited number of studies looking at the psychosocial aspects of chelation therapy. Poor adherence to iron chelation therapy was documented to negatively impact survival (<LINK REF="REF-Abetz-2006" TYPE="REFERENCE">Abetz 2006</LINK>), although older age was consistently associated with lower levels of chelation adherence (<LINK REF="REF-Evangeli-2010" TYPE="REFERENCE">Evangeli 2010</LINK>).</P>
<P>The role of iron chelation on cardiac function has been of general interest after reports that indirect measures of cardiac iron loading, the myocardial T2*, showed a statistically significant difference, favouring deferiprone over DFO in one trial (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>) and favouring deferiprone combined with DFO over DFO alone in another trial<B> </B>(<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>).<B> </B>However, a meta-analysis of the influence of iron chelators on myocardial iron and cardiac function in thalassaemia reported that while DFO and deferiprone both reduced myocardial iron by similar amounts, there was no significant difference between the two chelators nor was there any improvement in the left ventricular ejection fraction (LVEF) as a measure of cardiac function (<LINK REF="REF-Mamtani-2008" TYPE="REFERENCE">Mamtani 2008</LINK>). They were able to analyse data on over 290 patients and also suggest there was a publication bias in smaller studies, favouring reporting of improvements in LVEF but not myocardial iron (<LINK REF="REF-Mamtani-2008" TYPE="REFERENCE">Mamtani 2008</LINK>).<B> </B>
</P>
<P>The Italian Society of Haematology produced a systematic review of the available data surrounding the wider questions of iron chelation therapy in thalassaemia patients but did not undertake formal meta-analysis of the identified studies (<LINK REF="REF-Angelucci-2008" TYPE="REFERENCE">Angelucci 2008</LINK>). A later systematic review and meta-analysis of all iron chelation therapies in thalassaemia, focusing on the role of combined or sequential therapy versus monotherapy and examining 16 trials with 1500 patients, concluded that lower final liver iron concentrations were associated with combined chelator therapy compared with monotherapy. There were no significant differences in heart T2* signal during combined or sequential therapy versus monotherapy, although there was an improvement in the LVEF after combined or sequential therapy compared to monotherapy (P = 0.01 and P &lt; 0.00001 respectively) (<LINK REF="REF-Maggio-2011" TYPE="REFERENCE">Maggio 2011</LINK>).</P>
<P>These somewhat disparate findings in generally small series of patients highlight the need for continued systematic analysis of chelation therapy for thalassaemia.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-08-07 11:59:27 +0100" MODIFIED_BY="[Empty name]">
<P>To summarise data from trials on the effects and safety of deferiprone as an iron chelating agent in people with transfusion-dependent thalassaemia and to compare the safety and effectiveness of deferiprone for thalassaemia with desferrioxamine.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-08-14 11:11:15 +0100" MODIFIED_BY="Sheila A Worsley">
<SELECTION_CRITERIA MODIFIED="2013-04-25 12:39:36 +0100" MODIFIED_BY="Sheila A Worsley">
<CRIT_STUDIES>
<P>Randomised controlled trials (RCTs).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People of any age, with thalassaemia, who are transfusion-dependent, from any setting worldwide.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-06-22 13:10:17 +0100" MODIFIED_BY="Sheila A Worsley">
<P>For deferiprone (all schedules and doses), the following comparisons were considered:</P>
<OL>
<LI>deferiprone compared with placebo;</LI>
<LI>deferiprone compared with another iron chelating treatment schedule;</LI>
<LI>deferiprone dose A compared with deferiprone dose B.</LI>
</OL>
<P>No trials comparing deferiprone with placebo were identified.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-04-25 12:39:36 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-09-10 16:05:29 +0100" MODIFIED_BY="Tracey Remmington">
<OL>
<LI>Mortality</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-04-25 12:39:36 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Evidence of reduced end organ damage due to iron deposition:</LI>
<OL>
<LI>cardiac failure</LI>
<LI>endocrine disease</LI>
<LI>surrogate markers of end organ damage (e.g. liver enzymes, fasting glucose, cardiac dysfunction)</LI>
<LI>histological evidence of liver fibrosis</LI>
</OL>
<LI>Measures of iron overload - including serum ferritin, assessment of liver and other tissue iron levels by biopsy with biochemical measurement by SQUID (superconducting quantum interference device) or by MRI (magnetic resonance imaging) and iron excretion (urine and faecal) over 24 hours.</LI>
<LI>Adverse events*, including</LI>
<OL>
<LI>neutropenia and agranulocytosis</LI>
<LI>arthralgia, joint effusions</LI>
<LI>gastrointestinal disturbances</LI>
<LI>liver fibrosis</LI>
<LI>other</LI>
</OL>
<LI>Participant compliance with iron chelation treatment.</LI>
<LI>Cost of interventions</LI>
</OL>
<P>* The review of adverse events was confined solely to those reported in the RCTs included in this review. No adverse event data were collected from non-randomised trials or observational studies.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-08-07 12:00:14 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-08-07 12:00:14 +0100" MODIFIED_BY="[Empty name]">
<P>Relevant trials were identified from the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register using the terms: thalassaemia AND (deferiprone OR 1,2-dimethyl-3-hydroxyproid-4-one). <BR/>The Haemoglobinopathies Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of <I>The Cochrane Library</I>) and quarterly searches of MEDLINE. Unpublished work is identified by searching the abstract books of five major conferences: the European Haematology Association annual conference; the American Society of Hematology annual conference; the British Society for Haematology Annual Scientific Meeting; the Caribbean Health Research Council Meetings; and the National Sickle Cell Disease Program Annual Meeting. For full details of all searching activities for the Haemoglobinopathies Trials Register, please see the relevant section of the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/CF/frame.html">Cochrane Cystic Fibrosis and Genetic Disorders Review Group</A> Module. </P>
<P>Date of the last search of the Haemoglobinopathies Trials Register: 1 March 2013.</P>
<P>In addition, the following databases were searched for the review update in March 2013:</P>
<UL>
<LI>CENTRAL (<I>The Cochrane Library</I> 2013, Issue 1) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)</LI>
<LI>PubMed (epublications only) (5 March 2013) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)</LI>
<LI>MEDLINE (1948 to 5 March 2013) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)</LI>
<LI>Embase (1974 to 5 March 2013) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)</LI>
<LI>UKBTS/SRI Transfusion Evidence Library (www.transfusionevidencelibrary.com) (1980 to 5 March 2013) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)</LI>
<LI>LILACS (1982 to 5 March 2013) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)</LI>
<LI>KoreaMed (1997 to 5 March 2013) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)</LI>
<LI>IndMed (1986 to 5 March 2013) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)</LI>
<LI>PakMediNet (1995 to 5 March 2013) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)</LI>
<LI>Databases of ongoing trials (all years to 5 March 2013): Novartis Clinical Trial Results database (<A HREF="http://www.novartisclinicaltrials.com/">www.novartisclinicaltrials.com</A>); ClinicalTrials.gov; WHO International Clinical Trials Registry Platform (ICTRP); ISRCTN Register; Hong Kong Clinical Trials Register (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</LI>
</UL>
<P>Search strategies were designed to search for all iron chelators and no language restrictions were placed upon any of the searches. Search strategies used for the original searches in June 2006 can be found in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-03-21 14:26:21 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Handsearching of reference lists</HEADING>
<P>The review authors checked the reference lists of all identified trials, relevant review articles and current treatment guidelines for further literature, but limited these searches to the 'first generation' reference lists.</P>
<P>Contact was made with the manufacturer of deferiprone (Apotex) and other iron chelators (Novartis, Biomedical Frontiers, CIPLA, Lipomed) and selected experts requesting details of unpublished trials that involve deferiprone for the original review (2006), but not for the 2013 update.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-08-14 11:11:15 +0100" MODIFIED_BY="Sheila A Worsley">
<STUDY_SELECTION MODIFIED="2013-08-07 12:54:33 +0100" MODIFIED_BY="Sheila A Worsley">
<P>An information specialist (CD) undertook electronic searches for potentially relevant papers. The Cystic Fibrosis and Genetic Disorders Group carried out additional searches. From the papers identified, the information specialist (CD) removed references that were duplicates, clearly irrelevant or previously screened. One author (SJB or SAF) screened all titles and abstracts of papers identified for relevancy. Two authors working independently, for both the original review (Senani Williams and CD), and the 2013 update (SJB or SAF and CD) excluded only trials that were clearly irrelevant and assessed all other trials using the criteria indicated above. Agreement between the authors was good and they resolved any discrepancies entirely by themselves: any disagreements related to the interpretation of clinical characteristics.</P>
<P>They recorded reasons for the exclusion of trials that did not meet the review's eligibility criteria. They have included trials where important screening information is lacking in the '<LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>' section of the review.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-08-07 12:58:36 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Aside from details relating to the risk of bias of the included trials, the authors extracted two groups of data (as below).</P>
<OL>
<LI>Trial characteristics: place and date of publication; population characteristics; setting; detailed nature of intervention, of comparator and of outcomes. Key purposes of these data were to define unexpected clinical heterogeneity of included trials independently from analysis of results.</LI>
<LI>Results of included trials, in respect of each of the main outcomes indicated in the review question and failure to report data for a particular outcome, were recorded. For dichotomous outcomes the numbers of events in treatment and control groups were recorded. For continuous outcomes, mean and standard deviation (SD) at baseline, end of treatment and change from baseline were recorded where possible. The 'denominators' for all outcomes were intended to be the numbers randomly allocated to treatment and control group. However, several of the included trials did not report outcome data by numbers randomised. For these trials the 'denominators' are the number of participants for whom outcome data were reported.</LI>
</OL>
<P>For both the original review (CD, Senani Williams) and the update (SJB and either SAF, OC or SG), two review authors independently extracted data onto trial-specific data extraction forms (created and previously piloted by two authors (DR, SJB)). At update stage, the authors made minor adjustments to the layout as required. The two authors undertaking data extraction resolved disagreements by consensus. Disagreements related to interpretation of clinical outcomes. Once they had resolved disagreements, the authors recorded the consensus data onto a third data extraction form. Two review authors (SJB, SAF) transcribed this into the computer software Review Manager 5.1 (<LINK REF="REF-Review-Manager-2011" TYPE="REFERENCE">Review Manager 2011</LINK>).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-08-07 13:07:46 +0100" MODIFIED_BY="Sheila A Worsley">
<P>The authors undertook assessment of the risk of bias for all included trials (original and trials identified in the update) using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), as summarised below. They resolved any disagreements by discussion.</P>
<OL>
<LI>Generation of random sequence.</LI>
<LI>Concealment of treatment allocation schedule.</LI>
<LI>Blinding of clinician (person delivering the treatment), participant and outcome assessors to treatment allocation.</LI>
<LI>Completeness of the outcome data, checking for possible attrition bias through withdrawals, loss to follow up and protocol violations.</LI>
<LI>Selective reporting bias, checking that all of a trial's pre-specified outcomes and all expected outcomes of interest to the review have been reported.</LI>
<LI>Other sources of bias in the included trials.</LI>
<LI>An overall risk of bias assessment was made based on items 1 to 6 above. An explicit judgement about whether trials are at high risk of bias was made according to criteria given in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).The likely magnitude and direction of the bias was assessed with reference to items 1 to 6, with particular emphasis on the likely impact of bias on the findings.</LI>
</OL>
<P>The authors rated the above criteria were rated according to criteria identified in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). This assigns ratings of low, high or unclear risk of bias. The authors recorded these ratings in each trial's 'Risk of Bias' table. In addition, the authors provided a narrative summary of the findings of this assessment alongside the individual ratings. They reported the overall risk of bias assessment in the results section of this review.<BR/>
</P>
<P>The authors anticipated that the issue of blinding would be a challenge in the identified trials, given the different routes of administration of the iron chelators currently available (deferiprone: oral; desferrioxamine: predominantly subcutaneous infusion over 8 hours to 12 hours). It would have been very difficult to blind either the clinician or the participant to the trial treatments. However, blinding of the outcome assessor to the treatment allocation would have been possible for these trials and has been given particular attention.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-08-07 13:17:35 +0100" MODIFIED_BY="Sheila A Worsley">
<P>The main method of analysis was quantitative but the authors made an overall interpretation from a balanced assessment of the patterns of results identified across the included trials. Due to the disparity in methods of reporting results between trials, in order to formally assess as many trials as possible, the authors analysed outcomes using both end of trial data and mean change from baseline data where appropriate. Where the papers did not report a SD for the mean change from baseline and the trial did not report sufficient data to enable SD calculation (i.e. a correlation coefficient), the authors did not want to make the necessary assumptions about unknown statistical distributions (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>) and in this case, they used end of trial data to analyse reported outcomes.</P>
<P>The authors presented results as risk ratio (RR) for binary data and mean difference (MD) for continuous data. The authors provided 95% confidence intervals (CI) for all measures of effect size. The authors analysed all participants in the treatment groups to which they had been randomised, with the exception of one trial (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>). In this trial, the authors analysed end of trial data according to the treatment received rather than the treatment group to which the participants were randomised.</P>
<P>The authors took care to record the method of data analysis used in the two eligible cross-over trials. Although neither of the two cross-over trials presented outcome data in a way that would have helped in the undertaking of a meta-analysis (paired-samples analysis) (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>), this was not the reason why the authors analysed data from these two cross-over trials qualitatively. Differences in the interventions being compared and the clinical setting of the trials precluded data from the cross-over trials being pooled in a meta-analysis with data from the parallel group trials.</P>
<P>To facilitate comparison of results between trials, where SDs were not explicitly stated, the authors converted the standard error (SE) of the mean to the SD. Within this review, unless otherwise stated, the authors present data as mean and SD. Further, the authors have changed the units of serum ferritin concentration where necessary from µg/L or pmol/L to ng/ml and the units of liver iron concentration changed from mg/g to µg/g, to facilitate the pooling, analysis and plotting of outcome data. Where results of individual trials were displayed graphically and estimation was considered reasonable, the authors estimated values visually from the graphs and stated this within tabulated results.</P>
<P>In one trial, the ratio of geometric means was used to describe the difference in change between treatment arms and exact P values were reported (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). The authors calculated the SE from the exact P value using methods described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). In a second paper, the ratio of geometric means was reported for baseline and end of trial measurements; however, exact P values were not available for all treatment arms and therefore the authors could not calculate the difference in mean change (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>).</P>
<P>The authors had intended to group the outcomes into those measured at six-monthly intervals, but this proved impossible due to the limited amount of outcome data reported in the included trials. Please refer to the results section to determine how they grouped outcome measures. The authors analysed extracted data using Review Manager 5.1 (<LINK REF="REF-Review-Manager-2011" TYPE="REFERENCE">Review Manager 2011</LINK>).</P>
<P>The authors presented individual trial results for each outcome in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.<BR/>
</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-08-07 13:18:33 +0100" MODIFIED_BY="Sheila A Worsley">
<P>For the original review, the authors extracted data from one cross-over trial using the same data extraction form as for the parallel-design trials. They took care to extract and record baseline, intervention and outcome data by cross-over arm. However, this trial reported baseline data across all participants, and outcome data were reported by intervention (as per a parallel design trial) and not by the sequence of the intervention.</P>
<P>There were no further unit of analysis issues in the update.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-08-07 13:21:15 +0100" MODIFIED_BY="Sheila A Worsley">
<P>For the original review, authors requested missing data from the investigators of two trials,who supplied these missing data. In addition, during the analysis of results, authors contacted three trial authors by e-mail, requesting the individual patient data (IPD) from their trial. All three responded to the initial e-mail but were unwilling or unable to provide their IPD. The authors did not contact investigators of six trials to request IPD. A tenth trial provided IPD in the report of their trial.</P>
<P>In the update, the authors did not contact any trial investigators requesting missing data due to time constraints and resource limitations.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-08-07 13:23:12 +0100" MODIFIED_BY="Sheila A Worsley">
<P>The authors assessed statistical heterogeneity of treatment effects between trials by using a chi-squared test with a significant level at P &lt; 0.1. They used the I<SUP>2</SUP> statistic to quantify the amount of possible heterogeneity (I<SUP>2</SUP> greater than 30% moderate heterogeneity; and I<SUP>2</SUP> greater than 75% considerable heterogeneity) (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The number of trials included did not allow further exploration of heterogeneity by sensitivity and subgroup analysis in any of the meta-analyses undertaken.<BR/>
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-08-07 13:24:18 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Although the authors did not undertake any quantitative assessment of publication bias, they made attempts to minimise the likelihood of publication bias by the use of a comprehensive search strategy, the handsearching of relevant conference abstract books and contacting the manufacturers of deferiprone and other iron chelators. They plan to undertake an assessment of publication bias in future updates of this review, if they identify a sufficient number of studies.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-08-14 11:09:41 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Authors undertook meta-analyses using RevMan 5.1 (<LINK REF="REF-Review-Manager-2011" TYPE="REFERENCE">Review Manager 2011</LINK>). They used a fixed-effect model for combining data in the first instance. Where they identified considerable heterogeneity in a fixed-effect meta-analysis, they repeated the analysis using a random-effects model. For many outcomes, meta-analysis was prohibited due to diversity in the method or timing of the outcome measurement across trials. Authors also did not undertake any meta-analysis where differences in clinical outcome baseline levels occurred and they deemed the risk of selection bias to be unclear or high. They based conclusions on inferences drawn from clearly tabulated results from included trials, as well as on qualitative and quantitative summary measures. They considered both direction and magnitude of effects. They present individual trial results in additional tables.</P>
<P>Analyses based on means are not appropriate for heavily skewed data. Where authors knew data were skewed, they performed analyses on a log scale and presented these data as the ratio of geometric means.</P>
<P>For analyses of adverse events, the authors pooled trials reporting the same adverse event in a meta-analysis only if both arms of the trial reported occurrences of adverse events or if the absence of an adverse event in either (but not both) treatment arm was specifically reported or could be clearly inferred without ambiguity. They only undertook meta-analysis of dose reduction or temporary or permanent withdrawal when the total number of adverse events was clearly stated.</P>
<P>They analysed outcome data from different time points separately in this review.<BR/>
</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-08-14 11:11:15 +0100" MODIFIED_BY="[Empty name]">
<P>Although intended, due to an insufficient number of trials, the authors were unable to perform subgroup analysis for any of the outcome measures. If sufficient trials become available in future updates of this review, the authors plan to undertake a subgroup analysis of pre-defined measures of iron overload or end organ damage.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-08-07 13:34:29 +0100" MODIFIED_BY="Sheila A Worsley">
<P>The authors did not undertake any sensitivity analyses due to the paucity of trials included in meta-analyses. They will undertake sensitivity analyses in future updates of this review if they identify sufficient trials.<BR/>
</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-08-22 10:21:10 +0100" MODIFIED_BY="Sheila A Worsley">
<STUDY_DESCRIPTION MODIFIED="2013-08-07 14:02:46 +0100" MODIFIED_BY="Sheila A Worsley">
<SEARCH_RESULTS MODIFIED="2013-08-07 13:37:28 +0100" MODIFIED_BY="[Empty name]">
<P>In total, the searches identified 2974 references updated to March 2013. Initial screening and de-duplication of the citations and trials for relevance by one author (CD) excluded 2081 references. The titles and abstracts of 893 references were then screened by two authors independently and 793 were excluded for not meeting the review's eligibility criteria. The remaining 100 references were assessed on the basis of their full text for inclusion or exclusion using the criteria indicated above. Of these, 36 trials, comprising 40 references, were excluded and 13 trials comprising 20 references were included as '<LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>'. This left 17 trials (40 references) for inclusion in the review. See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for PRISMA study flow diagram.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-08-07 13:55:09 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Seventeen trials described in 40 papers (including secondary publications) with 1061 participants (range 13 to 213) were included in this review. One paper presented data for two separate trials: the trials will be presented separately in this review (<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>). Sixteen trials were parallel in design and one was a cross-over trial (<LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>). Four trials were three-arm comparisons (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>). Three of these trials compared deferiprone alone, deferiprone and DFO in combination and DFO alone (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>). These three trials were subdivided by intervention arms for outcome analysis within this review.</P>
<P>Sixteen trials involved a comparison of deferiprone alone with DFO alone, or either DFO or deferiprone as monotherapy compared with combined deferiprone and DFO. From these 16 individual trials there were eight comparisons between deferiprone alone and DFO alone (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>); five comparisons between deferiprone alone and deferiprone in combination with DFO (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>) and nine comparisons between deferiprone in combination with DFO and DFO alone (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). One trial compared two doses of deferiprone (<LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>). No trials comparing deferiprone with placebo were identified.</P>
<P>These trials were published between 1990 and 2010 and conducted internationally: three in Italy; two in Canada; two in Egypt; two in Italy and Greece, two in Hong Kong; two in India; two in Turkey and one each in Iran and the Lebanon. Two trials were presented as an abstract (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>). One of these trials has never been published as a full journal article, although the primary author of this study indicated that additional information was published on the FDA website by the trial sponsors and these data have been included in this review (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>). There is no record on any bibliographic database of a full journal article for the second trial (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>). The other 15 trials were published as full journal articles. All included trials were published in English.</P>
<SUBSECTION>
<HEADING LEVEL="4">Trial design characteristics - interventions</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(A) Deferiprone alone compared with DFO alone</HEADING>
<P>There were eight comparisons of deferiprone alone with DFO alone (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>).</P>
<P>In seven of these trials deferiprone was given daily at 50 to 100 mg/kg/day in two or three oral divided doses (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). Treatment with DFO was given as a subcutaneous injection at a dose of 20 to 60 mg/kg/day for 8 to 12 hours and for 5 to 7 days a week. In an eighth trial, the intended dose of chelators was not reported, however, the mean (and SD) dose received was reported as 36.7 (2.8) mg/kg/night.. This trial was stopped prematurely by the sponsoring pharmaceutical company (Apotex) (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>).</P>
<P>In six of the eight trials, DFO was administered subcutaneously at a dose of between 23 and 60 mg/kg/day over 5 and 7 days per week (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). One cross-over trial designed to compare excretion of iron in urine and stool, administered DFO subcutaneously over 12 hours per day for three days (<LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>). The details of the dose or schedule of administration for DFO was not reported in the eighth trial (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>).</P>
<P>The duration of trial treatment lasted six months (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>), one year (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>) and two years (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>). The intended duration of treatment in one trial was 18 months (<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>). However, this trial was stopped early: treatment duration ranged from 1 to 20 months (median duration 18 months). In the cross-over trial, the duration of treatment was three days per treatment arm with each participant receiving treatment over six days. There was a gap of three to four weeks between each treatment arm for participants (<LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>). Duration of treatment was not stated in one trial (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>).</P>
<P>Participants in four trials had previously been exposed to DFO (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). In one trial, administration of DFO (dose unreported) had ceased 72 hours preceding the start of the trial (<LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>). In two trials, prior to enrolment, participants had received DFO at a dose of 50 mg/kg as a subcutaneous infusion over 12 hours per night, five times a week (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>) or at a mean (SD) dose of 39 (8) mg/kg/day for 5 to 7 days per week (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). The dose of DFO treatment prior to enrolment was not reported in the fourth trial (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(B) Deferiprone alone compared with deferiprone and DFO in combination</HEADING>
<P>There were five comparisons between deferiprone alone with deferiprone and DFO in combination (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). In these trials, the schedule for deferiprone only was 75 mg/kg/day (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>) or between 60 and 83 mg/kg/day (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>), administered orally in divided doses. In all five trials, DFO was administered as a subcutaneous infusion at a dose of 20 to 50 mg/kg/day for two or three days a week.</P>
<P>The duration of trial treatment was six months in one trial (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>) and one year in two trials (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>) but was not stated in the fourth trial (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>). In the fifth trial, the planned duration was five years but the trial was stopped early because of beneficial effects in terms of serum ferritin reduction (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). In this trial, the mean (SD) duration of treatment was 2.5 (2.2) years for deferiprone only and 2.9 (2.1) years for deferiprone in combination with DFO.</P>
<P>Three trials reported prior iron chelation therapy. Prior exposure to DFO was reported in two trials, although details of the dose and schedule were not reported (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>) . A third trial reported prior treatment with either DFO (50 mg/kg/day, 8 to 12 hours for 5 days per week) or deferiprone (75 mg/kg/day for 7 days per week) although the duration of prior treatment was not reported (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(C) Deferiprone and DFO in combination compared with DFO alone</HEADING>
<P>There were nine comparisons between deferiprone and DFO in combination with DFO alone (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>).</P>
<P>Deferiprone was given orally at a dose of 25 mg/kg/day (<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>), 75 mg/kg/day (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>), or 60 to 83 mg/kg/day (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). These oral divided doses were given daily in six trials (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>), five days per week in two trials (<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>) or for four days per week in one trial (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>).</P>
<P>When given in combination with deferiprone, DFO was given twice weekly in all nine trials, at a daily dose of between 23 to 60 mg/kg/day (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>) or 2 g (<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>). The schedule for DFO alone ranged from 20 to 60 mg/kg administered 5 to 7 days a week for all nine trials. One trial also administered an oral placebo; no further details are reported (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>).</P>
<P>The duration of treatment was six months (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>), 12 months (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>) and between one and 20 months (<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>). Although in the latter trial, only participants who had received at least six months of treatment were included in the assessment of efficacy (<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>). One trial did not report treatment duration (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>).</P>
<P>Six of the nine trials reported prior exposure to iron chelation therapy (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>); all six trials reported prior DFO treatment although only two reported the dose and schedule of prior treatment received. In one trial, patients received DFO at a dose of 40 mg/kg/day for 5 to 7 nights per week for "several years" (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>). A further trial reported prior exposure to DFO at a mean (SD) dose of 36.4 (11.1) mg/kg/day for 5.5 days per week but treatment duration was not reported (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). In this trial, participants were excluded from the trial if they had previously received deferiprone. A third trial reported prior exposure to DFO less than four times per week but the dose and duration was not reported (<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>).</P>
<P>
<B>(D) Deferiprone dose A versus deferiprone dose B</B>
</P>
<P>One trial compared doses of deferiprone (<LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>). The treatment schedules for this trial were either 50 mg/kg/day or 75 mg/kg/day. The duration of trial treatment was one year. No participants had received iron chelation therapy prior to trial enrolment.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-08-07 14:02:46 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Following full text eligibility assessment, 36 trials were excluded from the review. See the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table for further details. In summary, 25 were not RCTs, six trials did not include an eligible comparator arm, in three trials all participants received all interventions and two were commentaries on other studies (one excluded and one included). One of the trials included in the original review was excluded in this update as participants in this cross-over trial were not randomised to their first treatment arm (<LINK REF="STD-Fassos-1994" TYPE="STUDY">Fassos 1994</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Studies awaiting classification</HEADING>
<P>Three trials included in this section in the original review have now been moved to included studies (<LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). A further two have been excluded: both were from the same trial (<LINK REF="STD-Grady-2002" TYPE="STUDY">Grady 2002</LINK>). </P>
<P>Thirteen trials described in 25 papers are currently listed as studies awaiting classification, see '<LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>' for further details. The ongoing trial from the original review (<LINK REF="STD-NCT00115349a" TYPE="STUDY">NCT00115349a</LINK>) and one additional trial (<LINK REF="STD-N0277104959" TYPE="STUDY">N0277104959</LINK>) identified from ongoing trials databases have been classified under '<LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>'. We have been unable to identify any publications resulting from either trial. An additional two trials published in abstract form only have been included as '<LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>'; no further publications relating to these trials have been identified and the trial details contained in these abstracts were deemed insufficient for inclusion (<LINK REF="STD-Badawy-2010" TYPE="STUDY">Badawy 2010</LINK>; <LINK REF="STD-Unal-2009" TYPE="STUDY">Unal 2009</LINK>). A further study could not be conclusively identified as randomised; this study requires translation to further investigate the validity of the methods used before inclusion in the review (<LINK REF="STD-Kompany-2009" TYPE="STUDY">Kompany 2009</LINK>). Eight trials identified from the final search period (June 2011 to March 2013) are also potentially relevant and have been included as '<LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>' although have not been fully evaluated for eligibility (<LINK REF="STD-Alpendurada-2012" TYPE="STUDY">Alpendurada 2012</LINK>; <LINK REF="STD-Aydinok-2012" TYPE="STUDY">Aydinok 2012</LINK>; <LINK REF="STD-Evans-2011" TYPE="STUDY">Evans 2011</LINK>; <LINK REF="STD-Jain-2011" TYPE="STUDY">Jain 2011</LINK>; <LINK REF="STD-Maggio-2012" TYPE="STUDY">Maggio 2012</LINK>; <LINK REF="STD-Mirbehbahani-2012" TYPE="STUDY">Mirbehbahani 2012</LINK>; <LINK REF="STD-Pantalone-2011" TYPE="STUDY">Pantalone 2011</LINK>;<LINK REF="STD-Pepe-2013" TYPE="STUDY">Pepe 2013</LINK>).</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-08-14 11:18:19 +0100" MODIFIED_BY="Sheila A Worsley">
<P>The risk of bias across all included trials is summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and detailed below.</P>
<ALLOCATION MODIFIED="2013-08-07 14:07:47 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Six trials provided details regarding the methods used to generate the randomisation sequence. Two trials were deemed as having a low risk of bias; one used sealed envelopes (<LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>) and another trial used randomisation codes generated and maintained at a site external to the trial site (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>). Four trials reported permuted block randomisation and the risk of bias was classified as unclear (<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). In the remaining 11 trials no description was given as to which methods were used to generate the random sequence, hence these were also classified as having an unclear risk of bias (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>).</P>
<P>The method of randomisation (as described above) was deemed adequate to conceal treatment allocation with a low risk of bias in three trials (<LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). Two trials reported that the randomisation sequence was not concealed prior to allocation and the concealment of allocation was therefore deemed inadequate with a high risk of bias (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>).</P>
<P>The risk of bias associated with concealment of treatment allocation was defined as unclear in the remaining 12 trials, as no description was given of the methods used to conceal the allocation of treatment from the clinicians (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-08-07 14:08:47 +0100" MODIFIED_BY="Sheila A Worsley">
<P>In 12 trials the blinding of participants, clinicians and outcome assessors was not reported and the risk of bias in these trials was unclear (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). Blinding of participants and clinicians was also unclear in a further trial, although the authors of this trial did state that cardiac treatment was undertaken by a clinician blinded to treatment allocation (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>).</P>
<P>The blinding of participants and clinicians was not undertaken in four trials, but this is unsurprising given the difference in the methods of administration between treatment arms (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>). However, in all four of these trials, outcome assessors were blinded to treatment allocation which was deemed adequate and the these trials were therefore considered to have a low risk of bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-08-14 11:18:19 +0100" MODIFIED_BY="Sheila A Worsley">
<P>All but one of the included trials lost fewer than 20% of the randomised participants by the time of statistical analysis of the trial data (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>). All participants were analysed in the treatment groups to which they had been randomised, with the exception of one trial (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>).</P>
<P>Nine trials were considered to have a low risk of bias (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>).</P>
<P>Seven trials were considered to have a high risk of bias due to incomplete data (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>).</P>
<P>An imbalance in missing data across the treatment arms was noted in three trials (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>). In the first of these, four withdrawals were reported; these all occurred in the DFO group (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>). A second trial reported three withdrawals associated with the outcome of mortality only in participants receiving deferiprone, although the authors did not specify in which of the two deferiprone treatment groups these withdrawals occurred (<LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>). All randomised participants were analysed for all other outcomes in this trial. One trial lost three (30%) of the 10 randomised participants in the DFO alone group: two participants were excluded and one participant changed treatment groups (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>). No reasons were given as to why two participants were excluded from the trial. Follow-up data were not presented for the two excluded participants. End of trial data were analysed according to the treatment received rather than the treatment group to which the participants were randomised. Data from this trial were included in a meta-analysis within this review as it was clear to the authors which data were missing and what data analysis had been undertaken within the trial. However, given these noted concerns, the results from the meta-analysis need to be read with caution (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>).</P>
<P>A further trial with a high risk of bias reported variable numbers of participants included in the analysis for each outcome (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). Whilst the number of withdrawals and reasons were reported, the number of participants withdrawn from the trial conflicts with the number included in each analysis.</P>
<P>Three trials were stopped prematurely (<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>). One trial lost 46% of randomised participants (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>). This trial collected and reported outcome data for participants who had completed two years of treatment. Of 71 participants entering the trial, 13 (18%) had withdrawn and 20 (28%) had not completed two years on follow up. Outcome data were presented for 54% of randomised participants. This trial was stopped prematurely by the sponsoring pharmaceutical company (Apotex) when concerns were raised about the safety and effectiveness of deferiprone and the company made, as yet unproven allegations, over the conduct of the trial (<LINK REF="REF-Nathan-2002" TYPE="REFERENCE">Nathan 2002</LINK>; <LINK REF="REF-Viens-2004" TYPE="REFERENCE">Viens 2004</LINK>). Two trials were prematurely stopped after 18 months. In one trial, an unexpected sudden death of a participant in the deferiprone arm prompted the termination of the trial (<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>). The second trial sought to demonstrate an equivalence of treatment, with 80% power and a 0.2 chance of committing a Type 1 error. The trial investigators stated that to achieve this, 26 participants were needed, but to account for a large dropout rate, a total of 60 participants would be required (<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>). A further trial was stopped early before the planned five years of treatment were completed for all patients due to observed beneficial effects in terms of serum ferritin levels reduction in one of the treatment arms (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). In this trial 33 participants had withdrawn prior to termination of the trial.</P>
<P>The risk of bias was deemed to be unclear in one further trial (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). Tanner reported seven participants (four in the treatment group and three in the comparator group) who withdrew from the trial but the number of participants included in the final outcome assessment was not reported and the risk of bias due to incomplete outcome data was therefore unclear (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-08-07 14:32:39 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Seven of the included trials were considered to have some risk of bias due to selective reporting, as they failed to report pre-specified outcomes (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>). Outcome measures which were pre-specified in individual trials but not subsequently reported included liver iron concentration (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>), total iron binding capacity (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>), ferritin concentrations (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>), iron excretion (<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>), liver function tests (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>), hepatic markers (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>), monthly blood counts (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>), renal function (<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>), absolute neutrophil count (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>), alanine aminotransferase (ALT) (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>), serum zinc levels (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>) and serum creatinine levels (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). In addition, compliance was pre-specified as an outcome in two trials (<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>) but no compliance data were reported. </P>
<P>The remaining ten trials had a low risk of bias for this domain (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-08-07 14:36:20 +0100" MODIFIED_BY="Sheila A Worsley">
<SUBSECTION>
<HEADING LEVEL="4">Support and sponsorship</HEADING>
<P>Eleven trials documented sources of funding (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). Two trials received funding from a governmental agency: Medical Research Council of Canada (<LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>); and a European Community grant (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>). One trial was supported by university funds (<LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>) and four received funding from a thalassaemia society: Children's Thalassaemia Foundation in Hong Kong (<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>); Sicilian Thalassaemic Association (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>); Cooley's Anemia Foundation (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>) and UK Thalassaemia Society (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). The Tanner trial also acknowledged funding from CORDA as well as other charitable organisations.</P>
<P>Four trials documented sponsorship by the manufacturer of deferiprone: Apotex (<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>) or CIPLA Ltd (<LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>). Four trials reported the supplier of the trial treatment deferiprone: Lipomed, Switzerland (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>). Two trials reported the supplier of DFO: Novartis, Basel, Switzerland (<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>).</P>
<P>In one trial, although sources of funding were not reported, the authors declared that the trial was conducted "without the influence of the non-commercial sponsor" (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Power calculations</HEADING>
<P>Six trials documented power calculations (<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). All of these trials calculated sample sizes required to obtain 80% power to detect an effect. One trial calculated statistical power based on a 30 ng/ml difference in mean serum ferritin concentration after one year of DFO therapy (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>) and two trials based power calculations on a difference in myocardial T2* of 5% (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>) or a change of 0.75 standard deviations (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>); all of these trials achieved their target sample sizes. One trial calculated sample sizes based on repeated measure analyses; this trial achieved the target recruitment sample sizes but not all participants completed five years of treatment due to early termination of the trial (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). Two trials calculated power based on liver iron content of participants in earlier pilot studies (<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>). Neither of these studies achieved their target recruitment sample sizes due to the trials being stopped early.</P>
<P>The remaining 11 trials did not describe any power calculations (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>).</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-08-22 10:21:10 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Details of the baseline and end of trial values for serum ferritin concentration, urinary iron excretion, liver iron concentration and myocardial T2* reported by the included trials are presented in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>Results are presented for each comparison. Where there is disparity between trials in the method of outcome data reporting between trials which prohibits the calculation of mean change from baseline in all trials, outcome results are reported as both end of trial data and mean change from baseline. Outcome data in the three multi-arm trials (three arms) are presented in the results sections (A to C) due to the nature of the interventions in these trials (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>).</P>
<P>Most biochemical measures have a set of values known as 'normal ranges' defined with reference to a population sample of healthy people. Current normal ranges are 17 ng/ml to 30 ng/ml (or µg/L) for serum ferritin, up to 1.8 mg Fe/g dry weight for liver iron concentration and &gt; 20 ms for myocardial T2* as a measure of cardiac iron.</P>
<SUBSECTION>
<HEADING LEVEL="3">A. Deferiprone alone compared with DFO alone</HEADING>
<P>There were eight comparisons of deferiprone alone with DFO alone (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Mortality</HEADING>
<P>Only one trial reported mortality as an outcome (<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>). One death occurred in the deferiprone treatment arm after six months of treatment; this death was attributed to cardiac complications and thought not to be related to deferiprone treatment.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Evidence of reduced end organ damage</HEADING>
<P>Four trials reported cardiac function as an outcome (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). One trial did not report data, only that "there was no significant difference in cardiac function" between treatment arms (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). In the Maggio trial, cardiac function was measured by sonography to determine LVEF (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>). In the Pennell trial, cardiac function was assessed using cardiovascular magnetic resonance to measure left ventricular (LV) and right ventricular (RV) end-systolic and end-diastolic volume (ESV, EDV) and ejection fraction (EF) (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). In the remaining trial, the method of measurement was not reported, however, unpublished data for LVEF were obtained from the original investigators (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>).</P>
<P>At six months, the Pennell trial showed no significant difference in mean change of LVEF from baseline between treatment arms, MD 1.48% (95% CI -0.08 to 3.04) (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). However, at 12 months, meta-analysis of three trials showed a significant difference in mean change from baseline for LVEF between treatment arms in favour of deferiprone, MD 1.60% (95% CI 0.24 to 2.97) (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Considerable heterogeneity was observed between these three trials (I<SUP>2 </SUP>= 75%) and the MD using a random-effects model was no longer significant between treatment arms, MD 1.76% (95% CI -1.42 to 4.93) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). No clear clinical differences between the trials were identified which could account for this heterogeneity, although baseline LVEF values were lower (62% and 63%) in the <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK> trial than those in the <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK> trial (68.4%, 69.7%). No significant difference in mean change in LVEF was observed between treatment groups at 24 months as reported by one trial (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>): MD 7.60% (95% CI -0.65 to 15.85) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>)</P>
<P>Data to calculate mean change from baseline were not available for right ventricular ejection fraction (RVEF); however no significant differences were observed in mean RVEF at six months, MD 0.60% (95% CI -1.88 to 3.08), or 12 months, MD 2.30% (95% CI -0.22 to 4.82) (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>Two trials reported liver fibrosis as an outcome although the Ha trial did not report results separately for each treatment arm (<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>). In the Maggio trial, liver fibrosis was scored according to the Ishak scoring system (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>). There was no significant difference in the mean of fibrosis Ishak scores between treatment arms after 12 months, MD -0.10 (95% CI -0.98 to 0.78) (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>Evidence of reduced end organ damage as an outcome was not reported by any of the remaining trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Measures of iron overload</HEADING>
<P>The aim of iron chelation therapy is to reduce serum ferritin and liver iron concentration and increase urinary iron excretion and myocardial T2* measures.</P>
<SUBSECTION>
<HEADING LEVEL="6">a. Serum ferritin concentration</HEADING>
<P>Six trials reported serum ferritin concentration as an outcome (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). Data to calculate mean change in serum ferritin concentration from baseline to end of trial were available in five trials (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). A further trial presented data graphically and the mean change has been estimated from the graph; SDs were not reported in this trial (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). Individual trial data for serum ferritin concentration are presented in an additional table (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>); mean change from baseline data are shown in a further table (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). The results from these trials were not pooled overall due to the pronounced baseline differences between the treatment arms in two trials (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>) and the variation in treatment duration: six months (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>); 12 months (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>); and 24 months (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>).</P>
<P>At six months, two trials showed a statistically significant difference in mean change in serum ferritin concentration from baseline in favour of DFO, MD 2108.62 ng/ml (95% CI 882.76 to 3334.48) (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>); MD 465.00 ng/ml (95% CI 53.70 to 876.30) (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). In a third trial, the mean change in serum ferritin concentration was not significantly different between the two treatment arms, MD -324.20 ng/ml (95% CI -1805.21 to 1156.81) (<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>At 12 months, neither of two trials showed a significant difference in mean change in serum ferritin concentration between treatment arms: MD 10.00 ng/ml (95% CI -220.94 to 240.94) (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>); MD 285.00 ng/ml (95% CI -109.9 to 679.89) (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>At 24 months, there was no significant difference in mean change in serum ferritin concentration between treatment arms, MD 185.00 ng/ml (95% CI -270.52 to 640.52) (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b. Urinary iron excretion</HEADING>
<P>Six trials measured urinary iron excretion (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>; Olivieri 1997), but only one of these trials presented data to calculate mean change in urinary iron excretion (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>). Of the remaining five trials, three reported mean urinary iron excretion after treatment but did not report baseline values (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>). One trial reported mean percentage urinary iron excretion over the period of study, calculated as mean urinary iron excretion divided by total iron excretion (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>). The fifth trial reported only that "the change in urinary iron excretion from baseline to month 24 was not different between DFO and deferiprone subjects" (<A HREF="http://archie.cochrane.org/sections/documents/view?document=891800092511044744&amp;format=REVMAN#STD-Olivieri-1997">Olivieri 1997</A>). Individual trial data are presented in additional tables (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>Six trials measured urinary iron excretion (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>), but only one of these trials presented data to calculate mean change in urinary iron excretion (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>). Of the remaining five trials, three reported mean urinary iron excretion after treatment but did not report baseline values (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>), and one trial reported mean percentage urinary iron excretion over the period of study (defined as mean urinary iron excretion divided by the total iron excretion) (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>). The fifth trial (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>) reported only that "the change in urinary iron excretion from baseline to month 24 was not different between DFO and deferiprone subjects". Individual trial data are presented in additional tables (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>i. At end of trial</P>
<P>In two trials there were statistically significant differences in mean urinary iron excretion between the treatment arms, favouring deferiprone in one trial, MD 0.20 mg/24h (95% CI 0.08 to 0.32) (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>) and favouring DFO in the other trial, MD -4.10 mg/24h (95% CI -8.12 to -0.08) (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). There was no statistically significant difference in mean urinary iron excretion between the treatment arms in the other two trials, MD -3.18 mg/24h (95% CI -7.13 to 0.77) (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>) and MD -5.90 mg/24h (95% CI -13.22 to 1.42) (<LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). In one trial there was a significant difference in mean % urinary iron excretion over the study period, MD 70.00% (95% CI 57.69 to 82.31) (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<P>The data for this outcome were not pooled overall in a meta-analysis because the time points for the measurement of urinary iron excretion varied (12 months (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>), early after starting treatment (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>), 24 hours after starting treatment (<LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>)) and because of variation in means of measurement (mg/24 hours (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>), as a mean of quarterly readings (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>) and mean urinary iron excretion (%) (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>)).</P>
<P>ii. Change from baseline</P>
<P>In the trial reporting data to analyse mean change from baseline there was no statistically significant difference in mean change between the treatment arms, MD 0.20 mg/24h (95% CI -4.00 to 4.40) (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">c. Liver iron concentration</HEADING>
<P>Liver iron concentration was reported as an outcome in five trials (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). In one trial, data were presented graphically; baseline and endpoint values are estimated from the graph (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). The individual trial data are presented in an additional table (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>); mean change from baseline data are also presented in an additional table (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). Liver iron concentration was also measured in one additional trial but individual outcome data were not reported (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>). Liver iron concentration was measured by magnetic spectrometry (SQUID) in one trial (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>), by a combination of SQUID and biopsy analysis in one trial (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>) and by atomic spectrophotometry in two trials (<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>). In one trial the method used to assess liver biopsy was not reported (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). One trial measured liver iron concentration in a subset of participants (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>). The subset comprised participants from both treatment groups who agreed to undergo a liver biopsy; the baseline characteristics of the subset were very similar to the baseline characteristics of the trial participants overall.</P>
<P>i. At end of trial</P>
<P>Liver iron concentration at the end of the trial was reported in three trials (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>). Analysis of these three trials was carried out on a log scale due to the apparent skewing of the data in one of the trials (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>).</P>
<P>One trial reported liver iron concentration (mg/kg dry liver weight (d/w)) at 12 months (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). At the end of the trial, the mean (SD) liver iron concentration was approximately 11.5 (6.3) mg/g d/w for DFO and 7.5 (3.6) mg/g d/w for deferiprone (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>); values of liver iron concentration in the deferiprone treated patients were 0.67 times those in patients treated with DFO: ratio of geometric means, 0.67 (95% CI 0.48 to 0.94), favouring deferiprone (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
<P>One trial reported liver iron concentration (mg/g d/w) at 24 months (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>). The mean (SD) liver iron concentration values at 24 months were 8.90 (2.83) for deferiprone and 7.78 (4.68) for DFO, ratio of geometric means, 1.27 (95% CI 0.90 to 1.80).<BR/>
</P>
<P>Two trials reported end of trial measurements for this outcome at between 30 and 34 months from the start of the trial; the mean (SD) time to end of trial was 34.6 (6.7) months for DFO and 30 (2.4) months for deferiprone (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>) and 33 ( 6.1) months (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>). At the end of the trial, mean liver iron concentration for deferiprone was almost two-fold higher than for DFO in one trial (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>), favouring DFO in this trial, ratio of geometric means 1.98 (95% CI 1.41 to 2.79) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). In the second trial, the mean value in patients who received deferiprone was 0.69 times that in patients who received DFO although this did not reach statistical significance, ratio of geometric means 0.69 (95% CI 0.42 to 1.12) (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). The results from these two trials were not pooled due to the presence of hepatitis C in 86% of participants in one trial (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>) with no details of hepatitis C levels in participants in other trials and the different techniques used to assess liver iron concentration between the trials.<BR/>
</P>
<P>ii. Change from baseline</P>
<P>Five trials reported change from baseline in liver iron concentration (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). Liver iron concentration decreased from baseline to the end of the trial in both treatment groups in three trials (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>) (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). In these trials, the greatest decrease was observed in the DFO group in two trials (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>) and in the deferiprone group in one trial (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>). In two other trials, liver iron concentration had increased at the end of the trial in both treatment groups (<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>); the increase was greatest in the deferiprone treated group, favouring DFO.</P>
<P>Four trials reported SDs for mean change from baseline (<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>), although the data were skewed in one of these trials and data from this trial were therefore excluded from analysis of mean change from baseline (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>). For the remaining three trials, the difference in mean change from baseline between treatment groups was calculated. There was no statistically significant difference in mean change in liver iron concentration in any trial: MD 2.73 mg/g d/w at six months (95% CI -0.79 to 6.25) (<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>); MD 0.61 mg/g d/w at 12 months (95% CI -0.80 to 2.02) (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>), and MD -0.33 mg/g d/w at 24 months (95% CI -3.56 to 2.90) (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). Data from these trials were not pooled due to variation in time points for outcome measurements.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">d. Myocardial T2*</HEADING>
<P>Myocardial T2* was reported as an outcome measure in one trial (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). Results were reported on a log scale as geometric means; baseline and endpoint data are reported in an additional table (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Low T2* values were an entry criteria in this trial. T2* values increased at six and 12 months in both treatment arms; the increase was two-fold higher at 12 months in patients who received deferiprone (26.9% increase from baseline) compared with those who received DFO (12.8%). There was a small statistically significant difference between treatment arms in myocardial T2* levels, favouring deferiprone. The geometric mean value of myocardial T2* was approximately 10% higher in patients who received deferiprone than those who received DFO after six months, ratio of geometric means 1.09 (95% CI 1.01 to 1.18) and at the end of the trial (12 months), ratio of geometric means 1.12 (95% CI 1.02 to 1.23), favouring deferiprone (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">e. Chelation efficiency</HEADING>
<P>Mean chelation efficiency over the trial was reported in one trial (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>) (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). Chelation efficiency was calculated as [Iron excretion (mg/kg/day) / chelator dose (mg/kg/day)] x [molecular weight of the respective chelator /56] x n x 100, where 56 is the molecular weight of iron and n = 3 with deferiprone and n = 1 with DFO. There was a statistically significant difference in mean chelation efficiency in favour of DFO for this treatment comparison, MD -16.45% (95% CI -25.85% to -7.05%) (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">f. Plasma non-transferrin bound iron (NTBI)</HEADING>
<P>Plasma NTBI (mM) was measured by one trial (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>) (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). Mean results at the end of treatment (time point not defined) were reported. There was a statistically significant difference in mean plasma NTBI at the end of treatment in favour of the DFO treatment arm, MD 2.28 mM (95%CI 1.78 to 2.78) (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">g. Total Iron excretion</HEADING>
<P>Total iron excretion (mg/kg/day) at the end of the trial was reported in one trial (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>) (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). Total iron excretion per day was calculated as [iron transfused/year (mg) + (liver iron concentration at time 0 - liver iron concentration at time 1 year) x 10.6 x body weight in kg] / number of days of treatment. There was no statistically significant difference in mean total iron excretion between the treatment arms, MD -0.21 mg/kg/day (95% CI -0.43 to 0.01) (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Adverse events due to deferiprone</HEADING>
<P>Adverse events were reported as an outcome in six trials (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>) although one trial (<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>) did not report adverse events incidences per treatment arm; adverse event data for this trial has not been reported in the review. Another trial (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>) did not differentiate adverse events between deferiprone alone and deferiprone in combination with DFO and therefore adverse events in this trial could not be incorporated into meta-analyses. See an additional table for details of adverse events reported in individual trials (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>).<BR/>
<BR/>One trial reported data that enabled a comparison of the risk of experiencing any adverse event (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>). In this trial, there was a statistically significant increased risk of experiencing an adverse event in participants receiving deferiprone compared with those receiving DFO, RR 2.24 (95% CI 1.19 to 4.23) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). The remaining trials did not provide enough data to allow for an analysis of the risk of experiencing cumulative adverse events between the treatment arms.</P>
<P>Permanent treatment withdrawal due to adverse events was reported in two trials (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>). All of the permanent treatment withdrawals in both trials occurred in patients who received deferiprone. Only one trial reported temporary treatment withdrawals which occurred in four participants in each treatment arm (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>).</P>
<P>Two trials reported dose reduction due to adverse events (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>); both trials reported dose reduction in the deferiprone treatment arm, due to arthropathy (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>) and nausea (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>). Only one of these trials reported details of the reduction in deferiprone: the dose was reduced to 50 mg/kg (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). The Maggio trial also reported dose reduction in patients receiving DFO alone, due to pain or erythema or transient hypertransaminasaemia (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>).</P>
<P>Joint pain or arthralgia was reported as an adverse event in four of the five trials; two of these documented joint pain in both treatment arms (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>), whereas in a third trial joint pain was only reported in patients who received deferiprone (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>). The fourth trial reported joint pain in patients who received deferiprone (with or without DFO in combination) but no joint pain was reported in patients receiving DFO alone (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>). Meta-analysis of data from the first three trials showed a significant increased risk of joint pain or arthralgia associated with deferiprone, RR 2.64 (95% CI 1.21 to 5.77) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>Three trials reported gastrointestinal symptoms in the form of nausea or vomiting in patients receiving deferiprone (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). No cases of nausea or vomiting were reported in the DFO treatment arm although in one trial an absence of gastrointestinal symptoms in participants receiving DFO could not be clearly inferred (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). A meta-analysis of two trials showed a significantly increased risk of nausea or vomiting, or both, associated with deferiprone, RR 11.71 (95% CI 1.57 to 87.31) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>Five trials reported incidence of neutropenia or leucopenia, or both (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). In two of these trials, one case of neutropenia (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>) and two cases of leucopenia (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>) were reported only in patients who received deferiprone. Three cases of agranulocytosis were observed in a third trial, all of which occurred in patients who received deferiprone (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>). The fourth trial reported one case of neutropenia which occurred in a patient treated with DFO and one case of agranulocytosis in a patient who received deferiprone (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). No cases of neutropenia or leucopenia were observed in the Gomber trial (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>). When data were pooled across trials, neither treatment arm showed a significantly increased risk of neutropenia, leucopenia or agranulocytosis, RR 2.51 (95% CI 0.66 to 9.55) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
<P>Two trials observed increased liver transaminase in patients receiving either deferiprone or DFO, reported as hypertransaminasaemia (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>) or jaundice and very high liver enzymes (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). In one trial, hypertransaminaemia was reported in over 20% of patients who received deferiprone compared with only one case of hypertransaminasaemia in patients who received DFO, RR 16.45 (95% CI 2.24 to 120.79) (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). The second trial reported two patients (one in each treatment group) with jaundice or very high liver enzymes, RR 1.10 (95% CI 0.07 to 16.43) (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). The combined risk of increased liver transaminase was significantly higher patients treated with deferiprone than DFO, RR 8.90 (95% CI 2.08 to 38.11) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>Three trials reported adverse events specifically related to the administration of DFO, including skin reactions/swelling (5 out of 23, 21.7%) and systemic allergy (1 out of 23, 4.3%) (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>); pain or erythema at site of injection (6 out of 73) (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>) and local reactions at infusion site (12 out of 31, 38.7%) (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>).</P>
<P>Other adverse events reported in patients receiving deferiprone included infection (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>) and anorexia (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Participant compliance</HEADING>
<P>Participant compliance with iron chelation was measured in four trials (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>); see an additional table for individual trial data (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>). Two of these trials did not provide data for this outcome (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>). Although the first of these reported "excellent compliance during the study period" and documented four patients who were excluded from the trial due to lack of compliance, all of whom were randomised to the DFO treatment arm. At 12 months, there was no significant difference in participant compliance between treatment groups, MD 1.00 (95% CI -2.88 to 4.88) (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). However, in one trial at three years, there was a statistically significant difference in participant compliance in favour of deferiprone, MD 23.30% (95%CI 21.52 to 25.08) (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>) (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Cost of treatment</HEADING>
<P>The cost of treatment was reported in one trial (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>). Full details are presented in an additional table (<LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>).</P>
<P>As this trial was undertaken in India, cost is presented in rupees. In a comparison of the costs of treatment per week of deferiprone versus DFO; deferiprone was the cheaper treatment: 126 rupees with deferiprone and 900 rupees with DFO. Costs were based on a participant weighing 10 kg.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">B. Deferiprone alone compared with deferiprone and DFO in combination</HEADING>
<P>There were five comparisons between deferiprone alone with deferiprone and DFO in combination (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Mortality</HEADING>
<P>Mortality was reported in two trials (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). In the first trial, one individual randomised to receive deferiprone and DFO in combination, died at the start of the trial due to arrhythmia-induced congestive heart failure (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>). One death due to arrhythmia whilst receiving deferiprone and DFO in combination was also reported in the second trial (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). In this latter trial, a further five deaths were reported in patients in whom the randomised treatment was withdrawn and treatment changed to DFO alone due to adverse events; mortality occurred 11 to 60 months after withdrawal of the randomised treatment.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Evidence of reduced end organ damage</HEADING>
<P>Two trials reported evidence of reduced end organ damage as an outcome, although the latter of these reported only that "there was no significant difference in cardiac function" between treatment arms (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). In the Aydinok trial, cardiac function was measured by echocardiogram to determine LVEF (%) (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>). In this trial, the mean LVEF after 12 months was not significantly different between the two treatment arms, MD -5.20% (95% CI -12.39 to 1.99) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>One trial reported liver fibrosis as an outcome, scored according to the Ishak scoring system (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>). In this trial, results were presented graphically, the graphs being of insufficient quality to enable estimation of fibrosis scores. However, the trial authors reported that the fibrosis score "did not change significantly after one year in patients in any of the treatment arms".</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Measures of iron overload</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a. Serum ferritin concentration</HEADING>
<P>Four trials reported serum ferritin concentration as an outcome; individual trial data are shown in an additional table (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>); mean change from baseline are reported in a further table (<LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>). One trial presented data graphically and the mean change has been estimated from the graph; SDs were not reported in this trial (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>).</P>
<P>i. At end of trial</P>
<P>Of the three trials which reported SDs for end of trial data (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>), none showed a significant difference between treatment arms in serum ferritin concentration after six months, MD 46.10 ng/ml (95% CI -1156.78 to 1248.98) (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) or after 12 months, MD -255.00 ng/ml (95% CI -2564.49 to 2054.49) (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>); and MD 233.00 ng/ml (95% CI -23.74 to 489.74) (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). The latter trial reported data for each year over five years of follow up; these results are described as change from baseline below.</P>
<P>ii. Change from baseline</P>
<P>Data to calculate mean change in serum ferritin from baseline to end of trial were available in two trials (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). In the Gomber trial, there was no statistically significant difference in mean change in serum ferritin concentration between the two treatment arms, MD 720.96 ng/ml (95% CI -167.14 to 1609.06) (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). Mean serum ferritin concentration increased from baseline to six month end of trial in both treatment arms, the greater increase was observed in the deferiprone arm.</P>
<P>The Maggio trial reported results for up to five years of follow up (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). After one year of follow up, both arms of the trial reported a reduction in serum ferritin concentration with a significantly greater reduction in patients receiving deferiprone in combination with DFO, MD 285.00 ng/ml (95% CI 74.53 to 495.47) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). A reduction in serum ferritin concentration was maintained across the five years of follow up in the combined treatment arm. In patients receiving deferiprone only, a reduction in mean serum ferritin concentration from baseline values was observed at two and five years of follow-up although an increase was reported at three and four years of follow up. A significant difference in mean change of serum ferritin concentration in patients receiving deferiprone in combination with DFO was maintained over four years of follow up. At four years, MD 579.00 ng/ml (95% CI 116.11 to 1041.89) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). At five years, there was no significant difference in mean change of serum ferritin concentration between the two treatment arms, MD 281.00 ng/ml (95% CI -215.35 to 777.35) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>) although the number of patients in each treatment arm was considerably reduced after five years of follow-up due to early termination of the trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b. Urinary iron excretion</HEADING>
<P>Urinary iron excretion was measured in three trials (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>). As none of these trials presented baseline data for this outcome, mean change in urinary iron excretion from baseline to end of trial could not be calculated. See additional tables for individual trial data (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>One trial showed a statistically significant difference in mean urinary iron excretion (%) over the period of trial in favour of deferiprone alone, MD 14.00% (95% CI 0.87 to 27.13) (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). There was no statistically significant difference in mean urinary iron excretion between treatment arms in the other two trials, MD -2.36 mg/24h (95% CI -5.70 to 0.98) (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>) and MD -0.07 mg/24h (95% CI -0.24 to 0.10) (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>). Data for mean urinary iron excretion after treatment was not pooled overall in a meta-analysis because of variation in the means of measurement: mg/24 hours (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>); as a mean of quarterly readings (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>) and as mean urinary iron excretion over the trial (%) (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">c. Liver iron concentration</HEADING>
<P>Five trials measured liver iron concentration (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). However, in the Gomber trial, liver iron concentration, although measured, was not reported as an outcome (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>). Liver iron concentration was measured by atomic emission spectrophotometry in one trial (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>). A second trial measured liver iron content by T2* MRI in a subset of patients with a mean (SD) duration from entry into the trial until the final MRI scan of 16 (5) months in the combined deferiprone and DFO group and 14 (6) months in patients receiving deferiprone alone (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). The method used for liver biopsy assessment was not reported in two trials (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>).</P>
<P>In the 2005 Aydinok trial, liver iron concentration was measured but data were not individually reported (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>). In addition, one trial presented data graphically and the mean change was estimated from the graph (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). Data to calculate mean change in liver iron concentration from baseline to end of trial were available in two trials, although SDs could not be calculated (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK> (<LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>). Data to calculate the mean liver iron concentration (mg/g dry weight) at the end of the trial was reported in all three trials (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>).</P>
<P>In the two trials reporting liver iron concentration after 12 months of treatment, the combined mean difference from meta-analysis of these two trials was not significant: 1.45 mg/g d/w (95% CI -0.91 to 3.82) (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>) (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). The trial measuring liver iron concentration by T2* MRI showed a reduction in liver T2* with deferiprone alone compared with an increase in liver T2* with combined chelation therapy (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>) (<LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>). The differences in follow-up time across this subset of patients prohibited calculation of the mean change in liver iron concentration; however the trial reported no significant differences in the T2* signals of the liver between the two treatment groups (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">d. Myocardial T2*</HEADING>
<P>Myocardial T2* was reported as an outcome in one trial (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>); baseline and endpoint data are shown in an additional table (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). In this trial, myocardial T2* was measured by T2* MRI in a subset of patients with a mean (SD) duration from entry into the trial until the final MRI scan of 16 (5) months in the combined deferiprone and DFO group and 14 (6) months in patients receiving deferiprone alone. The differences in duration of follow up time across this subset of patients prohibited calculation of the mean change in myocardial iron concentration; however the trial reported no significant differences in the T2* signals of the heart between the two treatment groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">e. Chelation efficiency</HEADING>
<P>Chelation efficiency (%) was reported by one trial (as described in the previous comparison) (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>) (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). There was no statistically significant difference in chelation efficiency between the treatment arms, MD -0.69% (95%CI -1.53 to 0.15) (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">f. Plasma non-transferrin bound iron (NTBI)</HEADING>
<P>Plasma NTBI was measured in one trial as change in concentration from baseline (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>) (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). Concentration was measured as millimolar (mM). Mean results at the end of treatment (time point not defined) were reported. There was a small statistically difference in mean plasma NTBI in at the end of treatment in favour of deferiprone and DFO, MD 2.16 mM (95% CI 1.49 to 2.83) (<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">g. Total Iron excretion</HEADING>
<P>Two trials reported total iron excretion (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>). In both trials, total iron excretion per day was calculated as:</P>
<P>[iron transfused/year (mg) + (liver iron concentration at time 0 - liver iron concentration at time 1 year) x 10<SUP>6</SUP> x body weight in kg] / number of days of treatment.</P>
<P>In the first trial, total iron excretion was reported at the end of the trial (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>) (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). There was a small statistically significant difference in mean total iron excretion in favour of deferiprone combined with DFO, MD -0.13 mg/kg/day (95%CI -0.21 to -0.05) (<LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>). In the second trial, mean change in total iron excretion from baseline was reported (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>). This trial also showed a statistically significant difference in the mean change in total iron excretion in favour of deferiprone and DFO compared with deferiprone alone, MD -0.21 mg/kg/day (95% CI -0.39 to -0.03) (<LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Adverse events due to deferiprone</HEADING>
<P>Adverse events were reported as an outcome in four trials (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>) although the Gomber trial did not report adverse events per treatment arm, i.e. between patients who received deferiprone alone or deferiprone with DFO, and therefore adverse events in this trial could not be incorporated into meta-analyses (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>). See an additional table for details of adverse events reported in the individual trials (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>).</P>
<P>None of the trials reporting adverse events provided sufficient data to allow an analysis of the risk of experiencing cumulative adverse events between the treatment arms.</P>
<P>Permanent treatment withdrawal due to adverse events was observed in three trials (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>); this occurred in patients who received deferiprone alone and deferiprone with DFO in all three trials. Temporary treatment withdrawal was reported in one trial in participants receiving deferiprone (with or without DFO) due to arthropathy (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>). Additionally, Magggio reported temporary treatment withdrawals, stating "no statistically significant difference in temporary and definitive discontinuation of treatment between the groups", but no further data were provided (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>).</P>
<P>Two trials reported dose reduction (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). In the first of these trials, the dose of deferiprone was reduced to 50 mg/kg due to arthropathy; this was reported in four patients (two in each treatment arm) (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). In the latter trial, dose reduction was reported in 49% (deferiprone alone) and 56.5% (deferiprone with DFO) of participants; no further details were given (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>).</P>
<P>Joint pain was observed in three trials (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). In one trial, joint pain or arthralgia occurred in over 30% of all patients who received deferiprone (with or without DFO) (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). The combined risk of joint pain was not significantly higher for either treatment group, RR 1.03 (95% CI 0.53 to 2.01) (<LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>).</P>
<P>Two trials reported gastrointestinal disturbance or nausea or vomiting in both treatment arms, although neither treatment arm was associated with an increased risk, RR 1.74 (95% CI 0.90 to 3.35) (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>) (<LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>). The third trial also reported nausea and vomiting, but for both treatment arms combined, and therefore, results could not be combined in a meta-analysis (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>).</P>
<P>Leucopenia or neutropenia, or both, were reported in three trials, in patients who received deferiprone alone and in patients who received deferiprone in combination with DFO (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). One patient in the combined treatment group with neutropenia reported in the Aydinok trial subsequently developed agranulocytosis (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>). Agranulocytosis was also observed in a total of four patients who received deferiprone alone (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). No significant increased risk of leucopenia, neutropenia and/or agranulocytosis was associated with either treatment group, RR 0.71 (95% CI 0.38 to 1.32) (<LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>).</P>
<P>Two trials observed increased liver transaminase in patients receiving either deferiprone or the combined therapy, reported as at least two-fold increase in ALT (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>) or jaundice or very high liver enzymes (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). Meta-analysis of these two trials showed that neither treatment arm was associated with a significantly increased risk of high liver transaminase, RR 0.73 (95% CI 0.45 to 1.17) (<LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>).<B> </B>A third trial reported "transient fluctuations" in ALT levels in patients who received DFO with deferiprone but no change in ALT levels in those who were treated with DFO alone (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>).</P>
<P>Two trials reported adverse events specifically related to the administration of DFO (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). The first of these reported "mild local reactions observed in several patients treated with DFO" (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>), whilst the second reported the occurrence of skin reactions/swelling (3 out of 22, 13.6%) (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>).</P>
<P>Other adverse events reported in both treatment arms included anorexia (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). Musculoskeletal pain was also reported in patients receiving the combined therapy (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Participant compliance</HEADING>
<P>Three trials measured participant compliance (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>) (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>). Neither of the first two trials reported data for this outcome, although the first trial described overall compliance for the two treatment arms as "generally excellent during the entire study period" and noted one patient who missed more than one chelation dose per week due to problems with swallowing (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>). The second trial reported "excellent compliance during the study period" (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). In the third trial, mean compliance with deferiprone was reported as over 90% in both treatment arms, whereas mean compliance with DFO was 70.6% (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Cost of treatment</HEADING>
<P>The cost of treatment was reported in one trial (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>); full details are presented in an additional table (<LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>). As this trial was undertaken in India costs are presented in rupees. In a comparison of the costs of treatment per week of deferiprone versus deferiprone and DFO, deferiprone was the cheaper treatment: 126 rupees with deferiprone and 486 rupees with deferiprone and DFO. Costs were based on a participant weighing 10 kg.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">C. Deferiprone and DFO in combination compared with DFO alone</HEADING>
<P>There were nine comparisons between deferiprone and DFO in combination with DFO alone (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Mortality</HEADING>
<P>Mortality as an outcome was not reported by any of these trials.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Evidence of reduced end organ damage</HEADING>
<P>Three trials reported evidence of reduced end organ damage as an outcome (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). The El-Beshlawy trial reported only that "there was no significant difference in cardiac function" between treatment arms (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). The remaining two trials reported cardiac function by LVEF (%), measured by echocardiogram (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>) or cardiac magnetic resonance (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). Neither trial reported data to calculate mean change in LVEF from baseline (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). However, both trials showed a significant difference in mean LVEF (%) at 12 months and when combined in a meta-analysis, LVEF was shown to be significantly reduced in patients who received DFO alone compared with deferiprone in combination with DFO, MD 6.22% (95% CI 4.32 to 8.12) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). Considerable heterogeneity was observed between these two trials (I<SUP>2 </SUP>= 89%); the difference between treatment arms remained significant under a random-effects model, MD 6.08% (95% CI 0.28 to 11.88). No clear clinical differences between these two trials were identified which could account for this heterogeneity.</P>
<P>One trial reported liver fibrosis as an outcome, but results were not reported separately for each treatment arm and therefore are not presented here (<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Measures of iron overload</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a. Serum ferritin concentration</HEADING>
<P>Serum ferritin concentration was reported as an outcome in eight trials (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>); one trial presented data graphically and the mean change is estimated from the graph (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). Individual trial data are reported in an additional table (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>); mean change from baseline to endpoint data are reported in a further table (<LINK REF="TBL-10" TYPE="TABLE">Table 10</LINK>). One trial reported serum ferritin levels at baseline and end of trial as geometric means with coefficient of variation (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). In a second trial, data were observed as skewed (<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>); the skewed nature of these data was only observed because data were presented as individual patient data (IPD) (<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>); such data were not available in the remaining trials.</P>
<P>i. At end of trial</P>
<P>In view of the skewed data observed in the Mourad trial and the form of reporting of results in the Tanner trial, serum ferritin concentration at endpoint was analysed on a log scale as ratio of geometric means (<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>).</P>
<P>Three trials reported serum ferritin at six months follow up; all three trials showed a significant difference between treatment arms in favour of the combined treatment of deferiprone with DFO (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>): ratio of geometric means 0.66 ng/ml (95% CI 0.48 to 0.91) (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>); ratio of geometric means 0.64 ng/ml (95% CI 0.45 to 0.92) (<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>); ratio of geometric means 0.90 ng/ml (95% CI 0.86 to 0.95) (<LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). Results at six months were not pooled in a meta-analysis due to pronounced baseline differences between the treatment arms in one trial (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>).</P>
<P>At 12 months follow up, combined evidence from meta-analysis of three trials showed a significant difference between treatment arms, favouring deferiprone combined with DFO (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>). The mean value in patients who received combination therapy was 0.86 times that in patients who received DFO alone, ratio of geometric means 0.86 (95% CI 0.81 to 0.91) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
<P>ii. Change from baseline</P>
<P>Data to calculate mean change in serum ferritin from baseline to end of trial were available in eight trials (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>), although only three trials reported SDs or sufficient data to allow calculation of the SD (<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>). There were statistically significant differences in mean change in serum ferritin concentration at six months in two trials (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>). In one trial, mean change favoured combined deferiprone and DFO, MD -2046.00 micromol/l (95%CI -3902.00 to -190.00) (<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>) (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>). In the second trial, mean change favoured DFO, MD 1387.66 ng/ml (95% CI 222.13 to 2553.19) (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>) (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>). The CIs were wide suggesting considerable variation in the results for individual participants (<LINK REF="TBL-10" TYPE="TABLE">Table 10</LINK>), which may have arisen from the pronounced baseline differences in this trial (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>). The Galanello trial, with mean change in serum ferritin concentration data at 12 months showed no significant difference in mean change, MD 101.00 ng/ml (95% CI -252.44 to 454.44) (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>) (<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>).</P>
<P>In the remaining trials with data reported for serum ferritin concentration, the mean change was a reduction in serum ferritin concentration for both treatment arms at six months (<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>) and 12 months (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>) (<LINK REF="TBL-10" TYPE="TABLE">Table 10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b. Urinary iron excretion</HEADING>
<P>Urinary iron excretion was measured by five trials (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>). Individual trial data are reported in an additional table (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). In one of these trials, outcome data were only reported for one treatment arm and will not be addressed further in these results (<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>). Of the remaining four trials, three, did not present baseline data for this outcome, thus not enabling mean change from baseline to end of trial to be calculated (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>).</P>
<P>In the trial reporting data at six months, mean urinary iron excretion at the end of trial was not statistically different between the treatment arms, MD -0.82 mg/24h (95%CI -5.67 to 4.03) (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>).Two trials showed a statistically significant difference in urinary iron excretion measurement after treatment, both in favour of combined treatment of deferiprone and DFO: one after 12 months, MD 0.23 mg/24h (95% CI 0.04 to 0.42) (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>); and one as a mean of quarterly readings, MD 0.27 mg/24h (95% CI 0.13 to 0.41) (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>). An additional trial which reported mean % urinary iron excretion over the trial and showed a statistically significant difference between treatment arms in favour of combined deferiprone with DFO, MD 56.00% (95% CI 42.44 to 169.56) (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>) (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>). Data for mean urinary iron excretion after treatment were not pooled overall in a meta-analysis because the time points for the measurement of urinary iron excretion varied (six months (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>) and 12 months (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>)) and because of variation in the means of measurement (mg/24h (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>), as a mean of quarterly readings (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>) and as a % mean urinary iron excretion (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>)).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">c. Liver iron concentration</HEADING>
<P>Liver iron concentration was reported as an outcome measure in four trials (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>); mean change in liver iron concentration from baseline to end of trial was reported in two of these trials (<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>). The third trial reported liver iron concentration as a geometric mean of liver T2* (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). One trial presented data graphically and the mean change is estimated from the graph (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). Individual trial data are presented in an additional table (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>); mean change from baseline data are reported in a further table (<LINK REF="TBL-11" TYPE="TABLE">Table 11</LINK>).</P>
<P>Liver iron concentration was measured by atomic absorption spectrophotometry in one trial (<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>) and by magnetic spectrometry (SQUID) in a second trial (<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>). One trial used liver T2* measured by cardiovascular magnetic resonance (CMR) to quantify liver iron concentration (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). The method of liver biopsy assessment was not reported in one trial (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>).</P>
<P>Two trials reporting mean change in liver iron concentration were not pooled in a meta-analysis due to variation in treatment duration: six months (<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>); and 12 months (<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>). Mean change in liver iron concentration was not significantly different between the treatment arms in either of these trials: MD 0.13 mg/g d/w (95% CI -8.41 to 8.67) (<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>); MD 0.17 mg/g w/w (95% CI -0.11 to 0.45) (<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>) (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>). In the Tanner trial, the geometric mean of liver T2* was reported at baseline and after treatment (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). Exact P values were not available for all trial arms and therefore SDs could not be calculated. However, this trial reported a between-group difference in geometric means of 39% (95% CI 20% to 61%) in favour of the combined treatment group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">d. Myocardial T2*</HEADING>
<P>One trial reported myocardial T2* as an outcome measure (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). In this trial, the between group difference in geometric means of myocardial T2* was reported as significantly in favour of the combined treatment group, with an estimated 10% (95% CI 2% to 19%) increase in the combined group compared with the DFO group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">e. Chelation efficiency</HEADING>
<P>Chelation efficiency (%) was reported in one trial as described above (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>) (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). There was a statistically significant difference in mean chelation efficiency in favour of DFO, MD -15.76 (95%CI -25.16 to -6.36) (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">f. Plasma non-transferrin bound iron (NTBI)</HEADING>
<P>Plasma NTBI was measured by one trial (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>) (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). Mean results at the end of treatment (time point not defined) were reported. There was no statistically significant difference in mean plasma NTBI at the end of treatment between the treatment arms, MD 0.12 mM (95%CI -0.60 to 0.84) (<LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">g. Total iron excretion</HEADING>
<P>In one trial, total iron excretion (mg/kg/day) was reported at the end of the trial (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>). Total iron excretion per day was calculated as:</P>
<P>[iron transfused/year (mg) + (liver iron concentration at time 0 - liver iron concentration at time 1 year) x 10.6 x body weight in kg] / number of days of treatment.</P>
<P>There was no statistically significant difference in total iron excretion between the treatment arms, MD -0.08 mg/kg/day (95%CI -0.31 to 0.15) (<LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>). See additional tables for actual trial data (<LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Adverse events</HEADING>
<P>Adverse events were measured as an outcome in eight trials (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>); although one trial with three treatment arms did not differentiate adverse events between patients who received deferiprone alone or deferiprone with DFO and therefore this trial could not be included in meta-analyses (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>). See an additional table for details of the adverse events experienced in each trial (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). A further trial did not report adverse event incidences per treatment arm and adverse event data for this trial have not been reported in this review (<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>).</P>
<P>Two trials reported data that enabled a comparison of the risk of experiencing any adverse event (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>). Both trials observed a greater proportion of adverse events in patients receiving deferiprone with DFO than those receiving DFO alone. When data were pooled into a meta-analysis, there was a statistically significant increased risk of experiencing an adverse event in participants receiving deferiprone with DFO compared with those receiving DFO alone, RR 3.04 (95% CI 1.18 to 7.83) (<LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). The remaining trials did not provide enough data to allow for an analysis of the risk of experiencing cumulative adverse events between the treatment arms.</P>
<P>Three trials each reported permanent treatment withdrawals due to adverse events (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>); only the latter trial reported permanent treatment withdrawals in the DFO only treatment arm. Two other trials did not observe any permanent withdrawals throughout the trial (<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>).</P>
<P>A reduction in deferiprone dose was reported in two trials (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>). In the first of these, the deferiprone dose was reduced to 50 mg/kg in two participants due to arthropathy (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). The second trial reported temporary dose reduction in "some" patients with gastrointestinal disturbances; no further details were given (<LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>) .</P>
<P>Joint pain or arthralgia was reported as an adverse event in five trials (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). Two of these reported patients with joint pain in both treatment arms (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>); a further trial observed arthralgia only in patients receiving the combined therapy (<LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>). Incidences of joint pain were also reported in the combined deferiprone with DFO treatment arm in the two other trials (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>), although the absence of joint pain in patients receiving DFO alone could not be clearly inferred and these trials could not be included in a meta-analysis. A meta-analysis of the first three trials showed no significant increased risk of joint pain or arthralgia for either treatment, RR 1.58 (95% CI 0.66 to 3.80) (<LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<P>Six trials reported gastrointestinal disturbance or nausea and vomiting (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). One trial reported gastrointestinal disturbance in both treatment arms (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>), whilst the remaining five trials only observed gastrointestinal disturbance in patients receiving deferiprone combined with DFO (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>). In three of these trials incidence of gastrointestinal disturbance in patients receiving DFO alone could not be clearly inferred without ambiguity (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>). Additionally, in three trials the number of affected patients was reported separately for nausea or vomiting (or both), diarrhoea and abdominal pain; any overlap between the number of patients reported in each of these groups could not be ruled out (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>). Meta-analysis of the two trials with sufficient data showed a significant increased risk of gastrointestinal disturbance associated with deferiprone combined with DFO, RR 2.11 (95% CI 1.02 to 4.37) (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>) (<LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<P>Cases of neutropenia or leucopenia, or both, were reported in three trials (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). Two of these trials reported incidences of neutropenia in a total of three patients receiving deferiprone in combination with DFO (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>), and one case of agranulocytosis in a patient in the combined therapy arm. One trial also reported neutropenia in one patient who received DFO alone (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). A further case of neutropenia in a patient receiving DFO alone was reported by a third trial (<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>). No cases of neutropenia or leucopenia were observed in the Abdelrazik trial. When data from these trials were pooled in a meta-analysis, no significant increased risk of neutropenia, leucopenia or agranulocytosis (or a combination of these) was observed for either treatment arm, RR 1.80 (95% CI 0.45 to 7.17) (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>) (<LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<P>Three trials observed patients with increased liver transaminase occurring in both treatment arms, reported as: elevated ALT at least two-fold above normal values (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>); a transient increase in ALT three times the normal upper limit in HCV positive patients (<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>); and as jaundice or very high liver enzymes (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). When combined, no significantly increased risk of increased liver transaminase was observed in either treatment group, RR 1.73 (95% CI 0.83 to 3.61) (<LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). A fourth trial reported transient fluctuations in serum alanine ALT levels in patients receiving combined deferiprone and DFO treatment but not in patients receiving DFO alone (<LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>). A fifth trial reported that no significant change in ALT was observed over the trial period in either treatment group (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>).</P>
<P>Adverse events specifically related to the administration of DFO were reported in five trials (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). Skin allergic reactions occurred in 8 out of 45 (17.8%) (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>), 11 out 40 (27.5%) (<LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>) and 12 out 14 (85.7%) (<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>) of all patients, and in 6% and 3% in the DFO and combined treatment arms respectively (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). Abscess at the site of infusion was also reported by two trials, in 1 out of 30 (3.3%) patients (<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>) and 1 out of 40 (2.5%) patients (<LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>).</P>
<P>Other adverse events in patients receiving deferiprone with DFO reported in one trial included musculoskeletal pain, anorexia, and insomnia (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Participant compliance</HEADING>
<P>Participant compliance with DFO was measured in six trials (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>); see an additional table for individual trial data (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>). Two trials reported compliance rates with DFO (<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>) which in the first trial was 96.1% in the combined treatment arm and 95.7% for DFO alone (<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>), and in the second trial was 91.4% in the combined treatment arm and 92.6% for DFO alone (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>). The latter trial also reported a compliance rate of 82.4% for deferiprone; deferiprone compliance was not reported in the other trial.</P>
<P>Two further trials did not provide compliance rates, but reported compliance descriptively. In one trial, compliance was rated as "excellent" in 91% of participants in the deferiprone and DFO arm and 79% of participants in the DFO arm; and as "good" in 9% of participants in the deferiprone and DFO arm and 21% of participants in the DFO arm (<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>). The final trial reported "excellent compliance during the study period" and documented four patients who were excluded from the trial due to lack of compliance, all of whom received DFO alone (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>).</P>
<P>Although reported as measured, the remaining two trials did not report the results for this outcome (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Cost of treatment</HEADING>
<P>The cost of treatment was reported in one trial (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>). Full details are presented in an additional table (<LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>). As this trial was undertaken in India, cost is presented in rupees. In a comparison of the costs of treatment per week of deferiprone and DFO versus DFO, deferiprone and DFO was the cheaper treatment, 486 rupees with deferiprone and DFO and 900 rupees with DFO. Costs were based on a participant weighing 10 kg.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">D. Deferiprone dose A versus deferiprone dose B</HEADING>
<P>One trial compared different doses of deferiprone (50 mg/kg/day versus 75 mg/kg/day) (<LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Mortality</HEADING>
<P>This trial reported one death in a patient receiving deferiprone at a dose of 50 mg/kg/day. This individual, who presented with leucopenia with neutropenia, developed severe respiratory tract infection after 11 months of therapy and following treatment with oral amoxacillin for 48 hours, was hospitalised and died within 24 hours of this diphtheria-like infection.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Evidence of reduced end organ damage</HEADING>
<P>Evidence of reduced end organ damage as an outcome was not reported by this trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Measures of iron overload</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a. Serum ferritin concentration</HEADING>
<P>Data to calculate mean change in serum ferritin from baseline to end of trial were available in this trial (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). The mean change was a reduction in serum ferritin in both treatment arms; the MD was not calculated due to the absence of SDs or sufficient data (i.e. a correlation coefficient) to enable calculation of these. However, the MD between treatment arms at the end of the trial was not significant between the two doses of deferiprone, MD -223.00 ng/ml (95% CI -1342.67 to 896.67) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b. Urinary iron excretion</HEADING>
<P>Urinary iron excretion was not reported as an outcome in this trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">c. Liver iron concentration</HEADING>
<P>Liver iron concentration was not reported as an outcome in this trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">d. Myocardial T2*</HEADING>
<P>Myocardial T2* was not reported as an outcome in this trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">e. Chelation efficiency</HEADING>
<P>Chelation efficiency (%) was not reported as an outcome in this trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">f. Plasma non-transferrin bound iron (NTBI)</HEADING>
<P>Plasma NTBI was not reported as an outcome in this trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">g. Total Iron excretion</HEADING>
<P>Total iron excretion was not reported as an outcome in this trial.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Adverse events</HEADING>
<P>Adverse events associated with deferiprone were reported in this trial, see an additional table (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). In particular, joint pain was reported in 29% of patients who received the higher dose of deferiprone (75 mg/kg/day) compared with 50% in patients who received the lower dose (50 mg/kg/day). Cases of leucopenia with neutropenia were also reported in both treatment arms with similar rates: 23% in patients who received the lower dose of deferiprone; and 24% in patients who received the higher dose. Of the 12 patients on either treatment dose who experienced neutropenia with leucopenia, treatment was withdrawn temporarily in 10 patients and withdrawn permanently in one patient, whilst one patient died from infection. A total of 19 patients reported infections as an adverse event; these were not reported separately for each treatment arm.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Participant compliance with deferiprone treatment</HEADING>
<P>Participant compliance with deferiprone treatment was not reported as an outcome in this trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Cost of treatment</HEADING>
<P>The cost of treatment was not reported as an outcome in this trial.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-08-08 12:05:34 +0100" MODIFIED_BY="Sheila A Worsley">
<P>The aims of this systematic review were to summarise data from trials on the efficacy and safety of deferiprone as an iron chelating agent in people with transfusion-dependent thalassaemia and to compare the efficacy and safety of deferiprone with desferrioxamine. Both aims were severely compromised by incompatible trial design or reporting of data, or both, and clinical diversity of participants between the trials.</P>
<P>This updated review complements a concurrent systematic review of iron chelation entitled 'Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia', which we previously undertook and which we have now also updated (<LINK REF="REF-Fisher--2013" TYPE="REFERENCE">Fisher 2013</LINK>). All but one of the trials presented in this current review are common to both papers (<LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>).</P>
<P>Seventeen RCTs were eligible for analysis in this review. Within these trials there were five different intervention comparisons: five trials compared deferiprone to DFO; two trials compared deferiprone alone to deferiprone combined with DFO; six trials compared deferiprone combined with DFO to DFO alone; three trials included a three-way comparison of deferiprone, DFO and deferiprone with DFO; and one trial compared different doses of deferiprone.</P>
<P>There was little opportunity for meta-analysis for the majority of outcomes; analysis of data was principally a commentary on the findings from each included trial. Few trials measured long-term outcomes, mortality was only measured in four trials and evidence of reduced end-organ damage was measured in six trials. Although measures of iron overload were reported in all but one trial, meta-analysis was not possible for most outcomes due to different methods of assessment and measurement of outcomes used, variation in time points and a lack of sufficient data reporting. Trials aimed at evaluating iron chelators may benefit from the development and application of agreed standardised sets of outcomes to be collected and reported, ideally through the Core Outcome Measures in Effectiveness Trials (COMET) initiative (<A HREF="http://www.comet-initiative.org">www.comet-initiative.org</A>), which will better enable results of trials to be compared, contrasted and combined as appropriate (see also '<LINK TAG="IMPLICATIONS_RESEARCH" TYPE="SECTION">Implications for research</LINK>' below).</P>
<P>Mortality was reported by four trials; each trial reported the death of one individual receiving deferiprone (with or without DFO). Most of these deaths were due to cardiac complications and could not be attributed to therapy. However, one patient receiving deferiprone presented with leucopenia with neutropenia, developed a severe respiratory tract infection after 11 months and died as a result of this infection (<LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>). One trial reported five further deaths in patients who withdrew from randomised treatment (deferiprone with or without DFO) and switched to DFO alone (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>).</P>
<P>Reporting of long-term outcomes was limited and inconclusive; few trials reported evidence of reduced end organ damage as an outcome. The effect of deferiprone and DFO has attracted some interest since reports that cardiac iron load may be reduced by deferiprone (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). The earlier trials measuring cardiac iron load indirectly by measurement of the MRI T2* signal had suggested deferiprone may reduce cardiac iron more quickly than DFO. In a direct comparison of patients with low T2* (high cardiac iron) receiving deferiprone or DFO, T2* values increased in both treatment arms; the increase was two-fold higher at 12 months in patients who received deferiprone (26.9% increase from baseline) compared with those who received DFO (12.8%) (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). In a trial of DFO compared with DFO and deferiprone, increases in myocardial T2* (representing a reduction in cardiac iron) was significantly in favour of the combined treatment group, with an estimated 10% (95% CI 2% to 19%) increase in the combined group compared with the DFO group (<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>).</P>
<P>In the comparison of deferiprone versus DFO monotherapy, meta-analysis of three trials which reported LVEF as a measure of cardiac function showed no significant differences between treatment arms (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). However, in a meta-analysis of two trials which compared LVEF between patients who received combined deferiprone with DFO and those who received DFO alone, LVEF was shown to be significantly reduced in patients who received DFO alone compared with combination therapy (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>).</P>
<P>There have been reports of deaths due to heart disease in trial participants. A recent trial did report a sudden death, probably due to a cardiac arrhythmia, although the death was not attributed to deferiprone (<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>). Two further cardiac-related deaths were reported in patients receiving deferiprone (with or without DFO) (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). There are many reports of the incidence of cardiac disease in observational studies, but it is impossible to compare the rates of cardiac dysfunction or disease in such studies.</P>
<P>The significance of differences in improvements in LVEF and MRI T2* and how they translate into the ability to prevent cardiac disease is unclear in the absence of more data and longer follow up of randomised participants (<LINK REF="REF-Neufeld-2006" TYPE="REFERENCE">Neufeld 2006</LINK>). It is clear from retrospective and prospective clinical studies that intensified DFO treatment, by either subcutaneous or intravenous route, can reverse cardiac dysfunction because of iron overload and increase survival in thalassaemia-major patients with early or overt cardiomyopathy (<LINK REF="REF-Maggio-2007" TYPE="REFERENCE">Maggio 2007</LINK>). Any benefit of deferiprone to prevent heart disease needs to be evaluated in appropriately-powered trials with robust measures of cardiac iron load and function.</P>
<P>In the absence of long-term follow up in all but one trial (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>) and with limited data on mortality or end organ damage, data on the effects of chelation therapy rely on markers of iron overload or measurements of iron loading or excretion.</P>
<P>In the direct comparison of deferiprone and DFO, after six months, a statistically significant difference in mean change in serum ferritin concentration in favour of DFO was observed in two trials (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>); a third trial found no significant difference between treatment arms (<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>). However, none of the trials which reported longer-term follow up showed a significant difference in mean change in serum ferritin concentration between treatment arms, at 12 months (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>) or 24 months (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>). </P>
<P>In a single large trial with four years of follow up, there was a significant difference in mean change of serum ferritin concentration in patients receiving deferiprone in combination with DFO compared to deferiprone alone (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>). Furthermore, in three trials comparing DFO to DFO and deferiprone, meta-analysis showed a significant difference between treatment arms, favouring the combined therapy (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>).</P>
<P>These results suggest an advantage of combined therapy with DFO and deferiprone over monotherapy to reduce iron stores as measured by serum ferritin. Can such advantages for combination therapy be supported by other measurements of iron fluxes or stores, or both? Measures of urinary iron excretion are difficult to interpret as comparative measures of efficacy since these estimates do not include biliary iron excretion, and so would underestimate the total iron excretion for DFO. Hence no real conclusion can be made examining measurements of urinary iron excretion in five trials comparing deferiprone with DFO (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>).</P>
<P>In three trials which compared deferiprone alone with combination therapy, no significant differences were observed in serum ferritin concentration between treatment groups either at the end of the trial or as mean change from baseline, with the exception of one trial with a planned follow up of five years (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>) In this trial, a significant difference in mean change from baseline was observed in favour of patients receiving deferiprone combined with DFO over deferiprone monotherapy; this significant difference was maintained over four years of study. Of note, this large trial was terminated early due to the beneficial effects of combined treatment in terms of serum ferritin reduction compared with deferiprone alone.</P>
<P>In the comparison of combination therapy with DFO alone, all three trials which reported serum ferritin concentration after six months reported significantly lower serum ferritin values in patients who received DFO combined with deferiprone (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>). Furthermore, after 12 months, meta-analysis of three trials showed a significant difference between treatment arms in favour of deferiprone combined with DFO (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>; <LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>). Two trials which reported a significant difference between treatment arms in mean change in serum ferritin concentration from baseline favoured different treatment regimens.</P>
<P>Urinary iron excretion was measured in six trials comparing deferiprone with DFO (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>). However, in all but one of these trials, no baseline data were presented for this outcome and therefore mean change from baseline to end of trial could not be calculated (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>). As already stated, these estimates of urinary iron excretion do not include biliary iron excretion, and so would underestimate the total iron excretion for DFO.</P>
<P>Of three trials which compared deferiprone with combination therapy, only one showed a significant difference in urinary iron concentration at the end of the trial in favour of deferiprone (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>). However, in the comparison of combined therapy with DFO alone, two trials showed a significant difference in urinary iron concentration at the end of the trial in favour of deferiprone combined with DFO (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). In addition, one trial which reported mean percentage urinary iron excretion over the trial period showed a significantly greater level of urinary iron excretion in patients who received combined therapy compared with DFO alone (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>). Only one other trial reported urinary iron excretion for this comparison and this trial found no significant difference between treatment arms (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>). Data from the majority of trials did not allow analysis of mean change from baseline between treatment arms. Nevertheless, the data suggest addition of deferiprone to DFO increases urinary iron excretion over DFO alone.</P>
<P>One trial used three other measures of iron burden and chelation, namely total iron excretion, chelation efficiency and plasma NTBI (<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>). There was a small statistically significant difference in total iron excretion in favour of deferiprone compared with deferiprone and DFO. The results of other comparisons were not significant.</P>
<P>Liver iron concentration is a valuable measure of stored iron. Indeed, direct measurement of liver iron is the gold standard by which other assays are validated. Five trials comparing deferiprone with DFO reported liver iron concentration (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). However, conflicting results were observed between trials. Liver iron concentration at the end of the trial was significantly lower in the deferiprone treatment group in one trial (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>), significantly lower in the DFO group in a second trial (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>), and showed a non-significant difference in favour of DFO in a third trial (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>). None of three trials reporting mean change from baseline found significant differences between treatment groups (<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>).</P>
<P>Neither trial which reported liver iron concentration for the comparison of deferiprone alone versus combination therapy found significant differences in liver iron concentration at the end of the trial (<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>; <LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>). Similarly, in the comparison of deferiprone with DFO versus DFO alone, neither trial reporting this outcome found a significant difference in mean change from baseline between treatment arms (<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>; <LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>).</P>
<P>Pooling of liver iron concentration was generally was prevented by differences in techniques used for measurement of liver iron content between trials (SQUID, atomic spectrophotometry, liver T2*) as well as the variable presence of hepatitis C and the wide variation in treatment duration between and possibly within trials. In addition, the degree of reporting of results (displayed graphically or a lack of SDs or CIs) in a number of trials was inadequate to formally assess differences between treatment groups.</P>
<P>Only one trial compared different doses of deferiprone (<LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>). This trial only reported serum ferritin concentration as a measure of iron overload. No difference in serum ferritin concentration at the end of the trial was observed between patients who received 50 mg/kg/day and those who received 75 mg/kg/day. Evidence of reduced end organ damage was not reported as an outcome in this trial.</P>
<P>There is therefore no conclusive or consistent evidence for the improved efficacy of combined deferiprone and DFO therapy against monotherapy from direct or indirect measures of liver iron.</P>
<P>Given the apparently similar efficacy of deferiprone and DFO, the safety, compliance and cost of these drugs are of special interest. Indeed the safety of chelation therapy has been somewhat controversial. Treatment with DFO has been in clinical usage for some 20 years longer than deferiprone and adverse events as a result of DFO therapy have been observed, with epidemiological data suggesting that adverse events may be dose-related (<LINK REF="REF-Porter-1989a" TYPE="REFERENCE">Porter 1989a</LINK>; <LINK REF="REF-Porter-2002" TYPE="REFERENCE">Porter 2002</LINK>). The longer-term safety profile is much less certain for deferiprone than for DFO, although in the late 1990s liver fibrosis appeared to be associated with deferiprone during a clinical trial (<LINK REF="REF-Olivieri-1998" TYPE="REFERENCE">Olivieri 1998</LINK>).</P>
<P>Adverse event data were reported in 14 trials, but differences in how adverse events were measured (number of events or events per person), the time points for measurement and the lack of standard reporting of the severity of reactions precluded pooling of data across the trials in many instances.</P>
<P>In a direct comparison of DFO against deferiprone, meta-analysis showed an 11.7-fold increased risk of gastrointestinal side effects associated with deferiprone (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>), an 8.9-fold increased risk of raised liver transaminase levels (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>) and a 2.6-fold increased risk of joint pain or arthralgia (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>; <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). Furthermore, the FDA review of the primary data from the trial conducted by Pennell concluded that "Regarding safety, adverse events related to elevation of serum alanine aminotransferase levels were reported in 38% of the deferiprone group and in 18% of the deferoxamine group. In the context of additional concerns, this observation signals the potential for deferiprone induced liver toxicity." (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>).</P>
<P>Local adverse events specifically related to the administration of DFO are well described. Local reactions at infusion sites occurred in 17.8% (n = 45) (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>), 27.5% (n = 40) (<LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>), 85.7% (n = 14) (<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>) and 38.7% (n = 31) (<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>) of patients; local abscesses at the site of infusion occurred in 3.3% (n = 30) (<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>) and 2.5% (n = 40) (<LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>) of patients; and systemic allergy occurred in 4.3% (n = 23) of patients (<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>).</P>
<P>Three trials reported data that enabled a comparison of the risk of experiencing any adverse event. In a comparison of DFO versus deferiprone, there was a statistically significant 2.2-fold increased risk of experiencing an adverse event in participants receiving deferiprone compared with those receiving DFO (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>). Furthermore, two trials observed a greater proportion of adverse events in patients receiving deferiprone with DFO than those receiving DFO alone; meta-analysis showed a statistically significant three-fold increased risk of experiencing an adverse event in participants receiving deferiprone with DFO compared with those receiving DFO alone (<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>; <LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>). The danger of raised liver enzymes or agranulocytosis with deferiprone means that close monitoring of full blood counts and liver function is required and precludes its use where close monitoring is not available.</P>
<P>However, these conclusions must be viewed with some caution, given that RCTs are not designed to measure the adverse effects of an intervention and thus data from RCTs does not represent a formal comparison of adverse events caused by iron chelation therapy. A complete review of adverse events should be the subject of a separate, formal analysis incorporating data from non-RCTs and observational studies. Nevertheless, reporting of serious adverse events from post-marketing surveillance, has shown that use of deferiprone may be associated with fatal agranulocytosis and when used at more than 100 mg/kg/day a neurological syndrome of cerebellar and psychomotor retardation that has progressively regressed after deferiprone has been discontinued (<LINK REF="REF-Henter-2007" TYPE="REFERENCE">Henter 2007</LINK>; <LINK REF="REF-Swedish-Orphan-Drug-2007" TYPE="REFERENCE">Swedish Orphan Drug 2007</LINK>). It is now recommended that weekly full blood counts are monitored in people receiving deferiprone (<LINK REF="REF-Swedish-Orphan-Drug-2007" TYPE="REFERENCE">Swedish Orphan Drug 2007</LINK>).</P>
<P>A further major concern of DFO is compliance. It has been suggested that participants given an oral iron chelator may be more compliant with treatment than those given a continuous subcutaneous infusion of DFO. Eleven trials reported compliance, with this suggestion being supported in two trials (<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>) although reporting of compliance in other trials was often purely descriptive. The observed differences may be medically important, especially as the difference in compliance associated with these two iron chelators may become greater outside the rigours and discipline of a formal RCT setting. Thus, objective assessment of safety and compliance with these chelating agents will require studies with long-term follow up in a variety of settings.</P>
<P>Several factors have contributed to the disappointing absence of meta-analyses of trial results. Trials included participants with substantial clinical and demographic diversity which was not always fully defined. In particular, there were differences in the measurement of outcomes across trials, notably the different techniques used to assess liver iron concentration between trials, the presence of hepatitis C in participants in one trial (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>), the skewed nature of the data in two trials (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>) and the undermining of the randomisation process (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>). Some trials failed to report baseline data, making valid comparisons impossible between trials. Moreover, where reported, baseline values for serum ferritin and liver iron concentration differed substantially between trials, and in two trials between treatment arms (<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>; <LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>). The impact of these differences on any overall results is difficult to evaluate due to the limited number of trials and the small sample sizes of the included trials. The skewed nature of the data in two trials gives rise to concerns of the likely skewing of the data in the remaining trials. Without obtaining the IPD from all trials, this issue could not be confirmed.</P>
<P>Variation in the time points used for outcome measurement was also a factor that precluded meta-analysis. While very short-term outcome measurement was the appropriate objective of the two iron balance trials and measures of iron overload can be assessed over a six or twelve month period, much longer follow up is needed to examine the effect of iron chelation on mortality and reduced end-organ damage or other toxicity.</P>
<P>The validity of the data is a third issue to note. With the exception of two trials (<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>; <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>), the sample sizes of the included trials were small with 40 or fewer per treatment arm. Only six trials presented information on sample sizes required to power the trial around a main outcome, whilst several trials failed to clearly state the primary endpoint for analysis. Data were presented in abstract form for one trial, presumably with a lack of peer review and limiting the amount of data that can be reported.</P>
<P>The risk of bias of the included trials was difficult to assess given the general absence of information on randomisation and blinding to treatment allocation. As such, the influence of the quality of the included trials was not explored with respect to the robustness of any results. With the interventions in these trials, blinding to treatment allocation would be impossible for clinician and participant in all but one trial in which different doses of deferiprone were compared. However, blinding of outcome assessors would be desirable as a means of minimising bias, particularly where subjective measurements such as functional status and histological results are concerned.</P>
<P>Although no quantitative assessment of publication bias was undertaken, attempts were made to minimise the likelihood of publication bias by the use of a comprehensive search strategy, the handsearching of relevant conference abstract books and contacting the manufacturers of deferiprone and other iron chelators.</P>
<P>This review has highlighted the difficulty of undertaking an analysis in such intervention comparisons, not least the limited ability to pool and meta-analyse crucial aspects of measures of iron stores and chelation across the trials. These difficulties seem to be inherent in the population being studied. Children with thalassaemia may enter trials at different points in their clinical course, after variable amounts of blood transfusion, with variable endogenous iron loading, with different prior treatment and with differing biochemical levels as a result of past treatment and their thalassaemia. It seems unlikely that any one particular methodology could overcome these problems in future trials. It would therefore be important that each RCT comparing iron chelators or different schedules, doses or methods of administration of iron chelators should provide extensive details of baseline measures, collect follow-up data at times appropriate to the outcomes of interest and be sufficiently powered to provide a significant comparison within the trial.</P>
<P>These difficulties highlight the importance not only in designing trials to optimise subsequent meta-analysis, but of ensuring IPD are made available to the scientific community. Perhaps deposition of the IPD for an RCT will ultimately become a requirement for publication in the same way as molecular data for experimental data is deposited in public databases now. Moreover, consensus on the appropriate methods and sampling to measure iron overload would greatly help data from future trials to be combined. Finally, accurate recording of compliance and adverse events for different schedules of iron chelation should be an essential feature of future trials.</P>
<P>There is clearly an absence of adequate RCTs for understanding the relative benefit of DFO and deferiprone in long-term studies. Nevertheless, there has been some considerable use of combined DFO and deferiprone therapy. There are now many reports of a decline in the incidence of cardiac disease and mortality in observational studies since the implementation of regular measurement of myocardial T2* to detect those patients at risk of developing cardiac disease and subsequent intensification of chelation therapy in those with MRI evidence of myocardial iron loading. It is unclear whether the observed declines in mortality have followed improved detection of those at risk of cardiac disease or specific chelation regimens.</P>
<P>The absence of high quality data from RCTs to support specific recommendations for the use of deferiprone is not just the conclusion of this review but also the considered view of the FDA in the United States of America. The FDA reviewed an application to license deferiprone in 2011, having previously rejected an application in 2009. At that time Apotex, the manufacturer of deferiprone, was advised that the FDA would require at least one new RCT as well as a full audit of the original trial led by Dr Olivieri in Toronto. However, neither further RCTs nor other requested audits were submitted by Apotex, and Apotex abandoned its application for full approval despite previous and continued claims of efficacy and safety. Downgraded approval of deferiprone under the lower 'accelerated' standards, as "last resort treatment of iron overload in thalassemia, myelodysplasia and sickle cell disease" was later provided. This decision arose from the lack of new RCT evidence and the failure to provide answers to the FDA's questions on efficacy and safety.</P>
<P>In summary, there were insufficient data available to fulfil the aim of this review; namely to determine the effectiveness of the iron chelating agent deferiprone in people with transfusion-dependent thalassaemia and to compare the efficacy and safety of deferiprone with other iron chelating agents. Deferiprone is indicated for the treatment of iron overload in patients with thalassaemia major when DFO is contraindicated or inadequate. Intensified DFO treatment by either subcutaneous or intravenous route and/or use of other oral iron chelators remains the established treatment to reverse cardiac dysfunction because of iron overload. Indeed, the FDA have approved deferiprone only as "last resort treatment of iron overload in thalassemia" and combination therapy with DFO and deferiprone has been used in spite of the lack of RCT data in specific clinical situations, particularly where there is evidence of myocardial iron deposition or where compliance with continuous DFO is a severe problem, or both. Factors are suggested that should be considered in further trials to improve the efficacy and applicability of deferiprone in people with iron overload.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-08-08 12:13:04 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-08-08 12:10:35 +0100" MODIFIED_BY="[Empty name]">
<P>Both deferiprone and DFO produce a significant reduction in iron stores in transfusion-dependent, iron-overloaded people. There is no evidence to suggest that either treatment is more clinically efficacious over the length of these trials or has a greater reduction of clinically significant end organ damage.</P>
<P>The significance of differences in improvements in LVEF and MRI T2* and how these are translated into the ability to prevent cardiac disease is unclear in the absence of more data and longer follow up of randomised participants. Intensified DFO treatment (subcutaneously or intravenously) or use of other oral iron chelators, or both, remains the established treatment to reverse cardiac dysfunction because of iron overload.</P>
<P>The results of this review do suggest an advantage of combined therapy with DFO and deferiprone over monotherapy to reduce iron stores as measured by serum ferritin. However, there is no conclusive or consistent evidence for the improved efficacy of combined deferiprone and DFO therapy against monotherapy from direct or indirect measures of liver iron.</P>
<P>Direct comparison of DFO versus deferiprone showed an increased risk of gastrointestinal side effects, increased liver transaminase levels and joint pain or arthralgia associated with deferiprone. Local adverse events specifically related to the administration of DFO are well-described. Deferiprone, used alone or in combination with DFO, is associated with a statistically significant increased risk of side effects compared to DFO.</P>
<P>There is no evidence to change current treatment recommendations, namely that deferiprone is indicated for the treatment of iron overload in patients with thalassaemia major when DFO is contraindicated or inadequate. The FDA have approved deferiprone as "last resort treatment of iron overload in thalassemia". The spectrum and incidence of adverse events vary between the two drugs and people treated with both drugs must be kept under close medical supervision. In particular, the danger of raised liver enzymes or agranulocytosis with deferiprone means that close monitoring of full blood counts and liver function is required and this precludes its use where close monitoring is not available. The major difference in the route of administration between oral deferiprone and subcutaneous infusion of DFO may lead to differences in compliance, but the majority of the included trials in which compliance was reported achieved good to excellent compliance with deferiprone and DFO. Therefore, practical issues, patient factors and cost will continue to be the determinants of choice.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-08-08 12:13:04 +0100" MODIFIED_BY="[Empty name]">
<P>It is a major concern that adequate RCTs to demonstrate the clinical efficacy and safety of deferiprone for such an important clinical indication have not been completed some 15 years after the drug was initially available for clinical use.</P>
<P>There are four implications for further research, derived from this review.</P>
<P>First, the most urgent need is for long-term (i.e. minimum of five years) prospective trials starting in early life, before there is a significant iron loading and carried through to adolescence and beyond.</P>
<P>Secondly, future trials should include outcomes that enable a comparison of the long-term clinical efficacy and safety of these agents. Trials comparing the two drugs should use comparable and combinable measures of pharmacological and clinical outcomes that have been validated or may be validated as associated with outcome. Liver and cardiac iron burden, liver histology and cardiac function are of special interest. Measures and outcomes should therefore include serum ferritin, liver histology, direct measures of hepatic iron stores and indirect measures of hepatic and cardiac iron using magnetic resonance or similar techniques, and measures of cardiac function including LVEF. To combine data it is necessary to have full data including the SD for baseline and end of trial data and the change between start and finish for all participant groups. Ideally, agreed standardised sets of outcomes should be collected and reported, ideally though the COMET initiative (<A HREF="http://www.comet-initiative.org">www.comet-initiative.org</A>), which will better enable results of trials to be compared, contrasted and combined as appropriate. Where necessary, agreement to use IPD should be forthcoming.</P>
<P>Thirdly, information is required about minimal clinically important differences for people with transfusion-dependent thalassaemia receiving iron chelation therapy, i.e. what level of difference in tissue (liver and cardiac iron) concentration would lead to a clinically important difference in survival. This information need not be derived from RCTs, but from observational studies specifically designed for this task. The reporting of adverse events would require comparable indices and outcomes to be used across trials to allow more comprehensive pooling of data.</P>
<P>Finally, there are few data on the relative cost of these chelating agents, but this will clearly be of major interest in many countries where iron chelators are widely used.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-05-16 12:46:04 +0100" MODIFIED_BY="Sheila A Worsley">
<P>This project (Ref. NIHR-RP-PG-0310-1004) is supported by National Institute of Heath Research (NIHR), UK.</P>
<SUBSECTION>
<HEADING LEVEL="5">For the update (2013):</HEADING>
<P>We thank Dr Sally Hopewell for providing methodological advice for this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">For the original review (2006):</HEADING>
<P>We thank Dr Senani Williams (eligibility assessment, data extraction and analysis, quality assessment and content expert), Dr Jo Howard (development of protocol and content expert) and Professor Chris Hyde (development of protocol, data analysis and methodological expert) for their contribution as authors to the original review.</P>
<P>We thank Neelam Thapar for her thoughts and comments on the protocol and Simon Stanworth for his help with data verification and comments on the review.</P>
<P>We thank Jon Deeks and Phil Alderson for their advice and comments on the methods section of this review.</P>
<P>We thank Carol Lefebvre for providing advice on the search strategy.</P>
<P>Dr Antoni Addis prepared an initial draft for this review and we acknowledge his contribution. However, Dr Addis had no involvement with the preparation of the protocol and was not involved in any stage of the review process.</P>
</SUBSECTION>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-08-08 12:14:38 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Sheila Fisher (for the 2013 update): searching and selection of trials; eligibility assessment; data extraction and analysis; input of trial results; quality assessment; methodological expert; wrote the abstract, results and discussion sections for the update.</P>
<P>Susan Brunskill: development of protocol; searching and selection of trials; eligibility assessment; data extraction and analysis; input of trial results; quality assessment; methodological expert; wrote the abstract, results and discussion sections for the original review.</P>
<P>Carolyn Doree: eligibility assessment; searching and selection of trials; data extraction and analysis; quality assessment and verification of data entry.</P>
<P>Onima Chowdhury: (for the 2013 update): data extraction.</P>
<P>Sarah Gooding: (for the 2013 update): data extraction.</P>
<P>David Roberts: development of protocol and content expert.</P>
<P>All authors were involved in drawing conclusions and making specific recommendations for future research.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-08-14 11:09:02 +0100" MODIFIED_BY="[Empty name]"/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-08-22 10:25:19 +0100" MODIFIED_BY="Sheila A Worsley">
<STUDIES MODIFIED="2013-08-14 13:31:42 +0100" MODIFIED_BY="Sheila A Worsley">
<INCLUDED_STUDIES MODIFIED="2013-08-05 22:52:09 +0100" MODIFIED_BY="Sheila A Worsley">
<STUDY DATA_SOURCE="PUB" ID="STD-Abdelrazik-2007" MODIFIED="2012-08-03 16:15:25 +0100" MODIFIED_BY="[Empty name]" NAME="Abdelrazik 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-04-12 14:16:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Abdelrazik N</AU>
<TI>Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience</TI>
<SO>Hematology</SO>
<YR>2007</YR>
<VL>12</VL>
<NO>6</NO>
<PG>577-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-03 16:15:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abdelrazik N</AU>
<TI>Pattern of iron chelation therapy in Egyptian children with beta-thalassaemia: one-year Mansoura University Childrens Hospital experience [abstract]</TI>
<SO>Haematologica</SO>
<YR>2007</YR>
<VL>92 Suppl 1</VL>
<PG>Abstract 1146</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aydinok-2005" NAME="Aydinok 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aydinok Y, Evans P, Terzi A, Cetiner N, Porter JB</AU>
<TI>Randomised, prospective evaluation of iron balance, chelation efficiency, urine excretion and NTBI progression with deferiprone (DFP) or deferoxamine (DFO) monotherapy or with combined DFP plus DFO [abstract]</TI>
<SO>Blood</SO>
<YR>2005</YR>
<VL>106</VL>
<NO>11 Pt 1</NO>
<PG>2698</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aydinok-2007" MODIFIED="2013-08-05 22:49:11 +0100" MODIFIED_BY="[Empty name]" NAME="Aydinok 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-04-12 14:19:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aydinok Y, El-Beshlawy A, von Orelli-Leber C, Czarnecki-Tarabishi C, Manz C</AU>
<TI>A randomized controlled trial comparing the combination therapy of deferiprone (DFP) and Desferrioxamine (DFO) versus DFP or DFO monotherapy in patients with thalassaemia major [abstract]</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>108</VL>
<NO>11</NO>
<PG>Abstract 557</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-05 22:49:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G et al</AU>
<TI>A randomized, controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassaemia major</TI>
<SO>Haematologica</SO>
<YR>2007</YR>
<VL>92</VL>
<NO>12</NO>
<PG>1599-606</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-24 11:57:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manz C, El-Beshlawy A, Aydinok Y, Leber C, Czarnecki-Tarabishi C</AU>
<TI>A randomized, controlled, prospective clinical study comparing the combination therapy of deferiprone (L1) and desferrioxamine (DFO) with L1 and DFO monotherapy in patients with thalassaemia major [abstract]</TI>
<SO>Haematologica</SO>
<YR>2006</YR>
<VL>91 Suppl 12</VL>
<PG>Abstract 515</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Choudhry-2004" MODIFIED="2011-07-19 08:53:19 +0100" MODIFIED_BY="Sheila A Worsley" NAME="Choudhry 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-07-19 08:53:19 +0100" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Choudhry VP, Pati HP, Saxena A, Malaviya AN</AU>
<TI>Deferiprone, efficacy and safety</TI>
<SO>Indian Journal of Pediatrics</SO>
<YR>2004</YR>
<VL>71</VL>
<NO>3</NO>
<PG>213-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El_x002d_Beshlawy-2008" MODIFIED="2013-08-05 22:49:40 +0100" MODIFIED_BY="[Empty name]" NAME="El-Beshlawy 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-08-05 22:49:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I et al</AU>
<TI>Iron chelation in thalassaemia: combined or monotherapy? The Egyptian experience</TI>
<SO>Annals of Hematology</SO>
<YR>2008</YR>
<VL>87</VL>
<NO>7</NO>
<PG>545-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galanello-2006" MODIFIED="2012-04-12 14:22:38 +0100" MODIFIED_BY="[Empty name]" NAME="Galanello 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-04-12 14:22:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V et al</AU>
<TI>A prospective randomised controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassaemia</TI>
<SO>Haematologica</SO>
<YR>2006</YR>
<VL>91</VL>
<NO>9</NO>
<PG>1241-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-01 09:10:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galanello R, Kattamis A, Piga A, Tricta F</AU>
<TI>Safety and efficacy of alternate desferrioxamine and deferiprone compared to desferrioxamine alone in the treatment of iron overload in transfusion-dependent thalassemia patients [abstract]</TI>
<SO>Blood</SO>
<YR>2004</YR>
<VL>104</VL>
<NO>11 Pt 1</NO>
<PG>Abstract 3611</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gomber-2004" MODIFIED="2011-07-19 08:57:22 +0100" MODIFIED_BY="Sheila A Worsley" NAME="Gomber 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-07-19 08:57:22 +0100" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gomber S, Saxena R, Mada N</AU>
<TI>Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassaemic children</TI>
<SO>Indian Pediatrics</SO>
<YR>2004</YR>
<VL>41</VL>
<NO>1</NO>
<PG>21-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ha-_x0028_i_x0029_-2006" NAME="Ha (i) 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW et al</AU>
<TI>A randomised controlled study evaluating the safety and efficacy of deferiprone treatment in thalassaemia major patients from Hong Kong</TI>
<SO>Hemoglobin</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>2</NO>
<PG>263-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ha-_x0028_ii_x0029_-2006" NAME="Ha (ii) 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW et al</AU>
<TI>A randomised controlled study evaluating the safety and efficacy of deferiprone treatment in thalassaemia major patients from Hong Kong</TI>
<SO>Hemoglobin</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>2</NO>
<PG>263-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maggio-2002" MODIFIED="2008-09-12 11:59:21 +0100" MODIFIED_BY="Tracey Remmington" NAME="Maggio 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galia M, Midiri M, Bartolotta V, Morabito A, Rizzo M, Mangiagli A et al</AU>
<TI>Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study</TI>
<SO>Hemoglobin</SO>
<YR>2003</YR>
<VL>27</VL>
<NO>2</NO>
<PG>63-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-12 11:59:21 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maggio A, Capra M, Ciaccio C, Magnano C, Rizzo M, Mangiagili A et al</AU>
<TI>Evaluatrion of efficacy of LI versus desferrioxamine by clinical randomised multicentric study [abstract]</TI>
<SO>Blood</SO>
<YR>1999</YR>
<VL>94</VL>
<NO>10 Suppl 1</NO>
<PG>34b</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P et al</AU>
<TI>Deferiprone versus deferoxamine in patients with thalassaemia major: a randomised clinical trial</TI>
<SO>Blood Cells, Molecules and Diseases</SO>
<YR>2002</YR>
<VL>28</VL>
<NO>2</NO>
<PG>196-208</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maggio-2009" MODIFIED="2012-04-12 14:24:47 +0100" MODIFIED_BY="Sheila A Worsley" NAME="Maggio 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-04-12 14:23:43 +0100" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A et al</AU>
<TI>Decrease of mortality during deferiprone treatments: results from a large randomised cohort of thalassemia major patients under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies [abstract]</TI>
<SO>Blood</SO>
<YR>2008</YR>
<VL>112</VL>
<NO>11</NO>
<PG>Abstract 3885</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-12 14:24:07 +0100" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A et al</AU>
<TI>Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies</TI>
<SO>Blood Cells, Molecules and Diseases</SO>
<YR>2009</YR>
<VL>42</VL>
<NO>3</NO>
<PG>247-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-12 14:24:47 +0100" MODIFIED_BY="Sheila A Worsley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A et al</AU>
<TI>Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial</TI>
<SO>British Journal of Haematology</SO>
<YR>2009</YR>
<VL>145</VL>
<NO>2</NO>
<PG>245-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-29 10:22:07 +0000" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F et al</AU>
<TI>Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in beta-thalassemia major patients</TI>
<SO>Hemoglobin</SO>
<YR>2011</YR>
<VL>35</VL>
<NO>3</NO>
<PG>206-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mourad-2003" NAME="Mourad 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mourad FH, Hoffbrand, AV, Sheikah-Taha M, Koussa S, Khoriaty AI, Taher A</AU>
<TI>Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overload thalassaemia patients</TI>
<SO>British Journal of Haematology</SO>
<YR>2003</YR>
<VL>121</VL>
<NO>1</NO>
<PG>187-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olivieri-1990" MODIFIED="2012-02-28 15:04:39 +0000" MODIFIED_BY="[Empty name]" NAME="Olivieri 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri NF, Kopren G, St Louis P, Freedman M, McClelland R, Templeton D</AU>
<TI>Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassaemia patients</TI>
<SO>Seminars in Haematology</SO>
<YR>1990</YR>
<VL>27</VL>
<NO>2</NO>
<PG>101-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J et al</AU>
<TI>Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>336</VL>
<NO>8726</NO>
<PG>1275-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri NF, Koren G, Hermann C, Chung D, McClelland R, Freedman M et al</AU>
<TI>Effective iron chelation with L1 in patients with thalassemia major: iron balance and dose response studies [abstract]</TI>
<SO>Blood</SO>
<YR>1989</YR>
<VL>174</VL>
<NO>7 Suppl 1</NO>
<PG>51a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;No issue number&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri NF, Templeton DM, Koren G, Chung D, Herman C, Freedman MH et al</AU>
<TI>Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1990</YR>
<VL>612</VL>
<PG>369-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olivieri-1997" MODIFIED="2013-08-05 22:52:09 +0100" MODIFIED_BY="Tracey Remmington" NAME="Olivieri 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-06-26 15:30:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ApoPharma Inc</AU>
<TI>US Food and Drug Administration. Oncologic drugs advisory committee briefing document: NDA #21-825</TI>
<SO>http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm271469.htm</SO>
<YR>Accessed 01 June 2013</YR>
<VL>Appendix A</VL>
<PG>100-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-12 14:28:24 +0100" MODIFIED_BY="Tracey Remmington" NOTES="&lt;p&gt;Availability: Guillermo Ruiz-Reyes, MD, Laboratorios Clinicos de Puebla, Blvd Diaz Ordaz, 808 Anzures, Puebla, Pue 72530, Mexico. Poster Paper No. 213&lt;/p&gt;" NOTES_MODIFIED="2012-04-12 14:28:24 +0100" NOTES_MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hackman R, Berkovitch M, Sher G, Brittenham G, Koren G, Olivieri N</AU>
<TI>Studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in patients with beta-haemoglobinopathies: The Canadian trial [abstract]</TI>
<SO>Proceedings of the 25th Congress of the International Society of Hematology; 1994 April 17-21; Cancun</SO>
<YR>1994</YR>
<PG>213</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-24 11:58:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri N and The Iron Chelation Research Group</AU>
<TI>Randomized trial of deferiprone (LI) and deferoxamine (DFO) in thalassemia major [abstract]</TI>
<SO>Blood</SO>
<YR>1996</YR>
<VL>10 Suppl 1</VL>
<PG>651a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-12 11:58:05 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri NF, Brittenham GM. Armstrong SAM, Basran RK, Daneman R, Daneman N et al</AU>
<TI>First prospective randomised trial of the iron chelators (L1) and deferoxamine [abstract]</TI>
<SO>Blood</SO>
<YR>1995</YR>
<VL>86</VL>
<NO>10 Suppl 1</NO>
<PG>249a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-05 16:04:59 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri NF, Brittenham GM</AU>
<TI>Evidence of progression of myocardial iron loading as determined by magnetic resonance imaging (MRI) in thalassaemia patients during treatment with deferiprone (L1) and deferoxamine (DFO) [abstract]</TI>
<SO>Blood</SO>
<YR>1999</YR>
<VL>94</VL>
<NO>10 Suppl 1</NO>
<PG>35b</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-12 14:30:05 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri NF, Brittenham GM</AU>
<TI>Final results of the randomised trial of deferiprone (L1) and deferoxamine (DFO) [abstract]</TI>
<SO>Blood</SO>
<YR>1997</YR>
<VL>90</VL>
<NO>10 Suppl 1</NO>
<PG>264a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-12 14:30:13 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A et al</AU>
<TI>Survival in medically treated patients with homozygous beta-thalassemia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>331</VL>
<NO>9</NO>
<PG>574-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-05 22:52:09 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pope E, Berkovitch M, Olivieri N, Koren G</AU>
<TI>First prospective randomized trial of subcutaneous deferoxamine and the orally active chelating agent L1</TI>
<SO>Proceedings of the 96th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1995 March 15-17; San Diego</SO>
<YR>1995</YR>
<VL>World Meeting Number 951 0002</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pennell-2006" MODIFIED="2012-04-12 14:31:07 +0100" MODIFIED_BY="Sheila A Worsley" NAME="Pennell 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-10-18 14:15:30 +0100" MODIFIED_BY="Sheila A Worsley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessops A et al</AU>
<TI>Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>107</VL>
<NO>9</NO>
<PG>3738-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-12 14:31:07 +0100" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith GC, Alpendurada F, Carpenter JP, Alam MH, Berdoukas V, Karagiorga M et al</AU>
<TI>Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload</TI>
<SO>Journal of Cardiovascular Magnetic Resonance</SO>
<YR>2011</YR>
<VL>13</VL>
<NO>1</NO>
<PG>34</PG>
<IDENTIFIERS MODIFIED="2012-01-31 11:42:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tamaddoni-2010" MODIFIED="2012-03-01 09:12:42 +0000" MODIFIED_BY="Sheila A Worsley" NAME="Tamaddoni 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-29 10:22:47 +0000" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tamaddoni A, Ramezani MS</AU>
<TI>Comparison between deferoxamine and combined therapy with deferoxamine and deferiprone in iron overloaded thalassemia patients</TI>
<SO>Iranian Red Crescent Medical Journal</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>6</NO>
<PG>655-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanner-2007" MODIFIED="2012-10-24 11:58:44 +0100" MODIFIED_BY="Sheila A Worsley" NAME="Tanner 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-10-24 11:58:44 +0100" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alpendurada F, Carpenter JP, Smith GC, Tanner MA, Banya W, Galanello R et al</AU>
<TI>Effect of myocardial iron removal on right ventricular function: insights from a randomized, placebo controlled, double blind trial in thalassemia major [abstract]</TI>
<SO>European Heart Journal</SO>
<YR>2010</YR>
<VL>31 Suppl 1</VL>
<PG>Abstract P451</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-12 14:33:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tanner M</AU>
<TI>The effect of combined therapy with deferoxamine and deferiprone on myocardial iron and endomethial function in thalassaemia major: a randomised controlled trial using cardiovascular magnetic resonance [abstract]</TI>
<SO>Proceedings of the European Haematology Association 11th Congress</SO>
<YR>2006</YR>
<PG>Abstract 0517</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-12 14:34:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanner MA, Galanello R, Dessi C, Agus A, Smith GC, Westwood MA et al</AU>
<TI>Improved endothelial function with combined chelation therapy in thalassaemia major [abstract]</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>108</VL>
<NO>11</NO>
<PG>Abstract 1770</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-12 14:35:09 +0100" MODIFIED_BY="Sheila A Worsley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A et al</AU>
<TI>A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance</TI>
<SO>Circulation</SO>
<YR>2007</YR>
<VL>115</VL>
<NO>14</NO>
<PG>1876-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-12 14:35:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Khan M et al</AU>
<TI>A randomized, placebo controlled double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance [abstract]</TI>
<SO>Blood</SO>
<YR>2005</YR>
<VL>106</VL>
<NO>11 Pt 1</NO>
<PG>Abstract 3655</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-08-14 13:31:08 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Agouzal-2010" MODIFIED="2012-10-24 12:08:27 +0100" MODIFIED_BY="Sheila A Worsley" NAME="Agouzal 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-10-24 12:08:27 +0100" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Agouzal M, Quyou A</AU>
<TI>Practice of iron chelation in the therapeutic center of thalassemia in Morocco [abstract]</TI>
<SO>Vox Sanguinis: 31st International Congress of the International Society of Blood Transfusion in Joint Cooperation with the 43rd Congress of the DGTI; Berlin, Germany</SO>
<YR>2010</YR>
<PG>Abstract P-0879</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-al-Refaie-1992" MODIFIED="2010-12-21 14:33:36 +0000" MODIFIED_BY="[Empty name]" NAME="al Refaie 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV</AU>
<TI>Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1</TI>
<SO>British Journal of Haematology</SO>
<YR>1992</YR>
<VL>82</VL>
<NO>2</NO>
<PG>431-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-2002" NAME="Anderson 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ</AU>
<TI>Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9332</NO>
<PG>516-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Athanassiou-2003" NAME="Athanassiou 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Athanassiou MM, Tzimouli V, Economou M, Taparkou A, Tourkantoni N, Kanakoudi TF</AU>
<TI>Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment (2)</TI>
<SO>Acta Haematologica</SO>
<YR>2003</YR>
<VL>110</VL>
<NO>4</NO>
<PG>224-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Athanassiou_x002d_Metaxa-2004" MODIFIED="2010-09-24 16:25:11 +0100" MODIFIED_BY="[Empty name]" NAME="Athanassiou-Metaxa 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-09-24 16:25:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Athanassiou-Metaxa M, Kousi A, Hatzipantelis ES, Tsatra I, Ikonomou M, Perifanis V et al</AU>
<TI>Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassaemia patients</TI>
<SO>Haematologica</SO>
<YR>2004</YR>
<VL>89</VL>
<NO>4</NO>
<PG>e55-e56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bartfay-1999" NAME="Bartfay 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bartfay WJ, Lehotay DC, Sher GD, Bartfay E, Tyler B, Luo X et al</AU>
<TI>Erythropoiesis: comparison of cytotoxic aldehyde generation in beta-thalassaemia patients chelated with deferoxamine or deferiprone (L1) versus no chelation</TI>
<SO>Haematology</SO>
<YR>1999</YR>
<VL>4</VL>
<NO>1</NO>
<PG>67-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cassinerio-2012" MODIFIED="2013-08-05 22:53:29 +0100" MODIFIED_BY="[Empty name]" NAME="Cassinerio 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-08-05 22:53:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cassinerio E, Roghi A, Pedrotti P, Brevi F, Zanaboni L, Graziadei G et al</AU>
<TI>Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients</TI>
<SO>Annals of Hematology</SO>
<YR>2012</YR>
<VL>91</VL>
<NO>9</NO>
<PG>1443-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christoforidis-2007" MODIFIED="2012-04-12 14:36:53 +0100" MODIFIED_BY="[Empty name]" NAME="Christoforidis 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-04-12 14:36:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christioforidis A, Zevgaridou E, Tsatra I, Perifanis V, Vlachaki E, Papassoitirou I et al</AU>
<TI>Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone</TI>
<SO>Journal of Paediatric Haematology and Oncology</SO>
<YR>2007</YR>
<VL>29</VL>
<NO>9</NO>
<PG>598-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1997" NAME="Cohen 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen A, Galanello R, Piga A, Vullo C</AU>
<TI>A Multi-Center Safety Trial of the Oral Iron Chelator Deferiprone</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1998</YR>
<VL>850</VL>
<PG>223-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diav_x002d_Citrin-1997" MODIFIED="2012-04-12 14:37:33 +0100" MODIFIED_BY="Tracey Remmington" NAME="Diav-Citrin 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-04-12 14:37:33 +0100" MODIFIED_BY="Tracey Remmington" NOTES="&lt;p&gt;Availability: American Society for Clinical Pharmacology and Therapeutics, 1718 Gallagher Road, Norristown, PA 19401-2800. Poster Paper&lt;/p&gt;" NOTES_MODIFIED="2012-04-12 14:37:33 +0100" NOTES_MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Diav-Citrin O, Atanackovic G, Loebstein R, Koren G</AU>
<TI>Investigation of variability in response to deferiprone (L1) inpatients with beta-thalassemia major [abstract]</TI>
<SO>Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 March 5-8; San Diego</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drakonaki-2010" MODIFIED="2011-11-29 10:27:21 +0000" MODIFIED_BY="Sheila A Worsley" NAME="Drakonaki 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-29 10:27:21 +0000" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drakonaki EE, Maris TG, Maragaki S, Klironomos V, Papadakis A, Karantanas AH</AU>
<TI>Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in beta-thalassemic patients: a quantitative magnetic resonance imaging study</TI>
<SO>Hemoglobin</SO>
<YR>2010</YR>
<VL>34</VL>
<NO>1</NO>
<PG>95-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elalfy-2006" MODIFIED="2012-04-12 14:38:01 +0100" MODIFIED_BY="[Empty name]" NAME="Elalfy 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-04-12 14:38:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elalfy MS, Abdin I</AU>
<TI>Liver status in a cohort of polytransfused b-thalasseamie major (BTM) on long term desferrioxamine (DFO) or Deferiprone (L1) [abstract]</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>108</VL>
<NO>11</NO>
<PG>Abstract 3732</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fassos-1994" MODIFIED="2010-12-23 12:18:05 +0000" MODIFIED_BY="[Empty name]" NAME="Fassos 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-12-23 12:18:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fassos FF, Klein J, Fedrnandes D, Matsui D, Olivieri N, Koren G</AU>
<TI>Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassaemia</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1994</YR>
<VL>55</VL>
<NO>1</NO>
<PG>70-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fragatou-2007" MODIFIED="2012-03-01 09:13:24 +0000" MODIFIED_BY="[Empty name]" NAME="Fragatou 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-03-01 09:13:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fragatou S, Politis C, Vandiadi K, Tsiapras D, Douskou M</AU>
<TI>Cardiac function in thalassaemics on combined deferoxamine and deferiprone therapy</TI>
<SO>Haematologica</SO>
<YR>2007</YR>
<VL>92</VL>
<PG>299, Abstract 0801</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galanello-2001" MODIFIED="2012-04-12 14:38:24 +0100" MODIFIED_BY="Tracey Remmington" NAME="Galanello 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-04-12 14:38:24 +0100" MODIFIED_BY="Tracey Remmington" NOTES="&lt;p&gt;Availability: BIOIRON 2001, P.O. Box 3496, South Brisbane, Qld. 4101, Australia; phone: 61-7-3844-1138; fax: 61-7-3844-0909; email: bioiron@icms.com.au. Poster Paper No. P78&lt;/p&gt;" NOTES_MODIFIED="2012-04-12 14:38:24 +0100" NOTES_MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Galanello R, Doneddu I, Dessi C, Defraia E, Dolci C, Leoni G et al</AU>
<TI>Iron chelation in thalassemia major: Combined treatment with deferiprone (DFP) and desferrioxamine (DFO) [abstract]</TI>
<SO>Proceedings of the BIO IRON World Congress on Iron Metabolism; 2001 August 18-23; Cairns</SO>
<YR>2001</YR>
<PG>P78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goulas-2012" MODIFIED="2013-08-14 13:31:08 +0100" MODIFIED_BY="[Empty name]" NAME="Goulas 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-08-14 13:31:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Goulas V, Kourakli-Symeonidis A, Camoutisis C</AU>
<TI>Comparative effects of three iron chelation therapies on the quality of life in Greek patients with homozygous transfusion-dependent beta-thalassemia</TI>
<SO>http://www.hindawi.com/isrn/hematology/2012/139862/cta/</SO>
<YR>(Accessed 01 August 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grady-2002" MODIFIED="2012-04-12 14:39:12 +0100" MODIFIED_BY="[Empty name]" NAME="Grady 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-04-12 14:38:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grady RW, Berdoukas V, Rachmilewitz EA, Galanello R, Borgna-Pignatti C, Ladis V</AU>
<TI>When deferiprone and desferrioxamine are combined iron excretion is enhanced [abstract]</TI>
<SO>Blood</SO>
<YR>2001</YR>
<VL>98</VL>
<NO>11 Pt 1</NO>
<PG>494a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-21 14:32:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Grady RW, Berdoukas VA, Rachmilewitz EA, Galanello R, Borgna-Pignatti C, Ladis V et al</AU>
<TI>Combinations of desferrioxamine and deferiprone markedly enhance iron excretion [abstract]</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>100</VL>
<PG>241a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-12 14:39:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grady RW, Hilgartner MW, Giardina PJ</AU>
<TI>Deferiprone: its efficacy relative to that of desferal [abstract]</TI>
<SO>Blood</SO>
<YR>1996</YR>
<VL>88</VL>
<NO>10</NO>
<PG>310a</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hershko-1996" MODIFIED="2012-10-24 11:59:03 +0100" MODIFIED_BY="Tracey Remmington" NAME="Hershko 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-10-24 11:59:03 +0100" MODIFIED_BY="Tracey Remmington" NOTES="&lt;p&gt;Availability: Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, United Kingdom, Selected abstracts available. Paper No. 570&lt;/p&gt;" NOTES_MODIFIED="2012-10-24 11:59:03 +0100" NOTES_MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hershko C, Hoffbrand A, Olivieri N, Al-Refaie F, Tondury P, Wonke B</AU>
<TI>International study group on oral iron chelators: Results of long-term deferiprone (LI) therapy [abstract]</TI>
<SO>Proceedings of the 2nd Meeting of the European Haematology Association; 1996 May 29 - Jun 1; Paris</SO>
<YR>1996</YR>
<PG>570</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kattamis-2003" MODIFIED="2010-09-24 16:34:19 +0100" MODIFIED_BY="[Empty name]" NAME="Kattamis 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-09-24 16:34:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C</AU>
<TI>Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion</TI>
<SO>Haematologica</SO>
<YR>2003</YR>
<VL>88</VL>
<NO>12</NO>
<PG>1423-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kontoghiorghes-1987" NAME="Kontoghiorghes 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T et al</AU>
<TI>Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one</TI>
<SO>British Medical Journal</SO>
<YR>1987</YR>
<VL>295</VL>
<NO>6612</NO>
<PG>1509-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lai-2010" MODIFIED="2011-11-29 10:30:22 +0000" MODIFIED_BY="Sheila A Worsley" NAME="Lai 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-29 10:30:22 +0000" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F et al</AU>
<TI>Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone</TI>
<SO>Blood Cells, Molecules and Diseases</SO>
<YR>2010</YR>
<VL>45</VL>
<NO>2</NO>
<PG>136-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loebstein-1997" NAME="Loebstein 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loebstein R, Dalal I, Nisbet-Brown E, Berkovitch M, Meydan N, Andrews D et al</AU>
<TI>Immune function in patients with beta-thalassamia receiving the orally active iron-chelating agent deferiprone</TI>
<SO>British Journal of Haematology</SO>
<YR>1997</YR>
<VL>98</VL>
<NO>3</NO>
<PG>597-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marshall-2003" NAME="Marshall 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marshall R, Tricta F, Galanello R, Leoni G, Kirkland D, Minto S et al</AU>
<TI>Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study</TI>
<SO>Mutagenesis</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>5</NO>
<PG>457-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nielsen-1995" NAME="Nielsen 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nielsen P, Fischer R, Engelhardt R, Tondury P, Gabbe EE, Janka GE</AU>
<TI>Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone</TI>
<SO>British Journal of Haematology</SO>
<YR>1995</YR>
<VL>91</VL>
<NO>4</NO>
<PG>827-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olivieiri-1993" MODIFIED="2013-08-05 22:54:42 +0100" MODIFIED_BY="[Empty name]" NAME="Olivieiri 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-08-05 22:54:42 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Availability: The American Society of Hematology, 1101 Connecticut Ave., NW, Suite 700, Washington, DC 20036, Abstracts $30.. Paper No. 1238&lt;/p&gt;" NOTES_MODIFIED="2013-08-05 22:54:42 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Olivieri N, Brittenham G, Koren G</AU>
<TI>Reduction in hepatic iron stores with the oral iron chelator L1 inpatients with transfusion-dependent thalassemia and sickle cell disease: First three years of the Canadian trial [abstract]</TI>
<SO>Proceedings of the 35th Annual Meeting and Exposition of the American Society of Hematology; 1993 December 3-7; St. Louis</SO>
<YR>1993</YR>
<PG>1238</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peng-2003" NAME="Peng 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH</AU>
<TI>Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan</TI>
<SO>European Journal of Haematology</SO>
<YR>2003</YR>
<VL>70</VL>
<NO>6</NO>
<PG>392-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peng-2006" MODIFIED="2012-10-24 11:59:35 +0100" MODIFIED_BY="[Empty name]" NAME="Peng 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-10-24 11:59:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peng CT, Wu KH, Tsai CC, Ysai CH</AU>
<TI>Deferirpone in patients with beta-thalassamiea major for 4 years in the Chinese population in Taiwan</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>2004 Suppl 1</YR>
<VL>34</VL>
<PG>20-61; Abstract 138</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-24 11:59:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Peng CT, Wu KH, Tsai CH, Yang CP, Wang LW, Jang RC et al</AU>
<TI>Study of deferiprone or deferoxamine versus combination therapy in iron-loaded thalassaemia patients in Taiwan</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>18 Suppl</VL>
<PG>Abstract 3736</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pepe-2006" NAME="Pepe 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pepe A, Lombardi M, Positano V, Cracolici E, Capra M, Malizia R et al</AU>
<TI>Evaluation of the efficacy of oral deferiprone in beta-thalassaemia major by multislice multiecho T2*</TI>
<SO>European Journal of Haematology</SO>
<YR>2006</YR>
<VL>76</VL>
<NO>3</NO>
<PG>183-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ricchi-2010" MODIFIED="2011-11-29 10:31:01 +0000" MODIFIED_BY="Sheila A Worsley" NAME="Ricchi 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-29 10:31:01 +0000" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ricchi P, Ammirabile M, Spasiano A, Costantini S, Cinque P, Di Matola T et al</AU>
<TI>Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study</TI>
<SO>European Journal of Haematology</SO>
<YR>2010</YR>
<VL>85</VL>
<NO>1</NO>
<PG>36-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-St-Pierre-2003" NAME="St Pierre 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;St Pierre TG, Fischer R, Engelhardt R, Brittenham GM, Nathan DG, Olivieri NF et al. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility [multiple letters]. Lancet 2003;361(9352):182-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>St Pierre TG</AU>
<TI>Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<NO>9352</NO>
<PG>182</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taher-2001" MODIFIED="2012-04-05 16:05:26 +0100" MODIFIED_BY="Tracey Remmington" NAME="Taher 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-04-05 16:05:26 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F</AU>
<TI>Comparison between deferoxamine and deferiprone (L1) in iron-loaded patients</TI>
<SO>European Journal of Haematology</SO>
<YR>2001</YR>
<VL>67</VL>
<NO>1</NO>
<PG>30-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanner-2008" MODIFIED="2010-10-07 13:32:42 +0100" MODIFIED_BY="[Empty name]" NAME="Tanner 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-07 13:32:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanner MA, Galanello R, Dessi C, Smirth GC, Westwood MA, Agus A et al</AU>
<TI>Combined chelation therapy in thalassaemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction</TI>
<SO>Journal of Cardiovascular Magnetic Resonance</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>1</NO>
<PG>12-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsakok-2004" MODIFIED="2012-04-12 14:41:03 +0100" MODIFIED_BY="[Empty name]" NAME="Tsakok 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-04-12 14:41:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsakok AD</AU>
<TI>Deferiprone versus deferoxamine in patients with thalassaemia major: a randomized clinical trial</TI>
<SO>Blood Cells, Molecules and Diseases</SO>
<YR>2004</YR>
<VL>32</VL>
<NO>1</NO>
<PG>139-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vlachaki-2007" MODIFIED="2012-04-12 14:41:19 +0100" MODIFIED_BY="[Empty name]" NAME="Vlachaki 2007" YEAR="2006">
<REFERENCE MODIFIED="2012-04-12 14:41:19 +0100" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vlachaki E, Ioannidou-Papagiannaki E, Haralambidou-Vranitsa SH, Perifanis V, Tsigga A, Klonizakis I et al</AU>
<TI>Progenitor haemopoietic cells in the peripheral blood of thalassemic patients with desferioxamine or deferiprone chelation therapy [abstract]</TI>
<SO>Hematology</SO>
<YR>2005</YR>
<VL>90 Suppl 2</VL>
<PG>Abstract 1065</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-29 10:32:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vlachaki E, Ioannidou-Papagiannaki E, Tziomalos K, Haralambidou-Vranitsa S, Perifanis V, Klonizakis I et al</AU>
<TI>Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy</TI>
<SO>European Journal of Haematology</SO>
<YR>2007</YR>
<VL>78</VL>
<NO>1</NO>
<PG>48-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006" MODIFIED="2010-09-24 16:13:46 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-09-24 16:13:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang CH, Wu KH, T FJ, Peng CT, T CH</AU>
<TI>Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassaemia major patients</TI>
<SO>Hemoglobin</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>2</NO>
<PG>257-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zareifar-2009" MODIFIED="2011-11-29 10:35:08 +0000" MODIFIED_BY="Sheila A Worsley" NAME="Zareifar 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-11-29 10:35:08 +0000" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zareifar S, Jabbari A, Cohan N, Haghpanah S</AU>
<TI>Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia</TI>
<SO>Archives of Iranian Medicine</SO>
<YR>2009</YR>
<VL>12</VL>
<NO>5</NO>
<PG>488-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-08-14 13:31:42 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alpendurada-2012" MODIFIED="2013-08-14 13:31:42 +0100" MODIFIED_BY="[Empty name]" NAME="Alpendurada 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-08-14 13:31:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alpendurada F, Smith GC, Carpenter JP, Nair SV, Tanner MA, Banya W et al</AU>
<TI>Effects of combined deferiprone with deferoxamine on right ventricular function in thalassemia major</TI>
<SO>Journal of Cardiovascular Magnetic Resonance</SO>
<YR>2012</YR>
<VL>14</VL>
<NO>1</NO>
<PG>8</PG>
<IDENTIFIERS MODIFIED="2013-05-16 13:08:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-16 13:08:05 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/1532-429X-14-8"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aydinok-2012" MODIFIED="2013-08-05 22:55:21 +0100" MODIFIED_BY="[Empty name]" NAME="Aydinok 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-03-12 14:31:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aydinok Y, Evans P, Manz CY, Porter JB</AU>
<TI>Probing the origin of chelatable iron during deferiprone and combination therapies: insights from plasma NTBI and LPI determinations</TI>
<SO>ASH Annual Meeting Abstracts</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>21</NO>
<PG>5158</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-05 22:55:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aydinok Y, Evans P, Manz CY, Porter JB</AU>
<TI>Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response</TI>
<SO>Haematologica</SO>
<YR>2012</YR>
<VL>97</VL>
<NO>6</NO>
<PG>835-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Badawy-2010" MODIFIED="2012-10-24 11:59:53 +0100" MODIFIED_BY="Sheila A Worsley" NAME="Badawy 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-29 10:37:09 +0000" MODIFIED_BY="Sheila A Worsley" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Badawy S, Hassan TH, Hesham MAA, Badr MA</AU>
<TI>Evaluation of iron chelation therapy in beta-thalassemic patients in Zagazig University Hospital</TI>
<SO>Pediatric Blood and Cancer; Proceedings of the 23rd Annual Meeting of the American Society of Pediatric Hematology/Oncology, ASPHO, Montreal, Canada</SO>
<YR>2010</YR>
<PG>799-800, Poster 124</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-24 11:59:53 +0100" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hassan T, Badr M, Hesham M, Badawy S</AU>
<TI>Evaluation of iron chelation therapy in beta-thalassemia major patients in East Delta of Egypt</TI>
<SO>Haematologica</SO>
<YR>2010 Suppl 2</YR>
<VL>95</VL>
<PG>701, Abstract 1810</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-2011" MODIFIED="2012-12-20 09:20:18 +0000" MODIFIED_BY="[Empty name]" NAME="Evans 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-12-20 09:20:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Evans P, Aydinok Y, Manz C, Porter J</AU>
<TI>Origin of chelatable iron during deferiprone and combination therapies: Insights from plasma NTBI and LPI</TI>
<SO>American Journal of Hematology</SO>
<YR>2011</YR>
<VL>86</VL>
<PG>9: E84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jain-2011" MODIFIED="2013-08-05 23:01:39 +0100" MODIFIED_BY="[Empty name]" NAME="Jain 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-08-05 23:01:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jain R, Perkins J, Johnson S, Harimoorthy V, Desai P, Chudgar U et al</AU>
<TI>A prospective study for determination of the mean red cell transfusion requirement compared on the basis of iron overload and type of chelation therapy in multiply transfused thalassaemia major patients</TI>
<SO>Transfusion Medicine</SO>
<YR>2011</YR>
<VL>21</VL>
<NO>1</NO>
<PG>46-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kompany-2009" MODIFIED="2013-08-08 13:29:52 +0100" MODIFIED_BY="Sheila A Worsley" NAME="Kompany 2009" YEAR="">
<REFERENCE MODIFIED="2013-08-08 13:29:52 +0100" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kompany F, Mohammadi S, Sigari N, Hadizadeh N, Rezaie N, Gharibi FSM</AU>
<TI>Comparative efficacy of deferrioxamine and combination of deferiprone and deferrioxamine on echocardiographic indices in beta thalassemic patients</TI>
<SO>Scientific Journal of Kurdistan University of Medical Sciences</SO>
<YR>2009</YR>
<VL>14</VL>
<NO>2</NO>
<PG>21-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maggio-2012" MODIFIED="2013-03-15 07:57:57 +0000" MODIFIED_BY="[Empty name]" NAME="Maggio 2012" YEAR="2011">
<REFERENCE MODIFIED="2012-12-20 09:20:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maggio A, Capra M, Cuccia L, Gagliardotto F, Rigano P, Calvaruso G et al</AU>
<TI>Long-term use of deferiprone enhances significantly the left ventricular ejection function in thalassemia major</TI>
<SO>ASH Annual Meeting Abstracts; 53rd American Society of Hematology (ASH) Annual Meeting, 10-13 December 2011, San Diego, USA</SO>
<YR>2011</YR>
<VL>118</VL>
<PG>21; Abstract 5302</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-12 14:22:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maggio A, Vitrano A, Lucania G, Capra M, Cuccia L, Gagliardotto F et al</AU>
<TI>Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalssemia major patients</TI>
<SO>American Journal of Hematology</SO>
<YR>2012</YR>
<VL>87</VL>
<NO>7</NO>
<PG>732-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mirbehbahani-2012" MODIFIED="2012-12-20 09:20:18 +0000" MODIFIED_BY="[Empty name]" NAME="Mirbehbahani 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-12-20 09:20:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mirbehbahani N, Jahazi A, Rahim AHH</AU>
<TI>The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients</TI>
<SO>Hematology</SO>
<YR>2012</YR>
<VL>17</VL>
<NO>3</NO>
<PG>183-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-N0277104959" MODIFIED="2010-12-16 15:47:20 +0000" MODIFIED_BY="[Empty name]" NAME="N0277104959" YEAR="2003">
<REFERENCE MODIFIED="2010-12-16 15:47:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wonke B</AU>
<TI>A randomised controlled prospective trial using Ferriprox versus placebo and conventional intravenous and subcutaneous iron chelation</TI>
<SO>National Research register: N0277104959</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00115349a" MODIFIED="2010-12-16 15:44:08 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00115349a" YEAR="2009">
<REFERENCE MODIFIED="2010-12-16 15:43:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>National Heart, Lung and Blood Institute (NHLBI)</AU>
<TI>Combination therapy compared with single-drug therapy in patients with cardiac diseases</TI>
<SO>ClinicalTrials.gov: NCT00115349</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pantalone-2011" MODIFIED="2012-12-20 09:20:18 +0000" MODIFIED_BY="[Empty name]" NAME="Pantalone 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-12-20 09:20:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F et al</AU>
<TI>Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: Main findings and clinical follow-up of a large multicenter randomized clinical trial in beta-thalassemia major patients</TI>
<SO>Hemoglobin</SO>
<YR>2011</YR>
<VL>35</VL>
<NO>3</NO>
<PG>206-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pepe-2013" MODIFIED="2013-08-14 13:29:34 +0100" MODIFIED_BY="Sheila A Worsley" NAME="Pepe 2013" YEAR="2010">
<REFERENCE MODIFIED="2013-08-14 13:29:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pepe A, Meloni A, Pepe P, Capra M, D'Ascola DG, Santodirocco M et al</AU>
<TI>Prospective comparison on cardiac and hepatic iron and cardiac function by MR in thalssemia major patients treated with combination deferiprone-desferrioxamine versus deferiprone and desferrioxamine in monotherapy</TI>
<SO>Blood</SO>
<YR>2011</YR>
<VL>118</VL>
<NO>21</NO>
<PG>Abstract</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-14 13:29:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Pepe A, Meloni A, Rossi G, Cuccia L, D'Ascola GD, Santodirocco M et al</AU>
<TI>Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy</TI>
<SO>http://www.jcmr-online.com/content/pdf/1532-429X-15-1.pdf</SO>
<YR>(Accessed 01 August 2013)</YR>
<IDENTIFIERS MODIFIED="2013-08-08 13:30:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-16 13:07:14 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/1532-429X-15-1"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-08 13:30:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pepe A, Meloni A, Rossi G, Ruffo GB, D'Ascola DG, Santodirocco M et al</AU>
<TI>Cardiac iron and function by CMR in thalassemia major patients treated with combined deferiprone and desferrioxamine regimen versus monotherapies: a multi-center, observational and prospective study</TI>
<SO>European Heart Journal</SO>
<YR>2012</YR>
<VL>33</VL>
<PG>805</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-08 13:31:51 +0100" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pepe A, Rossi G, Meloni A, Dell'Amico MC, Capra M, Caruso V et al</AU>
<TI>Prospective comparison on cardiac iron and liver iron by MR in thalassemia major patients treated with combination deferiprone-desferrioxamine versus deferiprone and desferrioxamine in monotherapy</TI>
<SO>ASH Annual Meeting Abstracts</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>21</NO>
<PG>5164</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-08 13:31:34 +0100" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pepe A, Rossi G, Meloni A, Dell'Amico MC, Capra M, Caruso V et al</AU>
<TI>Prospective comparison on cardiac iron and liver iron by MR in thalassemia major patients treated with combination deferiprone-desferrioxamine versus deferiprone and desferrioxamine in monotherapy</TI>
<SO>Haematologica, Proceedings of the 15th Congress of the European Hematology Association, Barcelona, Spain</SO>
<YR>2010 Suppl 2</YR>
<VL>95</VL>
<PG>696 Abstract 1797</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Unal-2009" MODIFIED="2013-08-08 13:32:04 +0100" MODIFIED_BY="Sheila A Worsley" NAME="Unal 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-08-08 13:32:04 +0100" MODIFIED_BY="Sheila A Worsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Unal S, Hazirolan T, Beton B, Karabulut E, Gumruk F</AU>
<TI>The cardiac effects of desferrioxamine deferiprone combination therapy and desferrioxamine monotherapy in thalassemic patients</TI>
<SO>Haematologica</SO>
<YR>2009 Suppl 2</YR>
<VL>94</VL>
<PG>514-5, Abstract 1295</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2013-03-15 10:30:26 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-EU_x005f_2009_x002d_014666_x002d_25" MODIFIED="2013-03-15 10:30:26 +0000" MODIFIED_BY="[Empty name]" NAME="EU_2009-014666-25" YEAR="">
<REFERENCE MODIFIED="2013-03-15 10:30:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Fondazione Franco e Piera Cutino (Sponsors)</AU>
<TI>Sequential deferasirox-deferiprone versus deferasirox or deferiprone multicentre randomized trial</TI>
<SO>EU Clinical Trials Register: 2009-014666-25</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IRCT201110087677N1" MODIFIED="2013-03-15 10:29:55 +0000" MODIFIED_BY="[Empty name]" NAME="IRCT201110087677N1" YEAR="">
<REFERENCE MODIFIED="2013-03-15 10:29:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Akramipoor R</AU>
<TI>The comparative study of incidence of lens opacity between Osfereal and Deferoxamine in major thalassemia</TI>
<SO>Iranian Registry of Clinical Trials: IRCT20110087677N1</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01511848" MODIFIED="2012-12-20 09:20:59 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01511848" YEAR="1848">
<REFERENCE MODIFIED="2012-12-20 09:20:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mohsen Saleh Elalfy; Ain Shams University</AU>
<TI>Study of efficacy, safety of combined deferasirox and deferiprone versus combined deferiprone and desferal in conditions of iron overload</TI>
<SO>ClinicalTrials.gov: NCT01511848</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-08-22 10:25:19 +0100" MODIFIED_BY="Sheila A Worsley">
<ADDITIONAL_REFERENCES MODIFIED="2013-08-22 10:25:19 +0100" MODIFIED_BY="Sheila A Worsley">
<REFERENCE ID="REF-Abetz-2006" MODIFIED="2012-01-31 11:38:09 +0000" MODIFIED_BY="[Empty name]" NAME="Abetz 2006" TYPE="JOURNAL_ARTICLE">
<AU>Abetz L, Baladi JF, Jones P, Rofail D</AU>
<TI>The impact of iron overload and its treatment on quality of life: results from a literature review</TI>
<SO>Health and Quality of Life Outcomes</SO>
<YR>2006</YR>
<VL>4</VL>
<PG>73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Agarwal-1992" MODIFIED="2012-10-24 12:01:59 +0100" MODIFIED_BY="Tracey Remmington" NAME="Agarwal 1992" TYPE="JOURNAL_ARTICLE">
<AU>Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N et al</AU>
<TI>Long term assessment of efficacy and safety of L1, an oral iron chelator in transfusion-dependent thalassaemia: Indian trial</TI>
<SO>British Journal of Haematology</SO>
<YR>1992</YR>
<VL>82</VL>
<NO>2</NO>
<PG>460-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aldouri-1990" MODIFIED="2012-10-24 12:02:03 +0100" MODIFIED_BY="Tracey Remmington" NAME="Aldouri 1990" TYPE="JOURNAL_ARTICLE">
<AU>Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE et al</AU>
<TI>High incidence of cardiomyopathy in beta-thalassaemia patients receiving transfusion and iron chelation: reversal by intensified chelation</TI>
<SO>Acta Haematologica</SO>
<YR>1990</YR>
<VL>84</VL>
<NO>3</NO>
<PG>113-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Angelucci-2008" MODIFIED="2012-01-27 11:01:08 +0000" MODIFIED_BY="[Empty name]" NAME="Angelucci 2008" TYPE="JOURNAL_ARTICLE">
<AU>Angelucci E, Barosi G, Camaschella C, Cappellini MD, Cazzola M, Galanello R et al</AU>
<TI>Practice guidelines for the management of iron overload in thalassemia major and related disorders</TI>
<SO>Haematologica</SO>
<YR>2008</YR>
<VL>93</VL>
<NO>5</NO>
<PG>741-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bacon-1983" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Bacon 1983" TYPE="JOURNAL_ARTICLE">
<AU>Bacon BR, Tavil AS, Brittenham GM, Park CH, Recknagel RO</AU>
<TI>Hepatic lipid peroxidation in vivo in rats with chronic iron overload</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1983</YR>
<VL>71</VL>
<NO>3</NO>
<PG>429-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berdoukas-2000" MODIFIED="2012-10-24 12:02:11 +0100" MODIFIED_BY="Tracey Remmington" NAME="Berdoukas 2000" TYPE="JOURNAL_ARTICLE">
<AU>Berdoukas V, Bohane T, Eagle C, Lindeman R, DeSilva K, Tobias V et al</AU>
<TI>The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1)</TI>
<SO>Transfusion Science</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>3</NO>
<PG>239-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borgna_x002d_Pignatti-1998" MODIFIED="2012-10-24 12:02:16 +0100" MODIFIED_BY="Tracey Remmington" NAME="Borgna-Pignatti 1998" TYPE="JOURNAL_ARTICLE">
<AU>Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR et al</AU>
<TI>Survival and disease complications in thalassemia major</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1998</YR>
<VL>850</VL>
<PG>227-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borgna_x002d_Pignatti-2004" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Borgna-Pignatti 2004" TYPE="JOURNAL_ARTICLE">
<AU>Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC et al</AU>
<TI>Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine</TI>
<SO>Haematologica</SO>
<YR>2004</YR>
<VL>89</VL>
<NO>10</NO>
<PG>1187-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brittenham-1994" MODIFIED="2012-10-24 12:02:23 +0100" MODIFIED_BY="Tracey Remmington" NAME="Brittenham 1994" TYPE="JOURNAL_ARTICLE">
<AU>Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE et al</AU>
<TI>Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>331</VL>
<NO>9</NO>
<PG>567-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brittenham-2003" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Brittenham 2003" TYPE="JOURNAL_ARTICLE">
<AU>Brittenham GM, Nathan DG, Olivieri NF, Porter JB, Pippard M, Vichinsky EP et al</AU>
<TI>Deferiprone and hepatic fibrosis</TI>
<SO>Blood</SO>
<YR>2003</YR>
<VL>101</VL>
<NO>12</NO>
<PG>5089-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caro-2002" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Caro 2002" TYPE="OTHER">
<AU>Caro JJ, Huybrechts KF, Green TC</AU>
<TI>Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassaemia major: a systematic review</TI>
<SO>http://www.biomedcentral.com/1471-2326/2/4</SO>
<YR>2002 (accessed 21 May 2007)</YR>
<VL>2</VL>
<NO>4</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ceci-2002" MODIFIED="2012-10-24 12:02:32 +0100" MODIFIED_BY="Tracey Remmington" NAME="Ceci 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ceci A, Felisi M, Catapano M, Baiardi P, Cipollina L, Ravera S et al</AU>
<TI>The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients</TI>
<SO>British Journal of Haematology</SO>
<YR>2002</YR>
<VL>118</VL>
<NO>1</NO>
<PG>330-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-2003" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Cohen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Cohen AR, Galanello R, Piga A, DeSanctis V, Tricta F</AU>
<TI>Safety and effectiveness of long term therapy with the oral iron chelator deferiprone profile of the oral iron chelator: a multicentre study</TI>
<SO>Blood</SO>
<YR>2003</YR>
<VL>102</VL>
<NO>5</NO>
<PG>1583-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davies-1983" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Davies 1983" TYPE="JOURNAL_ARTICLE">
<AU>Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER</AU>
<TI>Ocular toxicity of high-dose intravenous desferrioxamine</TI>
<SO>Lancet</SO>
<YR>1983</YR>
<VL>23</VL>
<NO>2</NO>
<PG>181-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2013-08-07 13:05:11 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks J, Higgins J, Altman D</AU>
<TI>Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Del-Vecchio-2000" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Del Vecchio 2000" TYPE="JOURNAL_ARTICLE">
<AU>Del Vecchio GC, Crollo E, Schettini F, Fischer R, De Mattia D</AU>
<TI>Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting</TI>
<SO>Acta Haematologica</SO>
<YR>2000</YR>
<VL>104</VL>
<NO>2-3</NO>
<PG>99-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ehlers-1991" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Ehlers 1991" TYPE="JOURNAL_ARTICLE">
<AU>Ehlers KH, Giardina PJ, Leser ML, Engle MA, Hilgartner MW</AU>
<TI>Prolonged survival in patients with beta-thalassemia major treated with desferrioxamine</TI>
<SO>Journal of Paediatrics</SO>
<YR>1991</YR>
<VL>118</VL>
<NO>4 Pt 1</NO>
<PG>540-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analysis involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Evangeli-2010" MODIFIED="2012-01-27 10:59:20 +0000" MODIFIED_BY="[Empty name]" NAME="Evangeli 2010" TYPE="JOURNAL_ARTICLE">
<AU>Evangeli M, Mughal K, Porter JB</AU>
<TI>Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review</TI>
<SO>Hemoglobin</SO>
<YR>2010</YR>
<VL>34</VL>
<NO>3</NO>
<PG>305-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fischer-2003" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Fischer 2003" TYPE="JOURNAL_ARTICLE">
<AU>Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A</AU>
<TI>Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with thalassaemia major: applicability of SQUID biomagnetic liver susceptometry</TI>
<SO>British Journal of Haematology</SO>
<YR>2003</YR>
<VL>121</VL>
<NO>6</NO>
<PG>938-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fisher--2013" MODIFIED="2013-08-22 10:25:19 +0100" MODIFIED_BY="Tracey Remmington" NAME="Fisher  2013" TYPE="COCHRANE_REVIEW">
<AU>Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ</AU>
<TI>Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>8</NO>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS MODIFIED="2013-08-22 10:25:19 +0100" MODIFIED_BY="Tracey Remmington">
<IDENTIFIER MODIFIED="2013-08-22 10:25:19 +0100" MODIFIED_BY="Tracey Remmington" TYPE="DOI" VALUE="10.1002/14651858.CD004450.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gabutti-1996" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Gabutti 1996" TYPE="JOURNAL_ARTICLE">
<AU>Gabutti V, Piga A</AU>
<TI>Results of long-term iron-chelating therapy</TI>
<SO>Acta Haematologica</SO>
<YR>1996</YR>
<VL>95</VL>
<NO>1</NO>
<PG>26-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gallant-1986" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Gallant 1986" TYPE="JOURNAL_ARTICLE">
<AU>Gallant T, Freedman MH, Vellend H, Francombe WH</AU>
<TI>Yersinia sepsis in patients with iron overload treated with deferoxamine</TI>
<SO>New England Journal of Medicine</SO>
<YR>1986</YR>
<VL>314</VL>
<NO>25</NO>
<PG>1643</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henter-2007" MODIFIED="2008-09-10 16:04:48 +0100" MODIFIED_BY="Tracey Remmington" NAME="Henter 2007" TYPE="JOURNAL_ARTICLE">
<AU>Henter JI, Karlen J</AU>
<TI>Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia</TI>
<SO>Blood</SO>
<YR>2007</YR>
<VL>109</VL>
<NO>12</NO>
<PG>5157-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hider-1984" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Hider 1984" TYPE="CORRESPONDENCE">
<AU>Hider RC, Kontoghiorghes G, Silver J, Stockham MA</AU>
<TI>Pharmaceutically active hydroxypyridones</TI>
<SO>GB patent 21-46989</SO>
<YR>1984</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2013-08-08 13:32:54 +0100" MODIFIED_BY="Sheila A Worsley" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT and Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2013-08-08 13:33:28 +0100" MODIFIED_BY="Sheila A Worsley" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-08-07 13:05:32 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<PB>Wiley - Blackwell</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoffbrand-1998" MODIFIED="2012-10-24 12:02:58 +0100" MODIFIED_BY="Tracey Remmington" NAME="Hoffbrand 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hoffbrand AV, Al-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J et al</AU>
<TI>Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients</TI>
<SO>Blood</SO>
<YR>1998</YR>
<VL>91</VL>
<NO>1</NO>
<PG>295-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kontoghiorghes-1990" MODIFIED="2012-10-24 12:03:08 +0100" MODIFIED_BY="Tracey Remmington" NAME="Kontoghiorghes 1990" TYPE="JOURNAL_ARTICLE">
<AU>Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J et al</AU>
<TI>Long term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-1 (L1), I: iron chelation and metabolic studies</TI>
<SO>British Journal of Haematology</SO>
<YR>1990</YR>
<VL>76</VL>
<NO>2</NO>
<PG>295-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kontzogolou-1996" MODIFIED="2012-10-24 12:03:13 +0100" MODIFIED_BY="Tracey Remmington" NAME="Kontzogolou 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kontzoglou G, Koussi A, Tsatra J, Noussios G, Vital V, Sagarakis G et al</AU>
<TI>Sensorineural hearing loss in children with thalassemia major in Northern Greece</TI>
<SO>International Journal of Pediatric Otorhinolaryngology</SO>
<YR>1996</YR>
<VL>35</VL>
<NO>3</NO>
<PG>223-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kushner-2001" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Kushner 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kushner JP, Porter JP, Olivieri NF</AU>
<TI>Secondary iron overload</TI>
<SO>Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program</SO>
<YR>2001</YR>
<VL>1</VL>
<PG>47-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lucas-2002" MODIFIED="2012-10-24 12:03:25 +0100" MODIFIED_BY="Tracey Remmington" NAME="Lucas 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lucas GN, Perera BJ, Fonseka EA, Silva DD, Fernandopulle M, Karunatilaka DH et al</AU>
<TI>Experience with the oral iron chelator deferiprone in transfusion-dependent children</TI>
<SO>Ceylon Medical Journal</SO>
<YR>2002</YR>
<VL>47</VL>
<NO>4</NO>
<PG>119-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maggio-2007" MODIFIED="2012-03-20 12:44:28 +0000" MODIFIED_BY="[Empty name]" NAME="Maggio 2007" TYPE="JOURNAL_ARTICLE">
<AU>Maggio A</AU>
<TI>Light and shadows in the iron chelation treatment of haematological diseases</TI>
<SO>British Journal of Haematology</SO>
<YR>2007</YR>
<VL>138</VL>
<NO>4</NO>
<PG>407-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maggio-2011" MODIFIED="2012-01-27 11:54:19 +0000" MODIFIED_BY="[Empty name]" NAME="Maggio 2011" TYPE="JOURNAL_ARTICLE">
<AU>Maggio A, Filosa A, Vitrano A, Aloj G, Kattamis A, Ceci A et al</AU>
<TI>Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials</TI>
<SO>Blood Cells, Molecules and Diseases</SO>
<YR>2011</YR>
<VL>47</VL>
<NO>3</NO>
<PG>166-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mamtani-2008" MODIFIED="2012-01-27 11:03:29 +0000" MODIFIED_BY="[Empty name]" NAME="Mamtani 2008" TYPE="JOURNAL_ARTICLE">
<AU>Mamtani M, Kulkarni H</AU>
<TI>Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: systematic review and meta-analysis</TI>
<SO>British Journal of Haematology</SO>
<YR>2008</YR>
<VL>141</VL>
<NO>6</NO>
<PG>882-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mazza-1998" MODIFIED="2012-10-24 12:03:37 +0100" MODIFIED_BY="Tracey Remmington" NAME="Mazza 1998" TYPE="JOURNAL_ARTICLE">
<AU>Mazza P, Amurri B, Lazzari G, Masi C, Palazzo G, Spartera MA et al</AU>
<TI>Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia</TI>
<SO>Haematologica</SO>
<YR>1998</YR>
<VL>83</VL>
<NO>6</NO>
<PG>496-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Modell-2000" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Modell 2000" TYPE="JOURNAL_ARTICLE">
<AU>Modell B, Khan M, Darlison M</AU>
<TI>Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<NO>9220</NO>
<PG>2051-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nathan-2002" MODIFIED="2008-09-10 16:04:48 +0100" MODIFIED_BY="Tracey Remmington" NAME="Nathan 2002" TYPE="JOURNAL_ARTICLE">
<AU>Nathan DG, Weatherall DJ</AU>
<TI>Academic freedom in clinical research</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>347</VL>
<NO>17</NO>
<PG>1368-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neufeld-2006" MODIFIED="2008-09-10 16:04:48 +0100" MODIFIED_BY="Tracey Remmington" NAME="Neufeld 2006" TYPE="JOURNAL_ARTICLE">
<AU>Neufeld EJ</AU>
<TI>Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>107</VL>
<NO>9</NO>
<PG>3436-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olivieri-1986" MODIFIED="2012-10-24 12:03:46 +0100" MODIFIED_BY="Tracey Remmington" NAME="Olivieri 1986" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri NF, Buncic R, Chew E, Gallant T, Harrison RV, Keenan N et al</AU>
<TI>Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions</TI>
<SO>New England Journal of Medicine</SO>
<YR>1986</YR>
<VL>314</VL>
<NO>14</NO>
<PG>869-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olivieri-1992" MODIFIED="2012-10-24 12:00:53 +0100" MODIFIED_BY="Tracey Remmington" NAME="Olivieri 1992" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri NF, Koren G, Matsui D, Liu PP, Blendis L, Cameron R et al</AU>
<TI>Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia</TI>
<SO>Blood</SO>
<YR>1992</YR>
<VL>79</VL>
<NO>10</NO>
<PG>2741-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olivieri-1994" MODIFIED="2012-10-24 12:03:52 +0100" MODIFIED_BY="Tracey Remmington" NAME="Olivieri 1994" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A et al</AU>
<TI>Survival in medically treated patients with homozygous beta-thalassemia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>331</VL>
<NO>9</NO>
<PG>574-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olivieri-1995a" MODIFIED="2012-10-24 12:03:56 +0100" MODIFIED_BY="Tracey Remmington" NAME="Olivieri 1995a" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri NF, Brittenham GM, Armstrong SAM, Barsran RK, Daneman R, Daneman N et al</AU>
<TI>First prospective randomized trial of the iron chelators deferiprone and deferoxamine [abstract]</TI>
<SO>Blood</SO>
<YR>1995</YR>
<VL>86 Suppl 1</VL>
<PG>249a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olivieri-1995b" MODIFIED="2012-10-24 12:04:00 +0100" MODIFIED_BY="Tracey Remmington" NAME="Olivieri 1995b" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG et al</AU>
<TI>Iron-chelation therapy with oral deferiprone in patients with thalassemia major</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>332</VL>
<NO>14</NO>
<PG>918-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olivieri-1997a" MODIFIED="2012-10-24 12:01:03 +0100" MODIFIED_BY="Tracey Remmington" NAME="Olivieri 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri NF, Brittenham GM</AU>
<TI>Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO) [abstract]</TI>
<SO>Blood</SO>
<YR>1997</YR>
<VL>90 Suppl 1</VL>
<PG>264a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olivieri-1997b" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Olivieri 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri NF, Brittenham GM</AU>
<TI>Iron-chelating therapy and the treatment of thalassemia</TI>
<SO>Blood</SO>
<YR>1997</YR>
<VL>89</VL>
<NO>3</NO>
<PG>739-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olivieri-1998" MODIFIED="2012-10-24 12:04:12 +0100" MODIFIED_BY="Tracey Remmington" NAME="Olivieri 1998" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri N, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA et al</AU>
<TI>Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<NO>7</NO>
<PG>417-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olivieri-1999" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Olivieri 1999" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri NF</AU>
<TI>The beta-thalassemias</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>2</NO>
<PG>99-109</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pati-1999" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Pati 1999" TYPE="JOURNAL_ARTICLE">
<AU>Pati HP, Choudry VP</AU>
<TI>Deferiprone (L1) associated neutropenia in beta thalassaemia major: an Indian experience</TI>
<SO>European Journal of Haematology</SO>
<YR>1999</YR>
<VL>63</VL>
<NO>4</NO>
<PG>267-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Piga-1988" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Piga 1988" TYPE="JOURNAL_ARTICLE">
<AU>Piga A, Luzzatto L, Capalbo P, Gambotto S, Tricta F, Gabutti V</AU>
<TI>High dose desferrioxamine as a cause of growth failure in thalassaemic patients</TI>
<SO>European Journal of Haematology</SO>
<YR>1988</YR>
<VL>40</VL>
<NO>4</NO>
<PG>380-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pippard-1978" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Pippard 1978" TYPE="JOURNAL_ARTICLE">
<AU>Pippard MJ, Letsky EA, Callender ST, Weatherall DJ</AU>
<TI>Prevention of iron loading in transfusion-dependent thalassaemia</TI>
<SO>Lancet</SO>
<YR>1978</YR>
<VL>1</VL>
<NO>8075</NO>
<PG>1178-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Porter-1989a" MODIFIED="2008-09-10 16:04:48 +0100" MODIFIED_BY="Tracey Remmington" NAME="Porter 1989a" TYPE="JOURNAL_ARTICLE">
<AU>Porter J, Huehns E</AU>
<TI>The toxic effects of desferrioxamine</TI>
<SO>Balliere's Clinical Haematology</SO>
<YR>1989</YR>
<VL>2</VL>
<NO>2</NO>
<PG>459-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Porter-1989b" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Porter 1989b" TYPE="JOURNAL_ARTICLE">
<AU>Porter JB, Jawson MS, Huehns ER, East CA, Hazell JWP</AU>
<TI>Desferrioxamine ototoxicity: evaluation of risk factors in thalassamic patients and guidelines for safe dosage</TI>
<SO>British Journal of Haematology</SO>
<YR>1989</YR>
<VL>73</VL>
<NO>3</NO>
<PG>403-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Porter-2002" MODIFIED="2008-09-10 16:04:48 +0100" MODIFIED_BY="Tracey Remmington" NAME="Porter 2002" TYPE="JOURNAL_ARTICLE">
<AU>Porter J, Davis BA</AU>
<TI>Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia</TI>
<SO>Best Practice Research in Clinical Haematology</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>2</NO>
<PG>329-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Propper-1976" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Propper 1976" TYPE="JOURNAL_ARTICLE">
<AU>Propper RD, Shurin SB, Nathan DG</AU>
<TI>Reassessment of the use of desferrioxamine B in iron overload</TI>
<SO>New England Journal of Medicine</SO>
<YR>1976</YR>
<VL>294</VL>
<NO>26</NO>
<PG>1421-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Propper-1977" MODIFIED="2012-10-24 12:01:32 +0100" MODIFIED_BY="Tracey Remmington" NAME="Propper 1977" TYPE="JOURNAL_ARTICLE">
<AU>Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF et al</AU>
<TI>Continuous subcutaneous administration of deferoxamine in patients with iron overload</TI>
<SO>New England Journal of Medicine</SO>
<YR>1977</YR>
<VL>297</VL>
<NO>8</NO>
<PG>418-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-2011" MODIFIED="2012-02-29 09:43:11 +0000" MODIFIED_BY="[Empty name]" NAME="Review Manager 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Richardson-1993" MODIFIED="2012-10-24 12:01:13 +0100" MODIFIED_BY="Tracey Remmington" NAME="Richardson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Richardson ME, Matthews RN, Alison JF, Menahem S, Mitvalsky J, Byrt E et al</AU>
<TI>Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major</TI>
<SO>Australian and New Zealand Journal of Medicine</SO>
<YR>1993</YR>
<VL>23</VL>
<NO>6</NO>
<PG>656-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rombos-2000" MODIFIED="2012-10-24 12:04:36 +0100" MODIFIED_BY="Tracey Remmington" NAME="Rombos 2000" TYPE="JOURNAL_ARTICLE">
<AU>Rombos Y, Tzanetea R, Konstantopoulos K, Simitizis S, Zervas C, Kyriaki P et al</AU>
<TI>Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1)</TI>
<SO>Haematologica</SO>
<YR>2000</YR>
<VL>85</VL>
<NO>2</NO>
<PG>115-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Swedish-Orphan-Drug-2007" MODIFIED="2012-10-24 12:04:44 +0100" MODIFIED_BY="Tracey Remmington" NAME="Swedish Orphan Drug 2007" TYPE="OTHER">
<AU>Swedish Orphan Drug International AB</AU>
<TI>Ferriprox (Deferiprone) Summary of Product Charcteristics</TI>
<SO>www. Swedishorphan.com</SO>
<YR>(accessed 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tondury-1990" MODIFIED="2012-10-24 12:05:04 +0100" MODIFIED_BY="Tracey Remmington" NAME="Tondury 1990" TYPE="JOURNAL_ARTICLE">
<AU>Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A, Hirt A, Hoffbrand AV, Lottenbach AM et al</AU>
<TI>L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major</TI>
<SO>British Journal of Haematology</SO>
<YR>1990</YR>
<VL>76</VL>
<NO>4</NO>
<PG>550-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tondury-1998" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Tondury 1998" TYPE="JOURNAL_ARTICLE">
<AU>Tondury P, Zimmermann A, Nielsen P, Hirt A</AU>
<TI>Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients</TI>
<SO>British Journal of Haematology</SO>
<YR>1998</YR>
<VL>101</VL>
<NO>3</NO>
<PG>413-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Viens-2004" MODIFIED="2008-09-10 16:04:48 +0100" MODIFIED_BY="Tracey Remmington" NAME="Viens 2004" TYPE="JOURNAL_ARTICLE">
<AU>Viens AM, Savulescu J</AU>
<TI>Introduction to the Olivieri symposium</TI>
<SO>Journal of Medical Ethics</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wanless-2002" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Wanless 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R et al</AU>
<TI>Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>100</VL>
<NO>5</NO>
<PG>1566-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weatherall-2002" MODIFIED="2008-09-10 16:04:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Weatherall 2002" TYPE="BOOK">
<AU>Weatherall DJ, Clegg JB</AU>
<SO>The Thalassaemia Syndromes</SO>
<YR>2002</YR>
<EN>4th</EN>
<PB>Blackwell Science</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolfe-1985" MODIFIED="2012-10-24 12:01:20 +0100" MODIFIED_BY="Tracey Remmington" NAME="Wolfe 1985" TYPE="JOURNAL_ARTICLE">
<AU>Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R et al</AU>
<TI>Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major</TI>
<SO>New England Journal of Medicine</SO>
<YR>1985</YR>
<VL>312</VL>
<NO>25</NO>
<PG>1600-3</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-08-08 12:59:55 +0100" MODIFIED_BY="Sheila A Worsley">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-08-08 12:36:35 +0100" MODIFIED_BY="Sheila A Worsley" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-08-08 12:15:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abdelrazik-2007">
<CHAR_METHODS MODIFIED="2013-08-05 20:34:33 +0100" MODIFIED_BY="[Empty name]">
<P>2-arm parallel randomised controlled trial.<BR/>Number of centres: 1.<BR/>Duration of treatment:12 months.<BR/>Follow up: not stated.<BR/>
<BR/>
</P>
<P>Number (N) of participants:<BR/>
<U>N randomised:</U> 60 (30 to each arm).<BR/>
<U>N analysed:</U> 60 (30 to each arm).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-08 12:15:36 +0100" MODIFIED_BY="[Empty name]">
<P>Children with thalassaemia.<BR/>Age: treatment group: mean (SD) 12 (5.1) years; comparator group: mean (SD) 14 (2.1) years.<BR/>Sex: treatment group: 60% male; comparator group: 50% male.<BR/>Ethnicity: not stated.<BR/>Trial undertaken: outpatient clinic of a children's hospital in Egypt.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:15:55 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: deferiprone: 75 mg/kg/day for 4 days/week taken 1 hour before meals with DFO: 40 mg/kg/day subcutaneously for 8 - 10 hours on 2 days/week; (DFO mean (SD) dose at baseline: 37 (4.5) &amp; end of trial: 37.9 (7.8) mg/kg/day].<BR/>
<BR/>Comparator group: DFO 40 mg/kg/day subcutaneously for 8 - 10 hours on 5 - 7 days/week (mean (SD) dose at baseline: 35.5 (7.5) &amp; end of trial: 34.4 (6.5) mg/kg/day).</P>
<P>
<BR/>All participants had 1 day off chelation therapy at the weekend.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-05 20:37:35 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>"Efficacy" (primary outcome)</LI>
<LI>Compliance</LI>
<LI>Safety</LI>
<LI>Serum ferritin</LI>
<LI>Total iron binding capacity and ferritin concentrations</LI>
<LI>Urinary iron excretion</LI>
<LI>Liver &amp; renal function</LI>
<LI>Cardiac assessment (LVEF &amp; shortening function)</LI>
<LI>Iron balance</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 20:44:01 +0100" MODIFIED_BY="[Empty name]">
<P>Prior exposure to iron chelators: DFO at a daily dose of 40 mg/kg/day by subcutaneous infusion pump over 8 - 10 hours, 5 - 7 nights a week for "several years".<BR/>Source of funding: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-05 21:09:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aydinok-2005">
<CHAR_METHODS MODIFIED="2013-08-05 20:41:52 +0100" MODIFIED_BY="[Empty name]">
<P>3-arm parallel RCT.<BR/>Number of centres: not stated, but assumed 2.<BR/>Duration of treatment: not stated.<BR/>Follow up: not stated.<BR/>
<BR/>
</P>
<P>Number (N) of participants:<BR/>
<U>N randomised</U>: 25 (treatment group: 12; comparator group 1: 5; comparator group 2: 8).<BR/>
<U>N analysed</U>: 25 (treatment group: 12; comparator group 1: 5; comparator group 2: 8).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-22 13:26:56 +0100" MODIFIED_BY="Tracey Remmington">
<P>Thalassaemia participants.<BR/>Age: not stated.<BR/>Sex: not stated.<BR/>Ethnicity: not stated.<BR/>Trial undertaken: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-05 21:09:30 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: deferiprone: 75 mg/kg/day orally, 7 days a week.<BR/>
<BR/>
</P>
<P>Comparator group 1: deferiprone: 75 mg/kg/day and DFO 40 - 50 mg/kg/day as a subcutaneous infusion, 2 days a week.<BR/>
<BR/>
</P>
<P>Comparator group 2: DFO by subcutaneous injection, 40 - 50 mg/kg/day over 5 days/week.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-05 20:45:45 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Measures of iron overload: liver iron concentration; total iron excretion; chelation efficiency (%); average urinary iron excretion; plasma NTBI</LI>
</OL>
<P>Primary outcome: not identified.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 20:42:53 +0100" MODIFIED_BY="[Empty name]">
<P>Prior exposure to iron chelators: all participants had previously received DFO.<BR/>Source of funding: not stated.<BR/>Abstract publication.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-08 12:18:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aydinok-2007">
<CHAR_METHODS MODIFIED="2013-08-05 20:47:25 +0100" MODIFIED_BY="[Empty name]">
<P>2-arm parallel RCT.<BR/>Number of centres: 1<BR/>Duration of treatment: 12 months.<BR/>Follow up: not stated.<BR/>
<BR/>
</P>
<P>Number (N) of participants:<BR/>
<U>N randomised</U>: 24 (12 to each arm).<BR/>
<U>N analysed</U>: 20 (treatment group: 12; comparator group: 8). Trial reported details of why data from 4 participants were not analysed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-05 20:49:54 +0100" MODIFIED_BY="[Empty name]">
<P>Participants aged 4 years or older with thalassaemia major.<BR/>Age: treatment group: mean (SD) 15.9 (4.2) years; comparator group: mean (SD) 16.6 (4.8) years. Age range for both: 9 - 23 years.<BR/>Sex: not stated.<BR/>Ethnicity: not stated.<BR/>Trial undertaken: Turkey.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:18:16 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment arm: deferiprone: 75 mg/kg/day, daily (mean (SD) dose: 78.2 (2.6) mg/kg/day).<BR/>
<BR/>Comparator group: deferiprone: 75 mg/kg/day, daily (mean (SD) dose: 78.2 (1.4) mg/kg/day) with DFO 50 mg/kg/day subcutaneously twice weekly (mean (SD) dose: 43.8 (2.8) mg/kg).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-05 20:48:14 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Changes in liver iron concentration and serum ferritin (primary)</LI>
<LI>Total iron excretion</LI>
<LI>Urinary iron excretion</LI>
<LI>Iron balance</LI>
<LI>Cardiac function (Echo)</LI>
<LI>Toxicity</LI>
<LI>Assessment of tolerance to treatment and quality of life</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 20:48:03 +0100" MODIFIED_BY="[Empty name]">
<P>All participants had had prior exposure to DFO (dose, schedule and duration were not reported) and all had a washout period of 2 weeks with no iron chelation before initiating trial treatment.<BR/>Source of funding: none stated although the drugs were supplied by Lipomed AG, Switzerland.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-08 12:18:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Choudhry-2004">
<CHAR_METHODS MODIFIED="2013-08-08 12:18:58 +0100" MODIFIED_BY="[Empty name]">
<P>3-arm parallel RCT.<BR/>Number of centres: 1<BR/>Duration of treatment: 12 months.<BR/>Follow up: not stated.<BR/>
<BR/>
</P>
<P>Number (N) of participants:<BR/>
<U>N randomised</U>: 75 (treatment group: 30; comparator group 1: 21; comparator group 2: 24).<BR/>
<U>N analysed:</U> 75 (treatment group: 30; comparator group 1: 21; comparator group 2: 24) for all outcomes except mortality where the number analysed was deferiprone: 48 (details of the 'missing' 3 were reported); comparator group 2: 24</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-05 20:52:59 +0100" MODIFIED_BY="[Empty name]">
<P>Paediatirc participants with thalassaemia major.<BR/>Age range for both: 4 - 14 years.<BR/>Sex: 55% male participants across the whole trial.<BR/>Ethnicity: not stated.<BR/>Trial undertaken: India</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-05 20:53:23 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment arm: deferiprone: 50 mg/kg/day, daily.<BR/>
<BR/>Comparator group 1: deferiprone: 75 mg/kg/day, daily.<BR/>
<BR/>
</P>
<P>Comparator group 2: control: no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-22 10:33:37 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Ferritin</LI>
<LI>Leucopenia/agranulocytosis</LI>
<LI>Arthropathy</LI>
</OL>
<P>Primary outcome: not identified.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 20:52:43 +0100" MODIFIED_BY="[Empty name]">
<P>No participant had received iron chelation therapy before trial enrolment.<BR/>Source of funding: trial supported by CIPLA Ltd, makers of deferiprone.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-08 12:20:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-El_x002d_Beshlawy-2008">
<CHAR_METHODS MODIFIED="2013-08-05 20:55:48 +0100" MODIFIED_BY="[Empty name]">
<P>3-arm parallel RCT.<BR/>Number of centres: 1.<BR/>Duration of treatment: 54 weeks.<BR/>Follow up: not stated.<BR/>
<BR/>
</P>
<P>Number (N) of participants:<BR/>
<U>N randomised</U>: 66 (treatment group: 21; comparator group 1: 22; comparator group 2: 23).<BR/>
<U>N analysed</U>: variable across outcomes. Minimum and maximum numbers analysed were: treatment: 16 - 22; comparator group 1: 17 - 21; comparator group 2: 15 - 23). Trial reported details of why data from 4 participants in the treatment group, 3 in comparator group 1 and 3 in comparator group 2 were withdrawn from treatment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-08 12:20:06 +0100" MODIFIED_BY="[Empty name]">
<P>Transfusion-dependent participants aged 4 years and older with thalassaemia major.<BR/>Age: treatment group: mean (SD) 11 (4.9) years (data only given for 20/23 participants); comparator group 1: mean (SD) 10.8 (5.1) years (data only given for 18/21); comparator group 2: 13.1 (5.9) years (data only given for 18/22).<BR/>Sex: treatment group: 44.4% male; comparator group 1: 66.67% male; comparator group 2: 55% male.<BR/>Ethnicity: not stated.<BR/>Trial undertaken: Haematology outpatients clinic, Cairo University Children Hospital, Egypt.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-05 20:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment arm: deferiprone: 60 - 83 mg/kg/day orally for 7 days a week (mean (SD) dose = 71.1 (7.1) mg/kg/day) with DFO: 23 - 50 mg/kg/day subcutaneously over 8 hours for 2 days a week (mean (SD) dose 42.4 (5.5) mg/kg/day).<BR/>
<BR/>Comparator group 1: deferiprone: 60 - 83 mg/kg/day, daily for 7 days a week (mean (SD) dose: 71.1 (7.1) mg/kg/day).<BR/>
<BR/>
</P>
<P>Comparator group 2: DFO: 23 - 50 mg/kg/day subcutaneously over 8 hours for 5 days a week (mean (SD) dose: 42.4 (5.5) mg/kg/day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-22 10:47:03 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Liver function</LI>
<LI>Liver iron concentration</LI>
<LI>Serum ferritin</LI>
<LI>Urinary iron excretion</LI>
<LI>Net iron balance</LI>
<LI>Compliance</LI>
<LI>Complications of treatment</LI>
</OL>
<P>Primary outcome: not identified.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 20:56:15 +0100" MODIFIED_BY="[Empty name]">
<P>The trial did not report details as to whether participants had received prior iron chelation therapy.<BR/>Source of funding: none stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-08 12:21:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Galanello-2006">
<CHAR_METHODS MODIFIED="2013-08-05 21:06:08 +0100" MODIFIED_BY="[Empty name]">
<P>2-arm parallel RCT.<BR/>Number of centres: multicentre (3 centres).<BR/>Duration of treatment: 12 months.<BR/>Follow up: not stated.<BR/>
<BR/>
</P>
<P>Number (N) of participants:<BR/>
<U>N randomised</U>: 60 (treatment group: 30; comparator group: 30).<BR/>
<U>N analysed</U>: 59 (treatment group: 29; comparator group: 30. The reason for the withdrawal (intolerance to deferiprone) was reported by the trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-05 21:07:42 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were 10 years or older with a diagnosis of thalassaemia major undergoing iron chelation therapy with subcutaneous DFO with a serum ferritin value between 1000 and 4000 µg/l over the previous year.<BR/>
<BR/>Age: treatment group: mean (SD) 18.7 (4.8) years; comparator group: mean (SD) 19.8 (6.1) years.<BR/>Sex: treatment group: 55% male; comparator group: 40% male.<BR/>Ethnicity: not stated.<BR/>Trial undertaken: Italy and Greece.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:21:29 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: deferiprone: 25 mg/kg/ body weight 3 x daily for 5 days a week with DFO: 20 - 60 mg/kg/day subcutaneously on 2 days a week. (mean (SD) dose DFO for the 29 participants who completed the trial at baseline: 36.0 (5.8) mg/kg/day and end of trial: 33.3 (6.64) mg/kg/day).<BR/>
<BR/>Comparator group: DFO: 20 - 60 mg/kg/day subcutaneously on 5 - 7 days a week (mean (SD) dose baseline: 34.8 (8.9) mg/kg/day and at end of trial: 37.8 (8.9) mg/kg/day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-22 11:40:59 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Serum ferritin change at 1 year</LI>
<LI>Liver iron concentration (measured by SQUID) change at 1 year</LI>
<LI>ALT</LI>
<LI>Full blood count</LI>
<LI>Zinc levels</LI>
<LI>Adverse events</LI>
<LI>Participant compliance</LI>
</OL>
<P>Primary outcome: not identified.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 21:06:29 +0100" MODIFIED_BY="[Empty name]">
<P>The trial inferred that participants had previously received DFO treatment but no details as to dose, schedule or duration were reported.<BR/>Source of funding: Apotex Research Inc, Toronto, Canada.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-08 12:22:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gomber-2004">
<CHAR_METHODS MODIFIED="2013-08-05 21:11:48 +0100" MODIFIED_BY="[Empty name]">
<P>3-arm parallel RCT.<BR/>Number of centres: 1.<BR/>Trial dates: not stated.<BR/>Duration of treatment: 6 months.<BR/>Follow up: none.</P>
<P>
<BR/>Number (N) of participants:</P>
<P>
<U>N randomised</U>: 30 (10 per treatment arm).<BR/>
<U>N analysed</U>: 28 (treatment group: 11; comparator group 1: 10; comparator group 2: 7).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-22 13:29:51 +0100" MODIFIED_BY="[Empty name]">
<P>Children with thalassaemia.<BR/>Age: not stated.<BR/>Sex: not stated.<BR/>Ethnicity: assumed Indian.<BR/>Trial undertaken: Thalassaemia Day Care Centre, Department of Paediatrics, Delhi, India.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-05 21:12:53 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: deferiprone: 75 mg/kg/day orally in 2 - 3 divided doses, 7 days a week.<BR/>Comparator group 1: deferiprone: 75 mg/kg/day in 2 - 3 divided doses and DFO 40 mg/kg/day as a subcutaneous infusion over 8 - 10 hours 2 days a week.<BR/>Comparator group 2: DFO by subcutaneous injection, 40 mg/kg/day over 8 - 10 hours a day, 5 days/week.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:22:15 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Serum ferritin levels at baseline and end of trial (primary outcome)</LI>
<LI>24 hour urinary iron excretion</LI>
<LI>Monthly blood counts</LI>
<LI>Liver function tests (measured 3 monthly)</LI>
<LI>Kidney function tests (measured 3 monthly)</LI>
<LI>Hepatic markers (hbsag)</LI>
<LI>Adverse events</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 21:12:27 +0100" MODIFIED_BY="[Empty name]">
<P>Prior exposure to iron chelators: not reported.<BR/>Source of funding: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-08 12:23:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ha-_x0028_i_x0029_-2006">
<CHAR_METHODS MODIFIED="2013-08-08 12:23:11 +0100" MODIFIED_BY="[Empty name]">
<P>2-arm parallel RCT.<BR/>Number of centres: 5.<BR/>Trial dates: not stated.<BR/>Duration of treatment: median (range) duration: 18 months (1 to 20 months). Only patients receiving at least 6 months of treatment were included for efficacy assessment.<BR/>Follow up: none.<BR/>
<BR/>
</P>
<P>Number (N) of participants:</P>
<P>
<U>N randomised</U>: 36 (treatment group: 20; comparator group: 16).<BR/>
<U>N analysed</U>: 31 (treatment group: 17; comparator group: 14). The trial reported details of why 5 participants were excluded from the analysis.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-08 12:23:29 +0100" MODIFIED_BY="Tracey Remmington">
<P>Thalassaemia major participants. <BR/>Age: range 8 - 40 years (median: 20 years).<BR/>Sex: not stated for this trial alone.<BR/>Ethnicity: Chinese.<BR/>Trial undertaken: 5 paediatric units in Hong Kong.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:23:40 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: deferiprone: 75 mg/kg/day orally in 3 divided doses, 1 hour before food, 7 days a week and DFO 30 - 60 mg/kg/day as a subcutaneous infusion over 8 hours 2 days a week.</P>
<P>
<BR/>Comparator group: DFO by subcutaneous injection, 30 - 60 mg/kg/day, 5 - 7 days/week.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-05 21:15:30 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Reduction of serum ferritin (primary outcome)</LI>
<LI>Liver iron concentration (measured through liver biopsies &amp; atomic absorption spectophotometry)</LI>
<LI>Liver fibrosis &amp; grading (using the Knodell scoring system) through pre &amp; post biopsies</LI>
<LI>Adverse events: biweekly blood counts, liver &amp; renal functioning &amp; rheumatoid factor; monthly determinations of neutropenia &amp; agranulocytosis, gastrointestinal and joint symptoms</LI>
<LI>Participant compliance</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-08 12:23:48 +0100" MODIFIED_BY="[Empty name]">
<P>Prior exposure to iron chelators: not reported.<BR/>Source of funding: Children's Thalassaemia Foundation, Hong Kong.<BR/>Only individuals deemed to be poorly chelated (liver iron content &gt; 7 mg/g dry weight) were eligible for randomisation in this trial.</P>
<P>Trial was stopped after 18 months recruitment due to an unexpected sudden death in the deferiprone treatment arm in <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-08 12:26:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ha-_x0028_ii_x0029_-2006">
<CHAR_METHODS MODIFIED="2013-08-08 12:24:49 +0100" MODIFIED_BY="[Empty name]">
<P>2-arm parallel RCT.<BR/>Number of centres: 5.<BR/>Trial dates: not stated.<BR/>Duration of treatment: median (range) duration: 18 months (1 to 20 months). Only individuals receiving at least 6 months of treatment were included for efficacy assessment.<BR/>Follow up: none.</P>
<P>
<BR/>Number (N) of participants:</P>
<P>
<U>N randomised</U>: 13 (treatment group: 6; comparator group: 7).<BR/>
<U>N analysed</U>: 13 (treatment group: 6; comparator group: 7).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-08 12:25:49 +0100" MODIFIED_BY="Tracey Remmington">
<P>Thalassaemia major patients.<BR/>Age: median (range): 20 years (8 - 40 years).<BR/>Sex: not stated for this trial alone.<BR/>Ethnicity: 12 Chinese, 1 Pakistani.<BR/>Trial undertaken: 5 paediatric units in Hong Kong.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:25:55 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: deferiprone: 75 mg/kg/day orally in 3 divided doses, 1 hour before food, 7 days a week.</P>
<P>
<BR/>Comparator group: DFO by subcutaneous injection, 30 - 60 mg/kg/day, 5 - 7 days/week.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-05 21:18:36 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Reduction of serum ferritin (primary outcome)</LI>
<LI>Liver iron concentration (measured through liver biopsies &amp; atomic absorption spectophotometry)</LI>
<LI>Liver fibrosis &amp; grading (using the Knodell scoring system) through pre &amp; post biopsies</LI>
<LI>Adverse events: biweekly blood counts, liver &amp; renal functioning &amp; rheumatoid factor; monthly determinations of neutropenia &amp; agranulocytosis, gastrointestinal and joint symptoms</LI>
<LI>Participant compliance</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-08 12:26:25 +0100" MODIFIED_BY="[Empty name]">
<P>Prior exposure to iron chelators: not reported.<BR/>Source of funding: Children's Thalassaemia Foundation, Hong Kong.<BR/>Only individuals deemed to be well chelated (liver iron content &#8806; 7 mg/g dry weight) were eligible for randomisation in this trial.</P>
<P>Trial was stopped after 18 months recruitment due to an unexpected sudden death in the deferiprone treatment arm.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-08 12:27:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maggio-2002">
<CHAR_METHODS MODIFIED="2013-08-05 21:39:51 +0100" MODIFIED_BY="[Empty name]">
<P>2-arm parallel RCT.<BR/>Number of centres: 15.</P>
<P>Trial dates: September 1994 - October 1997.<BR/>Duration of treatment: 1 year.<BR/>Follow up: none (36 patients underwent liver biopsy before and after treatment with a mean (SD) follow up until second biopsy 30 (2.4) months and 34 (6.7) months for deferiprone and DFO respectively).</P>
<P>
<BR/>Number (N) of participants:</P>
<P>
<U>N randomised</U>: 144 (treatment group: 71; comparator group: 73).<BR/>
<U>N analysed</U>: 144 (treatment group: 71; comparator group: 73).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-08 12:26:52 +0100" MODIFIED_BY="[Empty name]">
<P>Thalassaemia major participants.<BR/>Age: treatment group: mean (SD) 20 (5.3) years; comparator group: mean (SD) 21 (4.2) years.<BR/>Sex: treatment group: 52%; comparator group: 47%.<BR/>Ethnicity: not stated.<BR/>Trial undertaken: "participating centres" in Italy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:27:05 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: deferiprone: 75 mg/kg/day orally in 3 divided doses, 7 days a week.</P>
<P>
<BR/>Comparator: DFO by subcutaneous injection, 50 mg/kg for 12 hours a day, 5 days a week.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-05 21:25:22 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Change in serum ferritin following 1 year of treatment (primary outcome)</LI>
<LI>Liver iron concentration (g/gram of dry liver), measured by biopsy</LI>
<LI>Liver fibrosis &amp; inflammation: measured monthly (Ishak)</LI>
<LI>Liver iron concentration measured monthly by NMR</LI>
<LI>Heart iron content measured monthly by NMR</LI>
<LI>Heart function measured monthly by ultrasound</LI>
<LI>24 hr urinary iron excretion measured monthly during treatment</LI>
<LI>RBC units in year before and during trial</LI>
<LI>Adverse events</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-08 12:27:13 +0100" MODIFIED_BY="[Empty name]">
<P>Prior exposure to iron chelators: DFO: 50 mg/kg, subcutaneously over 12 hours, 5-times weekly, duration not reported.<BR/>Source of funding: European Community grant and Sicilian Thalassaemic Association.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-08 12:28:39 +0100" MODIFIED_BY="Sheila A Worsley" STUDY_ID="STD-Maggio-2009">
<CHAR_METHODS MODIFIED="2013-08-08 12:27:35 +0100" MODIFIED_BY="Sheila A Worsley">
<P>2-arm parallel RCT.<BR/>Number of centres: 25</P>
<P>Trial dates: September 2000 - January 2008.<BR/>Duration of treatment: the planned duration of treatment was 5 years. However, because of beneficial effects observed after the interim analysis at January 2008 the trial was stopped before the planned 5 years of treatment were completed for all patients.<BR/>Follow up: outcome data recorded for duration of treatment.<BR/>
<BR/>
</P>
<P>Number (N) of participants:<BR/>
<U>N randomised</U>: 213 (treatment group: 105; comparator group: 108).<BR/>
<U>N analysed</U>: 58 after 5 years (treatment group: 32; comparator group: 26). The number of patients analysed decreased with the number of years of follow up studied due to early termination of the trial (for follow-up period of 1/2/3/4/5 years, treatment group: 78/65/55/38/32; comparator group: 74/53/44/33/26); 33 patients withdrew from the trial with no loss to follow up.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-05 21:29:54 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Thalassaemia major patients over 13 years old with a serum ferritin concentration of 800 - 3000 ug/l.<BR/>Age: treatment group: mean (SD) 23 (8.0) years; comparator group: mean (SD) 23 (7.8) years.<BR/>Sex: treatment group: 49.1% male; comparator group: 38.9% male.<BR/>Ethnicity: not stated.<BR/>Trial undertaken: 25 centres of the Italian Society for the Study of Thalassaemia and Haemoglobinopathies (SoSTE).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:28:27 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Treatment: deferiprone: 75 mg/kg/day orally in 3 divided doses for 4 days/week and DFO: 50 mg/kg subcutaneously over 8 - 12 hours for remaining 3 days/week.<BR/>
<BR/>Comparator: deferiprone: 75 mg/kg/day orally in 3 divided doses daily.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:28:39 +0100" MODIFIED_BY="Sheila A Worsley">
<OL>
<LI>Differences between multiple observations of serum ferritin concentrations (primary outcome)</LI>
<LI>Survival analysis</LI>
<LI>Adverse events</LI>
<LI>Costs</LI>
<LI>T2* (heart and liver) in a subset of patients from January 2004</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 21:28:50 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Prior exposure to iron chelators: deferiprone 75 mg/kg/day orally for 7 days/week or DFO 50 mg/kg/day 8 - 12 hours for 5 days/week. Duration not reported.<BR/>Source of funding: the trial was reported as "conducted without the influence of the non-commercial sponsor" with no other details of sponsorship.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-08 12:29:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mourad-2003">
<CHAR_METHODS MODIFIED="2013-08-05 21:32:37 +0100" MODIFIED_BY="[Empty name]">
<P>2-arm parallel RCT.<BR/>Number of centres: 1.<BR/>Trial dates: not stated.<BR/>Duration of treatment: 1 year.<BR/>Follow up: none.</P>
<P>
<BR/>Number (N) of participants:</P>
<P>
<U>N randomised</U>: 25 (treatment group: 11; comparator group: 14).<BR/>
<U>N analysed</U>: 25 (treatment group: 11; comparator group: 14).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-05 21:33:36 +0100" MODIFIED_BY="[Empty name]">
<P>Beta thalassaemia participants, severely iron overloaded and previously poorly chelated.<BR/>Age range: 12 - 40 years.<BR/>Sex: treatment group: 64% male; comparator group: 43% male.<BR/>Ethnicity: not stated.<BR/>Trial undertaken: Chronic Care Centre, Beirut, Lebanon</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:29:14 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: deferiprone: 75 mg/kg/day orally in 3 divided doses, 7 days a week, DFO by subcutaneous injection, daily dose of 2 g over 8 - 12 hours, 2 days a week.<BR/>
<BR/>Comparator group: DFO by subcutaneous injection, 40 - 50 mg/kg over 8 - 12 hours a day, 5 - 7 days/week.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-05 21:33:04 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Mean serum iron concentration at baseline, 6 &amp; 12 months (primary outcome)</LI>
<LI>Number RBC units during the trial</LI>
<LI>Iron excretion at 1 &amp; 12 months</LI>
<LI>Haemoglobin level measured weekly for 3 months then monthly for 9 months</LI>
<LI>Liver function measured weekly for 3 months then monthly for 9 months</LI>
<LI>Renal function measured weekly for 3 months then monthly for 9 months</LI>
<LI>Side effects</LI>
<LI>Participant compliance</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 21:32:57 +0100" MODIFIED_BY="[Empty name]">
<P>Prior exposure to iron chelators: DFO, less than 4 times a week, dose and duration not reported.<BR/>Source of funding: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-08 12:30:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Olivieri-1990">
<CHAR_METHODS MODIFIED="2013-08-05 21:35:30 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over trial.<BR/>Number of centres: 1.<BR/>Trial dates: not stated.<BR/>Duration of treatment: 6 days (3 days each arm), treatment arms separated by 3 - 4 weeks.<BR/>Follow up: none.</P>
<P>
<BR/>Number (N) of participants:<BR/>
<U>N randomised</U>: 20 - cross-over trial.<BR/>
<U>N analysed</U>: 20 - cross-over trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-08 12:30:18 +0100" MODIFIED_BY="[Empty name]">
<P>Transfusion-dependent, homozygous thalassaemia participants (24), transfusion-dependent Diamond-Blackfan anaemia (2).<BR/>Age: mean (range) 22 years (8 - 49 years).<BR/>Sex: not stated.<BR/>Ethnicity: not stated.<BR/>Trial undertaken: Hospital for Sick Children, Toronto.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:30:21 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: deferiprone 50 mg/kg/day orally in 3 divided doses (at 08.00, 16.00 and 24.00 hours) for trial days 2, 3 and 4.<BR/>
<BR/>Comparator group: DFO by infusion 50 mg/kg, 12 hours a day, on trial days 2, 3 and 4.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-22 12:32:59 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Mean daily urinary iron excretion (mg/day) during treatment</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 21:36:12 +0100" MODIFIED_BY="[Empty name]">
<P>Prior exposure to iron chelators: DFO ceased 72 hours preceding trial, mean (SD) total of dose taken 89.4 (31.9) g/kg. Duration not reported.<BR/>Source of funding: Medical Research Council, Canada.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-05 21:38:54 +0100" MODIFIED_BY="Sheila A Worsley" STUDY_ID="STD-Olivieri-1997">
<CHAR_METHODS MODIFIED="2013-08-05 21:37:41 +0100" MODIFIED_BY="[Empty name]">
<P>2-arm parallel RCT.<BR/>Number of centres: 2.<BR/>Trial dates: November 1993 - September 1995.<BR/>Duration of treatment: analysis undertaken after 24 months (mean (SD) duration 33 (1.0) months, range 24 - 43 months).<BR/>Follow up: none.</P>
<P>
<BR/>Number (N) of participants:</P>
<P>
<U>N randomised</U>: 64 (treatment group: 32; comparator group: 32)</P>
<P>
<U>N analysed</U>: 37 (treatment group: 19; comparator group: 18). The trial reports details for why 7 and 6 participants respectively were not included in the analysis. The remaining participants had not completed 24 months treatment at the time of analysis for this trial report.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Thalassaemia participants.<BR/>Age range: not stated.<BR/>Sex: not stated.<BR/>Ethnicity: not stated.<BR/>Trial undertaken: Hospital Centres in Toronto and Montreal, Canada. These data are from the Toronto participants only.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-05 21:38:47 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: deferiprone mean dose: not stated. No further details given.<BR/>
<BR/>Comparator: DFO, by subcutaneous injection, mean (SD) dose: 36.7 (2.8) mg/kg/night. No further details given.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-18 12:04:56 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Change in liver iron concentration (measured by SQUID or biopsy) between 12 months prior to randomisation &amp; 24 months duration on trial treatment.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 21:38:54 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Prior exposure to iron chelators: not reported.<BR/>Source of funding: not stated.<BR/>Abstract publication; additional trial data reported on the US Food and Drug Administration website.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-05 21:46:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pennell-2006">
<CHAR_METHODS MODIFIED="2013-08-05 21:42:48 +0100" MODIFIED_BY="[Empty name]">
<P>2-arm parallel RCT.<BR/>Number of centres: 4.</P>
<P>Trial dates: December 2002 - March 2005.<BR/>Duration of treatment: 1 year.<BR/>Follow up: outcome data recorded for duration of treatment.</P>
<P>
<BR/>Number (N) of participants:</P>
<P>
<U>N randomised</U>: 61 (treatment group: 29; comparator group: 32).<BR/>
<U>N analysed:</U> variable across outcomes. Minimum and maximum numbers analysed were: treatment group: 27 - 29; comparator group: 30 - 32. Trial reported details of why data from 2 participants in the treatment group and 1 in the comparator group were withdrawn from treatment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-05 21:45:46 +0100" MODIFIED_BY="[Empty name]">
<P>Transfusion-dependent homozygous patients with beta-thalassaemia major.<BR/>Age: mean (SD) treatment group: 25.1 (5.8) years; mean (SD) comparator group: 26.2 (4.7) years.<BR/>Sex: treatment group: 52% male; comparator group: 50% male.<BR/>Ethnicity: Greek/Italian: treatment group: 16/13; comparator group: 18/14.<BR/>Trial undertaken: 4 participating centres in Italy and Greece.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-05 21:46:26 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: deferiprone: initial dose 75 mg/kg/day increasing to 100 mg/kg/day. Mean actual dose: 92 mg/kg/day.<BR/>
<BR/>Comparator group: DFO by subcutaneous injection, 50 mg/kg for 5 or more days a week.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-05 21:43:02 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Change over 1 year in myocardial T2* (primary outcome)</LI>
<LI>Cardiac volumes &amp; function</LI>
<LI>Liver iron concentration</LI>
<LI>Serum ferritin</LI>
<LI>Absolute neutrophil count</LI>
<LI>Adverse events</LI>
<LI>ALT</LI>
<LI>Serum zinc levels</LI>
<LI>Serum creatinine levels</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 21:46:34 +0100" MODIFIED_BY="[Empty name]">
<P>Prior exposure to iron chelators: DFO at a mean (SD) dose of 39 (8) mg/kg/day for 5 - 7days/week.<BR/>Trial sponsor: Apotex (manufacturer of deferiprone).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-08 12:32:55 +0100" MODIFIED_BY="Sheila A Worsley" STUDY_ID="STD-Tamaddoni-2010">
<CHAR_METHODS MODIFIED="2013-08-05 21:49:14 +0100" MODIFIED_BY="Sheila A Worsley">
<P>2-arm parallel RCT.<BR/>Number of centres: 1.<BR/>Duration of treatment: 12 months.</P>
<P>Trial dates: non stated.<BR/>Follow up: not stated.<BR/>
<BR/>
</P>
<P>Number (N) of participants:<BR/>
<U>N randomised</U>: 80 (treatment group: 40; comparator group: 40).<BR/>
<U>N analysed</U>: 80.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-05 21:51:57 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Thalassaemia major patients.</P>
<P>Age: at least 10 years old; mean (SD) treatment group: 18.7 (4.8) years; mean (SD) comparator group: 17.8 (6.1) years.<BR/>Sex: treatment group: 55% male; comparator group: 52.5% male.<BR/>Ethnicity: not stated.<BR/>Trial undertaken: Iran.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:32:39 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Treatment: deferiprone: 75 mg/kg/daily orally and DFO by subcutaneous injection, daily dose of 40 - 50 mg/kg/day, 2 days a week.<BR/>
<BR/>Comparator: DFO by subcutaneous injection, 40 - 50 mg/kg/day, 5 days/week.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:32:55 +0100" MODIFIED_BY="Sheila A Worsley">
<OL>
<LI>Haemoglobin, hematocrit, whole blood count, absolute neutrophil and platelet count measurements taken every 1 - 3 weeks</LI>
<LI>Liver and renal function checked monthly</LI>
<LI>Serum ferritin (controlled every three months)</LI>
<LI>Adverse effects and compliance at each transfusion visit</LI>
</OL>
<P>Primary outcome: not identified.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 21:49:38 +0100" MODIFIED_BY="[Empty name]">
<P>Prior exposure to iron chelators: DFO received by all patients, dose and duration not reported.<BR/>Source of funding: Babol University of Medical Sciences.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-08 12:34:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tanner-2007">
<CHAR_METHODS MODIFIED="2013-08-08 12:33:14 +0100" MODIFIED_BY="[Empty name]">
<P>2-arm parallel RCT.<BR/>Number of centres: multicentre (12 centres).<BR/>Duration of treatment: 12 months.<BR/>Follow up: not stated.<BR/>
<BR/>
</P>
<P>Number (N) of participants:<BR/>
<U>N randomised</U>: 65 (treatment group: 32; comparator group: 33).<BR/>
<U>N analysed</U>: not reported. <BR/>
<U>N completing treatment</U>: 60 (treatment group: 28; comparator group: 30). The reason for the withdrawal was not fully reported by the trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-08 12:33:26 +0100" MODIFIED_BY="[Empty name]">
<P>Participants aged 18 years or older with a diagnosis of beta thalassaemia, currently maintained on subcutaneous DFO and with a myocardial T2* between 8 - 20 ms.<BR/>Age: treatment group: mean (SD) 28.8 (4.2) years; comparator group: mean (SD) 28.7 (5.3) years. Age range for both arms was 18 - 42 years.<BR/>Sex: treatment group: 44% male; comparator group: 39% male.<BR/>Ethnicity: not stated.<BR/>Trial undertaken: thalassaemia out-patients clinics in Sardinia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:34:03 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group: deferiprone: 75 mg/kg daily for 7 days a week with DFO: 40 - 50mg/kg subcutaneously for 5 days a week (DFO actual dose: 34.9 mg/kg for 5 days).<BR/>
<BR/>Comparator: DFO: 40 - 50 mg/kg subcutaneously for 5 days a week (DFO actual dose: 43.4 mg/kg for 5 days) with an oral placebo (no further details reported).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:34:39 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Change over 1 year in myocardial T2* (primary outcome)</LI>
<LI>Change in liver T2* at 12 months</LI>
<LI>Serum ferritin</LI>
<LI>Left ventricular volume &amp; function</LI>
<LI>Brachial artery reactivity as a marker of heart failure</LI>
<LI>Participant compliance with chelation treatments</LI>
<LI>Adverse events</LI>
<LI>BNP test</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 21:55:09 +0100" MODIFIED_BY="[Empty name]">
<P>Prior exposure to iron chelation: DFO mean (SD) dose 36.4 (11.1) mg/kg per day for 5.5 day/week (equivalent to 40.5 mg/kg for 5 d/week). Participants were excluded if they had previously received deferiprone.<BR/>Source of funding: CORDA, Royal Brompton &amp; Harefield Hospitals Charitable funds, Cooley's Anemia Foundation, Apotex, UK Thalassaemia Society, University College London Special trustees Charity.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ALT: alanine aminotransferase<BR/>BNP: Brain natriuretic peptide<BR/>DFO: desferrioxamine<BR/>hbsag: hepatitis b surface antigen<BR/>Hr: hour<BR/>N: number<BR/>LVEF: left ventricular ejection fraction<BR/>NTBI: non-transferrin bound iron<BR/>RCT: randomised controlled trial<BR/>RBC: red blood cell<BR/>SQUID: superconducting quantum interference device</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-08-08 12:44:14 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-10-18 10:15:01 +0100" MODIFIED_BY="Sheila A Worsley" STUDY_ID="STD-Agouzal-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-18 10:15:01 +0100" MODIFIED_BY="Sheila A Worsley">
<P>In the observational study reported in this abstract, patients were not randomised to their interventions (deferiprone or deferiprone with DFO), rather the patient's previous treatment was continued following enrolment into the study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-08 12:37:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-al-Refaie-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-08 12:37:16 +0100" MODIFIED_BY="[Empty name]">
<P>This is a study exploring the serum NTBI in people with beta-thalassaemia major. Serum samples were taken from people treated with either deferiprone of DFO and healthy volunteers. The aim of the study was not to compare clinical outcomes between the interventions. Included participants were not randomised to an intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-08 12:38:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-08 12:38:02 +0100" MODIFIED_BY="[Empty name]">
<P>This was a matched-patient study comparing myocardial iron content and cardiac function in people with thalassaemia major receiving long-term deferiprone and DFO. Individuals were not randomised between study arms, rather the DFO treated group were matched to the deferiprone treated group in a 2:1 ratio on the basis of age, sex and current ferritin concentration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-08 12:38:31 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Athanassiou-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-08 12:38:31 +0100" MODIFIED_BY="Tracey Remmington">
<P>This was a study of the immune status of thalassaemia patients receiving deferiprone alone or in combination with DFO. The study does not report data on any clinical outcome measures included in the '<LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>' for this review and patients were not randomised to their treatment groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-05 22:06:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Athanassiou_x002d_Metaxa-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-05 22:06:19 +0100" MODIFIED_BY="[Empty name]">
<P>This study was not a RCT, rather patients were assigned by the investigators to their treatment group (deferiprone monotherapy or deferiprone and DFO combined).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bartfay-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study compared the cytotoxic aldehyde generation in people with beta-thalassaemia chelated with deferiprone or DFO compared to non-chelated controls. The aim of the study was not to compare clinical outcomes between the interventions. Included participants were not randomised to an intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-08 12:38:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cassinerio-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-08 12:38:57 +0100" MODIFIED_BY="[Empty name]">
<P>A retrospective observational study of the efficacy of different iron chelation therapies on removal of myocardial iron content and LVEF assessed by cardiac magnetic resonance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-18 09:57:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christoforidis-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-18 09:57:21 +0100" MODIFIED_BY="[Empty name]">
<P>Deferiprone and DFO were given as combined treatment in this study, thus all patients received both interventions for the duration of this study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-05 22:02:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-05 22:02:23 +0100" MODIFIED_BY="[Empty name]">
<P>This trial was a multicentre safety trial of deferiprone in people with transfusion-dependent thalassaemia major. There was no comparator treatment arm in this trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-12 11:57:19 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Diav_x002d_Citrin-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-12 11:57:19 +0100" MODIFIED_BY="Tracey Remmington">
<P>This trial investigated variability in response to deferiprone in people with beta-thalassaemia major. There was no comparator treatment arm in this trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-18 10:04:34 +0100" MODIFIED_BY="Sheila A Worsley" STUDY_ID="STD-Drakonaki-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-18 10:04:34 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Patients were not randomised to their interventions (DFO monotherapy or deferiprone with DFO), rather the patient's previous treatment was continued following enrolment into the study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-18 09:57:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Elalfy-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-18 09:57:11 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were not randomised to their interventions (DFO or deferiprone with DFO), rather the patient's previous treatment was continued following enrolment into the study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-05 22:03:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fassos-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-05 22:03:18 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were not randomised to their first treatment arm in this cross-over study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-18 09:58:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fragatou-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-18 09:58:33 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were not randomised to the interventions, rather pre-existing clinical characteristics defined which interventions (deferiprone and DFO or DFO monotherapy) each patient received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Galanello-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial looks at the efficacy of iron chelation in people with thalassaemia major with poor compliance to DFO. All participants received combined therapy of deferiprone and DFO. There was no comparator treatment arm in this trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-08 12:39:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goulas-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-08 12:39:47 +0100" MODIFIED_BY="[Empty name]">
<P>The objective of this non-randomised study was to compare the quality of life, self-esteem, satisfaction and adherence to treatment of patients already receiving one of three treatments: deferiprone with DFO, DFO or deferasirox.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-05 22:03:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grady-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-05 22:03:29 +0100" MODIFIED_BY="[Empty name]">
<P>Although the study was of a cross-over design, patients were not randomised to their treatment group (deferiprone or DFO). The study does not include outcome measures that are relevant to this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hershko-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>This abstract reports the long-term data from the International Study Group on Oral Iron Chelators. The aim of the study was to provide information on the benefits and risks associated with long-term deferiprone in people with transfusional iron overload. The study did not include a comparison group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-08 12:40:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kattamis-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-08 12:40:02 +0100" MODIFIED_BY="[Empty name]">
<P>This was not a RCT, rather each patients received each phase of treatment (DFO monotherapy, deferiprone monotherapy or DFO and deferiprone combined) in the same consecutive pattern.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-08 12:40:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kontoghiorghes-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-08 12:40:13 +0100" MODIFIED_BY="[Empty name]">
<P>This trial was a multicentre safety trial of deferiprone in people with transfusion-dependent thalassaemia major. There was no comparator treatment arm in this trial. This trial was a small trial exploring urinary iron excretion following receipt of deferiprone alone or in combination with ascorbic acid in people with thalassaemia or myelodysplasia. Outcome data for the thalassaemia participants were not presented separately from the myelodysplasia participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-18 10:05:40 +0100" MODIFIED_BY="Sheila A Worsley" STUDY_ID="STD-Lai-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-18 10:05:40 +0100" MODIFIED_BY="Sheila A Worsley">
<P>This trial was not randomised; all patients were offered combined treatment of DFO and deferiprone but some either refused or experienced adverse effects due to deferiprone and were given DFO alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Loebstein-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial is neither randomised nor includes outcome measures that are relevant to the review. This trial studied immune function in people with thalassaemia: 36 received deferiprone and 21 received DFO and were treated in parallel.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-05 22:03:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marshall-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-05 22:03:53 +0100" MODIFIED_BY="[Empty name]">
<P>This was a matched patient cross-over study investigating the chromosomal aberration frequencies in people with thalassaemia major. Individuals treated long-term with deferiprone were matched for age, sex and iron overload with those treated long-term with DFO. This was not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-08 12:41:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nielsen-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-08 12:41:21 +0100" MODIFIED_BY="[Empty name]">
<P>This was a study of liver iron stores in patients with beta-thalassaemia major or other post-transfusional siderosis receiving treatment with deferiprone or parenteral DFO, or both. Individuals were not randomised to their respective treatment arms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-08 12:41:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Olivieiri-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-08 12:41:38 +0100" MODIFIED_BY="[Empty name]">
<P>This abstract reports data from the first 3 years of the Canadian trial which investigated the safety and effectiveness of deferiprone in people with transfusion-dependent thalassaemia and SCD. There was no comparator treatment arm in this trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-08 12:42:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peng-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-08 12:42:14 +0100" MODIFIED_BY="[Empty name]">
<P>This was a 3-year prospective clinical trial comparing deferiprone with DFO with regards to efficacy and side effects of these interventions on cardiac or hepatic systems, or both. Participants were not randomised to their treatment group; instead those who were unwilling or unable to use DFO were assigned to treatment with deferiprone: all other participants stayed on the DFO regimen.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-18 09:57:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peng-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-18 09:57:55 +0100" MODIFIED_BY="[Empty name]">
<P>Email communication with the authors confirmed that the two group of participants in this study were not randomised to their treatment arm (deferiprone or DFO), rather they were assigned to their treatment arm by clinicians.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pepe-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a matched patient study seeking to evaluate the efficacy of oral deferiprone in comparison to subcutaneous DFO by multislice multiecho T2*. Participants were not randomised between study arms, rather the DFO treated group were matched to the deferiprone treated group on the basis of age and sex.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-08 12:42:52 +0100" MODIFIED_BY="Sheila A Worsley" STUDY_ID="STD-Ricchi-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-08 12:42:52 +0100" MODIFIED_BY="Sheila A Worsley">
<P>In this retrospective study, patients were allocated to 1 of 4 treatment groups (differing doses or schedules of deferiprone with DFO) based on severity of iron overload and previous adverse effects to deferiprone therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-08 12:43:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-St-Pierre-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-08 12:43:13 +0100" MODIFIED_BY="[Empty name]">
<P>This is a commentary on the <LINK REF="STD-Anderson-2002" TYPE="STUDY">Anderson 2002</LINK> trial; in particular the misleading claims that the use of advanced magnetic resonance techniques has made possible the accurate assessment of both liver and cardiac iron. St Pierre discusses the appropriate use of T2* measurements and the interplay of other factors on T2* findings.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taher-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial aimed to compare the effectiveness, safety and participant compliance of deferiprone and DFO in people with thalassaemia major. Participants were not randomised to the treatment arms, rather those who were non-compliant with or unable to tolerate DFO received deferiprone: all other participants received DFO.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-18 09:57:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tanner-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-18 09:57:41 +0100" MODIFIED_BY="[Empty name]">
<P>All patients in this study received both deferiprone and DFO in a non-randomised method of treatment allocation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-08 12:44:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsakok-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-08 12:44:14 +0100" MODIFIED_BY="[Empty name]">
<P>This was a commentary on some of the statistical decisions made by <LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK> RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-18 09:57:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vlachaki-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-18 09:57:34 +0100" MODIFIED_BY="[Empty name]">
<P>Patients had already been assigned to their treatment (DFO or deferiprone) prior to the start of the study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-18 09:57:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-18 09:57:36 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were not randomised to the treatment (deferiprone or DFO) they received in this study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-18 10:18:11 +0100" MODIFIED_BY="Sheila A Worsley" STUDY_ID="STD-Zareifar-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-18 10:18:11 +0100" MODIFIED_BY="Sheila A Worsley">
<P>This trial aimed to evaluate the efficacy and safety of combined deferiprone with DFO compared with DFO monotherapy. Participants were not randomised to the treatment arms; treatment was allocated according to prior compliance with DFO treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>DFO: desferrioxamine<BR/>LVEF: left ventricular ejection fraction<BR/>NTBI: non-transferrin bound iron<BR/>RCT: randomised controlled trial<BR/>SCD: sickle cell disease<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-08-08 12:56:21 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2013-08-08 12:48:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alpendurada-2012">
<CHAR_METHODS MODIFIED="2013-08-08 12:44:55 +0100" MODIFIED_BY="[Empty name]">
<P>RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-05 22:07:15 +0100" MODIFIED_BY="[Empty name]">
<P>65 adult thalassaemia major patients with mild-moderate cardiac iron loading.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:48:30 +0100" MODIFIED_BY="[Empty name]">
<P>Group 1 (n = 32): DFO combined with deferiprone.</P>
<P>Group 2 (n = 33): DFO with placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-05 22:24:23 +0100" MODIFIED_BY="[Empty name]">
<P>Right ventricular function using cardiac MRI.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-16 12:46:47 +0100" MODIFIED_BY="[Empty name]">
<P>This trial was identified during the final search period (March 2013) and has not been fully evaluated to determine eligibility for inclusion, although patients are reported to be a subset of those included in the <LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK> study.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-08-08 12:46:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aydinok-2012">
<CHAR_METHODS MODIFIED="2013-08-08 12:45:01 +0100" MODIFIED_BY="[Empty name]">
<P>RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-08 12:45:30 +0100" MODIFIED_BY="[Empty name]">
<P>20 thalassaemia major patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:45:38 +0100" MODIFIED_BY="[Empty name]">
<P>Patients received one year of deferiprone monotherapy 75 mg/kg in 3 divided doses daily, either alone or in combination with DFO, 40 - 50 mg/kg sc, twice weekly on consecutive nights.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:46:15 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Urinary iron excretion</LI>
<LI>Transfusional iron loading rates</LI>
<LI>LIC</LI>
<LI>Plasma concentrations of NTBI and labile plasma iron</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 22:24:55 +0100" MODIFIED_BY="[Empty name]">
<P>This appears to be a substudy of <LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK> which has been included in this review.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-08-08 12:49:26 +0100" MODIFIED_BY="Sheila A Worsley" STUDY_ID="STD-Badawy-2010">
<CHAR_METHODS MODIFIED="2011-10-25 09:37:50 +0100" MODIFIED_BY="Sheila A Worsley">
<P>A retrospective-prospective randomised cohort study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-05 22:14:40 +0100" MODIFIED_BY="Sheila A Worsley">
<P>150 transfusion-dependent children with thalassaemia aged 8 years and over in east delta of Egypt who are on irregular DFO chelation therapy prior to study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:49:26 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Group 1 received deferiprone for 5 days/week alternating with DFO for 2 days/week.</P>
<P>Group 2 received daily deferiprone only.</P>
<P>Group 3 received DFO only for 5 days/week. Doses were the same for all groups: deferiprone 75 mg/kg/day; DFO 40 mg/kg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:46:46 +0100" MODIFIED_BY="Sheila A Worsley">
<OL>
<LI>Non-compliance</LI>
<LI>Adverse effects</LI>
<LI>Serum ferritin levels</LI>
<LI>Liver and kidney functions</LI>
<LI>Blood glucose level</LI>
<LI>Serum calcium and phosphorus/3 months</LI>
<LI>T3, T4, TSH, LH, FSH, echocardiography, bone density, auditory and visual examination</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-25 09:48:25 +0100" MODIFIED_BY="Sheila A Worsley">
<P>We have not identified any further publications to these conference abstracts.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-08-08 12:49:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evans-2011">
<CHAR_METHODS MODIFIED="2013-08-08 12:46:58 +0100" MODIFIED_BY="[Empty name]">
<P>RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-12-20 09:20:18 +0000" MODIFIED_BY="[Empty name]">
<P>21 thalassaemia major patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:49:51 +0100" MODIFIED_BY="[Empty name]">
<P>Group 1 received deferiprone monotherapy, 25 mg/kg tds (12 patients).</P>
<P>Group 2 received deferiprone at the same dose with DFO 40 - 50 mg/kg for 2 nights per week (12 patients).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-05 22:34:03 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>LIC</LI>
<LI>transfusional iron loading rates</LI>
<LI>Urinary iron excretion</LI>
<LI>Plasma NTBI and LPI concentrations</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 22:29:52 +0100" MODIFIED_BY="[Empty name]">
<P>Follow up at 52 weeks.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-08-08 12:47:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jain-2011">
<CHAR_METHODS MODIFIED="2013-08-08 12:47:53 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective comparative study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-12-20 09:20:18 +0000" MODIFIED_BY="[Empty name]">
<P>98 children with transfusion-dependent thalassaemia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-20 09:20:18 +0000" MODIFIED_BY="[Empty name]">
<P>Combined chelation therapy (DFO and oral chelation) versus oral chelation monotherapy versus DFO monotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-12-20 09:20:18 +0000" MODIFIED_BY="[Empty name]">
<P>Red cell transfusion requirement.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-16 12:46:54 +0100" MODIFIED_BY="[Empty name]">
<P>This trial, presented as a conference abstract, was identified during the final search period (March 2013) and has not been fully evaluated to determine eligibility for inclusion. In particular, it is unclear whether treatment allocation was randomised.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-08-08 12:50:31 +0100" MODIFIED_BY="Sheila A Worsley" STUDY_ID="STD-Kompany-2009">
<CHAR_METHODS MODIFIED="2013-08-08 12:47:43 +0100" MODIFIED_BY="Sheila A Worsley">
<P>RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-18 09:54:42 +0000" MODIFIED_BY="Sheila A Worsley">
<P>40 thalassaemia patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:50:31 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Intervention group: DFO sc for 3 days/week and deferiprone orally for 4 days/week.</P>
<P>Control group: sc DFO for 6 days/week. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-05 22:37:59 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Cardiac indices including: right ventricle diameter; LVEDD; LVESD; aortic root diameter, LVEF.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-18 10:05:20 +0000" MODIFIED_BY="Sheila A Worsley">
<P>This Iranian trial requires translation from Persian in order to establish whether the trial is appropriately randomised; only the abstract is published in English and does not provide sufficient information to determine whether this trial is eligible for inclusion.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-08-08 12:47:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maggio-2012">
<CHAR_METHODS MODIFIED="2013-08-08 12:47:41 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentre RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-12-20 09:20:18 +0000" MODIFIED_BY="[Empty name]">
<P>99 patients with thalassaemia major.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-05 22:31:19 +0100" MODIFIED_BY="[Empty name]">
<P>Long-term sequential deferiprone-deferoxamine versus deferiprone alone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:47:59 +0100" MODIFIED_BY="[Empty name]">
<P>LVEF.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 22:27:28 +0100" MODIFIED_BY="[Empty name]">
<P>This trial was identified during the final search period (March 2013) and has not been fully evaluated to determine eligibility for inclusion, although the background to this study as presented in this abstract suggests that this is a retrospective follow up of patients included in the <LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK> study.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-08-08 12:50:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mirbehbahani-2012">
<CHAR_METHODS MODIFIED="2013-08-08 12:48:13 +0100" MODIFIED_BY="[Empty name]">
<P>Controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-05 22:31:50 +0100" MODIFIED_BY="[Empty name]">
<P>26 patients with beta-thalassaemia major.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:48:06 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention group: DFO sc, every other day at 30 - 50 mg/kg/day mg/kg/day with deferiprone at 75 mg/kg/day in 3 divided oral doses.</P>
<P>Comparator group: DFO subcutaneously for 6 - 12 hours/day, 5 - 6 days per week at 30 - 50 mg/kg/day.</P>
<P>Participants were randomised to 6 months of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:50:48 +0100" MODIFIED_BY="[Empty name]">
<P>Serum ferritin (primary).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-16 12:47:08 +0100" MODIFIED_BY="[Empty name]">
<P>This trial was identified during the final search period (March 2013) and has not been fully evaluated to determine eligibility for inclusion.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-08-08 12:52:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-N0277104959">
<CHAR_METHODS MODIFIED="2013-08-08 12:51:01 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-08 12:51:12 +0100" MODIFIED_BY="[Empty name]">
<P>60 young thalassaemia participants with a myocardial T2* &lt; 10 ms: 30 participants with normal ejection fraction as measured by CMR; and 30 participants with reduced ejection fraction.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:51:38 +0100" MODIFIED_BY="[Empty name]">
<P>All participants to receive "the current gold standard continuous chelation therapy via implantable device such as pic line or a port-a-cath using disposable desferrioxamine infusors" (dose and schedule not reported).</P>
<P>Group 1: deferiprone 75 mg/kg/body weight (schedule not reported).</P>
<P>Group 2: placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:51:49 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Myocardial Iron measured by CMR T2* relaxometry.</LI>
<LI>Rest cardiac function, measured by CMR measurements in left ventricle of end diastolic volume, end systolic volume, ejection fraction and left ventricular mass.</LI>
<LI>Clinical events.</LI>
<LI>Compliance.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-08 12:52:00 +0100" MODIFIED_BY="[Empty name]">
<P>We have been unable to identify any publications from this trial, registered on the National Research Register. Moreover despite repeated emails to the study contact person (now retired) and potential colleagues, we have been unable to identify whether the trial was started and completed, if participants were randomised to treatment allocation and whether a publication has arisen from this trial.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-08-08 12:53:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00115349a">
<CHAR_METHODS MODIFIED="2013-08-08 12:52:47 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind (participant, caregiver and investigator), placebo-controlled RCT of parallel design.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-08 12:53:00 +0100" MODIFIED_BY="[Empty name]">
<P>Aged 18 years and older with transfusion dependent beta-thalassaemia, with a LVEF by MRI &lt; 56%, serum ferritin &gt; 1000 µg/L or ferritin between 500 and 1000 µg/L and cardiac T2* &lt; 20 ms. </P>
<P>Participants to be receiving DFO sc or iv and willing to chelate 7 days per week for 12 - 24 hours per day.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:53:10 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention group: DFO daily for 12 - 24 hours/day, 7 days a week either sc or iv at up to 50 - 60 mg/kg/day with deferiprone at 75 mg/kg/day in 3 divided oral doses.</P>
<P>Comparator group: DFO daily for 12 - 24 hours/day, 7 days a week either sc or iv at up to 50 - 60 mg/kg/day.</P>
<P>Participants were randomised to 1 year of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-05 22:22:29 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Rate of change in LVEF (MRI measured) from screening to 1 year (primary outcome)</LI>
<LI>Myocardial iron burden estimated by myocardial T2* at 1 year</LI>
<LI>Change in left ventricular volume from screening to 1 year</LI>
<LI>Change in Echo left ventricular volume, ejection fraction, shortening fraction and VCFc/Wall stress z score from screening to 1 year</LI>
<LI>Change in Holter monitor scores from screening to 1 year</LI>
<LI>Initiation or increase in cardiac medication during study</LI>
<LI>Adverse events during study</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-08 12:53:51 +0100" MODIFIED_BY="[Empty name]">
<P>Email correspondence with the study contact person (Professor John Porter) in February 2009 identified that the study had been terminated due to slow recruitment but that "there were interesting findings" and the study data were being held by the New England Research Institutes. No publication has yet arisen from this study.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-08-08 12:54:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pantalone-2011">
<CHAR_METHODS MODIFIED="2013-08-08 12:54:02 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentre open-label RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-12-20 09:20:18 +0000" MODIFIED_BY="[Empty name]">
<P>Beta-thalassaemia major patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:54:07 +0100" MODIFIED_BY="[Empty name]">
<P>Group 1: deferiprone 75 mg/kg 4 days/week combined with DFO 50 mg/kg/day for 3 days/week.</P>
<P>Group 2: deferiprone monotherapy daily, 75 mg/kg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:54:26 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Serum ferritin</LI>
<LI>Adverse events</LI>
<LI>Costs</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-05 22:11:24 +0100" MODIFIED_BY="[Empty name]">
<P>This trial, which included a 5-year follow up, was identified during the final search period (March 2013) and has not been fully evaluated to determine eligibility for inclusion.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-08-08 12:55:21 +0100" MODIFIED_BY="Sheila A Worsley" STUDY_ID="STD-Pepe-2013">
<CHAR_METHODS MODIFIED="2011-10-25 10:01:10 +0100" MODIFIED_BY="Sheila A Worsley">
<P>A prospective study of iron chelation efficacy in a large clinical setting. It is unclear whether patients were randomised to treatment arm.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-25 09:52:59 +0100" MODIFIED_BY="Sheila A Worsley">
<P>139 participants enrolled in the Myocardial Iron Overload in Thalassemia (MIOT) network with thalassaemia major.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:54:48 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Group 1 (n = 43): deferiprone (mean (SD) 66 (23) mg/kg/day for 6 (1) day/week) and DFO 41 (7) mg/kg/day for 4 (1) day/week).</P>
<P>Group 2 (n = 30): deferiprone only (mean (SD) 73 (16) mg/kg/day).</P>
<P>Group 3 (n = 66): DFO only (mean (SD) 41 (7) mg/kg/day for 5.5 days/week).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:55:21 +0100" MODIFIED_BY="Sheila A Worsley">
<OL>
<LI>Myocardial and LICs measured by T2*</LI>
<LI>Biventricular functions parameters</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-12 14:11:13 +0000" MODIFIED_BY="Sheila A Worsley"/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-08-08 12:55:51 +0100" MODIFIED_BY="Sheila A Worsley" STUDY_ID="STD-Unal-2009">
<CHAR_METHODS MODIFIED="2013-08-08 12:55:26 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Study of efficacy between 2 iron chelation treatment groups. It is unclear whether patients were randomised to treatment arm.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-08 12:55:37 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Beta-thalassaemia major patients currently maintained on sc DFO monotherapy; age 10 years and over and maintaining pre-transfusion haemoglobin &gt; 9 g/dL.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:55:51 +0100" MODIFIED_BY="Sheila A Worsley">
<P>Group 1 (n = 26): deferiprone 20 - 25 mg/kg/dose in addition to DFO 3 - 5 times/week 30 - 40 mg/kg/day.</P>
<P>Group 2 (n = 13): DFO monotherapy (dose not stated).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-05 22:43:07 +0100" MODIFIED_BY="Sheila A Worsley">
<OL>
<LI>Myocardial T2*</LI>
<LI>Ejection fraction levels</LI>
<LI>Serum ferritin levels</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-25 10:07:03 +0100" MODIFIED_BY="Sheila A Worsley">
<P>We have not identified any further publications to this conference abstract.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>CMR: cardiovascular magnetic resonance<BR/>DFO: desferrioxamine<BR/>FSH: follicle-stimulating hormone<BR/>iv: intravenously<BR/>LH: luteinizing hormone<BR/>LIC: liver iron concentration<BR/>LPI: labile plasma iron<BR/>LVEDD: left ventricular end diastolic dimension<BR/>LVEF: left ventricular ejection fraction<BR/>LVESD: left ventricular end systolic dimension<BR/>MRI: magnetic resonance imaging<BR/>NTBI: non-transferrin bound iron<BR/>sc: subcutaneously<BR/>RCT: randomised controlled trial<BR/>TSH: thyroid-stimulating hormone<BR/>T3 &amp; T4: thyroid hormones<BR/>VCFc: velocity of circumferential fibre shortening<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-08-08 12:59:55 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-08-08 12:57:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EU_x005f_2009_x002d_014666_x002d_25">
<CHAR_STUDY_NAME MODIFIED="2013-08-05 22:44:01 +0100" MODIFIED_BY="[Empty name]">
<P>Sequential deferasirox-deferiprone versus deferasirox or deferiprone multicentre randomised trial.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-08-08 12:56:47 +0100" MODIFIED_BY="[Empty name]">
<P>RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-05 22:44:45 +0100" MODIFIED_BY="[Empty name]">
<P>Beta-thalassaemia major patients aged between 12 - 50 years and with a serum ferritin concentration &gt; 1000g/l. Planned number of participants: 363.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-05 22:48:48 +0100" MODIFIED_BY="[Empty name]">
<P>Sequential or monotherapy: deferasirox 30 mg/kg; deferiprone 75 mg/kg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:57:14 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome</P>
<OL>
<LI>Chelating efficacy assessment of sequential therapy deferasirox-deferiprone versus deferasirox or deferiprone alone</LI>
</OL>
<P>Secondary outcomes:</P>
<OL>
<LI>To assess in the sequential deferasirox-deferiprone treated group a reduction at least in 50% of cases of creatininemia significant increase (&gt; 33%) compared to the deferasirox alone group</LI>
<LI>To assess in the sequential deferasirox-deferiprone treated group a reduction at least in 70% of cases of neutropenia compared to the deferiprone alone group</LI>
<LI>To assess, using MRI, in a subgroup, the possible organ-specific (heart, liver, pancreas) iron overload variation during therapy.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-08-05 22:45:33 +0100" MODIFIED_BY="[Empty name]">
<P>July 2009.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-08-05 22:48:20 +0100" MODIFIED_BY="[Empty name]">
<P>Fondazione Franco e Piera Cutino, Italy.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-08-05 22:48:21 +0100" MODIFIED_BY="[Empty name]">
<P>Non-commercial sponsored study.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-08-08 12:58:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-IRCT201110087677N1">
<CHAR_STUDY_NAME MODIFIED="2013-08-05 22:48:16 +0100" MODIFIED_BY="[Empty name]">
<P>The comparative study of incidence of lens opacity between Osferal and Deferoxamine in major thalassaemia.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-08-08 12:57:35 +0100" MODIFIED_BY="[Empty name]">
<P>RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-08 12:57:40 +0100" MODIFIED_BY="[Empty name]">
<P>Male and female paediatric patients aged 1 to 14 years with major thalassaemia who have never received any chelator therapy prior to study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:58:00 +0100" MODIFIED_BY="[Empty name]">
<P>Group 1: Osferal (no dose or schedule details reported).</P>
<P>Group 2: DFO (no dose or schedule details reported).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-05 22:47:55 +0100" MODIFIED_BY="[Empty name]">
<P>Lens opacity (primary)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-08-05 22:47:46 +0100" MODIFIED_BY="[Empty name]">
<P>December 2010.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-08-05 22:47:44 +0100" MODIFIED_BY="[Empty name]">
<P>Vahid Falahati, Imam Reza Hospital, KUMS, Kermanshah, Iran (vahidfalahati89@yahoo.com).</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-08-08 12:58:12 +0100" MODIFIED_BY="[Empty name]">
<P>Estimated enrolment: 50 (25 per treatment arm).</P>
<P>Estimated study completion date: December 2011.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-08-08 12:59:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01511848">
<CHAR_STUDY_NAME MODIFIED="2013-08-05 22:47:34 +0100" MODIFIED_BY="[Empty name]">
<P>Study of efficacy, safety of combined deferasirox and deferiprone versus combined deferiprone and desferal in conditions of iron overload.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-08-08 12:58:34 +0100" MODIFIED_BY="[Empty name]">
<P>A prospective open-label phase 2/phase 3 cross-over RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-08 12:58:51 +0100" MODIFIED_BY="[Empty name]">
<P>Male and female participants with transfusional iron overload secondary to thalassaemia major or SCD aged 6 - 18 years with a serum ferritin &gt; 2500 ng/mL.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:59:00 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention group: DFO 40 mg/kg administered sc over 8 hours for 5 days, combined with oral deferiprone 75 mg/kg in 3 divided doses for 7 days.<BR/>
<BR/>
</P>
<P>Comparator group: oral deferasirox 20 mg/kg once daily for 5 days, combined with deferasirox 25 mg/kg 3 times per day; dose may be increased up to 100 mg/kg/day guided by serum ferritin levels.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-05 22:46:27 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>To assess efficacy of combining deferiprone and deferasirox compared to combined deferiprone and DFO in decreasing the serum ferritin level in conditions with severe chronic iron overload (primary)</LI>
<LI>To determine the safety upon administering the drugs in combination (deferiprone and deferasirox) compared to the combination of DFO and deferiprone</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-08-05 22:46:18 +0100" MODIFIED_BY="[Empty name]">
<P>February 2012.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-08-05 22:46:13 +0100" MODIFIED_BY="[Empty name]">
<P>Asst Prof Adly, Pediatric Hematology Clinic, Aim Shams University, Cairo, Egypt (amiradiabetes@yahoo.com).</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-08-08 12:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Estimated enrolment: 60 (30 per treatment arm).</P>
<P>Estimated study completion date: February 2013.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>DFO: desferrioxamine<BR/>MRI: magnetic resonance imaging<BR/>RCT: randomised controlled trial<BR/>sc: subcutaneously<BR/>SCD: sickle cell disease<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-08-08 12:31:24 +0100" MODIFIED_BY="Sheila A Worsley">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-08-05 21:20:17 +0100" MODIFIED_BY="Sheila A Worsley" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 10:18:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abdelrazik-2007">
<DESCRIPTION>
<P>The authors did not report any information about how randomisation was undertaken. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 10:48:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aydinok-2005">
<DESCRIPTION>
<P>The authors did not report any information about how randomisation was undertaken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-22 13:27:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aydinok-2007">
<DESCRIPTION>
<P>"The randomization sequence was generated by the Department of Mathematical Statistics at the University of Berne, Switzerland according to local policy". Following central registration of a subject by the investigator, the trial co-ordinator assigned the intervention according to the randomisation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-22 13:13:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Choudhry-2004">
<DESCRIPTION>
<P>Email correspondence between a review author and the corresponding author identified the following information regarding randomisation methods. "We make slips indicating the dose of deferiprone in a box. Patients were asked to pick up one slip from the box. Child was given the dose as mentioned on the slip".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 12:03:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Beshlawy-2008">
<DESCRIPTION>
<P>The authors did not report any information about how randomisation was undertaken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-11 16:16:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Galanello-2006">
<DESCRIPTION>
<P>The authors did not report any information about how randomisation was undertaken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 12:29:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomber-2004">
<DESCRIPTION>
<P>The authors did not report any information about how randomisation was undertaken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-05 21:16:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ha-_x0028_i_x0029_-2006">
<DESCRIPTION>
<P>Permutted block randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-05 21:20:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ha-_x0028_ii_x0029_-2006">
<DESCRIPTION>
<P>Permutted block randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-20 10:40:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maggio-2002">
<DESCRIPTION>
<P>The authors report "computer generated random list with permuted blocks of 10" were used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-20 10:41:12 +0000" MODIFIED_BY="Sheila A Worsley" RESULT="UNKNOWN" STUDY_ID="STD-Maggio-2009">
<DESCRIPTION>
<P>The authors report "computer generated random list with permuted blocks of 10" were used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 13:07:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mourad-2003">
<DESCRIPTION>
<P>The authors did not report any information about how randomisation was undertaken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 13:33:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olivieri-1990">
<DESCRIPTION>
<P>The authors did not report any information about how randomisation was undertaken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 13:38:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olivieri-1997">
<DESCRIPTION>
<P>The authors did not report any information about how randomisation was undertaken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-27 08:43:46 +0100" MODIFIED_BY="Sheila A Worsley" RESULT="UNKNOWN" STUDY_ID="STD-Pennell-2006">
<DESCRIPTION>
<P>The authors did not report any information about how randomisation was undertaken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-11 10:08:40 +0000" MODIFIED_BY="Sheila A Worsley" RESULT="UNKNOWN" STUDY_ID="STD-Tamaddoni-2010">
<DESCRIPTION>
<P>The authors did not report any information about how randomisation was undertaken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 14:29:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanner-2007">
<DESCRIPTION>
<P>The authors did not report any information about how randomisation was undertaken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-08-05 21:20:19 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 10:40:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abdelrazik-2007">
<DESCRIPTION>
<P>The authors did not report any information about how treatment allocation was concealed. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 10:48:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aydinok-2005">
<DESCRIPTION>
<P>The authors did not report any information about how treatment allocation was concealed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 08:39:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aydinok-2007">
<DESCRIPTION>
<P>The trial report states that the intervention was assigned according to the randomisation sequence "without concealing the sequence prior to allocation".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-22 13:14:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Choudhry-2004">
<DESCRIPTION>
<P>Email correspondence between a review author and the corresponding author identified the following information regarding randomisation methods. "We make slips indicating the dose of deferiprone in a box. Patients were asked to pick up one slip from the box. Child was given the dose as mentioned on the slip".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 12:03:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Beshlawy-2008">
<DESCRIPTION>
<P>The authors did not report any information about how treatment allocation was concealed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-11 16:16:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Galanello-2006">
<DESCRIPTION>
<P>The authors did not report any information about how treatment allocation was concealed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 12:29:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomber-2004">
<DESCRIPTION>
<P>The authors did not report any information about how treatment allocation was concealed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-05 21:16:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ha-_x0028_i_x0029_-2006">
<DESCRIPTION>
<P>Permutted block randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-05 21:20:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ha-_x0028_ii_x0029_-2006">
<DESCRIPTION>
<P>Permutted block randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 13:02:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maggio-2002">
<DESCRIPTION>
<P>The authors report "to ensure...., treatment was assigned by telephone contact of each participating centre with a physician of the co-ordinating centre who kept the randomisation sequence but was not otherwise involved in the study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-28 13:53:48 +0100" MODIFIED_BY="Sheila A Worsley" RESULT="YES" STUDY_ID="STD-Maggio-2009">
<DESCRIPTION>
<P>The authors report "to ensure allocation concealment, treatment was assigned by telephone contact from the coordinating centre".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 13:07:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mourad-2003">
<DESCRIPTION>
<P>The authors did not report any information about how treatment allocation was concealed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 13:33:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olivieri-1990">
<DESCRIPTION>
<P>The authors did not report any information about how treatment allocation was concealed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 13:38:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olivieri-1997">
<DESCRIPTION>
<P>The authors did not report any information about how treatment allocation was concealed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 13:59:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pennell-2006">
<DESCRIPTION>
<P>The authors did not report any information about whether treatment allocation was concealed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-11 10:11:24 +0000" MODIFIED_BY="Sheila A Worsley" RESULT="UNKNOWN" STUDY_ID="STD-Tamaddoni-2010">
<DESCRIPTION>
<P>The authors did not report any information about how treatment allocation was concealed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-18 12:05:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tanner-2007">
<DESCRIPTION>
<P>Trial reports that the patients and clinicians were aware of how treatment was to be allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-08-05 21:31:46 +0100" MODIFIED_BY="Sheila A Worsley" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-07-15 13:12:10 +0100" MODIFIED_BY="Sheila A Worsley" RESULT="UNKNOWN" STUDY_ID="STD-Abdelrazik-2007">
<DESCRIPTION>
<P>Cardiac assessment was undertaken by a clinician blinded to treatment allocation. It was unclear as to whether there was blinding to treatment allocation for assessment of the other outcomes. It was unclear whether participants and clinicians administering treatment were blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-23 11:43:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aydinok-2005">
<DESCRIPTION>
<P>The authors did not report any information as to whether participants, personnel or outcome assessors were blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-23 11:43:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aydinok-2007">
<DESCRIPTION>
<P>The authors did not report any information as to whether participants, personnel or outcome assessors were blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-23 11:52:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Choudhry-2004">
<DESCRIPTION>
<P>The authors did not report any information as to whether participants, personnel or outcome assessors were blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-23 12:03:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Beshlawy-2008">
<DESCRIPTION>
<P>The authors did not report any information as to whether participants, personnel or outcome assessors were blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-11 16:17:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Galanello-2006">
<DESCRIPTION>
<P>The authors did not report any information as to whether participants, personnel or outcome assessors were blinded to treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-23 12:29:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomber-2004">
<DESCRIPTION>
<P>The authors did not report any information as to whether participants, personnel or outcome assessors were blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-23 12:45:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ha-_x0028_i_x0029_-2006">
<DESCRIPTION>
<P>The authors did not report any information as to whether participants, personnel or outcome assessors were blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-23 12:45:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ha-_x0028_ii_x0029_-2006">
<DESCRIPTION>
<P>The authors did not report any information as to whether participants, personnel or outcome assessors were blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-23 13:03:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maggio-2002">
<DESCRIPTION>
<P>Outcome assessors were blinded to treatment allocation: "under code by physicians blinded to the trial treatment"<BR/>Statistical analysis was also performed under code by a biostatistician blinded to trial treatment. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-05 21:31:46 +0100" MODIFIED_BY="Sheila A Worsley" RESULT="YES" STUDY_ID="STD-Maggio-2009">
<DESCRIPTION>
<P>Outcome assessors were blinded to treatment allocation: "under code by physicians blinded to the trial treatment". Statistical analysis was also performed under code by a biostatistician blinded to trial treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-23 13:07:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mourad-2003">
<DESCRIPTION>
<P>The authors did not report any information as to whether participants, personnel or outcome assessors were blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-23 13:33:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olivieri-1990">
<DESCRIPTION>
<P>The authors did not report any information as to whether participants, personnel or outcome assessors were blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-23 13:38:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olivieri-1997">
<DESCRIPTION>
<P>The authors did not report any information as to whether participants, personnel or outcome assessors were blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-10 11:09:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pennell-2006">
<DESCRIPTION>
<P>The primary outcome was independently measured in a different country (UK) to where the trial took place and the findings were not communicated back to the clinicians during the course of the trial. No one else (participants, personnel, assessors of other outcomes were blinded to treatment allocation).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-10 11:09:44 +0000" MODIFIED_BY="Sheila A Worsley" RESULT="YES" STUDY_ID="STD-Tamaddoni-2010">
<DESCRIPTION>
<P>The authors reported by separate communication that outcome assessors but not clinicians were blinded to treatment allocation. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-23 14:29:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanner-2007">
<DESCRIPTION>
<P>The authors did not report any information as to whether participants, personnel or outcome assessors were blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-08-08 12:31:24 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-05 20:38:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abdelrazik-2007">
<DESCRIPTION>
<P>All randomised participants were included in the analysis for all outcomes: there were no missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-05 20:46:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aydinok-2005">
<DESCRIPTION>
<P>All randomised participants were included in the analysis for all outcomes: there were no missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-22 13:27:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aydinok-2007">
<DESCRIPTION>
<P>There was an imbalance in missing data across the treatment arms. 4 participants from the comparator group (DFO) were not included in the outcome analysis: 2 withdrew consent due to refusal to take DFO; 1 died from arrhythmia-induced congestive heart failure at the start of the trial and 1 developed agranulocytosis at week 14.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-05 20:54:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Choudhry-2004">
<DESCRIPTION>
<P>For all pre-specified outcomes, there were no missing data. However, for the non-pre-specified outcome, there were missing data in the deferiprone treated arms and whilst the reason why the participants (n = 3) were not included in the analysis was reported, the authors did not state which of the 2 deferiprone treated groups, the missing data were derived from.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-22 13:29:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-El_x002d_Beshlawy-2008">
<DESCRIPTION>
<P>Variable numbers of participants were included in the analysis for each outcome. The number of participants withdrawn from the trial was reported and reasons detailed, but this number does not tally with the numbers included in each analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-23 12:29:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Galanello-2006">
<DESCRIPTION>
<P>Although 1 participant in the treatment group was withdrawn due to intolerance to deferiprone, this is unlikely to effect the findings of the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-05 21:13:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gomber-2004">
<DESCRIPTION>
<P>No reasons for the missing data from 2 participants were reported.</P>
<P>1 participant in the DFO treatment arm opted to received deferiprone. Outcome data for this participant were analysed by received treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-05 21:17:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ha-_x0028_i_x0029_-2006">
<DESCRIPTION>
<P>Overall 5 participants were excluded from outcome analysis as the trial was stopped early due to an unexpected death in the deferiprone arm in <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>. Only participants who had completed a minimum of 6 months of treatment were included in the final analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-05 21:20:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ha-_x0028_ii_x0029_-2006">
<DESCRIPTION>
<P>All randomised participants were included in the analysis for all outcomes: there were no missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-05 21:26:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maggio-2002">
<DESCRIPTION>
<P>All randomised participants were included in the analysis for all outcomes: there were no missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-15 11:07:30 +0000" MODIFIED_BY="Sheila A Worsley" RESULT="NO" STUDY_ID="STD-Maggio-2009">
<DESCRIPTION>
<P>Statistical analysis was performed based on the "intention-to-treat" principle. However, the trial was stopped before the planned 5 years of treatment were completed for all patients due to success of treatment. A total of 33 patients (12 who received combined therapy and 21 who received deferiprone only) withdrew prior to termination of the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-05 21:34:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mourad-2003">
<DESCRIPTION>
<P>All randomised participants were included in the analysis for all outcomes: there were no missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-05 21:36:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olivieri-1990">
<DESCRIPTION>
<P>All randomised participants were included in the analysis for all outcomes: there were no missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-08 12:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Olivieri-1997">
<DESCRIPTION>
<P>The trial analysed data from 58% of randomised participants. Of the 42% randomised participants who were not available for outcome analysis:</P>
<UL>
<LI>22% randomised participants had not completed the required 24 months treatment at the time of analysis for this trial report;</LI>
<LI>16% deferiprone treated participants and 5% DFO treated participants were withdrawn due to treatment induced side effects.</LI>
</UL>
<P>This missing data may inappropriately effect the statistical findings of the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-05 21:47:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pennell-2006">
<DESCRIPTION>
<P>All participants were included in the analysis of the outcomes serum ferritin and adverse events.</P>
<P>Data from 1 participant in the comparator (DFO) group was not included in the analysis of the cardiac outcomes (primary outcome) and last observation carried forward method was used to accommodate the missing data from 3 other participants (2 treatment group and 1 from the comparator group) in the cardiac outcomes (primary outcome).</P>
<P>Two participants in each treatment group did not have a liver iron concentration assessment at 12 months and the data from these participants were missing from the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-05 21:52:16 +0100" MODIFIED_BY="Sheila A Worsley" RESULT="YES" STUDY_ID="STD-Tamaddoni-2010">
<DESCRIPTION>
<P>All randomised participants were included in the analysis for all outcomes: there were no missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-05 21:55:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanner-2007">
<DESCRIPTION>
<P>As the trial does not report the number of participants included in each outcome assessment. The trial reports the number completing treatment and the reasons why 4 participants in the treatment group (3 adverse events &amp; 1 participant request) and 3 (1 adverse event &amp; 2 participant requests) in the comparator group were withdrawn from the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-08-08 12:22:45 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-08 12:16:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Abdelrazik-2007">
<DESCRIPTION>
<P>The authors reported that whilst liver iron concentration was measured, this could only be performed in a small number of participants and the data were not presented in the manuscript. The manuscript also states that total iron binding capacity and ferritin concentrations would be measured, but data for this outcome were not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-05 20:46:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aydinok-2005">
<DESCRIPTION>
<P>Liver iron concentration was identified as an outcome to be measured in this trial but whilst it was reported to be measured, no actual data were presented rather the data for this outcome were converted into 'iron excretion' in mg/kg/day and only this is recorded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-15 11:07:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aydinok-2007">
<DESCRIPTION>
<P>All outcomes pre-specified were reported in the manuscript.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-08 12:19:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Choudhry-2004">
<DESCRIPTION>
<P>All outcomes pre-specified were reported in the manuscript.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 12:10:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El_x002d_Beshlawy-2008">
<DESCRIPTION>
<P>All outcomes pre-specified were reported in the manuscript. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 12:29:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Galanello-2006">
<DESCRIPTION>
<P>Compliance to deferiprone was pre-specified as an outcome but was not measured or reported in the manuscript.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-08 12:22:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gomber-2004">
<DESCRIPTION>
<P>Three pre-specified outcomes: monthly blood counts, liver function tests (measured 3 monthly) and hepatic markers were not reported on. Of these, liver function tests are critical outcomes for this participant population.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-15 11:07:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ha-_x0028_i_x0029_-2006">
<DESCRIPTION>
<P>All outcomes pre-specified were reported in the manuscript.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-15 11:07:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ha-_x0028_ii_x0029_-2006">
<DESCRIPTION>
<P>All outcomes pre-specified were reported in the manuscript.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 13:05:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maggio-2002">
<DESCRIPTION>
<P>All outcomes pre-specified were reported in the manuscript.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-28 14:08:34 +0100" MODIFIED_BY="Sheila A Worsley" RESULT="YES" STUDY_ID="STD-Maggio-2009">
<DESCRIPTION>
<P>All outcomes pre-specified were reported in the manuscript.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-18 12:04:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mourad-2003">
<DESCRIPTION>
<P>Data for two pre-specified outcomes were not reported in the paper: iron excretion at 1 and 12 months and renal function. Both are important clinical markers of the efficacy of iron chelation therapy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 13:34:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olivieri-1990">
<DESCRIPTION>
<P>All outcomes pre-specified were reported in the manuscript.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 13:39:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olivieri-1997">
<DESCRIPTION>
<P>All outcomes pre-specified were reported in the manuscript.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 14:24:02 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pennell-2006">
<DESCRIPTION>
<P>The following pre-specified outcomes were not reported in the manuscript: absolute neutrophil count; ALT; serum zinc levels and serum creatinine levels.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-11 10:14:52 +0000" MODIFIED_BY="Sheila A Worsley" RESULT="NO" STUDY_ID="STD-Tamaddoni-2010">
<DESCRIPTION>
<P>The following pre-specified outcomes were not reported in the manuscript: haemoglobin, hematocrit, whole blood count, absolute neutrophil and platelet count measurements, liver and renal function and compliance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 14:31:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tanner-2007">
<DESCRIPTION>
<P>All outcomes pre-specified were reported in the manuscript.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-08-08 12:19:32 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-22 13:26:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abdelrazik-2007">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 10:54:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aydinok-2005">
<DESCRIPTION>
<P>The trial was reported in an abstract thus there is little data available to make an assessment of whether the trial was free of other bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-22 13:28:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aydinok-2007">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-08 12:19:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Choudhry-2004">
<DESCRIPTION>
<P>The trial documented sponsorship by the manufacturer of deferiprone: CIPLA Ltd.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-22 13:14:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El_x002d_Beshlawy-2008">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-05 21:11:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Galanello-2006">
<DESCRIPTION>
<P>The last author of the paper is an Apotex Research Inc. employee: Apotex Research Inc. funded this trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 12:30:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomber-2004">
<DESCRIPTION>
<P>There was insufficient information to assess whether an important risk of bias exists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-05 21:17:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ha-_x0028_i_x0029_-2006">
<DESCRIPTION>
<P>Trial was stopped after 18 months recruitment due to an unexpected sudden death in the deferiprone treatment arm in <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-05 21:20:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ha-_x0028_ii_x0029_-2006">
<DESCRIPTION>
<P>Trial was stopped after 18 months recruitment due to an unexpected sudden death in the deferiprone treatment arm in <LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-22 13:30:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maggio-2002">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-28 14:07:19 +0100" MODIFIED_BY="Sheila A Worsley" RESULT="NO" STUDY_ID="STD-Maggio-2009">
<DESCRIPTION>
<P>The planned duration of treatment was 5 years. However, because of the beneficial effects, in terms of serum ferritin levels reduction in the sequential deferiprone-DFO group, observed after the interim analysis performed at January 2008, the trial was stopped before the planned 5 years of treatment were completed for all patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-22 13:30:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mourad-2003">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-22 13:31:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olivieri-1990">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-23 13:36:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olivieri-1997">
<DESCRIPTION>
<P>The trial was reported in an abstract thus there is little data available to make an assessment of whether the trial was free of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-22 13:31:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pennell-2006">
<DESCRIPTION>
<P>The trial documented sponsorship by the manufacturer of deferiprone: Apotex</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-22 13:31:44 +0100" MODIFIED_BY="Sheila A Worsley" RESULT="YES" STUDY_ID="STD-Tamaddoni-2010">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-05 21:25:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tanner-2007">
<DESCRIPTION>
<P>The trial documented sponsorship by the manufacturer of deferiprone: Apotex.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2013-08-09 10:56:59 +0100" MODIFIED_BY="Sheila A Worsley">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-08-09 10:56:59 +0100" MODIFIED_BY="Sheila A Worsley" NO="1">
<TITLE MODIFIED="2013-08-08 13:11:47 +0100" MODIFIED_BY="Sheila A Worsley">Individual trial data (mean (SD)): measures of iron overload</TITLE>
<TABLE COLS="11" ROWS="39">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Trial details</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Endpoint (treatment duration)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Intervention</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Serum ferritin: start</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Serum ferritin: end</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Urinary iron: start</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Urinary iron: end</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Liver iron: start</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Liver iron: end</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Myocardial T2*: start</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Myocardial T2*: end</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>12 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4500 (1250) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1250 (750) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.41 (0.27) mg/kg/24h</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.76 (0.49) mg/kg/24h</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4250 (1500) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1200 (850) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.35 (0.12) mg/kg/24h</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.53 (0.21) mg/kg/24h</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<LINK REF="STD-Aydinok-2005" TYPE="STUDY">Aydinok 2005</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>12 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4070 (3223) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3209 (2279) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.38 (0.22) mg/kg/day (mean on days of therapy)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30.7 (10.6) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28.6 (12.8) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4350 (3342) µg/L</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2954 (2765) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.88 (0.32) mg/kg/day (mean on days of therapy)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26.6 (5.4) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18.1 (11.6) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>12 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone (50 mg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6232 (3379) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4008 (1946) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone (75mg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7214 (4426) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3785 (2050) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3681 (2015) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7705 (1418) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>54 weeks</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2926 (1107) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 900 µg/L (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.38 (0.23)<SUP>a</SUP> mg/24h</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15.8 (7.1) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 7.5 (3.6) mg/g d/w (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2838 (967) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 1700 µg/L (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.18 (0.10)<SUP>a</SUP> mg/24h<SUP> </SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22.5 (10.1) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 11.5 (6.3) mg/g d/w (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2865 (983) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 1050 µg/L (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.45 (0.26)<SUP>a</SUP> mg/24h<SUP> </SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17.1 (9.1) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 6.5 (3.2) mg/g d/w (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>12 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2048 (685) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 1750 µg/L (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1629 (744) µg/g w/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2257 (748) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 1850 µg/L (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1629 (642) µg/g w/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>6 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2673 (886) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3423 (1581) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.78 (2.12) mg/day</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5077 (1715) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3718 (738) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7.96 (5.05) mg/day</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3348 (1526) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3377 (1222) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7.14 (4.99) mg/day</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>up to 20 months (trial terminated early)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>up to 20 months (trial terminated early)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>12 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2283 (754) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2061 (853) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11.4 (8.5) mg/24h</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15.8 (10.9) mg/24h</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3363 (5490) µg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2341 (2197) µg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2019 (678) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1787 (893) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15.7 (12.8) mg/24h</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19.9 (13.6) mg/24h</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3516 (2974) µg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3166 (2519) µg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>up to 5 years (trial terminated early)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1787 (735) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 mths:</P>
<P>1400 (770) ng/ml</P>
<P>5 years:</P>
<P>1369 (816) ng/ml<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Liver T2* 4.0 (2.9) ms<SUP>c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Liver T2* 4.4 (3.4) ms<SUP>c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20.1 (11.9) ms<SUP>c </SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21.8 (12.6) ms<SUP>c</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1890 (816) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 mths:</P>
<P>1633 (841) ng/ml</P>
<P>5 years:</P>
<P>1588 (1217) ng/ml<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Liver T2* 4.0 (5.9) ms<SUP>c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Liver T2* 3.5 (4.3) ms<SUP>c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25.0 (11.3) ms<SUP>c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26.0 (11.8) ms<SUP>c</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>12 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4153 (1715) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 mths:</P>
<P>3005 (1303) µg/L</P>
<P>12 mths:</P>
<P>2805 (1084) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22.9 (19.2) mg/kg/24hr</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5506 (2375) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 mths:</P>
<P>4856 (2615) µg/L</P>
<P>12 mths:</P>
<P>3998 (2409) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Olivieri-1990" TYPE="STUDY">Olivieri 1990</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>6 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12.3 (6.7) mg/kg/day</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18.2 (15.3) mg/kg/day</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>24 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8.9 (5.23) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13.7 (5.23) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6.9 (3.82) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7.9 (5.52) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>12 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1791 (1029) µg/L</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1610 (980.91) µg/L</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6.16 (6.0) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13.0 ms (32%)<SUP>d</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16.5 ms (+27%, CV 38%)<SUP>d</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2795 (2441) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2329 (2078.7) µg/L</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6.32 (5.8) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13.3 ms (30%)<SUP>d</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15.0 ms (+13%, CV 39%)<SUP>d</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>12 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2986 (612) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 mths: 2453 (318) ng/ml</P>
<P>12 mths: 2082 (221) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2945 (591) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 mths: 2702 (242) ng/ml</P>
<P>12 mths: 2451 (352) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>12 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1574 (CV 11) µg/L<SUP>d</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>598 (CV 14) µg/L<SUP>d</SUP>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Liver T2* 4.9 (CV 0.52) ms [&gt;19]<SUP>d</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10.7 ms<SUP>d</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11.7 (CV 0.08) ms [&gt;20]<SUP>d</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17.7 ms<SUP>d</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO + placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1379 (CV 10) µg/L<SUP>d</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1146 (CV 11) µg/L<SUP>d</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Liver T2* 4.2 (CV 0.62) ms [&gt;19]<SUP>d</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5.0 ms<SUP>d</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12.4 (CV 0.11) ms [&gt;20]<SUP>d</SUP>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15.7 ms<SUP>d</SUP>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>d/w = dry weight liver; w/w = wet weight liver.<BR/>
<SUP>a</SUP>Hepatic iron only, measured as [excretion = iron transfused + [(LIC t=o -LIC t=54 weeks) x 10.6 x wt/kg)]/no of days between biopsies]; faecal iron excretion not accounted for in calculations.<BR/>
<SUP>b</SUP>Serum ferritin measures were given annually for up to 5 years of follow up. Only values for the first 12 months (for consistency with reporting from other trials) and for 5 years are reported in this table.<BR/>
<SUP>c</SUP>The mean (SD) duration from entry into trial to time of T2* MRI basal assessment was 17 (18) months in the combined treatment group and 18 (17) in the deferiprone alone treatment group. Final evaluation was performed after a further 16 (5) months and 14 (6) months respectively. Global left ventricle heart T2* are reported here; paper also reports septum heart T2* values at baseline and endpoint.<BR/>
<SUP>d</SUP>Geometric mean (CV; coefficient of variation).</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2013-08-08 13:11:59 +0100" MODIFIED_BY="Sheila A Worsley" NO="2">
<TITLE MODIFIED="2013-08-08 13:11:59 +0100" MODIFIED_BY="Sheila A Worsley">Serum ferritin concentration (mean (SD)): deferiprone versus DFO</TITLE>
<TABLE COLS="10" ROWS="6">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Trial</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No Deferiprone/DFO</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Deferiprone:baseline</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Def: end trial</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Absolute change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>% change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>DFO: baseline</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>DFO: end trial</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Absolute change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>% change</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18/20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2926 (1107) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 900 µg/L (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of approx. 2026 µg/L</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not available</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2838 (967) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 1650 µg/L (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of approx. 1188 µg/L</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not available</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11/7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2672.9 (886.4) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3422.7 (1581.0) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 749.8 (1155.8) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 28%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5077.2 (1715.0) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3718.3 (738.4) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 1358.9 (1374.14) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 27%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6/7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 398.4 (1073) mmol/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not available</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 74.2 (1629) mmol/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not available</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>71/ 73</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2283 (754) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2061 (853) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 222 (783) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 9.7%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2019 (678) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1787 (893) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 232 (619) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 11.4%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>29 /32</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1791 (1029) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1610 (980.91) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 181 (826) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 10.1%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2795 (2441) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2329 (2078.7) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 466 (739) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 16.7%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2013-08-08 13:15:47 +0100" MODIFIED_BY="Sheila A Worsley" NO="3">
<TITLE MODIFIED="2013-08-08 13:15:09 +0100" MODIFIED_BY="Sheila A Worsley">Mean (SD) measures of iron overload: Aydinok 2005</TITLE>
<TABLE COLS="5" ROWS="5">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Treatment regimen</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Total iron excretion</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Plasma NTBI change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Chelation efficiency</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Urinary iron excretion</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.56 (0.09) mg/kg/day</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.00 (0.53) mM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6.65 (0.99) %</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>98 (14.8) %</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.77 (0.25) mg/kg/day</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.72 (0.45) mM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23.1 (10.7) %</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28 (10.3) %</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.69 (0.09) mg/kg/day</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.84 (0.87) mM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7.34 (0.91) %</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>84 (10.6) %</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mean value from across 5 measurement points: weeks 1, 12, 26, 38, 54. Calculated as [iron transfused/year (mg) + (LIC at time 0 - LIC at time 1 year) x 10.6 x body weight in kg]/ number of days of treatment.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Plasma NTBI was measured by HPLC at baseline and at weeks 1, 12, 26 and 54. Data were not reported for the outcome measurements at these time points.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chelation efficiency calculated as [iron excretion / chelator dose] multiplied by [molecular weight of the respective chelator /56] x n x 100, where 56 is the molecular weight of iron and n is 3 or 1 with deferiprone and DFO respectively.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Urine iron (%) mean over study calculated from mean urine iron excretion / total iron excretion.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>DFO: desferrioxamine<BR/>HPLC: high performance liquid chromatography<BR/>LIC: liver iron concentration<BR/>mM: millimolar (denotes a concentration of 1 micromole per litre)<BR/>NTBI: non-transferrin bound iron</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2013-08-08 13:16:12 +0100" MODIFIED_BY="Sheila A Worsley" NO="4">
<TITLE MODIFIED="2013-08-08 13:12:09 +0100" MODIFIED_BY="Sheila A Worsley">Liver iron concentration (mean (SD)): deferiprone versus DFO</TITLE>
<TABLE COLS="10" ROWS="6">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Trial</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No. Deferiprone/ DFO</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Deferiprone: baseline</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Def: end of study</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Absolute change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>% change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>DFO: baseline</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>DFO: end of study</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Absolute change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>% change</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17/15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15.8 (7.1) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 7.5 (3.6) mg/g d/w (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of approx. 8.5 mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22.5 (10.1) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 11.5 (6.3) mg/g d/w (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of approx. 11 mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6/7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 5.63 (4.24) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not available</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 2.90 (1.27) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not available</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21/15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3363 (5490) µg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2341 (2197) µg/g d/w (end of trial = median 30 months)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 1022 (3511) µg/g/ d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 30.4%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3516 (2974) µg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3166 (2519) µg/g d/w (end of trial = median 30 months)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 350 (524) µg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 9.95%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19/18</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8.90 (5.23) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13.70 (5.23) mg/g d/w (end of trial = mean 33 months)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 4.8 mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 53.9%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6.90 (3.82) mg/g d/w (end of trial = mean 33 months)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7.90 (5.52) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 1.0 mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 14.5%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27/30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6.16 (6.0) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 0.93 (2.9) mg/g d/w (-10% from baseline)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 10.1%<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6.32 (5.8) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 1.54 (2.5) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 24.4%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>d/w = dry weight liver<BR/>
<SUP>a</SUP>
<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK> reports a reduction of 10.1%, although note that this figure is not equal to % of absolute change over baseline value.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2013-08-09 10:04:21 +0100" MODIFIED_BY="Sheila A Worsley" NO="5">
<TITLE MODIFIED="2011-05-30 20:33:43 +0100" MODIFIED_BY="Sheila A Worsley">Adverse events</TITLE>
<TABLE COLS="8" ROWS="28">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Trial Name</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Prior iron chelation therapy</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Intervention</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Total Adverse Events</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Adverse Event Details</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Dose Reduction</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Temporary Withdrawal</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Permanent Withdrawal</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Prior DFO received at a daily dose of 40 mg/kg/day by sc infusion pump over 8 - 10h, 5 - 7 nights a week for "several years". </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8/30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1/30 (mild arthropathy); 1/30 (vomiting); 2/30 (abdominal pain); 1/30 (diarrhoea)<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> 3/30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none noted<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Previous DFO therapy. All patients had washout period of two weeks with no iron chelation therapy prior to initiating study treatment.</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1/12 (neutropenia); 1/12 (aseptic meningitis at week 45); 1/12 (acute cerebellar syndrome with dizziness, tinitus, truncal ataxia)<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (acute cerebellar syndrome)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1/9 (neutopenia weeks 4/10 with subsequent agranulocytosis week 14); 1/9 (arthralgia grade 2); &#8220;mild, local reactions observed in several patients treated with DFO&#8221;<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (agranulocytosis at week 14)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Choudhry-2004" TYPE="STUDY">Choudhry 2004</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>not reported</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone (50 mg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15/30 (joint pain: 6 mild, 8 moderate, 1 severe); 7/30 (leucopenia/neutropenia)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (leucopenia/neutropenia: drug immediately withdrawn and managed conservatively)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (2 neutropenia/leucopenia; 1 severe multiple joints involvement)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone (75 mg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6/21 (joint pain: 3 mild, 3 moderate); 5/21 (leucopenia/neutropenia)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (neutropenia/leucopenia)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (leucopenia/neutropenia: drug immediately withdrawn and managed conservatively)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (neutropenia/leucopenia)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>
</P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>not reported</P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1/21 (agranulocytosis); 1/21 (jaundice/very high liver enzymes); 8/21 (arthropathy); 7/21 (nausea/vomiting; 2/21 (anorexia)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (to 50 mg/kg due to arthropathy)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (1 agranulocytosis; 1 jaundice/very high liver enzymes)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported  </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1/23 (neutropenia); 1/23 (jaundice/very high liver enzymes); 5/23 (skin reactions/allergy, swelling); 1/23 (systemic allergy); 1/23 (arthropathy)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported  </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 /22 (neutropenia); 2/22 (jaundice/very high liver enzymes); 3/22 (skin reactions/allergy, swelling); 6/22 (arthropathy); 3/22 (musculoskeletal pain); 4/22 (nausea/vomiting); 2/22 (weakness, fever); 1/22 (insomnia; 5/22 (anorexia)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (to 50 mg/kg due to arthropathy)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (jaundice/very high liver enzymes)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Prior iron chelation therapy received: DFO treatment inferred but not explicitly stated.</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7/29</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5/29 (vomiting); 3/29 (abdominal pain); 1/29 (diarrhoea); 5/12 (transient increase in ALT three times of upper limit).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (neutropenia on day 2 after receiving DFO therapy only)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> 2/30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1/30 (abscess at site of infusion); 1/30 (allergic reaction); 1/30 (neutropenia); 1/14 (transient increase in ALT three times of upper limit).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>
<SUP>c</SUP>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>not reported</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone (with or without DFO in combination)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2/21 (arthropathy of large joints)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (arthropathy of large joints)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>no adverse effects observed</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>All participants had received DFO prior to trial enrollment.</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24/71</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16/71 (hypertransaminasemia); 3/71 (nausea); 2/71 (leucopenia); 2/71 (mild joint pain); 1/71 (infection)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (nausea). Dose and duration of reduction were not reported.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (3 transient hypertransaminasemia; 1 infection). Dose and duration of withdrawal were not reported.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (3 recurrence of hypertransaminaesima; 2 leukocytopenia). Timepoint for withdrawal was not reported.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11/73</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6/73 (pain/erythema at injection site); 2/73 (ototoxicity); 2/73 (infection); 1/73 (hypertransaminasemia)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 (6 pain and erythema at the injection site; 1 transient hypertransaminasemia). Dose and duration of reduction were not reported.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (2 infection (<I>Yersinia enterocolitiica</I>); 2 ototoxicity). Dose and duration of withdrawal were not reported.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>
<SUP>d</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>All patients treated with either DFO or deferiprone prior to study with one week washout period.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15/65 (neutropenia); 5/65 (arthralgia); 7/65 (gastrointestinal problems); 22/65 (&gt; 2-fold increase in ALT)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dose reduction reported in 25/51 (49%) patients. Dose and duration of reduction were not reported.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number of temporary withdrawals not reported, but "no statistically significant difference in temporary and definitive discontinuation of treatment between the groups"</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3/88 (agranulocytosis); 11/88 (neutropenia); 6/88 (arthralgia); 16/88 (gastrointestinal problems); 23/88 (&gt;2-fold increase in ALT</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dose reduction reported in 26/46 (56.5%) patients. Dose and duration of reduction were not reported.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number of temporary withdrawals not reported, but "no statistically significant difference in temporary and definitive discontinuation of treatment between the groups"</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>All participants had received DFO prior to trial enrolment</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5/11 (nausea); 3/11 (joint pain/swelling/stiffness)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12/14 (problems at site of injection: pain, itching, erythema, swelling and induration)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD VALIGN="TOP">
<P>not reported</P>
</TD>
<TD VALIGN="TOP">
<P>2/27 (agranulocytosis)</P>
</TD>
<TD VALIGN="TOP">
<P>none reported</P>
</TD>
<TD VALIGN="TOP">
<P>none reported</P>
</TD>
<TD VALIGN="TOP">
<P>2 (2 x agranulocytosis)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DFO</P>
</TD>
<TD VALIGN="TOP">
<P>not reported</P>
</TD>
<TD VALIGN="TOP">
<P>0/30 (agranulocytosis)</P>
</TD>
<TD VALIGN="TOP">
<P>none reported</P>
</TD>
<TD VALIGN="TOP">
<P>none reported</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>All participants had received DFO prior to trial enrolment.</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19/29 (gastrointestinal disturbance); 9/29 (increased appetite); 8/29 (pain/ swelling in joints); 1/29 (neutropenia)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12/31 (local reactions at infusion site); 6/31 (pain/swelling in joints)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>All participants had received DFO prior to trial enrolment.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3/40 (nausea); 3/40 (nausea with abdominal pain); 2/40 (diarrhoea); 2/40 (arthralgia); 8/40 (transient fluctuations in serum alanine ALT levels)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Temporary deferiprone dose reduction reported in "some" patients with gastrointestinal disturbances.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1/40 (abscess at site of infusion); 11/40 (skin allergic reactions)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>
<SUP>f</SUP>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Prior DFO received: mean dose 36.4 (11.1) mg/kg per day for 5.5 day/week (equivalent to 40.5 mg/kg for 5 d/week). No prior deferiprone received.</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>38% (gastrointestinal symptoms &#8211; generally mild); 3% (reactions at infusion site); 9% (joint pain/swelling); 1/28 (agranulocytosis; 2/28 (neutropenia)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (1 x agranulocytosis; 1 x reduction of myocardial T2* to &lt; 8ms; 1 x gastrointestinal symptoms; 1 x personal reasons)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO + Placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24% (gastrointestinal symptoms &#8211; generally mild); 6% (reactions at infusion site); 18% (joint pain/swelling)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (1 x artrial fibrillation; 2 x personal reasons)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>DFO: desferrioxamine<BR/>sc: subcutaneous</P>
<P>
<SUP>a</SUP>
<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>: 2 participants reported taste disorders and one patient reported transient dizziness and fatigue but type of therapy received by these participants was not reported in these patients.<BR/>
<SUP>b</SUP>
<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>: 5 participants developed nausea but type of therapy received by these participants was not reported.<BR/>
<SUP>c</SUP>
<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>: results for all participants receiving deferiprone alone or in combination were reported together in the paper.<BR/>
<SUP>d</SUP>
<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>: the period of observation for adverse effects was 307.98 person-years for combined deferiprone and DFO and 274.52 person-years for deferiprone only.<BR/>
<SUP>e</SUP>
<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>: other reported adverse events were fatigue (1); loss of appetite (1); headache (3); transient skin rash (2); abdominal discomfort (2). Treatment group was not reported for these adverse events which did not result in discontinuation of therapy.<BR/>
<SUP>f</SUP>
<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>: 28 participants completed combination treatment but actual sample sizes in which adverse events reported is unclear.<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2012-04-05 16:00:27 +0100" MODIFIED_BY="Sheila A Worsley" NO="6">
<TITLE MODIFIED="2011-05-31 10:16:45 +0100" MODIFIED_BY="Sheila A Worsley">Participant treatment compliance</TITLE>
<TABLE COLS="4" ROWS="26">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Study</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Intervention</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>How measured?</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Compliance Rate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Audit</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No results reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Audit</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No results reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Drug accounting at each visit - counting returned empty blisters of deferiprone and study specific questionnaire completed by patient or legal guardian at quaterly intervals.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8220;Generally excellent during the entire study period&#8221;. Only one patient who missed more than one chelation dose per week due to problems with swallowing.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Drug accounting at each visit - counting the used vials of DFO and study specific questionnaire completed by patient or legal guardian at quaterly intervals.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8220;Generally excellent during the entire study period&#8221; &#8211; no further details provided.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>
</P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Drug accounting at each visit; counting returned empty blisters of deferiprone and used vials of DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>"Compliance excellent during study period". 80% patients complained about difficulties in the parenteral use of DFO or problems inserting the needle. One patient dropped out for reasons of non-compliance.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Drug accounting at each visit; counting returned empty blisters of deferiprone.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>"Compliance excellent during study period". 76% patients complained about difficulties in the parenteral use of DFO or problems inserting the needle.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Drug accounting at each visit: counting returned used vials of DFO.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>"Compliance excellent during study period". 4 patients were excluded due to lack of compliance (timepoint not stated).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO: diary cards, weekly physical exam of infusion sites &amp; by the Crono infusion pump that recorded the number of completed infusions.</P>
<P>Deferiprone: pill counts, diary cards &amp; an electronic cap that recorded the time &amp; date of each opening of the tablet container.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>96.1 (5.0)% (compliance with DFO)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>diary cards, weekly physical exam of infusion sites &amp; by the Crono infusion pump that recorded the number of completed infusions.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>95.7 (5.7)%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>By reviewing the diaries maintained by the patients or their parents at each visit.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No results reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>By reviewing the diaries maintained by the patients or their parents at each visit.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No results reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Ha-_x0028_ii_x0029_-2006" TYPE="STUDY">Ha (ii) 2006</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>By reviewing the diaries maintained by the patients or their parents at each visit.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No results reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>By reviewing the diaries maintained by the patients or their parents at each visit.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No results reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Maggio-2002" TYPE="STUDY">Maggio 2002</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Compliance was not reported as an outcome in this trial. However the authors do note that 4/71 participants (6%) took a reduce dose of deferiprone due to low compliance. The dosage, duration and outcome of this change were not reported.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Compliance was not reported as an outcome in this trial. However the authors do note that 7/73 participants (10%) took a reduce dose of DFO due to low compliance. The dosage, duration and outcome of this change were not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>By counting pills in each returned bag of deferiprone and assessing the number of infusions of DFO registered on the electronic pump.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone: 92.7% (+/- 15.2%; range 27-100%);</P>
<P>DFO 70.6% (+/- 24.1%; range 25-100%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>By counting pills in each returned bag of deferiprone.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>93.6% (+/-9.7%; range 56-100%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>By counting the number of vials of DFO or tablets of deferiprone used. Trial does not report what constituted "adequate levels of adherence", but rates compliance as 'excellent' or 'good'.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Excellent (taking &gt;90% of recommended dose): 10 participants; good (taking 75% to 90% of recommended dose:) 1 participant.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>By counting the number of vials of DFO used. Trial does not report what constituted "adequate levels of adherence", but rates compliance as 'excellent' or 'good'.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Excellent (taking &gt;90% of recommended dose) : 11 participants; good (taking 75% to 90% of recommended dose): 3 participants.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Computerised bottles. Trial does not report what constituted "adequate levels of adherence".</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>94.9 +/- 6.69%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Ambulatory pumps. Trial does not report what constituted "adequate levels of adherence".</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>71.6 +/- 22.5%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Pennell-2006" TYPE="STUDY">Pennell 2006</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Using the medication event monitoring system device and calculated as the percent of openings with an interval &gt;4 hours recorded, divided by the number of doses prescribed. Trial does not report what constituted "adequate levels of adherence".</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>94 +/- 5.3%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Calculated as the percent of completed infusions, as determined by the Crono pumps, divided by the number of infusions prescribed. Trial does not report what constituted "adequate levels of adherence".</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>93 +/- 9.7%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>
</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Deferiprone + DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pill counting at bimonthly visits; % of complete DFO infusions divided by prescribed infusions.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO: 91.4 +/- 12.7%; deferiprone: 82.4 +/-18.1%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>% complete infusions divided by prescribed infusions.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>92.6 +/- 12.7%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2013-08-08 13:22:29 +0100" MODIFIED_BY="Sheila A Worsley" NO="7">
<TITLE MODIFIED="2012-02-29 15:32:18 +0000" MODIFIED_BY="Sheila A Worsley">Relative cost of treatment (participant = 10 kg): Gomber 2004</TITLE>
<TABLE COLS="4" ROWS="4">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Variables</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Group 1: Deferiprone</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Group 2: DFO</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Group 3: Deferiprone+DFO</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cost of drug</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Rs. 18: Rs. 6 per 250 mg capsule, 3 capsules daily.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Rs. 180: Rs.150 for vial of 500 mg +Rs. 30 for needle and syringe.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Rs. 198</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cost of treatment per week</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Rs. 126</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Rs. 900</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Rs. 486</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cost of treatment for 6 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Rs. 3024</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Rs. 21600</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Rs. 11664</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Rs = Rupees</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" MODIFIED="2013-08-08 13:23:47 +0100" MODIFIED_BY="Sheila A Worsley" NO="8">
<TITLE MODIFIED="2013-08-08 13:12:24 +0100" MODIFIED_BY="Sheila A Worsley">Serum ferritin concentration (mean (SD)): deferiprone versus deferiprone with DFO</TITLE>
<TABLE COLS="10" ROWS="5">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Trial</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No Treatment</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Deferiprone:baseline</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Def: end </B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Absolute change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>% change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Def+DFO: baseline</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Def+DFO: end </B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Absolute change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>% change</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8/12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4350 (3342) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2954 (2765) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 1396 µg/L (SD not reported)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 32%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4070 (3223) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3209 (2279) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 861 µg/L (SD not reported)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 32%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18/20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2926 (1107) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 900 µg/L (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of approx. 2026 µg/L</P>
<P> </P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not available</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2865 (983) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 1050 µg/L (estimated from graph)</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of approx. 1815 µg/L</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not available</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11/10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2672.90 (886.44) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3422.66 (1581.01) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 749.75 (1155.77) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 28%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3347.78 (1526.46) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3376.57 (1222.41) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 28.79 (915.86) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 0.9%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>74/78 (12 mths)</P>
<P>26/32 (5 years)</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1890 (816) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 mths:</P>
<P>1633 (841) ng/ml</P>
<P>5 years:</P>
<P>1588 (1217) ng/ml<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 mths:</P>
<P>reduction of 132 (724) ng/ml</P>
<P>5 years:</P>
<P>reduction of 115 (1009) ng/ml<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not available<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1787 (735) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 mths:</P>
<P>1400 (770) ng/ml</P>
<P>5 years:</P>
<P>1369 (816) ng/ml<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 mths:</P>
<P>reduction of 417 (589) ng/ml</P>
<P>5 years:</P>
<P>reduction of 396 (894) ng/ml<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not available<SUP>a</SUP>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>not all patients completed follow-up due to the trial being stopped early. Baseline values are shown for all randomised patients whereas endpoint values are given only for patients who completed follow up.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-09" MODIFIED="2013-08-08 13:23:57 +0100" MODIFIED_BY="Sheila A Worsley" NO="9">
<TITLE MODIFIED="2013-08-08 13:12:34 +0100" MODIFIED_BY="Sheila A Worsley">Liver iron concentration (mean (SD)): deferiprone versus deferiprone with DFO</TITLE>
<TABLE COLS="10" ROWS="4">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Trial</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Number</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Deferiprone: baseline</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Deferiprone: end</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Absolute change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>% change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Deferiprone + DFO: baseline</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Deferiprone + DFO: end</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Absolute change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>% change</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Aydinok-2007" TYPE="STUDY">Aydinok 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12/8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30.7 (10.6) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28.6 (12.8) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 2.1 mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 6.8%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26.6 (5.4) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18.1 (11.6) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 8.5 mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 32.0%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17/16</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15.8 (7.1) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 7.5 (3.6) mg/g d/w (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of approx. 8.3 mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17.1 (9.1) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 6.5 (3.5) mg/g d/w (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of approx. 10.6 mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Maggio-2009" TYPE="STUDY">Maggio 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20/34</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.0 (5.9) ms<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.5 (4.3) ms<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 0.4 ms</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.0 (2.9) ms<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.4 (3.4) ms<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 0.4 ms</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>d/w: dry weight liver<BR/>
<SUP>a</SUP>The mean (SD) duration from entry into trial to time of liver T2* MRI basal assessment was 17 (18) months in the combined treatment group and 18 (17) in the deferiprone alone treatment group. Final evaluation was performed after a further 16 (5) months and 14 (6) months respectively.<BR/>d/w: dry weight liver<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-10" MODIFIED="2013-08-08 13:24:41 +0100" MODIFIED_BY="Sheila A Worsley" NO="10">
<TITLE MODIFIED="2013-08-08 13:12:41 +0100" MODIFIED_BY="Sheila A Worsley">Serum ferritin concentration (mean (SD)): deferiprone with DFO versus DFO</TITLE>
<TABLE COLS="10" ROWS="9">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Trial</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No Def and DFO/ DFO</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Def + DFO: baseline</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Def + DFO: end trial</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Absolute change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>% change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>DFO: baseline</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>DFO: end trial</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Absolute change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>% change</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Abdelrazik-2007" TYPE="STUDY">Abdelrazik 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30/30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4500 (1250) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1250 (750) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 3250 ng/ml (SD not reported)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 72%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4250 (1500) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1200 (850) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 3050 ng/ml (SD not reported)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 72%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18/20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2865 (983) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 1050 µg/L (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of approx. 1815 µg/L</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not available</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2838 (967) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 1650 µg/L (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of approx. 1188 µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not available</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>29/30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2048 (685) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 1750 µg/L (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 248 (791) ug/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 12.1%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2257 (748) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 1850 µg/L (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 349 (573) ug/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 15.4%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Gomber-2004" TYPE="STUDY">Gomber 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10/ 7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3347.78 (+/- 1526.46) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3376.57 (1222.41) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 28.79 (915.86) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 0.9%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5077.18 1714.99) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3718 (738.39) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 1358.87 (1374.14) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 26.8%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17/ 14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 987.0 (2984) mmol/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not available</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 1059 (2285) mmol/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not available</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Mourad-2003" TYPE="STUDY">Mourad 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11/ 14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4153 (1715) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 mths: 3005 (1303) µg/L</P>
<P>12mths: 2805 (1084) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 mths:</P>
<P>reduction of 1148 µg/L</P>
<P>12 mths:</P>
<P>reduction of 1348 µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 mths:</P>
<P>reduction of 27.6%</P>
<P>12 mths:</P>
<P>reduction of 32.5%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5506 (2375) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 mths:</P>
<P>4856 (2615) µg/L</P>
<P>12 mths:</P>
<P>3998 (2409) µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 mths:</P>
<P>reduction of 650 µg/L</P>
<P>12 mths:</P>
<P>reduction of 1508 µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 mths:</P>
<P>reduction of 11.8%</P>
<P>12 mths:</P>
<P>reduction of 27.4%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Tamaddoni-2010" TYPE="STUDY">Tamaddoni 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40/40</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2986 (612) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 mths: 2453 (318) ng/ml</P>
<P>12 mths: 2082 (221) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 mths: reduction of 533 ng/ml</P>
<P>12 mths: reduction of 904 ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 mths: reduction of 17.8%</P>
<P>12 mths: reduction of 30.3%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2945 (591) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 mths: 2702 (242) ng/ml</P>
<P>12 mths: 2451 (352) ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 mths: reduction of 243 ng/ml</P>
<P>12 mths: 494 ng/ml</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 mths: reduction of 8.3%</P>
<P>12 mths: reduction of 16.8%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28/30<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1574 (11) µg/L<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>598 (CV 14) µg/L<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 976 µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 62%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1379 (CV 10) µg/L<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1146 (CV 11) µg/L<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 233 µg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 16.9%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>SD: standard deviation<BR/>
<SUP>a</SUP>28/32 patients completed treatment &#8211; actual sample size values for serum ferritin not given<BR/>
<SUP>b</SUP>values given are geometric mean (CV: coefficient of variation)<BR/>mths: months</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-11" MODIFIED="2013-08-08 13:26:22 +0100" MODIFIED_BY="Sheila A Worsley" NO="11">
<TITLE MODIFIED="2013-08-08 13:12:51 +0100" MODIFIED_BY="Sheila A Worsley">Liver iron concentration (mean (SD)): deferiprone with DFO versus DFO</TITLE>
<TABLE COLS="10" ROWS="5">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Trial</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Number</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Def + DFO: baseline</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Def + DFO: end</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Absolute change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>% change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>DFO: baseline</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>DFO: end</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Absolute change</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>% change</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-El_x002d_Beshlawy-2008" TYPE="STUDY">El-Beshlawy 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16/15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17.1 (9.1) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 6.5 (3.5) mg/g d/w (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of approx. 10.6 mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22.5 (10.1) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>approx. 11.5 (6.3) mg/g d/w (estimated from graph)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of approx. 11 mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Galanello-2006" TYPE="STUDY">Galanello 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>29/30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1629 (744) µg/g w/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 65 (615) µg FE/g liver</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 4.0%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1625 (642) µg/g w/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 239 (474) µg FE/g liver</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>reduction of 14.7%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Ha-_x0028_i_x0029_-2006" TYPE="STUDY">Ha (i) 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17/14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 0.95 (15.49) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not available</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 0.82 (8.25) mg/g d/w</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>not available</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Tanner-2007" TYPE="STUDY">Tanner 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28/32</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.9 (CV 0.52) ms<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10.7 ms<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 5.8 ms<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 18.4%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.2 (CV 0.62) ms<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5.0 ms<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 0.8 ms<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>increase of 20.0% </P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP> values given are geometric mean of liver T2* (CV, coefficient of variation)<BR/>d/w: dry weight liver<BR/>w/w: wet weight liver</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-08-09 13:08:20 +0100" MODIFIED_BY="Sheila A Worsley">
<COMPARISON ID="CMP-001" MODIFIED="2013-08-09 13:08:20 +0100" MODIFIED_BY="Sheila A Worsley" NO="1">
<NAME>Deferiprone alone versus DFO alone</NAME>
<CONT_OUTCOME CHI2="10.01388140420409" CI_END="3.085031977641551" CI_START="0.3228643265823883" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="1.7039481521119697" ESTIMABLE="YES" I2="60.055448646309166" I2_Q="2.009499430316516" ID="CMP-001.01" MODIFIED="2013-08-08 13:36:08 +0100" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.040194582578672255" P_Q="0.3604122685897416" P_Z="0.015599360461617175" Q="2.041014168080252" RANDOM="YES" SCALE="20.81" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="2.422761973566351" TOTALS="SUB" TOTAL_1="163" TOTAL_2="166" UNITS="" WEIGHT="300.0" Z="2.4181566302700186">
<NAME>Left ventricular ejection fraction: mean change from baseline (%)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.0408400699178357" CI_START="-0.08084006991783577" DF="0" EFFECT_SIZE="1.48" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" MODIFIED="2011-11-18 11:36:33 +0000" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="1.0" P_Z="0.06310482214585329" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="32" WEIGHT="100.0" Z="1.8584522226367362">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="3.0408400699178357" CI_START="-0.08084006991783577" EFFECT_SIZE="1.48" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="0.52" MODIFIED="2011-11-18 11:36:33 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="85" SD_1="2.7" SD_2="3.5" SE="0.7963616077792974" STUDY_ID="STD-Pennell-2006" TOTAL_1="29" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.967069684325562" CI_END="4.934206131343935" CI_START="-1.4183269655079485" DF="2" EFFECT_SIZE="1.7579395829179936" ESTIMABLE="YES" I2="74.89666741669392" ID="CMP-001.01.02" MODIFIED="2013-03-12 11:41:12 +0000" MODIFIED_BY="Sheila A Worsley" NO="2" P_CHI2="0.018619753596702204" P_Z="0.27802639694970854" STUDIES="3" TAU2="5.470780723993262" TOTAL_1="121" TOTAL_2="124" WEIGHT="100.0" Z="1.084763579185164">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="4.554606177887918" CI_START="1.005393822112082" EFFECT_SIZE="2.7800000000000002" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="0.32" MODIFIED="2012-04-13 12:09:56 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="86" SD_1="3.6" SD_2="3.4" SE="0.9054279527000421" STUDY_ID="STD-Pennell-2006" TOTAL_1="29" TOTAL_2="31" WEIGHT="41.749086284079475"/>
<CONT_DATA CI_END="1.3145499546493826" CI_START="-3.3145499546493826" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="1.0" MODIFIED="2012-04-13 12:09:56 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="90" SD_1="8.0" SD_2="6.0" SE="1.1809145335864624" STUDY_ID="STD-Maggio-2002" TOTAL_1="71" TOTAL_2="73" WEIGHT="38.25389470948342"/>
<CONT_DATA CI_END="10.325411205638101" CI_START="-0.5254112056381031" EFFECT_SIZE="4.8999999999999995" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="1.2" MODIFIED="2013-03-12 11:41:12 +0000" MODIFIED_BY="[Empty name]" ORDER="109" SD_1="10.6" SD_2="6.8" SE="2.7681178064663707" STUDY_ID="STD-Olivieri-1997" TOTAL_1="21" TOTAL_2="20" WEIGHT="19.99701900643711"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="15.852588892710344" CI_START="-0.6525888927103445" DF="0" EFFECT_SIZE="7.6" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" MODIFIED="2013-03-12 11:41:52 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.07107841130238177" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="10" WEIGHT="100.0" Z="1.8049761688313428">
<NAME>At 24 months</NAME>
<CONT_DATA CI_END="15.852588892710344" CI_START="-0.6525888927103445" EFFECT_SIZE="7.6" ESTIMABLE="YES" MEAN_1="8.5" MEAN_2="0.9" MODIFIED="2013-03-12 11:41:52 +0000" MODIFIED_BY="[Empty name]" ORDER="110" SD_1="10.4" SD_2="9.7" SE="4.210581907527747" STUDY_ID="STD-Olivieri-1997" TOTAL_1="13" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2013-08-08 13:36:17 +0100" MODIFIED_BY="Sheila A Worsley" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="9.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="58" TOTAL_2="63" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Right ventricular ejection fraction: mean at endpoint (%)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.01" MODIFIED="2011-11-18 11:40:35 +0000" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="3.0843841514704167" CI_START="-1.8843841514703996" EFFECT_SIZE="0.6000000000000085" ESTIMABLE="YES" MEAN_1="71.4" MEAN_2="70.8" MODIFIED="2011-11-18 11:40:35 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="87" SD_1="4.7" SD_2="5.2" SE="1.2675662262505398" STUDY_ID="STD-Pennell-2006" TOTAL_1="29" TOTAL_2="32" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.02" MODIFIED="2011-11-18 11:40:51 +0000" MODIFIED_BY="Sheila A Worsley" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="4.818535672245403" CI_START="-0.21853567224540837" EFFECT_SIZE="2.299999999999997" ESTIMABLE="YES" MEAN_1="72.2" MEAN_2="69.9" MODIFIED="2011-11-18 11:40:51 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="88" SD_1="5.3" SD_2="4.6" SE="1.2849907917243855" STUDY_ID="STD-Pennell-2006" TOTAL_1="29" TOTAL_2="31" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2013-08-08 13:36:24 +0100" MODIFIED_BY="Sheila A Worsley" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.65" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="21" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Liver fibrosis Ishak score: mean at endpoint</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.01" MODIFIED="2011-11-18 13:51:29 +0000" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="0.783382657987146" CI_START="-0.9833826579871462" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.2" MODIFIED="2011-11-18 13:51:29 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="93" SD_1="1.5" SD_2="1.2" SE="0.45071371971891105" STUDY_ID="STD-Maggio-2002" TOTAL_1="21" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2013-08-08 13:43:29 +0100" MODIFIED_BY="Sheila A Worsley" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="181" TOTAL_2="187" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum ferritin concentration: mean change from baseline (ng/ml)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DFO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="2" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.01" MODIFIED="2012-04-13 12:32:04 +0100" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="3334.4803917182967" CI_START="882.7596082817031" EFFECT_SIZE="2108.62" ESTIMABLE="YES" MEAN_1="749.75" MEAN_2="-1358.87" ORDER="1" SD_1="1155.77" SD_2="1374.14" SE="625.4504681656026" STUDY_ID="STD-Gomber-2004" TOTAL_1="11" TOTAL_2="7" WEIGHT="0.0"/>
<CONT_DATA CI_END="876.3006569382164" CI_START="53.69934306178351" EFFECT_SIZE="465.0" ESTIMABLE="YES" MEAN_1="151.0" MEAN_2="-314.0" MODIFIED="2012-04-13 12:32:04 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="2" SD_1="713.0" SD_2="921.0" SE="209.85113001182856" STUDY_ID="STD-Pennell-2006" TOTAL_1="29" TOTAL_2="32" WEIGHT="0.0"/>
<CONT_DATA CI_END="1156.8115297807692" CI_START="-1805.2115297807693" EFFECT_SIZE="-324.2" ESTIMABLE="YES" MEAN_1="-398.4" MEAN_2="-74.2" MODIFIED="2012-04-13 12:32:04 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="242" SD_1="1073.0" SD_2="1629.0" SE="755.6320123547163" STUDY_ID="STD-Ha-_x0028_ii_x0029_-2006" TOTAL_1="6" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.02" MODIFIED="2012-01-31 11:10:20 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="100" TOTAL_2="105" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="240.94195964171467" CI_START="-220.94195964171467" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="-222.0" MEAN_2="-232.0" ORDER="3" SD_1="783.0" SD_2="619.0" SE="117.82969557775314" STUDY_ID="STD-Maggio-2002" TOTAL_1="71" TOTAL_2="73" WEIGHT="0.0"/>
<CONT_DATA CI_END="679.8879474864345" CI_START="-109.8879474864346" EFFECT_SIZE="285.0" ESTIMABLE="YES" MEAN_1="-181.0" MEAN_2="-466.0" MODIFIED="2012-01-31 11:10:20 +0000" MODIFIED_BY="[Empty name]" ORDER="4" SD_1="826.0" SD_2="739.0" SE="201.47714478493498" STUDY_ID="STD-Pennell-2006" TOTAL_1="29" TOTAL_2="32" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.03" MODIFIED="2013-03-12 11:42:38 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>At 24 months</NAME>
<CONT_DATA CI_END="640.521942016643" CI_START="-270.52194201664304" EFFECT_SIZE="185.0" ESTIMABLE="YES" MEAN_1="187.0" MEAN_2="2.0" MODIFIED="2013-03-12 11:42:38 +0000" MODIFIED_BY="[Empty name]" ORDER="111" SD_1="840.0" SD_2="1104.0" SE="232.4134247413432" STUDY_ID="STD-Olivieri-1997" TOTAL_1="35" TOTAL_2="36" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2013-08-08 13:43:38 +0100" MODIFIED_BY="Sheila A Worsley" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="16.540539784330416" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="119" TOTAL_2="115" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Urinary iron excretion: mean at endpoint (mg/24h)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.01" MODIFIED="2012-04-13 12:34:12 +0100" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>As a mean of quarterly readings</NAME>
<CONT_DATA CI_END="0.3204769211279316" CI_START="0.07952307887206843" EFFECT_SIZE="0.2" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="0.18" MODIFIED="2011-07-12 10:05:59 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="51" SD_1="0.23" SD_2="0.1" SE="0.061468946408320846" STUDY_ID="STD-El_x002d_Beshlawy-2008" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.02" MODIFIED="2012-04-13 12:34:12 +0100" MODIFIED_BY="Sheila A Worsley" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="73" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="-0.07988552461567533" CI_START="-8.12011447538432" EFFECT_SIZE="-4.099999999999998" ESTIMABLE="YES" MEAN_1="15.8" MEAN_2="19.9" MODIFIED="2011-07-12 10:26:13 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="100" SD_1="10.9" SD_2="13.6" SE="2.0511165037186765" STUDY_ID="STD-Maggio-2002" TOTAL_1="71" TOTAL_2="73" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.03" MODIFIED="2012-04-13 12:34:09 +0100" MODIFIED_BY="Sheila A Worsley" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>Early after starting treatment</NAME>
<CONT_DATA CI_END="0.7652259609515117" CI_START="-7.125225960951511" EFFECT_SIZE="-3.1799999999999997" ESTIMABLE="YES" MEAN_1="4.78" MEAN_2="7.96" ORDER="7" SD_1="2.12" SD_2="5.05" SE="2.0129073758859604" STUDY_ID="STD-Gomber-2004" TOTAL_1="11" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.04" MODIFIED="2012-04-13 12:34:06 +0100" MODIFIED_BY="Sheila A Worsley" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>24 hours after starting treatment</NAME>
<CONT_DATA CI_END="1.4201440620975756" CI_START="-13.220144062097573" EFFECT_SIZE="-5.899999999999999" ESTIMABLE="YES" MEAN_1="12.3" MEAN_2="18.2" ORDER="8" SD_1="6.7" SD_2="15.3" SE="3.7348360071092817" STUDY_ID="STD-Olivieri-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2013-08-08 13:36:54 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="5" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Urinary iron excretion: mean over study (%)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone</GRAPH_LABEL_2>
<CONT_DATA CI_END="82.31371193417694" CI_START="57.686288065823064" EFFECT_SIZE="70.0" ESTIMABLE="YES" MEAN_1="98.0" MEAN_2="28.0" MODIFIED="2012-01-31 09:59:09 +0000" MODIFIED_BY="[Empty name]" ORDER="97" SD_1="14.8" SD_2="10.3" SE="6.282621533510779" STUDY_ID="STD-Aydinok-2005" TOTAL_1="12" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2013-08-08 13:37:02 +0100" MODIFIED_BY="Sheila A Worsley" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.75" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="71" TOTAL_2="73" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Urinary iron excretion: mean change from baseline (mg/24h)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.01" MODIFIED="2012-01-31 11:17:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="73" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="4.4011385521426005" CI_START="-4.0011385521426" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="4.2" MODIFIED="2012-01-31 11:17:23 +0000" MODIFIED_BY="[Empty name]" ORDER="5" SD_1="13.2" SD_2="12.5" SE="2.1434774237081116" STUDY_ID="STD-Maggio-2002" TOTAL_1="71" TOTAL_2="73" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-08-09 13:08:20 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.84" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Liver iron concentration: ratio of geometric means at endpoint (mg/g dry weight)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DFO</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of GM</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-03-01 15:08:21 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<IV_DATA CI_END="0.9396966153282638" CI_START="0.478259505851501" EFFECT_SIZE="0.6703870813919548" ESTIMABLE="YES" ESTIMATE="-0.3999" LOG_CI_END="-0.02701233741719071" LOG_CI_START="-0.32033638920903007" LOG_EFFECT_SIZE="-0.17367436331311042" MODIFIED="2012-03-01 15:08:21 +0000" MODIFIED_BY="[Empty name]" ORDER="158" SE="0.1723" STUDY_ID="STD-El_x002d_Beshlawy-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-03-12 11:54:13 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 24 months</NAME>
<IV_DATA CI_END="1.7966676494768827" CI_START="0.899484332933489" EFFECT_SIZE="1.2712491503214047" ESTIMABLE="YES" ESTIMATE="0.24" LOG_CI_END="0.2544677480342025" LOG_CI_START="-0.04600639672064164" LOG_EFFECT_SIZE="0.10423067565678046" MODIFIED="2013-03-12 11:54:13 +0000" MODIFIED_BY="[Empty name]" ORDER="113" SE="0.1765" STUDY_ID="STD-Olivieri-1997" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-08-09 13:08:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 31-36 months</NAME>
<IV_DATA CI_END="1.1247569574849892" CI_START="0.42114967979768225" EFFECT_SIZE="0.6882521576392031" ESTIMABLE="YES" ESTIMATE="-0.3736" LOG_CI_END="0.051058688290588" LOG_CI_START="-0.3755635251686978" LOG_EFFECT_SIZE="-0.16225241843905489" MODIFIED="2013-08-09 13:08:20 +0100" MODIFIED_BY="[Empty name]" ORDER="156" SE="0.2506" STUDY_ID="STD-Maggio-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
<IV_DATA CI_END="2.7633779915850063" CI_START="1.413609211924473" EFFECT_SIZE="1.976445441932034" ESTIMABLE="YES" ESTIMATE="0.6813" LOG_CI_END="0.4414402944104258" LOG_CI_START="0.15032936663094512" LOG_EFFECT_SIZE="0.2958848305206855" MODIFIED="2012-03-01 15:08:52 +0000" MODIFIED_BY="[Empty name]" ORDER="157" SE="0.171" STUDY_ID="STD-Olivieri-1997" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2013-08-08 13:37:17 +0100" MODIFIED_BY="Sheila A Worsley" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="11.35" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="46" TOTAL_2="50" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Liver iron concentration: mean change from baseline (mg/g dry weight)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DFO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.09.01" MODIFIED="2012-03-02 12:49:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="6.250676356339721" CI_START="-0.7906763563397208" EFFECT_SIZE="2.73" ESTIMABLE="YES" MEAN_1="5.63" MEAN_2="2.9" MODIFIED="2012-03-02 12:49:41 +0000" MODIFIED_BY="[Empty name]" ORDER="11" SD_1="4.24" SD_2="1.27" SE="1.7962964544809836" STUDY_ID="STD-Ha-_x0028_ii_x0029_-2006" TOTAL_1="6" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.09.02" MODIFIED="2012-02-28 18:49:08 +0000" MODIFIED_BY="Sheila A Worsley" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="2.023098441545335" CI_START="-0.8030984415453349" EFFECT_SIZE="0.61" ESTIMABLE="YES" MEAN_1="-0.93" MEAN_2="-1.54" MODIFIED="2011-04-05 09:32:00 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="10" SD_1="2.9" SD_2="2.5" SE="0.7209818408356863" STUDY_ID="STD-Pennell-2006" TOTAL_1="27" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.09.03" MODIFIED="2013-03-12 11:43:37 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 24 months</NAME>
<CONT_DATA CI_END="2.898654860080095" CI_START="-3.5586548600800954" EFFECT_SIZE="-0.32999999999999996" ESTIMABLE="YES" MEAN_1="0.36" MEAN_2="0.69" MODIFIED="2013-03-12 11:43:37 +0000" MODIFIED_BY="[Empty name]" ORDER="112" SD_1="4.87" SD_2="3.4" SE="1.64730315737805" STUDY_ID="STD-Olivieri-1997" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-08-08 13:37:25 +0100" MODIFIED_BY="Sheila A Worsley" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.06" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="2" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Myocardial T2*: ratio of geometric means of change from baseline</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of GM</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-01-13 08:28:05 +0000" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<IV_DATA CI_END="1.1786839970533989" CI_START="1.0076304049117413" EFFECT_SIZE="1.0898063283051287" ESTIMABLE="YES" ESTIMATE="0.086" LOG_CI_END="0.07139738717227391" LOG_CI_START="0.0033012637150854444" LOG_EFFECT_SIZE="0.03734932544367967" MODIFIED="2012-01-13 08:28:05 +0000" MODIFIED_BY="[Empty name]" ORDER="13" SE="0.04" STUDY_ID="STD-Pennell-2006" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-01-13 08:28:05 +0000" MODIFIED_BY="Sheila A Worsley" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<IV_DATA CI_END="1.226394141111758" CI_START="1.0160491548481958" EFFECT_SIZE="1.1162780704588713" ESTIMABLE="YES" ESTIMATE="0.11" LOG_CI_END="0.08863006708367079" LOG_CI_START="0.006914718935044594" LOG_EFFECT_SIZE="0.0477723930093577" MODIFIED="2012-01-13 08:28:05 +0000" MODIFIED_BY="[Empty name]" ORDER="14" SE="0.048" STUDY_ID="STD-Pennell-2006" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2013-08-08 13:37:33 +0100" MODIFIED_BY="Sheila A Worsley" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="28.25" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="5" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Chelation efficiency (%)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.11.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>At end of trial</NAME>
<CONT_DATA CI_END="-7.054497074374664" CI_START="-25.84550292562534" EFFECT_SIZE="-16.450000000000003" ESTIMABLE="YES" MEAN_1="6.65" MEAN_2="23.1" ORDER="15" SD_1="0.99" SD_2="10.7" SE="4.793712027229003" STUDY_ID="STD-Aydinok-2005" TOTAL_1="12" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2013-08-08 13:37:43 +0100" MODIFIED_BY="Sheila A Worsley" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.02" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="5" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Plasma NTBI: mean change from baseline (mM)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DFO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.12.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>At end of trial</NAME>
<CONT_DATA CI_END="2.775480807700151" CI_START="1.7845191922998493" EFFECT_SIZE="2.2800000000000002" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="0.72" ORDER="16" SD_1="0.53" SD_2="0.45" SE="0.2528009757365136" STUDY_ID="STD-Aydinok-2005" TOTAL_1="12" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2013-08-08 13:37:50 +0100" MODIFIED_BY="Sheila A Worsley" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.6" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="5" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Total iron excretion: mean at endpoint (mg/kg/day)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.13.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>At end of trial</NAME>
<CONT_DATA CI_END="0.014969375610648705" CI_START="-0.43496937561064863" EFFECT_SIZE="-0.20999999999999996" ESTIMABLE="YES" MEAN_1="0.56" MEAN_2="0.77" ORDER="17" SD_1="0.09" SD_2="0.25" SE="0.11478240283248997" STUDY_ID="STD-Aydinok-2005" TOTAL_1="12" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="11.111719163775296" CI_END="5.085945524221121" CI_START="2.1711470832113284" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="3.3230010217098034" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="22" I2="1.0054174527691973" I2_Q="17.743164738191556" ID="CMP-001.14" LOG_CI_END="0.7063717041179308" LOG_CI_START="0.3366892455010992" LOG_EFFECT_SIZE="0.521530474809515" METHOD="MH" MODIFIED="2013-08-09 12:17:06 +0100" MODIFIED_BY="Sheila A Worsley" NO="14" P_CHI2="0.4339520668693756" P_Q="0.3016653619321372" P_Z="3.201424149748329E-8" Q="4.862817767385206" RANDOM="NO" SCALE="657.36" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="535" TOTAL_2="556" WEIGHT="500.0" Z="5.530048416639606">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DFO</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.230886534392942" CI_START="1.1894186871971342" DF="0" EFFECT_SIZE="2.2432778489116516" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="11" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="0.6264313784043751" LOG_CI_START="0.07533475750514801" LOG_EFFECT_SIZE="0.3508830679547616" MODIFIED="2011-11-25 12:40:06 +0000" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="1.0" P_Z="0.01256673904488008" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="73" WEIGHT="100.00000000000001" Z="2.4958170669023514">
<NAME>Number of participants experiencing an adverse event</NAME>
<DICH_DATA CI_END="4.230886534392942" CI_START="1.1894186871971342" EFFECT_SIZE="2.2432778489116516" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="11" LOG_CI_END="0.6264313784043751" LOG_CI_START="0.07533475750514801" LOG_EFFECT_SIZE="0.3508830679547616" ORDER="18" O_E="0.0" SE="0.32371688308847557" STUDY_ID="STD-Maggio-2002" TOTAL_1="71" TOTAL_2="73" VAR="0.10479262039651775" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.272335528400757" CI_END="5.768852742564659" CI_START="1.2120145312397506" DF="2" EFFECT_SIZE="2.6442264185524382" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" I2="38.881573034247126" ID="CMP-001.14.02" LOG_CI_END="0.7610894531706881" LOG_CI_START="0.08350782676047151" LOG_EFFECT_SIZE="0.42229863996557976" MODIFIED="2012-04-13 13:45:04 +0100" MODIFIED_BY="Sheila A Worsley" NO="2" P_CHI2="0.19472501670344744" P_Z="0.014562858361430675" STUDIES="3" TAU2="0.0" TOTAL_1="121" TOTAL_2="127" WEIGHT="100.0" Z="2.4430713372138855">
<NAME>Risk of pain or swelling in joints</NAME>
<DICH_DATA CI_END="64.28487706796366" CI_START="1.1942307204776177" EFFECT_SIZE="8.761904761904763" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.808108817739046" LOG_CI_START="0.07708823881218833" LOG_EFFECT_SIZE="0.9425985282756172" MODIFIED="2011-11-25 12:54:04 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="101" O_E="0.0" SE="1.016810056751696" STUDY_ID="STD-El_x002d_Beshlawy-2008" TOTAL_1="21" TOTAL_2="23" VAR="1.0339026915113871" WEIGHT="13.170329387102873"/>
<DICH_DATA CI_END="3.610740141738432" CI_START="0.5626115334660543" EFFECT_SIZE="1.4252873563218391" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5575962341842453" LOG_CI_START="-0.2497913690970121" LOG_EFFECT_SIZE="0.15390243254361655" MODIFIED="2012-04-13 13:45:04 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="102" O_E="0.0" SE="0.4742634748005036" STUDY_ID="STD-Pennell-2006" TOTAL_1="29" TOTAL_2="31" VAR="0.22492584352984793" WEIGHT="80.02542999020602"/>
<DICH_DATA CI_END="105.1950429807947" CI_START="0.25104014660811524" EFFECT_SIZE="5.138888888888889" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.021995275399382" LOG_CI_START="-0.6002568201279286" LOG_EFFECT_SIZE="0.7108692276357266" MODIFIED="2012-04-13 13:45:04 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="103" O_E="0.0" SE="1.5403238612699595" STUDY_ID="STD-Maggio-2002" TOTAL_1="71" TOTAL_2="73" VAR="2.3725975975975975" WEIGHT="6.804240622691112"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.159787698333892" CI_END="87.30987940740582" CI_START="1.57021450812663" DF="1" EFFECT_SIZE="11.708767627222562" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" ID="CMP-001.14.03" LOG_CI_END="1.9410633883718391" LOG_CI_START="0.195958985741796" LOG_EFFECT_SIZE="1.0685111870568174" MODIFIED="2011-11-25 12:58:04 +0000" MODIFIED_BY="Sheila A Worsley" NO="3" P_CHI2="0.6893522590597007" P_Z="0.01638900752358776" STUDIES="2" TAU2="0.0" TOTAL_1="92" TOTAL_2="96" WEIGHT="100.0" Z="2.400135419466335">
<NAME>Risk of gastrointestinal disturbances</NAME>
<DICH_DATA CI_END="270.07754762829035" CI_START="0.9914507792030688" EFFECT_SIZE="16.363636363636363" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.4314884814609026" LOG_CI_START="-0.0037288415707404927" LOG_EFFECT_SIZE="1.213879819945081" MODIFIED="2011-11-25 12:55:16 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="107" O_E="0.0" SE="1.430458710068949" STUDY_ID="STD-El_x002d_Beshlawy-2008" TOTAL_1="21" TOTAL_2="23" VAR="2.0462121212121214" WEIGHT="49.233599019006746"/>
<DICH_DATA CI_END="136.82194716304528" CI_START="0.37830210677032067" EFFECT_SIZE="7.194444444444445" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.136155766735721" LOG_CI_START="-0.42216124010779205" LOG_EFFECT_SIZE="0.8569972633139645" MODIFIED="2011-11-25 12:55:16 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="108" O_E="0.0" SE="1.5027680736933038" STUDY_ID="STD-Maggio-2002" TOTAL_1="71" TOTAL_2="73" VAR="2.258311883311883" WEIGHT="50.766400980993254"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6099887479400703" CI_END="9.553902480052558" CI_START="0.6607458472022072" DF="3" EFFECT_SIZE="2.5125089827241607" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-001.14.04" LOG_CI_END="0.9801808039777724" LOG_CI_START="-0.1799655577351601" LOG_EFFECT_SIZE="0.40010762312130616" MODIFIED="2013-08-09 12:17:06 +0100" MODIFIED_BY="Sheila A Worsley" NO="4" P_CHI2="0.8941419263010463" P_Z="0.176409735505666" STUDIES="5" TAU2="0.0" TOTAL_1="159" TOTAL_2="164" WEIGHT="100.0" Z="1.3518924114020154">
<NAME>Risk of leucopenia, neutropenia and/or agranulocytosis</NAME>
<DICH_DATA CI_END="105.1950429807947" CI_START="0.25104014660811524" EFFECT_SIZE="5.138888888888889" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.021995275399382" LOG_CI_START="-0.6002568201279286" LOG_EFFECT_SIZE="0.7108692276357266" MODIFIED="2012-04-13 13:46:20 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="104" O_E="0.0" SE="1.5403238612699595" STUDY_ID="STD-Maggio-2002" TOTAL_1="71" TOTAL_2="73" VAR="2.3725975975975975" WEIGHT="17.12961891951736"/>
<DICH_DATA CI_END="75.5476577103769" CI_START="0.13554358017632465" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8782210039599212" LOG_CI_START="-0.8679210473201091" LOG_EFFECT_SIZE="0.505149978319906" MODIFIED="2012-04-13 13:46:22 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="105" O_E="0.0" SE="1.6130974345442786" STUDY_ID="STD-Pennell-2006" TOTAL_1="29" TOTAL_2="31" VAR="2.6020833333333333" WEIGHT="16.80728738070924"/>
<DICH_DATA CI_END="16.426858257107043" CI_START="0.07302348790535099" EFFECT_SIZE="1.0952380952380953" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2155545097483427" LOG_CI_START="-1.1365374271809954" LOG_EFFECT_SIZE="0.039508541283673655" MODIFIED="2013-08-09 10:27:14 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="106" O_E="0.0" SE="1.3816304467951577" STUDY_ID="STD-El_x002d_Beshlawy-2008" TOTAL_1="21" TOTAL_2="23" VAR="1.9089026915113871" WEIGHT="33.15619419649005"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-09 09:43:12 +0100" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="0.0" STUDY_ID="STD-Gomber-2004" TOTAL_1="11" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="23.14966234007013" CI_START="0.21331937945334684" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3645446608004614" LOG_CI_START="-0.6709696883511487" LOG_EFFECT_SIZE="0.3467874862246563" MODIFIED="2013-08-09 12:17:06 +0100" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="1.1956712046501872" STUDY_ID="STD-Olivieri-1997" TOTAL_1="27" TOTAL_2="30" VAR="1.4296296296296296" WEIGHT="32.90689950328335"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6638945880567286" CI_END="38.107014891158514" CI_START="2.0776171402947536" DF="1" EFFECT_SIZE="8.897852960312296" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" I2="62.46097707907109" ID="CMP-001.14.05" LOG_CI_END="1.5810049296938746" LOG_CI_START="0.3175655195557493" LOG_EFFECT_SIZE="0.9492852246248118" MODIFIED="2012-04-13 13:47:32 +0100" MODIFIED_BY="Sheila A Worsley" NO="5" P_CHI2="0.10264917721196509" P_Z="0.0032270637443996535" STUDIES="2" TAU2="0.0" TOTAL_1="92" TOTAL_2="96" WEIGHT="100.0" Z="2.9452379534642517">
<NAME>Risk of increased liver transaminase</NAME>
<DICH_DATA CI_END="120.79125674488023" CI_START="2.2404408796043787" EFFECT_SIZE="16.450704225352112" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="1" LOG_CI_END="2.0820354998076804" LOG_CI_START="0.3503334883069304" LOG_EFFECT_SIZE="1.2161844940573054" MODIFIED="2012-04-13 13:47:32 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="109" O_E="0.0" SE="1.017210333618746" STUDY_ID="STD-Maggio-2002" TOTAL_1="71" TOTAL_2="73" VAR="1.0347168628207601" WEIGHT="50.81327260897853"/>
<DICH_DATA CI_END="16.426858257107043" CI_START="0.07302348790535099" EFFECT_SIZE="1.0952380952380953" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2155545097483427" LOG_CI_START="-1.1365374271809954" LOG_EFFECT_SIZE="0.039508541283673655" MODIFIED="2012-04-13 13:47:32 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="110" O_E="0.0" SE="1.3816304467951577" STUDY_ID="STD-El_x002d_Beshlawy-2008" TOTAL_1="21" TOTAL_2="23" VAR="1.9089026915113871" WEIGHT="49.18672739102147"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.15" MODIFIED="2013-08-08 13:38:08 +0100" MODIFIED_BY="Sheila A Worsley" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="28.74" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="48" TOTAL_2="50" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Participant compliance (%)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.15.01" MODIFIED="2012-01-31 10:06:26 +0000" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="4.875049145611561" CI_START="-2.8750491456115608" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="93.0" MODIFIED="2011-04-05 09:38:25 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="26" SD_1="5.3" SD_2="9.7" SE="1.977102220335401" STUDY_ID="STD-Pennell-2006" TOTAL_1="29" TOTAL_2="32" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.15.02" MODIFIED="2012-01-31 10:06:26 +0000" MODIFIED_BY="Sheila A Worsley" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>At 3 years</NAME>
<CONT_DATA CI_END="25.079405271370778" CI_START="21.520594728629245" EFFECT_SIZE="23.30000000000001" ESTIMABLE="YES" MEAN_1="94.9" MEAN_2="71.6" MODIFIED="2011-04-05 09:36:49 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="44" SD_1="1.1" SD_2="3.7" SE="0.9078765147760303" STUDY_ID="STD-Olivieri-1997" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-08-09 12:26:57 +0100" MODIFIED_BY="Sheila A Worsley" NO="2">
<NAME>Deferiprone alone versus deferiprone and DFO in combination</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2013-08-08 13:38:19 +0100" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="13.84" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="8" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Left ventricular ejection fraction: mean at endpoint (%)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>Deferiprone and DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Deferiprone &amp; DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.01" MODIFIED="2011-11-25 12:44:23 +0000" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="1.987573909669961" CI_START="-12.387573909669939" EFFECT_SIZE="-5.199999999999989" ESTIMABLE="YES" MEAN_1="67.4" MEAN_2="72.6" MODIFIED="2011-11-18 12:54:39 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="89" SD_1="9.8" SD_2="6.6" SE="3.6671969313541553" STUDY_ID="STD-Aydinok-2007" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2013-08-08 13:38:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="93" TOTAL_2="100" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum ferritin concentration: mean at endpoint (ng/ml)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>Deferiprone and DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone &amp; DFO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.01" MODIFIED="2012-02-28 19:22:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="1248.979884108768" CI_START="-1156.779884108768" EFFECT_SIZE="46.09999999999991" ESTIMABLE="YES" MEAN_1="3422.7" MEAN_2="3376.6" MODIFIED="2012-02-28 19:22:12 +0000" MODIFIED_BY="[Empty name]" ORDER="233" SD_1="1581.0" SD_2="1222.4" SE="613.7255039362616" STUDY_ID="STD-Gomber-2004" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.02" MODIFIED="2012-02-28 19:22:01 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="82" TOTAL_2="90" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="2054.4940254197577" CI_START="-2564.4940254197577" EFFECT_SIZE="-255.0" ESTIMABLE="YES" MEAN_1="2954.0" MEAN_2="3209.0" MODIFIED="2012-02-28 19:21:51 +0000" MODIFIED_BY="[Empty name]" ORDER="236" SD_1="2765.0" SD_2="2279.0" SE="1178.3349304562491" STUDY_ID="STD-Aydinok-2007" TOTAL_1="8" TOTAL_2="12" WEIGHT="0.0"/>
<CONT_DATA CI_END="489.741317993449" CI_START="-23.741317993449" EFFECT_SIZE="233.0" ESTIMABLE="YES" MEAN_1="1633.0" MEAN_2="1400.0" MODIFIED="2012-02-28 19:22:01 +0000" MODIFIED_BY="[Empty name]" ORDER="235" SD_1="841.0" SD_2="770.0" SE="130.99287538882948" STUDY_ID="STD-Maggio-2009" TOTAL_1="74" TOTAL_2="78" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2013-08-08 13:43:59 +0100" MODIFIED_BY="Sheila A Worsley" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="241" TOTAL_2="278" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum ferritin concentration: mean change from baseline (ng/ml)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>Deferiprone and DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone &amp; DFO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="1609.0566605300778" CI_START="-167.13666053007762" EFFECT_SIZE="720.96" ESTIMABLE="YES" MEAN_1="749.75" MEAN_2="28.79" ORDER="27" SD_1="1155.77" SD_2="915.86" SE="453.11886725229175" STUDY_ID="STD-Gomber-2004" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.02" MODIFIED="2011-11-01 11:48:46 +0000" MODIFIED_BY="Sheila A Worsley" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="74" TOTAL_2="78" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="495.4673226849239" CI_START="74.53267731507611" EFFECT_SIZE="285.0" ESTIMABLE="YES" MEAN_1="-132.0" MEAN_2="-417.0" MODIFIED="2011-11-01 11:48:46 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="73" SD_1="724.0" SD_2="589.0" SE="107.38326027675164" STUDY_ID="STD-Maggio-2009" TOTAL_1="74" TOTAL_2="78" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.03" MODIFIED="2011-11-01 12:02:55 +0000" MODIFIED_BY="Sheila A Worsley" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="65" WEIGHT="0.0" Z="0.0">
<NAME>At 2 years</NAME>
<CONT_DATA CI_END="626.7887474117704" CI_START="72.01125258822964" EFFECT_SIZE="349.4" ESTIMABLE="YES" MEAN_1="-12.6" MEAN_2="-362.0" MODIFIED="2011-11-01 12:02:55 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="75" SD_1="732.0" SD_2="803.0" SE="141.527471728959" STUDY_ID="STD-Maggio-2009" TOTAL_1="53" TOTAL_2="65" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.04" MODIFIED="2011-11-01 12:03:15 +0000" MODIFIED_BY="Sheila A Worsley" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>At 3 years</NAME>
<CONT_DATA CI_END="724.6483343815806" CI_START="92.15166561841932" EFFECT_SIZE="408.4" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="-403.0" MODIFIED="2011-11-01 12:03:15 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="76" SD_1="870.0" SD_2="697.0" SE="161.35415593149014" STUDY_ID="STD-Maggio-2009" TOTAL_1="44" TOTAL_2="55" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.05" MODIFIED="2011-11-01 12:03:39 +0000" MODIFIED_BY="Sheila A Worsley" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>At 4 years</NAME>
<CONT_DATA CI_END="1041.8867021193482" CI_START="116.11329788065188" EFFECT_SIZE="579.0" ESTIMABLE="YES" MEAN_1="184.0" MEAN_2="-395.0" MODIFIED="2011-11-01 12:03:39 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="77" SD_1="1036.0" SD_2="940.0" SE="236.17102445276512" STUDY_ID="STD-Maggio-2009" TOTAL_1="33" TOTAL_2="38" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.06" MODIFIED="2011-11-01 12:01:52 +0000" MODIFIED_BY="Sheila A Worsley" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>At 5 years</NAME>
<CONT_DATA CI_END="777.3512979548989" CI_START="-215.35129795489888" EFFECT_SIZE="281.0" ESTIMABLE="YES" MEAN_1="-115.0" MEAN_2="-396.0" MODIFIED="2011-11-01 11:58:16 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="74" SD_1="1009.0" SD_2="894.0" SE="253.24511157860786" STUDY_ID="STD-Maggio-2009" TOTAL_1="26" TOTAL_2="32" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2013-08-08 13:38:49 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="44.92" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="8" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Urinary iron excretion: mean over study (%)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>Deferiprone and DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone &amp; DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone</GRAPH_LABEL_2>
<CONT_DATA CI_END="27.132977522930528" CI_START="0.8670224770694723" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="98.0" MEAN_2="84.0" MODIFIED="2012-01-31 10:13:34 +0000" MODIFIED_BY="[Empty name]" ORDER="98" SD_1="14.8" SD_2="14.6" SE="6.7006218616881625" STUDY_ID="STD-Aydinok-2005" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2013-08-08 13:38:57 +0100" MODIFIED_BY="Sheila A Worsley" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.72" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="28" TOTAL_2="26" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Urinary iron excretion: mean at endpoint (mg/24h)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>Deferiprone and DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone &amp; DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.05.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Early after starting treatment</NAME>
<CONT_DATA CI_END="0.9768879375169877" CI_START="-5.696887937516987" EFFECT_SIZE="-2.3599999999999994" ESTIMABLE="YES" MEAN_1="4.78" MEAN_2="7.14" ORDER="28" SD_1="2.12" SD_2="4.99" SE="1.7025251299707205" STUDY_ID="STD-Gomber-2004" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.05.02" MODIFIED="2012-01-31 11:31:41 +0000" MODIFIED_BY="Sheila A Worsley" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>As a mean of quarterly readings (mg/kg/day)</NAME>
<CONT_DATA CI_END="0.09788055127014894" CI_START="-0.23788055127014895" EFFECT_SIZE="-0.07" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="0.45" MODIFIED="2011-07-12 10:33:52 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="149" SD_1="0.23" SD_2="0.26" SE="0.0856549164139593" STUDY_ID="STD-El_x002d_Beshlawy-2008" TOTAL_1="17" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.8201969358639176" CI_END="3.817791776290833" CI_START="-0.9105920483385093" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.453599863976162" ESTIMABLE="YES" I2="64.5414833523437" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2013-08-08 13:39:10 +0100" MODIFIED_BY="Sheila A Worsley" NO="6" P_CHI2="0.0930850863442193" P_Q="1.0" P_Z="0.2281784844240552" Q="0.0" RANDOM="NO" SCALE="23.94" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="29" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="1.2050643462933903">
<NAME>Liver iron concentration: mean at endpoint (mg/g dry weight)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>Deferiprone and DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone &amp; DFO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.8201969358639176" CI_END="3.817791776290833" CI_START="-0.9105920483385093" DF="1" EFFECT_SIZE="1.453599863976162" ESTIMABLE="YES" I2="64.5414833523437" ID="CMP-002.06.01" MODIFIED="2012-01-27 13:02:58 +0000" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.0930850863442193" P_Z="0.2281784844240552" STUDIES="2" TAU2="0.0" TOTAL_1="29" TOTAL_2="24" WEIGHT="100.0" Z="1.2050643462933903">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="21.31952194550599" CI_START="-0.3195219455059881" EFFECT_SIZE="10.5" ESTIMABLE="YES" MEAN_1="28.6" MEAN_2="18.1" MODIFIED="2011-07-05 21:39:11 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="49" SD_1="12.8" SD_2="11.6" SE="5.520265694088767" STUDY_ID="STD-Aydinok-2007" TOTAL_1="12" TOTAL_2="8" WEIGHT="4.77473541027539"/>
<CONT_DATA CI_END="3.4227390160639266" CI_START="-1.4227390160639266" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="6.5" MODIFIED="2012-01-27 13:02:58 +0000" MODIFIED_BY="[Empty name]" ORDER="355" SD_1="3.6" SD_2="3.5" SE="1.2361140486122106" STUDY_ID="STD-El_x002d_Beshlawy-2008" TOTAL_1="17" TOTAL_2="16" WEIGHT="95.2252645897246"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2013-08-08 13:39:18 +0100" MODIFIED_BY="Sheila A Worsley" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.47" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="8" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Chelation efficiency (%)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>Deferiprone and DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone &amp; DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.07.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At end of trial</NAME>
<CONT_DATA CI_END="0.1534394793684336" CI_START="-1.5334394793684325" EFFECT_SIZE="-0.6899999999999995" ESTIMABLE="YES" MEAN_1="6.65" MEAN_2="7.34" ORDER="30" SD_1="0.99" SD_2="0.91" SE="0.43033417247529854" STUDY_ID="STD-Aydinok-2005" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2013-08-08 13:39:26 +0100" MODIFIED_BY="Sheila A Worsley" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="8" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Plasma NTBI: mean change from baseline (mM)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>Deferiprone and DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiporne</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone &amp; DFO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.08.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At end of trial</NAME>
<CONT_DATA CI_END="2.8333291700453835" CI_START="1.4866708299546167" EFFECT_SIZE="2.16" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="0.84" ORDER="31" SD_1="0.53" SD_2="0.87" SE="0.34354160349706314" STUDY_ID="STD-Aydinok-2005" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.09" MODIFIED="2013-08-08 13:39:35 +0100" MODIFIED_BY="Sheila A Worsley" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.58" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="24" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Total Iron excretion: mean at endpoint (mg/kg/day)</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>Deferiprone and DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.09.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At end of trial</NAME>
<CONT_DATA CI_END="-0.04948626353272782" CI_START="-0.21051373646727195" EFFECT_SIZE="-0.1299999999999999" ESTIMABLE="YES" MEAN_1="0.56" MEAN_2="0.69" ORDER="32" SD_1="0.09" SD_2="0.09" SE="0.04107919181288745" STUDY_ID="STD-Aydinok-2005" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.09.02" MODIFIED="2011-11-18 08:54:09 +0000" MODIFIED_BY="Sheila A Worsley" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Mean change from baseline</NAME>
<CONT_DATA CI_END="-0.02903470927711732" CI_START="-0.3909652907228826" EFFECT_SIZE="-0.20999999999999996" ESTIMABLE="YES" MEAN_1="0.36" MEAN_2="0.57" MODIFIED="2011-11-18 08:54:09 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="84" SD_1="0.27" SD_2="0.14" SE="0.09233092656309695" STUDY_ID="STD-Aydinok-2007" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.197602837002261" CI_END="1.2627474009607431" CI_START="0.7061279773611517" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9442781730816724" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="65" I2="0.0" I2_Q="43.16241704017305" ID="CMP-002.10" LOG_CI_END="0.10131648330232884" LOG_CI_START="-0.15111658106596468" LOG_EFFECT_SIZE="-0.024900048881817908" METHOD="MH" MODIFIED="2013-08-09 12:26:57 +0100" MODIFIED_BY="Sheila A Worsley" NO="10" P_CHI2="0.6165545936602029" P_Q="0.15252343719656825" P_Z="0.6990060873799382" Q="5.278197706120636" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="460" TOTAL_2="366" WEIGHT="400.0" Z="0.3866624932338286">
<NAME>Adverse Events</NAME>
<GROUP_LABEL_1>Deferiprone</GROUP_LABEL_1>
<GROUP_LABEL_2>Deferiprone and DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone &amp; DFO</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3093852648237123" CI_END="2.014475426920839" CI_START="0.5275519728337494" DF="2" EFFECT_SIZE="1.030893052502149" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="0.30416197412311974" LOG_CI_START="-0.27773474853637237" LOG_EFFECT_SIZE="0.013213612793373688" MODIFIED="2011-11-25 12:57:35 +0000" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.5196017806230753" P_Z="0.9290715275693641" STUDIES="3" TAU2="0.0" TOTAL_1="121" TOTAL_2="96" WEIGHT="100.0" Z="0.08901306425066415">
<NAME>Risk of pain or swelling in joints</NAME>
<DICH_DATA CI_END="5.649885067882092" CI_START="0.011636735757001682" EFFECT_SIZE="0.2564102564102564" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7520396133252286" LOG_CI_START="-1.9341688273782272" LOG_EFFECT_SIZE="-0.5910646070264992" MODIFIED="2011-11-25 12:51:54 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="108" O_E="0.0" SE="1.5778921350154418" STUDY_ID="STD-Aydinok-2007" TOTAL_1="12" TOTAL_2="9" VAR="2.4897435897435893" WEIGHT="12.741838486479294"/>
<DICH_DATA CI_END="3.3455669827375436" CI_START="0.5831959722474014" EFFECT_SIZE="1.3968253968253967" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5244697294604305" LOG_CI_START="-0.23418548406725676" LOG_EFFECT_SIZE="0.14514212269658688" MODIFIED="2011-11-25 12:51:54 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="109" O_E="0.0" SE="0.4456378278300368" STUDY_ID="STD-El_x002d_Beshlawy-2008" TOTAL_1="21" TOTAL_2="22" VAR="0.19859307359307354" WEIGHT="44.0379820319821"/>
<DICH_DATA CI_END="2.778970286471102" CI_START="0.28270921056353593" EFFECT_SIZE="0.8863636363636364" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4438839032039186" LOG_CI_START="-0.548660042123295" LOG_EFFECT_SIZE="-0.05238806945968823" MODIFIED="2011-11-25 12:51:54 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="110" O_E="0.0" SE="0.5830252266569732" STUDY_ID="STD-Maggio-2009" TOTAL_1="88" TOTAL_2="65" VAR="0.33991841491841496" WEIGHT="43.22017948153861"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0142805862276486" CI_END="3.3500005776590855" CI_START="0.8992881555505827" DF="1" EFFECT_SIZE="1.7356888662938486" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="11" I2="0.0" ID="CMP-002.10.02" LOG_CI_END="0.5250448819246457" LOG_CI_START="-0.046101126605330944" LOG_EFFECT_SIZE="0.23947187765965736" MODIFIED="2011-11-25 12:57:42 +0000" MODIFIED_BY="Sheila A Worsley" NO="2" P_CHI2="0.9048781281872593" P_Z="0.1002672027168186" STUDIES="2" TAU2="0.0" TOTAL_1="109" TOTAL_2="87" WEIGHT="100.00000000000001" Z="1.6435596100238743">
<NAME>Risk of gastrointestinal disturbances</NAME>
<DICH_DATA CI_END="5.361613460102722" CI_START="0.6268842646196124" EFFECT_SIZE="1.8333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7292955007704041" LOG_CI_START="-0.2028126312212413" LOG_EFFECT_SIZE="0.2632414347745814" MODIFIED="2011-11-25 12:52:37 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="97" O_E="0.0" SE="0.5475249307415597" STUDY_ID="STD-El_x002d_Beshlawy-2008" TOTAL_1="21" TOTAL_2="22" VAR="0.29978354978354976" WEIGHT="32.669039145907476"/>
<DICH_DATA CI_END="3.8653485236430027" CI_START="0.7374228583670975" EFFECT_SIZE="1.6883116883116882" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" LOG_CI_END="0.5871886586866601" LOG_CI_START="-0.13228340441795036" LOG_EFFECT_SIZE="0.22745262713435488" MODIFIED="2011-11-25 12:52:37 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="98" O_E="0.0" SE="0.4226214513117988" STUDY_ID="STD-Maggio-2009" TOTAL_1="88" TOTAL_2="65" VAR="0.1786088911088911" WEIGHT="67.33096085409254"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.08891995850397694" CI_END="1.3190094483595862" CI_START="0.38328875612160207" DF="2" EFFECT_SIZE="0.7110284739547259" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" I2="0.0" ID="CMP-002.10.03" LOG_CI_END="0.12024790650598215" LOG_CI_START="-0.4164739207038191" LOG_EFFECT_SIZE="-0.14811300709891848" MODIFIED="2013-08-09 12:26:57 +0100" MODIFIED_BY="Sheila A Worsley" NO="3" P_CHI2="0.9565138811236041" P_Z="0.27936904309227817" STUDIES="3" TAU2="0.0" TOTAL_1="121" TOTAL_2="96" WEIGHT="100.0" Z="1.081737856889247">
<NAME>Risk of leucopenia, neutropenia and/or agranulocytosis</NAME>
<DICH_DATA CI_END="10.443088767703047" CI_START="0.053863374382072" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0188289695829758" LOG_CI_START="-1.2687064427995756" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2011-11-25 12:50:02 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="105" O_E="0.0" SE="1.3437096247164249" STUDY_ID="STD-Aydinok-2007" TOTAL_1="12" TOTAL_2="9" VAR="1.8055555555555556" WEIGHT="5.898768736256716"/>
<DICH_DATA CI_END="15.690631300346018" CI_START="0.06994655905973891" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1956404174391426" LOG_CI_START="-1.1552336452625687" LOG_EFFECT_SIZE="0.02020338608828699" MODIFIED="2013-08-09 12:26:18 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="106" O_E="0.0" SE="1.3809150614452748" STUDY_ID="STD-El_x002d_Beshlawy-2008" TOTAL_1="21" TOTAL_2="22" VAR="1.906926406926407" WEIGHT="5.041389559475216"/>
<DICH_DATA CI_END="1.3258741860124879" CI_START="0.35845331984509904" EFFECT_SIZE="0.6893939393939394" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.12250231523550578" LOG_CI_START="-0.44556739300501824" LOG_EFFECT_SIZE="-0.16153253888475624" MODIFIED="2013-08-09 12:26:24 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="107" O_E="0.0" SE="0.3336869586108908" STUDY_ID="STD-Maggio-2009" TOTAL_1="88" TOTAL_2="65" VAR="0.11134698634698637" WEIGHT="89.05984170426807"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4907364119527697" CI_END="1.1741113735743756" CI_START="0.45178236342926187" DF="1" EFFECT_SIZE="0.7283150494687093" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" I2="0.0" ID="CMP-002.10.04" LOG_CI_END="0.06970929506715316" LOG_CI_START="-0.3450707269677884" LOG_EFFECT_SIZE="-0.13768071595031758" MODIFIED="2013-08-09 12:26:43 +0100" MODIFIED_BY="Sheila A Worsley" NO="4" P_CHI2="0.48359903846705765" P_Z="0.19320095802428006" STUDIES="2" TAU2="0.0" TOTAL_1="109" TOTAL_2="87" WEIGHT="100.00000000000001" Z="1.3011679940823158">
<NAME>Risk of increased liver transaminase</NAME>
<DICH_DATA CI_END="1.258921153247927" CI_START="0.4736670214050071" EFFECT_SIZE="0.7722107438016529" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="22" LOG_CI_END="0.0999985309167296" LOG_CI_START="-0.32452685154058236" LOG_EFFECT_SIZE="-0.11226416031192642" MODIFIED="2012-04-13 14:00:12 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="99" O_E="0.0" SE="0.24936831108995972" STUDY_ID="STD-Maggio-2009" TOTAL_1="88" TOTAL_2="65" VAR="0.06218455457585892" WEIGHT="89.62287510631198"/>
<DICH_DATA CI_END="3.0976997640705437" CI_START="0.03936633102421272" EFFECT_SIZE="0.3492063492063492" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4910393226788002" LOG_CI_START="-1.4048750599415514" LOG_EFFECT_SIZE="-0.4569178686313755" MODIFIED="2012-04-13 14:00:12 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="100" O_E="0.0" SE="1.1136694932787465" STUDY_ID="STD-El_x002d_Beshlawy-2008" TOTAL_1="21" TOTAL_2="22" VAR="1.2402597402597402" WEIGHT="10.37712489368803"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-08-09 12:33:22 +0100" MODIFIED_BY="Sheila A Worsley" NO="3">
<NAME>Deferiprone and DFO in combination versus DFO alone</NAME>
<CONT_OUTCOME CHI2="9.284244379399215" CI_END="8.1204479975321" CI_START="4.317963796492316" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="6.219205897012208" ESTIMABLE="YES" I2="89.22906421745104" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2013-08-08 13:39:53 +0100" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.0023113434314678827" P_Q="1.0" P_Z="1.4429087698304433E-10" Q="0.0" RANDOM="NO" SCALE="12.42" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="58" TOTAL_2="60" UNITS="" WEIGHT="100.00000000000001" Z="6.411292684529693">
<NAME>Left ventricular ejection fraction: mean at endpoint (%)</NAME>
<GROUP_LABEL_1>Deferiprone &amp; DFO</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone &amp; DFO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.284244379399215" CI_END="8.1204479975321" CI_START="4.317963796492316" DF="1" EFFECT_SIZE="6.219205897012208" ESTIMABLE="YES" I2="89.22906421745104" ID="CMP-003.01.01" MODIFIED="2011-11-18 13:28:19 +0000" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.0023113434314678827" P_Z="1.4429087698304433E-10" STUDIES="2" TAU2="0.0" TOTAL_1="58" TOTAL_2="60" WEIGHT="100.00000000000001" Z="6.411292684529693">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="11.639245788965777" CI_START="6.4007542110342435" EFFECT_SIZE="9.02000000000001" ESTIMABLE="YES" MEAN_1="78.04" MEAN_2="69.02" MODIFIED="2011-11-18 13:26:30 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="91" SD_1="4.12" SD_2="6.05" SE="1.3363744485235667" STUDY_ID="STD-Abdelrazik-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="52.68928880088174"/>
<CONT_DATA CI_END="5.864125034155457" CI_START="0.3358749658445608" EFFECT_SIZE="3.1000000000000085" ESTIMABLE="YES" MEAN_1="68.4" MEAN_2="65.3" MODIFIED="2011-11-18 13:28:19 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="92" SD_1="4.7" SD_2="6.0" SE="1.410293789048428" STUDY_ID="STD-Tanner-2007" TOTAL_1="28" TOTAL_2="30" WEIGHT="47.31071119911827"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-08-08 13:40:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.84" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="61" TOTAL_2="61" WEIGHT="0.0" Z="0.0">
<NAME>Serum ferritin concentration: ratio of geometric means at endpoint (ng/ml)</NAME>
<GROUP_LABEL_1>Deferiprone &amp; DFO</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone &amp; DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DFO</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of GM</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="2" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-04-13 14:44:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="61" TOTAL_2="61" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<IV_DATA CI_END="0.9148730191926675" CI_START="0.47614635676064526" EFFECT_SIZE="0.6600101930934101" ESTIMABLE="YES" ESTIMATE="-0.4155" LOG_CI_END="-0.03863918013120613" LOG_CI_START="-0.3222595343303961" LOG_EFFECT_SIZE="-0.18044935723080113" MODIFIED="2012-04-13 14:44:37 +0100" MODIFIED_BY="[Empty name]" ORDER="120" SE="0.1666" STUDY_ID="STD-Gomber-2004" TOTAL_1="10" TOTAL_2="7" WEIGHT="0.0"/>
<IV_DATA CI_END="0.924810315479626" CI_START="0.44958363811610846" EFFECT_SIZE="0.6448097286802024" ESTIMABLE="YES" ESTIMATE="-0.4388" LOG_CI_END="-0.03394733470761343" LOG_CI_START="-0.34718950261068043" LOG_EFFECT_SIZE="-0.19056841865914698" MODIFIED="2012-04-13 14:44:37 +0100" MODIFIED_BY="[Empty name]" ORDER="121" SE="0.184" STUDY_ID="STD-Mourad-2003" TOTAL_1="11" TOTAL_2="14" WEIGHT="0.0"/>
<IV_DATA CI_END="0.9489559552643015" CI_START="0.8610462091622164" EFFECT_SIZE="0.9039330328858641" ESTIMABLE="YES" ESTIMATE="-0.101" LOG_CI_END="-0.022753944400499992" LOG_CI_START="-0.06497354094395687" LOG_EFFECT_SIZE="-0.043863742672228416" MODIFIED="2012-04-13 14:44:37 +0100" MODIFIED_BY="[Empty name]" ORDER="119" SE="0.0248" STUDY_ID="STD-Tamaddoni-2010" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.9155526826252203" CI_END="0.9052388284038353" CI_START="0.8132206587893631" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.8579970375218542" ESTIMABLE="YES" I2="31.40237142965425" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-0.0432368261270857" LOG_CI_START="-0.08979159722010158" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.06651421167359367" MODIFIED="2013-08-08 13:40:07 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.23275331388290998" P_Q="1.0" P_Z="2.1370995772757063E-8" Q="0.0" RANDOM="NO" SCALE="2.84" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="81" TOTAL_2="84" WEIGHT="100.00000000000001" Z="5.60051982985153">
<NAME>Serum ferritin concentration: ratio of geometric means at endpoint (ng/ml)</NAME>
<GROUP_LABEL_1>Deferiprone &amp; DFO</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone &amp; DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DFO</GRAPH_LABEL_2>
<EFFECT_MEASURE>Ratio of GM</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="2.9155526826252203" CI_END="0.9052388284038353" CI_START="0.8132206587893631" DF="2" EFFECT_SIZE="0.8579970375218542" ESTIMABLE="YES" I2="31.40237142965425" ID="CMP-003.03.01" LOG_CI_END="-0.0432368261270857" LOG_CI_START="-0.08979159722010158" LOG_EFFECT_SIZE="-0.06651421167359367" MODIFIED="2012-04-13 15:52:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23275331388290998" P_Z="2.1370995772757063E-8" STUDIES="3" TAU2="0.0" TOTAL_1="81" TOTAL_2="84" WEIGHT="100.00000000000001" Z="5.60051982985153">
<NAME>At 12 months</NAME>
<IV_DATA CI_END="1.4811553762001783" CI_START="0.8089465423255588" EFFECT_SIZE="1.0946120409643074" ESTIMABLE="YES" ESTIMATE="0.0904" LOG_CI_END="0.17060061928210618" LOG_CI_START="-0.09208017695399831" LOG_EFFECT_SIZE="0.039260221164053935" MODIFIED="2012-04-13 14:44:47 +0100" MODIFIED_BY="[Empty name]" ORDER="122" SE="0.1543" STUDY_ID="STD-Abdelrazik-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="3.1410275316705487"/>
<IV_DATA CI_END="1.1012361076520025" CI_START="0.5301298602457393" EFFECT_SIZE="0.7640668451432231" ESTIMABLE="YES" ESTIMATE="-0.2691" LOG_CI_END="0.041880442729405574" LOG_CI_START="-0.2756177328897357" LOG_EFFECT_SIZE="-0.11686864508016503" MODIFIED="2012-04-13 14:44:47 +0100" MODIFIED_BY="[Empty name]" ORDER="124" SE="0.1865" STUDY_ID="STD-Mourad-2003" TOTAL_1="11" TOTAL_2="14" WEIGHT="2.1500369463592186"/>
<IV_DATA CI_END="0.9016534702721777" CI_START="0.8076108256096514" EFFECT_SIZE="0.8533376257615275" ESTIMABLE="YES" ESTIMATE="-0.1586" LOG_CI_END="-0.04496034146551827" LOG_CI_START="-0.0927978681941932" LOG_EFFECT_SIZE="-0.0688791048298557" MODIFIED="2012-04-13 14:44:47 +0100" MODIFIED_BY="[Empty name]" ORDER="123" SE="0.0281" STUDY_ID="STD-Tamaddoni-2010" TOTAL_1="40" TOTAL_2="40" WEIGHT="94.70893552197025"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2013-08-08 13:40:15 +0100" MODIFIED_BY="Sheila A Worsley" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="56" TOTAL_2="51" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum ferritin concentration: mean change from baseline (ng/ml)</NAME>
<GROUP_LABEL_1>Deferiprone and DFO</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone &amp; DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DFO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.04.01" MODIFIED="2011-04-05 11:09:16 +0100" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="27" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="2553.190265405913" CI_START="222.12973459408659" EFFECT_SIZE="1387.6599999999999" ESTIMABLE="YES" MEAN_1="28.79" MEAN_2="-1358.87" ORDER="33" SD_1="915.86" SD_2="1374.14" SE="594.6692258630603" STUDY_ID="STD-Gomber-2004" TOTAL_1="10" TOTAL_2="7" WEIGHT="0.0"/>
<CONT_DATA CI_END="-190.00164731627592" CI_START="-3901.998352683724" EFFECT_SIZE="-2046.0" ESTIMABLE="YES" MEAN_1="-987.0" MEAN_2="1059.0" ORDER="34" SD_1="2984.0" SD_2="2285.0" SE="946.9553355692259" STUDY_ID="STD-Ha-_x0028_i_x0029_-2006" TOTAL_1="17" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.04.02" MODIFIED="2011-04-05 11:11:15 +0100" MODIFIED_BY="Sheila A Worsley" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="454.4435550584875" CI_START="-252.4435550584875" EFFECT_SIZE="101.0" ESTIMABLE="YES" MEAN_1="-248.0" MEAN_2="-349.0" MODIFIED="2011-04-05 11:11:15 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="46" SD_1="791.0" SD_2="573.0" SE="180.33165805413014" STUDY_ID="STD-Galanello-2006" TOTAL_1="29" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2013-08-08 13:40:27 +0100" MODIFIED_BY="Sheila A Worsley" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.89" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="56" TOTAL_2="52" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Urinary iron excretion: mean at endpoint (mg/24h)</NAME>
<GROUP_LABEL_1>Deferiprone and DFO</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone &amp; DFO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.01" MODIFIED="2011-11-25 08:49:48 +0000" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="4.033918883917671" CI_START="-5.673918883917672" EFFECT_SIZE="-0.8200000000000003" ESTIMABLE="YES" MEAN_1="7.14" MEAN_2="7.96" ORDER="35" SD_1="4.99" SD_2="5.05" SE="2.4765347333954932" STUDY_ID="STD-Gomber-2004" TOTAL_1="10" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.02" MODIFIED="2011-11-25 08:49:54 +0000" MODIFIED_BY="Sheila A Worsley" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="0.4207653529724646" CI_START="0.039234647027535374" EFFECT_SIZE="0.22999999999999998" ESTIMABLE="YES" MEAN_1="0.76" MEAN_2="0.53" MODIFIED="2011-04-05 11:24:39 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="47" SD_1="0.49" SD_2="0.21" SE="0.09733105020153297" STUDY_ID="STD-Abdelrazik-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.03" MODIFIED="2011-11-25 08:50:04 +0000" MODIFIED_BY="Sheila A Worsley" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>As a mean of quarterly readings</NAME>
<CONT_DATA CI_END="0.40708076475042776" CI_START="0.1329192352495723" EFFECT_SIZE="0.27" ESTIMABLE="YES" MEAN_1="0.45" MEAN_2="0.18" MODIFIED="2011-07-12 10:35:09 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="150" SD_1="0.26" SD_2="0.1" SE="0.06994045086119097" STUDY_ID="STD-El_x002d_Beshlawy-2008" TOTAL_1="16" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2013-08-08 13:40:35 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="5" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Urinary iron excretion: mean over study (%)</NAME>
<GROUP_LABEL_1>Deferiprone and DFO</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DFO &amp; deferiprone</GRAPH_LABEL_2>
<CONT_DATA CI_END="69.55963655615012" CI_START="42.44036344384987" EFFECT_SIZE="56.0" ESTIMABLE="YES" MEAN_1="84.0" MEAN_2="28.0" MODIFIED="2012-01-31 10:35:06 +0000" MODIFIED_BY="[Empty name]" ORDER="105" SD_1="14.6" SD_2="10.3" SE="6.918309041955267" STUDY_ID="STD-Aydinok-2005" TOTAL_1="8" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.07" MODIFIED="2013-08-08 13:40:43 +0100" MODIFIED_BY="Sheila A Worsley" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="9.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="46" TOTAL_2="44" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Liver iron concentration: mean change from baseline</NAME>
<GROUP_LABEL_1>Deferiprone and DFO</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone &amp; DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DFO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.07.01" MODIFIED="2012-02-28 17:03:13 +0000" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months (mg/g dry weight)</NAME>
<CONT_DATA CI_END="8.667826888037933" CI_START="-8.407826888037931" EFFECT_SIZE="0.13" ESTIMABLE="YES" MEAN_1="0.95" MEAN_2="0.82" ORDER="37" SD_1="15.49" SD_2="8.25" SE="4.356114171170093" STUDY_ID="STD-Ha-_x0028_i_x0029_-2006" TOTAL_1="17" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.07.02" MODIFIED="2012-03-23 08:05:28 +0000" MODIFIED_BY="Sheila A Worsley" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months (mg/g wet weight)</NAME>
<CONT_DATA CI_END="0.4548392540014948" CI_START="-0.1068392540014948" EFFECT_SIZE="0.174" ESTIMABLE="YES" MEAN_1="-0.065" MEAN_2="-0.239" MODIFIED="2012-03-23 08:05:28 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="51" SD_1="0.615" SD_2="0.474" SE="0.1432879666242436" STUDY_ID="STD-Galanello-2006" TOTAL_1="29" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.08" MODIFIED="2013-08-08 13:41:00 +0100" MODIFIED_BY="Sheila A Worsley" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="27.28" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="5" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Chelation efficiency (%)</NAME>
<GROUP_LABEL_1>Deferiprone and DFO</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone &amp; DFO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.08.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>At end of trial</NAME>
<CONT_DATA CI_END="-6.360033878655138" CI_START="-25.159966121344866" EFFECT_SIZE="-15.760000000000002" ESTIMABLE="YES" MEAN_1="7.34" MEAN_2="23.1" ORDER="38" SD_1="0.91" SD_2="10.7" SE="4.7959892097459935" STUDY_ID="STD-Aydinok-2005" TOTAL_1="8" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.09" MODIFIED="2013-08-08 13:41:06 +0100" MODIFIED_BY="Sheila A Worsley" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="5" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Plasma NBTI: mean change from baseline (mM)</NAME>
<GROUP_LABEL_1>Deferiprone and DFO</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone &amp; DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DFO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.09.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>At end of trial</NAME>
<CONT_DATA CI_END="0.8404367459472311" CI_START="-0.6004367459472311" EFFECT_SIZE="0.12" ESTIMABLE="YES" MEAN_1="0.84" MEAN_2="0.72" ORDER="39" SD_1="0.87" SD_2="0.45" SE="0.3675765226452854" STUDY_ID="STD-Aydinok-2005" TOTAL_1="8" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.10" MODIFIED="2013-08-08 13:41:12 +0100" MODIFIED_BY="Sheila A Worsley" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.33" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="5" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Total iron excretion: mean at endpoint (mg/kg/day)</NAME>
<GROUP_LABEL_1>Deferiprone and DFO</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone &amp; DFO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.10.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>At end of trial</NAME>
<CONT_DATA CI_END="0.14783264102105595" CI_START="-0.3078326410210561" EFFECT_SIZE="-0.08000000000000007" ESTIMABLE="YES" MEAN_1="0.69" MEAN_2="0.77" ORDER="40" SD_1="0.09" SD_2="0.25" SE="0.1162432793756267" STUDY_ID="STD-Aydinok-2005" TOTAL_1="8" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="13.002093579773655" CI_END="2.9420222669042864" CI_START="1.358602308073058" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9992594234412138" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="31" I2="7.707170953857264" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="0.4686459553925531" LOG_CI_START="0.1330923480602002" LOG_EFFECT_SIZE="0.3008691517263767" METHOD="MH" MODIFIED="2013-08-09 12:33:22 +0100" MODIFIED_BY="Sheila A Worsley" NO="11" P_CHI2="0.36888863704516694" P_Q="0.8749210531274418" P_Z="4.401762409053714E-4" Q="1.2192387810950127" RANDOM="NO" SCALE="207.52" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="377" TOTAL_2="395" WEIGHT="500.0" Z="3.5147451170670774">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Deferiprone and DFO</GROUP_LABEL_1>
<GROUP_LABEL_2>DFO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone &amp; DFO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DFO</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.09707048256290043" CI_END="7.831367795013012" CI_START="1.1834688932275712" DF="1" EFFECT_SIZE="3.044368600682594" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" I2="0.0" ID="CMP-003.11.01" LOG_CI_END="0.893837620799761" LOG_CI_START="0.07315684724426619" LOG_EFFECT_SIZE="0.4834972340220136" MODIFIED="2011-08-09 15:03:59 +0100" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.7553739242944952" P_Z="0.02092179007804683" STUDIES="2" TAU2="0.0" TOTAL_1="59" TOTAL_2="60" WEIGHT="100.0" Z="2.3093928744117243">
<NAME>Number of participants experiencing an adverse event</NAME>
<DICH_DATA CI_END="9.092400541061908" CI_START="0.7820939122728747" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9586785591406364" LOG_CI_START="-0.1067410945960741" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2011-08-09 15:03:48 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="73" O_E="0.0" SE="0.6258327785172862" STUDY_ID="STD-Abdelrazik-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.39166666666666666" WEIGHT="60.40955631399318"/>
<DICH_DATA CI_END="16.005522978132642" CI_START="0.8190543724802425" EFFECT_SIZE="3.6206896551724137" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2042698692209484" LOG_CI_START="-0.08668726687898436" LOG_EFFECT_SIZE="0.558791301170982" MODIFIED="2011-08-09 15:03:59 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="74" O_E="0.0" SE="0.7583146120859863" STUDY_ID="STD-Galanello-2006" TOTAL_1="29" TOTAL_2="30" VAR="0.5750410509031199" WEIGHT="39.59044368600683"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.1897739971377685" CI_END="3.803324898364083" CI_START="0.6575485664213184" DF="2" EFFECT_SIZE="1.581414188172665" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" I2="61.46267638816204" ID="CMP-003.11.02" LOG_CI_END="0.5801634265264236" LOG_CI_START="-0.18207216473959656" LOG_EFFECT_SIZE="0.1990456308934135" MODIFIED="2011-11-25 12:46:34 +0000" MODIFIED_BY="Sheila A Worsley" NO="2" P_CHI2="0.07465442237232711" P_Z="0.3060117470038747" STUDIES="3" TAU2="0.0" TOTAL_1="94" TOTAL_2="96" WEIGHT="100.00000000000001" Z="1.0236264805824085">
<NAME>Risk of pain or swelling in joints</NAME>
<DICH_DATA CI_END="47.98687270671495" CI_START="0.8199556507567658" EFFECT_SIZE="6.2727272727272725" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6811224479846882" LOG_CI_START="-0.08620963682662751" LOG_EFFECT_SIZE="0.7974564055790303" MODIFIED="2011-11-25 12:46:34 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="94" O_E="0.0" SE="1.0381396150530795" STUDY_ID="STD-El_x002d_Beshlawy-2008" TOTAL_1="22" TOTAL_2="23" VAR="1.0777338603425561" WEIGHT="13.239208424950816"/>
<DICH_DATA CI_END="100.96614901769104" CI_START="0.24760774024984902" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0041757920103214" LOG_CI_START="-0.6062357833382839" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-11-25 12:46:34 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="95" O_E="0.0" SE="1.5333686811054679" STUDY_ID="STD-Tamaddoni-2010" TOTAL_1="40" TOTAL_2="40" VAR="2.351219512195122" WEIGHT="6.77004976275894"/>
<DICH_DATA CI_END="1.8878168664296529" CI_START="0.1408341801330692" EFFECT_SIZE="0.515625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2759598619129795" LOG_CI_START="-0.851291930124979" LOG_EFFECT_SIZE="-0.28766603410599967" MODIFIED="2011-11-25 12:46:34 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="96" O_E="0.0" SE="0.6621532826294602" STUDY_ID="STD-Tanner-2007" TOTAL_1="32" TOTAL_2="33" VAR="0.4384469696969697" WEIGHT="79.99074181229025"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5038695102267523" CI_END="4.368305321786514" CI_START="1.0152938088893417" DF="1" EFFECT_SIZE="2.1059708802707156" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" I2="33.50486905946908" ID="CMP-003.11.03" LOG_CI_END="0.6403129856795038" LOG_CI_START="0.0065917379290464165" LOG_EFFECT_SIZE="0.3234523618042751" MODIFIED="2011-11-25 12:57:55 +0000" MODIFIED_BY="Sheila A Worsley" NO="3" P_CHI2="0.2200773132685232" P_Z="0.045420669806675314" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="56" WEIGHT="100.0" Z="2.0007376495617613">
<NAME>Risk of gastrointestinal disturbances</NAME>
<DICH_DATA CI_END="164.845013967644" CI_START="0.5350273886403895" EFFECT_SIZE="9.391304347826088" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.217075815664269" LOG_CI_START="-0.2716239853975931" LOG_EFFECT_SIZE="0.9727259151333381" MODIFIED="2011-11-25 12:48:26 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="100" O_E="0.0" SE="1.4618745824064356" STUDY_ID="STD-El_x002d_Beshlawy-2008" TOTAL_1="22" TOTAL_2="23" VAR="2.1370772946859904" WEIGHT="6.246938866378734"/>
<DICH_DATA CI_END="3.461055768228007" CI_START="0.75876731758646" EFFECT_SIZE="1.6205357142857142" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5392085971671586" LOG_CI_START="-0.11989138376325932" LOG_EFFECT_SIZE="0.2096586067019497" MODIFIED="2011-11-25 12:48:26 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="101" O_E="0.0" SE="0.38715859139605163" STUDY_ID="STD-Tanner-2007" TOTAL_1="28" TOTAL_2="33" VAR="0.14989177489177488" WEIGHT="93.75306113362127"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2845032602067192" CI_END="7.1739193224626385" CI_START="0.4535900427208709" DF="2" EFFECT_SIZE="1.8038897893030799" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="12.453615854370687" ID="CMP-003.11.04" LOG_CI_END="0.8557564883134207" LOG_CI_START="-0.34333648771048725" LOG_EFFECT_SIZE="0.25621000030146673" MODIFIED="2013-08-09 12:33:22 +0100" MODIFIED_BY="Sheila A Worsley" NO="4" P_CHI2="0.319100088405459" P_Z="0.4022720485952931" STUDIES="4" TAU2="0.0" TOTAL_1="110" TOTAL_2="116" WEIGHT="100.00000000000001" Z="0.8375703687882481">
<NAME>Risk of leucopenia, neutropenia and/or agranulocytosis</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-09 12:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="246" O_E="0.0" SE="0.0" STUDY_ID="STD-Abdelrazik-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.704267824435277" CI_START="0.06959733614011215" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1960176932197213" LOG_CI_START="-1.1574073828289482" LOG_EFFECT_SIZE="0.019305155195386624" MODIFIED="2011-11-25 12:47:42 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="97" O_E="0.0" SE="1.382413539312998" STUDY_ID="STD-El_x002d_Beshlawy-2008" TOTAL_1="22" TOTAL_2="23" VAR="1.9110671936758894" WEIGHT="33.27930848190168"/>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-11-25 12:47:42 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="98" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Galanello-2006" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="51.05348460291735"/>
<DICH_DATA CI_END="152.39137692417276" CI_START="0.4419748175398094" EFFECT_SIZE="8.206896551724139" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.182960393117748" LOG_CI_START="-0.3546024748026362" LOG_EFFECT_SIZE="0.9141789591575559" MODIFIED="2013-08-09 12:31:08 +0100" MODIFIED_BY="Sheila A Worsley" ORDER="99" O_E="0.0" SE="1.4905769897552135" STUDY_ID="STD-Tanner-2007" TOTAL_1="28" TOTAL_2="33" VAR="2.221819762387714" WEIGHT="15.667206915180984"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2962579539296217" CI_END="3.6129629265271537" CI_START="0.8316718420884452" DF="2" EFFECT_SIZE="1.7334357595544458" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" I2="12.901771485325982" ID="CMP-003.11.05" LOG_CI_END="0.5578635051918005" LOG_CI_START="-0.08004800217493133" LOG_EFFECT_SIZE="0.23890775150843466" MODIFIED="2011-11-25 12:49:04 +0000" MODIFIED_BY="Sheila A Worsley" NO="5" P_CHI2="0.3172301467206705" P_Z="0.1420841747136823" STUDIES="3" TAU2="0.0" TOTAL_1="64" TOTAL_2="67" WEIGHT="99.99999999999999" Z="1.4680738101649635">
<NAME>Risk of increased liver transaminase</NAME>
<DICH_DATA CI_END="2.7529106241982273" CI_START="0.47445145421675067" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.43979211184824923" LOG_CI_START="-0.3238082178928758" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2011-11-25 12:49:04 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="102" O_E="0.0" SE="0.4485426135725302" STUDY_ID="STD-Abdelrazik-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.2011904761904762" WEIGHT="78.64413289802188"/>
<DICH_DATA CI_END="21.4517839091991" CI_START="0.2038012710249002" EFFECT_SIZE="2.090909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3314634135234054" LOG_CI_START="-0.6907931118046698" LOG_EFFECT_SIZE="0.3203351508593678" MODIFIED="2011-11-25 12:49:04 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="103" O_E="0.0" SE="1.1878834933089564" STUDY_ID="STD-El_x002d_Beshlawy-2008" TOTAL_1="22" TOTAL_2="23" VAR="1.4110671936758894" WEIGHT="10.985212214326866"/>
<DICH_DATA CI_END="43.267195826769616" CI_START="0.7864567399749217" EFFECT_SIZE="5.833333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6361587492217475" LOG_CI_START="-0.10432516128848371" LOG_EFFECT_SIZE="0.7659167939666319" MODIFIED="2011-11-25 12:49:04 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="104" O_E="0.0" SE="1.0223688645680165" STUDY_ID="STD-Galanello-2006" TOTAL_1="12" TOTAL_2="14" VAR="1.0452380952380953" WEIGHT="10.370654887651238"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-08-08 13:41:46 +0100" MODIFIED_BY="Sheila A Worsley" NO="4">
<NAME>Deferiprone dose A versus deferiprone dose B</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2013-08-08 13:41:46 +0100" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="21" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum ferritin concentration: mean at endpoint (ng/ml)</NAME>
<GROUP_LABEL_1>Deferiprone 75mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Deferiprone 50mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deferiprone 75 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deferiprone 50 mg</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.01" MODIFIED="2011-11-25 13:08:36 +0000" MODIFIED_BY="Sheila A Worsley" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="896.668913732696" CI_START="-1342.668913732696" EFFECT_SIZE="-223.0" ESTIMABLE="YES" MEAN_1="3785.0" MEAN_2="4008.0" MODIFIED="2011-11-25 13:08:36 +0000" MODIFIED_BY="Sheila A Worsley" ORDER="111" SD_1="2050.0" SD_2="1946.0" SE="571.2701470866309" STUDY_ID="STD-Choudhry-2004" TOTAL_1="21" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-08-09 12:33:23 +0100" MODIFIED_BY="Sheila A Worsley">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-08-08 14:05:47 +0100" MODIFIED_BY="Sheila A Worsley" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>PRISMA study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUIAAAMsCAYAAAAhzKufAABNA0lEQVR42u2dD4RVz///3+QtSRJJ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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-08-08 12:31:25 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATAAAAMYCAIAAADD+SzWAAAl70lEQVR42u3dv45cx3bF4QEMGA4Y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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-08-09 12:17:07 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.14" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Deferiprone alone versus DFO alone, outcome: 1.14 Adverse events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArYAAAMACAMAAADmOdQCAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAABx9UlEQVR42uy9C3Akx3km+OPRVf3ANJANQJwZDklgAJEOmaKlGXDw
GiytxlA0PedlrE3pIlYWRekiaJ3tE7VhnkLLVZiSVl6KPilCurAokV6ZSyt0srjjtazViGOLg6ME
NGbQGoI6mtYuaWAAcjgDUgC6AAwajUYD6MvMer+6q4Gubjz+jxxUVj7+zMr68q+/sv7OrCGAQOw2
1GIXIJC2CATSFoFwQl1op7Qk3t5+LRDNqKexfK2wbkqeKnd1b90zv8qO7VT08HM1deJKXZWuu05s
XNEv0BiS05TTFsiVvR9KaujVOuHFv3JpKE3LqP03/H2fG7qTtO3QTN37htWT5b70VVPiUNmre+dn
789wyUMwc2rj7TQ05Kpz3dloT9rlAuU0BXf0+NEPJTR0bbH3lFtDadoB9eQxvxu6o4yE2Dn4LUg9
Ioj5lHAS7oml8qIQTUE8Hg7TP/R/EgzRYRyPBAGighilozyeCQVjSpmSqwtDqxI82P+TWGC+v6lK
Fz4HG+wCW0OiEJlhEUkx2GpIa40IQnBYoNfLsinXXg2EYJO1YJi2J5RkEbngQ0lDWjIsBMIZraHs
/u0D2/bXYR3axxvCg21rdLhC22B4saudxs8vyukbod4n6eH5a9DUFQl1NdLwDQ19K6zMTwbbSq7u
Nfi3SihIq4YMrFfpuoehnh2Wemcau48yMvyrmqlZQ9ry3Nobfad4n1Dwa49WqaHcDri7++03eu9i
DT3wwDdOGNLuml9b6SFqQxsHz0b4TdrjtI1BHlZhYhLW+OmdMJmBLA1kAnL69CT8kB5uj1GKTV6G
Lhp+YZYOclrmdqVMadX9F2aXUb2Qp2Fee1WMxvhjYxE5eGPuy8xuaegLHtLTFiFzU/QTeuP4td9Z
nYZe/CkLbMLhc2dYQw/09QaMaZlLj0Tp00FBFxybpPdmz9M2BTX07tx/v3Llwyy4yfml8CwGw+qp
EqZj/aSxTGnVgWLb8jCrvSom49mRjddYIJzoPTbAX0o7c3ra5nUgd2z+nF6mPt7ka694Q78wDJ0s
sDjS953D7EPV5ugfqWmvsLQXHvtmAwzoujkW2w8TYLfSB2INnBkayimNo0GjEs0ZmJVK6Y03lCkF
t4GghLLwz8w4q6+SxRjq4xaONPOFZD97qEae625R08K9bbAMb75uGm+p6ty4gYYe3tDQ278438fm
N6Jijzp+5ljaabjympFcqdQ+oG1qlVInCB0z8TA/F+BoTgnKaO6Ar6nGaMdRjXTGMqVU9zl4Xgm+
nfh+aj42Eq7ShS+OrrI3sdD9/+ZNbjymZke06YMFmlYHt43T4Ij8fODXLlalodKFDNMO4fvr1rkC
mZsbvseclu2gwYTcUAHGO2hr9zht44fWfzEHU5fSbWMvyqbspeOR5KKxtemLx+XQ1LH08UtLajwv
s1hqdTece1l9nh068MzBQzXp2WpdevDku+nfn44tHRxrYOeBQO+wIS2cWDxHQ0+NHNGufbE6DRUG
2GzL4u2LDRf5dFdA7GkxpC0k2pitFhm5Ub5/j6df8qWhNbvIlSYOQ4BA7DLaCluYLEDsSdTvorYi
aRE7ciYBgUDaIpC2CATSFoEoC21TDaIwGElCi9kFl3nyuCCZHxTESM5DzqKIczgmtYS8FTLkM0kq
IHo4XFxq2K0n4jlICXExBbl40JZDCTm2nUqnvazWwQ9aQblux+Zqkbm8MJhPQkrO2yQ0AjTE1D4Q
hXxuW3dCbkQOhrfewGSDIDySo/0iNzDwFEBEmYYevlcYbEhut4FGN/HDywvXf/mBL6733GTy720H
V3ff/2fgu3++/IHfeql4zqJoh6GpKefilvYYMDXFijnkM7WkgOg3jkwVlXpkyqUn2pcz374Tbv7c
SuvB12vUopa8jm1vB/i/VoVDIGfhOTXRvLHg2FwtT+3gwtevfjn79KGx11nG6a9sJL99XSF04Oq9
b8zntnMn5AYuZ36w9QZ+78Q/teQXsmu3np+mGR8YPb8x87WnecrMsSvXHj3+pe020KhtPwPrEBpa
DajOkvRfLhIkAKF4q6pRHhFlL9cGzvYcvIeWeFrNDdB4bygHyXCwiQ/IcJh9tGbKQMkQjz8jhgu4
DrTE2SeihniL6mdLImKGt6c1JAgR15Lc/5Tnk/09nfQq//YbjmdY3pTip8v9QnXfUQv4tfIsOarD
QnankDX63wj/S1L0Oh9hYiEVureJ90WGtp2XdsDoBqwnCqq7ViFIRQVyKbm9yVBQ9wUWYe4YrXRT
/ri9cSgPpxTl03QyGBsYSm//ISzSqxILNjAXCEMqKLYqPtG5sEgMHROagCwcBB71bCAPv6YIO9gf
jqWGVsppJNTCsdAw46L+Maq+O5xi0/w5+A7/CN44Hj7LHShn+S8P6uD9IZMnUv5i75NwZ8+PZL/V
+SvQ2HU2ctzgfP1wpKfATPHchRP00XLiwprqZ7sZ7n+Yt+c680R189yU/U95Ptnf0yHPwHt6cjDT
c+FgVyTS1Qayny73C9V8Ry2Qr5Vniaay6V57X1Pu0ZuzTo+zbV1nG8ZZi+E7vRclnhqkbV8D5w97
9WvwbwMF78tssO+Fo73hQLvc3njvjza1tBr2xf8BWnFajKSgtrU2tzYpp6zD6+WxHYc3YKOwj1kg
3EPa+4Kzik90fU9Y98B7UHZJWIcM1zW5B1PZy3JKEF4rt227NAq9j0VMekeEiZ8DvE2Hzx/zob0K
k1HZAZbrnp9aS3B/2CBE5RuXaaZ5o5Ng0H7TE64+IMwOCkIz/U/U/GynZuFZntgPv79+xm2QGvxP
zf6eRtHHqeCvwtfoFUxQaYqfLoPmO2pBVr1WYO6ufwyb1gyJ3uT6iJRYT/UmAmsQnZA9S38Ik/Kg
ldS2O93zvpaJgLF55saywwujp1fEKVDa2w3HpnXSQ2eIyU6MhLtvgtBisFU8Kjwld1OZHAUDvbm+
Ig2cGl1ZHZ1SfaJFmNQbGITOTuYeXLPc0P0nEIocPyq2i03lbKCBtoFr46PQbdI7JyF2ghoJifWZ
9VHmZpJn54wVcuUnrr1kLsH9QDfhhHzFMaaQTpjaSTO4+bQOUUx2ZnPZzstGP9t+nvjvE9n3f9b9
ijX/U7O/p1H0faOrqf979EPcM/c8KH66DE+pvqMWaNdK1fkd//G/Gd1dVfbET9bH6k/eTEMb8Nn7
FT0FMe3q+93a+ytKx18Zm2duLO/bYP/JRAyU9uaNnqtXxpZj1MRIZ09MUo22sHZ5derD6U/xkQRl
chT8JTTRfwUbGBP7+8WY6hN90tjAryavZxM1kD4fmIBv0QZ+aHUuG+WDeqRMDTROgMUWrr2s3KgE
NxZYLayawMl3nxQU7Z+CU4YSi9fGaZtHVI/rFPOHrYOUZoXWyVHDaoZk4VbHnutv6n8uZvOzhVMz
Z8cmll3Laf6nZn9Pk2jh5JGTQqzGJvrjqu+ok1T5Wlfgow5SmYuESE3qdfqvjonNKk/w4ncmMLo2
GrCpMXPlGTGRzYHS3lGj1Fh6LZM32FodQmwikJdH0q3loe2hRC5xqHADc9nRRCap+kQnjA0MLOfS
+TrVogHorA/0zW7IfXZbuWkbjMdiP2RPIO7mP9PCH5SdzA78MdVN/L59HzrGaRfqJTKx/05LPAgt
bfK7ZAe9hRkYr9dvLfe4rINWOcOpzsKOopOJ7sSkxc+WtSd0/8IVcPs5uOJ/2smHBvf3dML0SM/w
NM3WMRPXZk+Ydgrf/7zjzxqC8rUy/fAg3OogtY6qmF/B/4A++O/sOlvj/Ic1X4OONj1Pp4t2eeLk
E1Y1ZiHI9/svhvvr1fbSPm3X8oQfyhGqRkLijNyb2dcgkXuQp4yspjLxSDmshJOBIg1s7gufPRlX
75UoX7acJyS2xk4GaTtb5AZmQjA6w5kWTHwuFYuHy0nb62Np4fPJF+HMyE0gJT7Bmr1+cfnrrLIR
GOW/bZq6lD5t8PT8WfJ/CZxKLkBvYln22K5bGR0C6cJXCVPAnCuXTqcvLYA0ev3HcnXLY/MFbFto
XoVAs8XPlrXnp2NtBy+63Q7F/5TlU/w9nUTHsrAWg+lj6Vvk30MxML/QxdsHDl884CBVvlbm49qb
+A0H9s3RXgnAIcrsX4fp86cXxxZY7PGLmVr16uW2O+ExB+/pEdOkyn+9IEniYKvS3p9feLxWy/MP
VyKZcQka6tqWL02z1RMOMfuRv8idXz/UdH6hDLStd3CyMr2j5boupE5dONGi3Kt5ZZEJnidSu5j+
KFUI3116/3nawOG6WQi2cV0xt/DvD6Ypx7YLL46LKTjc98qcZ5FC+PLEZ8ecZmH2g8OsGLp84J6x
LcxBtV5fLUse3zBzNFOWPOWAF9qK+dpwCZb08Ac3IBB2+qHAfnCYzZB83vnqiyAcKV4oEp6t3pU1
PD9QljyVoi0CgUDsPfxeheurR22LKAMqTCN0XETsQiBtEbuethFtRjnMQzlRi2hQnS9jUMTb0vEZ
Ioouc8zMn9XmpmrPVdoyvG5iSnXz3K5baKntRni1bQ3hXGO3FuqRe11ZTANmOtV19WBLE3PLA2dc
nCjugCHDbK7bvO4dpc34DpUY7xvuwKUdfNe291hDuawa8RHd/6k3puoh7kEbC4mNTeK9LLIpGEqC
cU1aBu4LKwzA/TFeiog0j+K/yvKoS6Eyv9JwTlnF1pSHqH6rus+tXEdOCEEqJLTQNrB4ZY1b7gvM
BBp9dql4MRBRxD8TChLIRUQi61K+dmyLGk+h+OxyX+ME/1Iaibeq/rSRkNoOfU1d7hPr6Cvs5m+L
KCNtk1e00Fv88KT2YL9PX9k7sWL69LC+1H98cznLfFE2/7E3bl2TVl6HVvc73ThL82j+q/OLakp7
VyTaE9Xy3Knn2Qwpfqu6z61cRyDUS472BucA/izSXa+siwuqL7DWDlYe2rrONqn+up9u6MtAc7fq
r74srr3Rd12Np1B8drmvcf+F7hzkui9kVX/ac2+p7dDqA+4Tu2bzFQ65+9siykjb5WYtxDVqyzmN
oA/rT/hg31GjgBcC/B/zBJgOQrd1TVptHVoF01GaR/NfzWg+naswOTuU0fKcYnkO8DxTczafW6WO
KXHl+OgL9Pz4JIj6uriyL7Dus8vKr8GxWdWpfkpeEXfyTcXoqVXWjp1SPHAVn13Z11iUPYA1f9pf
b1bboa/DK/vE2nyF59z9bRHbhPkrme40wEINzw+YI/jhzKGaPhhip3HtoAWHcwLzSx1ZUwuK/TRW
O1XyNB2770vvlUsYS8sZtDxj4fea6iEr/dB5ho0kpQ5oPA4vLcoSElkeOZxThRraYRfPkoeUSyLv
Twbv0K+EDsL/ZKj5zCFYboCZG9g3y0SWZ1DaodTHr5FV9fZnn11u+NiXDzrVu+cRH6qetrXixGNx
B9ssFu4D7opk+/0V93q1+cqa12LNpaDOyX/V6OCckvNYPWelmbP3TaTlRvM6cquJUb5uJXf1tKxx
a27HqNWBsAZSSvvTlrVjVZ9d2YM0Fuxv6g/GdH9arR3G+lhV3Ff4+w6+wohK0Faf9OHOlkO2WaBJ
kZdrPWUt2fYqfV5a1qQ1r0ML0PwqtRuM/quKvzv3Kw1qclie2ww+rorP7R/KjrFKHc39kR+dZHs5
EObWaVnj1twO7g9rnIKj9d2p9sCBccuFcJ/dVdnXeC7RLcwZ/GlBbYdeX1D2iZ0VukcuO/gKIyqr
bV0Qu8DmdWuu2/y96z544efWNWnN69DS+u6+KJn8V5U1W7lf6c9Mee4w3HHmt7o01ha5yFd/leto
7RJTp0b/vgXgaebFa1gXV8+jnTF/WONKq/NjGQL8x7PhROScefK6k/vsKr7GgVUYDhj8aUFth17f
lOwTGxgBwclXGOG3beu7CeTB1CvZHNyS/SgGp7IfubiCBNidtm1laSvUZIvmCdRmS2RgfgumZCyz
Xlu3GEDC7U7aVnZ9Wy/8KnnnkOxWWsINEGTtbkU9dgGiPFiyxfi35R96gCH2x0wCAoG0RSCQtgik
LQKxI2GcSZCI/tcOc7wk/+rN8VBeaEIlUjyn0g6vrZA8SFal2i9O6S/rtWsRxGNLbEX1hpllmCq0
3hdjOyQg+4e2vAckt5zElpM4H8rMWlWoVDSrmksqYURA0fyKVPvFSQ49YYqQiDfWWosaWmS6IZIl
u6nxpnYQaW+z1sVIkCRJPsg04AdJj3dRqr6McLI1kpdL12o5SOGnT1mukBR8yBWukPh4Dzwh7inK
D9rSQSoPdsLHqzJq9cGrxFcFnhWX9zvn9U5LWx2kW2W2sVxhUpf/6bZlDHmK8lPbEi93ViKV6sUd
cmukktpBeHZJKvEKvRrD7lIkaR+s2FJfSr9UkzPVvxektEYo74ZbaHgRa0AC/ZHnkJXAPuBtvauF
uJW+9VHZSl6mEsiOGjGSV4vKYa6gQKXW90JtKmEfrYtVaxnJxPElW6o6a6lVXd1JHR8fQFbWFr5W
U0MMWTXG7wfUF3gOmQ9yvDqvKM8PKhHKQfJj4lbyZza4dBPBpRmWLiB6RjlMvF4hMyjcr1Wntl6T
KdV8R/Y6irmJe54kQlTWPil8Ryp9v5ibeCUdF+uLPBeJdkDsnjfRPW8q1Bd5F0bKVnfyYitJVb5l
DXDkf1b2lQyB2DKiHP8fqV+cOyqHkbaIXYFU/rNz8/CO76a1gbapBlEY1HfQVVb1aNEXxRjWNwZT
EmMhSDYIwiM5yMX55l9NbO/XrysbWA3fKww2JFneYKwCXRaXmwDaWrzllNrC9kG3/TqTrQecywti
Q4r2wyDrB6Uf8znaFY20JcUunO2vLvc5rUHkoZSgLiUcV+uQEZZrG8zr6wGpeVvCovCpHFs9Ugy3
Ftq70V+0HFz4ETvOXW7wd1mTOn3d4MPLC9d/+YEvriun7TDFDj1HptQMb+hBOTE1djX7vROpACxk
1249Pz01BQ8kzm/M/M7TPM/MsbeuPnr8SzmaN/Lhnzzhe59NTU1dvyG5BjPf6oapckr96xfHcrW5
xteT75i36ssd6KEVkZPzga5H1p4eePQHtB94P86JfTQ0/ZWN5LevFxH/N+vpmbE/Y3TP55oE2lsA
3+yRm9/OvunLdfDaGnppqHZw4etXv6z9WFnNu7kZTUVTa7SV4vH+l6bay9gBntDO64s2KBuZN2eW
npp9ojLa9jOwDqGhVXXpWnm9WnmFVrZmK9uGMg45Op5D6naAHdmzsAYptvDgQfk14NlAHn5NWa7m
YH8olpKXOaybOFqRR9T1RMi0Fm95pN49EobltdkJ6+6p8irAazA5CQMQgmPKAozn4PIEDW0cysOp
oouJZ9YCovwb+0xu9nW2cOVMv70OHuLrSIkwd0z/3X6rmnc1O3udRtNWvgnfrZKBkBTfeIWt2Un/
zTfD260tlaFtLRwLmfanZOvV8hVaGwfPRroaszz4/Npy73eUDFl4D9s9mu0Gvg4ZITJPdcKDqawy
5IKgrT03UfrqB1sa8/3BWdNavGXB0T4mFYKPjS5a7hNfD5hvPn4eHmAHvl/zTXKotrU2tzbpQf44
7UM1RKl58KK9Dh7itdew7n5AjfuVIW8Hv5f3nr7wZpVmPXrfpnwF7d/cvzRVhLZLo9D7WMSwjiJf
r5ahi2kSedvMlVr6gqiu27pBR1YQQp3sdtUsN3TfwvZ+PSq2i7zB/cZl7ytB21RXgj2rHi6vIZ1a
TbA1dOHa/9r3J+YUeT3gfnVkcgrrodBisFU8ymz9Itbtb0OvonlPQxiSYcleBw/xxUjqoTOk9X/O
kLclDUy1f/ejvbdUh7b2Z5xUEdoGro2PQvddekTsBMiLyQ0z/aGMqT/dvKzeKX6XvpqMZhM1kD4f
YE/GhbUPrc5lo5ziI/pqgzGnLcTLjlBe9OHV75/7RL5vRexD8C2n9IR8GJF1oR5aWLu8OvXh9KeK
sfbUyZc/Lr8LNPW/nIIPFN6f/MpYOpZQT5r0vC3XTz7KaBK7r1obxC6+dRAUG4H/a32ppiK0hdjC
tZepBk2oulFbmbZWXkGWIQ1v6istsidWYDmXzteq5wCd9YG+Wf7qIsBtmsaqSMe1Wo3PsuC39E8y
jvehhnXOIK1a7aNBSOV41g4hNhHIF5aeuxtekbUSfXX9Ag113xEv9LOAWDqbyasN0vMmr8PZU1We
0zyUvYXbB83cRrih6VRlbNtgPBb7Ib1HNTAjW9N8vVqmMwUY76DWAFs6uRZu01eDrWfPQrE1djIE
4Yda2CKz9EknwegMlxoSPpeKyUu9HqjIclsbMOmD1E3+1A891NoBolO6CJ3j8GN6gR2dwN9nEzD+
Lr6kb/Y1SOQeLCy9+YHlOXlCsTm/zJYsVxYVts7CaZNgD+XISUGJ0BcgvrNmOsS7vPVV51ZWBEuv
tiq2LRxJz1Vo3vb6WFr4fPJFkBKfkEnG16tl689OX3o8/dIihBNHIDy6+Ltaib+gtlikdjH90RRE
vrv0/vPT9JlXFwCxjb9Az/7duYNpKo9ivSJrja1DzJfBwKQ2fHfx2KUlp/S588unkxK8kEwvH+OT
h9PJ0+nz9N61wCFm6xeWnp24R5llzfbf42G+9R+uRDLjErPbTAj2fYQVbggs3n1psWq0hYFf3ai8
HKf91VPbWig0dVhY8pSxKTMTA0RpKLRu78zRzFaL+tNWrT5yfRZayazP9W1vfdvYqreFjYPf/DjS
sFSIefe3q4bnBwqUFKAmWy3aQu5f/7/XfNdRNejfhSgrbSsCdKVB7EIgbRFIWwQCaYtAIG0RSFsE
YifQVpKhnYI95Ax/fyeqNcmHaqRKXACi/DB8dCU7cjmEEta3RdbuayOB6zd5TVvjioFKNOgJEjjn
LCeIvyMCcOmSXa5tzfqNWJcHN56oYZ6H+LWQuKVVkk8jAlm7x17JHG6ounKzQwbiH2PxPiGKaVu3
ly2pwFuY7yumIXURXmlrXueWFNKsPhoJ3te3RaCR4KRWJcMSuBIU0L5lZ23V17dF7HBtqz7w+VYj
+ouQ0Q6w2ATypiT+sGqnrG+L2ElAf1tEGYD+tggE0haBtEUgkLYIBNIWgbRFIHYHbSXDX3PIIySH
zxNeJUr2VPQrRFRC2xInMm6nOAJRAm2tHrdGl1pJkp1uDR63xmx6fs5EySbRWlYC488XjOIMG4T7
5s6L2JVw3yra5EerB/k+mRaPW93dlqhuscRNoq2saRtwszgtRSLoSINwo63k7fltdNh22BheIkaP
XMet401HYkslaDUgvNNW2yPbw0uU5NGGdeJt0Qe+tC0bGbE/jQQgxV+TyNbfpsxuvJ4yoN5FeJpJ
kIqrPheFa9Gvjr8BkwwlJCfpki0FFS6isLY1edxqJqgcVHxwzQ62hjP7z2GN2ZX3NpnL7Kgf1LzE
lqECv/lB7C5syd+2yEu9x3d+/L333kGl/W1L3lNBKmppIg8RO462pAw5TPmQ5IjyvZIhEEhbBAJp
i0DaIhC795VMcnxFUqepSnp1MnrHqMUtEnTvGcda9XlgOdEwcat469jaYyqDHjj7hbaF7vE2b76N
xpYJBcnRYcwwjAwREilWRnMg48WRt/vESJAMTq+Kc63F9RZcVru1O8aqQiweu7JrruugIOUYL8jX
faFtLWrL6CJrcb2FAqvdmuli8tw1+ueyKLth4PDst37WtRofjvaCMRbV7f6graPWc46z+NZ6/nZA
nNSiY6Sz6aJ9qkNGIm0tKsy7+4rkGLSfS6U/zEkJsYh9TVtS/BWtkCkquRKMeCA/KckwlZDFSFtv
r/5gthKsNJMKalPdMrYlE6cyRVqBhEXaalRUHWtNE02uHrZgdso1uYWbChk8drlcZd8mh1lYZVFb
9tpmbkyBNywli14GJxT2Lnbf+ral0hBpWwHg+rbF7RJk7b7HLvRJID7mRiBtEQikLQKBtEUgbREI
pC0CgbRFIG0RCKQtAoG0RSBtEQikLQKBtEUgbREIpC0CgbRFIJC2CKQtAoG0RSBKpW0krobCPJQT
5YiWiCBGciwUj8cF4d5WelRz6iEFRBTDtnpsuTyAlpH/LyzNqSktIby1exnGH5znGru1UI9894/L
5+mN9KE7Lq7w8BC0ZNNQ4JeaywNnIGaN3PovO4eKxQ05hO6AIby3+0Tb3mMN5bLKeWYt8DpsqKlz
kGOKrTUkCLIKzon38mNUEKMQGID7Y1z1ETGUhFxIFEIxWW1mQkGZz3lRiLIcYa6WW8IBMZwDWrYx
TmgapFh6yqhznwkFCeQiIpEVqh6n6NhHRDGqRJOImBFo2NA+xF6mbfKKFnqLH540POzHoUZ7AkOA
Ha73zjR2NzLWNsAPWUxTVyTUFc1pWm/jbO+dEE1l072ynoYbGvp4qHHwbKSLlZxf5Oq5551ozwGo
W4d1OiAiddA2GF7sajc289MNfRlo7g7nrHEyGsfDZ7lAis1Q/8NrrA1a+xB7mrbLzVqIK8WWcykt
LXMawqr2uyPJ2dYPv79+htGwoT/MeZyByctwpy5vOgqnIHNT9ABsyhEvzMqhLjg2CausBC+3CTeu
n1mF2lwyN7qWXK+lMiYzkDU2c4qVXIXJN61xMmhKVC0wNQfPgql9iD2HOtO7SztMGUK1Tz2jRsx8
q/9lSY4fWpyEuSdowsLlw4fGpzLtcOVKnmvB+ps/+UT7yIZSph0++Zftw5tN77vScMPNUzSyHR6F
9ptZ2lWW8QrN+ElZV072HXo4upr9zX//m7/q+XLP/6y5evNzz8EbG7yM/P8nWUkunwvX4+STuptp
XdObejTLprQP73EF0D61cybATjwWZzYiMwPa4QvaYjCpUK+8/tzM2fsm0jSwEOxuVZJSRoH0rA5W
4Mpr9kpTKcNpaubl8/0r0AzB4amRLD3WwpmhoTWHFqWSzi19kAk8ZYnU2ofY4xNg5lmkoaEhZiPS
iOb88oCeY2FUZDQN3b/wh9zgDV0e4ewIQsdREPV8ba9Su+FBuK3DWoUA4x00tzbZdn9dCj4GV6Ff
jAn99CjA0VzcPokmQsedzlfxfegYh1FDRCek9PYh9gFtnZDtvydumCsNnWQm49JYW+RiAztvDvQM
M6vyWPr4pUWD7LsvStCbuCNlFTd96fH0S3rGxeTSoQvfYHNxdexPPU0/Hkku2loxP5YhkLC3bhim
LqVPG2uGMyM3GdqH2Gvwb8XFeNmnTsXgVPYjF60vWan7L6D9Wm1UesVF/2gbqM2WWWIss1FTtxiw
xIY2IynkzT6jbb1vkss/0c/ZaWUtWKbKEGjbIhBIWwQCaYtA2iIQSFsEAmmLQBhhnABTt1RUNpdx
2C8MtJ1nCm1Ao25o5nTYMryUV/OUdw+oYheg7BCob2Cp5iceJetdbYgwFbZWYSpL7M2U9vpOK6Z5
W8u1EtjS/kjmzc5dtj7folBPeaTSR4Tny3Erbdv7nf9fhLVaGYVvhjpMlyHZu0A7kZyaSaQdRrMl
+i/qF229qRvJpFZ0rqgdWbWBru2jWurOZZIHqaRwaeI29kvV+MTeLLcGlrCfcQVQsBPrimUgZaet
Rd1o2/FuV4H6zF7f8nsvXULvSAbjwCrYxTZRt4DdDd2+VOaBVW8bMCbzyVKXSZlqe+DK/xmfifb7
RbZp23os788wkoiFUu400vLLuw8XLGO/pmI7dEsFs0pk+/28q21bZX9mMNqKDp1cZtvUz/JlUScF
G2BNJkVpaL8mUmTkGlSry5vxDn0ERv2krUv36VaXqUPc336q1m9+KtvS85fwAPdUhcsLoV7d/pkA
8zhvKzkzVJKtBP4PSNX7z18TwesLiV+X79QCQgjsQ9Z6sW0V68BmJJgfWkYpPKe5WCVsWwn8MOzM
l1Okfcwq0GZeeCFPZQpcpC1VmTIzT+ISj83cKyinm7iEu4lXoCs99XKlb0Wl3cRrkbU7k7dVLL3P
tC1in2LJ32kDf7UtArELjQQEAmmLQCBtEXsJNn/b4s6Bujtu+b1qC74ce/W3LbURRfIX8eK1Verd
39bQqaagye3WJNjklAtO1eruePuFtiU52PriVVu0uhKaVC7RRbx4bZV697c1qQtD0OR2a2yd3fHO
Vq2ie/b6DFi9uwKRiGQ4WHWS6w2p3jgnvhTdohdvKcNG8tQYycGV0eY8UllHRqWuOudhSCpLW4tn
rao6POmwXfl48tJosiVCljhkCpPO5qfvcBWkGopiqeKKy+aTQGzVkxLuSjGH0a13UEn+tqX+vKGY
lyspvWEe/G1LrdHqp2/O6lvX7wrb1vWuSyVqjsrbtibClNG4KNFp1vyiUKqV7V4jcTEM9F+f7c+Z
hML3kWztEVjZpz3ZSTewdDtTQs8Ob6gt/nbrErljWVvmd5IKvuIo3rOS94ZI+5S29V7NNWukL161
27Ntt+hy6s2Ttkiy7gxLDBOopATb1sXt1ibYye1W2jeOtgrQA2xHT3Fs1e22so/CynuA1SM3dilv
d4hhI/N076wmjiiDabTF6Y89/whFVxoE0haBQNoiEEhbxF5Bve21VSrugAQV97b1JFvzFy7x/buw
aNvas8WEePC3NTh/WNZEsXnYErD6ipgWu9WT9u/6tgUXhyW2nJXztvXmk6DeRqmsou1rzxYW4snf
lpgGhbHNDq671u88jkk7c33bJZ9mcesLqQ5JXiBJPkhGjePNa6GMKMl5XfJhzJCytdG8TLhUXKBl
5TXJUVLF1Ktjg//WJXNdqUqEbIG28pKfJoUBoB5g565oa76LxBepHm6nd2cj2/D35mjrcF8r/0nX
sTq3zw1LPjWviAcYkYyH4vfET1JXe8BIxZZgNrkJFPS39T781YHolt36C50dBr++89Z7fxDsdxT2
nSVWK7eAv22JPqBb/Va2h1HrPMQJ8aQGdpiy3RnL226loCS5uIqSCrRz19PWsIy902F/mwg+yjIs
U+tw0ZInSft3fVuDRcstNNMBjI6gjt62kq/LJFTVlRe8r2/rwd/WtrCtS6q5l03Zbc63uL6tg5LD
n4pUci5k+8+bvb6+bX2RZxlx2jAHscONoT3/Sl3IJ4HIb2bEwwsaolwWCynHrEF1b1guGJqpIm0R
iC2QNi/OXLuxIeVrJXUh7GjEttE+pYZe+H4qA5BZeun6amW0bapBFAYjSc3KjvNDS1jLMBwBS2Is
BMkGQXgkB7k4AzQJTwF8fVjJf68w2JBkeYMxn7stEmctFYVP5dhZQ7w8Upmc1rAgNOQgLl+fQ7W5
vCBS3ZJsGGT9oPRjPke7opFKKHbhwxFBUPqciGKohZUX4kofx9U6QGuHHkGR1BqlNE8/VIm+LcLx
WTn0o6nBTEW07eHlheu//MAX19UBBHwE9RzRBtIbelBOTI1dzX7vRCoAC9m1W89PT03BA4nzGzO/
8zTPM3PsrauPHv9SjuaNfPgnT/jYWa213bQ9m5vRVDS1BjPf6oapMkiV5WxuvvHMsfnc1NTU4sGx
nPlxeKCHZiAn5wNdj6w9PfDoD2g/8H6cE/toaPorG8lvXy9Syd+sp2fG/ozJzfyrVGh1nfb+N3vk
5rfDkFoHhdIOaK3Rr+5vD973zSl+Qpt3/YYx1spf3noxN9Velg4oWdvmGqfS/LSZMfaX683vPOG/
tv0MrENoaJVrUj5cm4KhpEDDAHlRiILIgrmIIIYUbQod2bOwBqlJ+ueg/MbwbCAPvybKqQf7Q7HU
0AofHBNH/ey09/KhtpqdvU5bAh/ZLI9UWc5q9tBrwGiV6h5ZMGe4h/9dg8lJGIAQHGP9QHEOLk/Q
0MahPJwqaoJl1gIiFw/NidRslt7umX57HYZ2vHdDT9yAz+vPyusJ9lxMkeEXq6RpU9HglWZ2IQDz
8vHq7zSmfKdtLRzTCMmx+Y+9cXojhqBx8GykqzHLg8+vLfd+R8mQhffAg0BblqeMzwiReTrgHkxl
L8upQXhNlTQBOT87bOyaOo5gEOC+q+WRqsk5ynvpaDYUMGdIXmF/8xCLwXl4gB3yLOImOVTbWptb
m/RQzzjtQ8bBj0UeitBuOnjRXoehHfdd0yO+CB8Swwox2vtF9ng+2hc+UR3Wxm54Yw4oA4z/fjR9
w8/8pu3SKPQ+ptu2ANNB6OaBLqZJZAt7pTYahWe10d5MyRnqZLerZrmh+xYIRY4fFdvFJpbaDwbD
zlfappWKWtJA7/nDZTKkVTnDK1SVQmo1YX3wLjfLl6mMTE5hPRRaDLaKR5mtX8S6/W3o5XImxN7u
JkiGJXsdhnYYr+4/JL4R7rlJVnVdiWl2yIxOVUnZbuYdY+/zm7aBa+Oj0H2XYfycAHmsDDP9ocwI
/unmZfVO8bv01WQ0m6iB9PkAezIurH1odS4b5RQfAe0JEYOaSrwPXD/5aPkn2lsHT45TqZ19q87D
ISEfRtifGkNoYe3y6tSH058qxtpTJ1/+uML8+2gPfiBSuB0mTmcDkyC/i4TyImteZ38mViXaLmSa
QLERtH8tfz0r+U1biC1ce5lq0ISqG1MpJbmWBRXFBm+KWoEaSszAci6dr1XPacfVB/pmuf0lwG2a
2VOJfkteh1+cKr/FtlR7doE/8v6Lc4Ya1jmDUKf10SCkcrwrOoTYRCBfZJbzbnhF0nlfC913xPnr
hFs7bJAraJW/d87DKlQLgZoGAWS7dl4+HiYP+zSIDLQNxmOxH9Krr4GZFh7R9irtBKYzBRjvoNZA
AhiPbxvXStSzZ6HYGjsZgvBDLZ3spQ0yEozOcKkh4XOpWJzPnx2AgP/ddqpm2ofh8X04wN+rQvCv
nTOI0DkOP6YX2NEJ/H02AePvAnYDs69BIvdgYfHNDyzPyROKIVnA0NAQe4cwgyar7TBOQIbElhAt
x042ZNvk/6jqMkOB1eANMmf5e3gwM1eBedvrY2nh88kXQUp8QiZZ3Qcv/ByeGjkC05ceT7+0COHE
EQiPLv6uVuIvIAyR2sX0R1MQ+e7S+89T62q4LgBiG+/g2b87dzCd5O+165XozWzfR3yYsPx3/e/l
UvPQ7Jxh7vzy6aQELyTTy8f4A3s6eTp9nt67FjjEbP0ijZ64R2n04qV0OikVbYdqW7A/P61bajw2
pbxmcL32dCX0QwGE3m5Xuqml7R0fv2Rta8XF1GFhyVPGpsxMDBClIQ7ublUzRzNbLepPW/X6Ukeu
QvP8kQVfx8/2FgqNra54yhf85seRhqVCzMvzwE5oeH6gQEkBarJVoy17Nf7Y3836Wx+ub4soN20r
APQAQ+xCIG0RSFsEAmmLQCBtEUhbBKJqMHy9Ur7Q2FeUkrz9KN0vmNZz9UO+8aoRu422O3Q5Rct6
ruUHAVz0bC8YCZIkKcvA8JAlGvQECZxzll/X+j00UNnuWm1rvIdsQWrL8uDGE8m4RzzxdSFxZC3C
E20LUoaYVnYnFSPY/tpSFrEd2lq2NHdLqASrdvxC5ogdQ1vzFiSkkGbdzazC4bAnXslc9S2fhZJI
EU2MQFRB26oPfL5PkL5rg9EOsNgE8o5CaNsiKgX0t0WUAehvi0AgbRFIWwQCaYtAIG0RSFsEYufC
OG+r7wZvPC8BDnt1anPASgaHbXf0GVlJ25nHvBU9sW94K9m2WbbvCGr1HZYsG5AWao2+xzt+Rdvh
tN02iBORweR6Q2xf1PQsSsjJ/9U2GohpyzRSJIshwugJ5N4awx7vBFm7W4wEq8et0aVW2R7W6HFr
zKbnV6lE1GKKpy5x4zpxYqlJXoEBUvghYFfEqnSyDcGIHaVt7R63ZgUEFo9bXbMRSd3n1EIF1X6Q
jA46pDjP5OqIpKtgUoiTjlnMp0TS97f10hpUtjudtpK3xz+RCmkn4vhYJeajhWsFzWmtOuJKJ81G
LfarN+dWObZGAnW7YQl18I6mrbaftlScyRJ4I7wnk3i7Gs1TcZNjUJHWqHmJ84smYke+kpHihCDe
eeNw010ey9a5jAKFnDMVfNyTwkPQ+acaEkGnzF00k1BgHkxyNiuJwXg0Bh0f/G6GbCG9TopbnKS0
0ePaGlSvu5C2Jo9bzQCUg8rj0+z/ajgz33cPbrJKFv7uJYHVzHV5sutZXeendLn2iAIM1q4SVM1P
0LbdcdiSv20RXVQeVeVVSqm14a/SfECl/W1L/twgFX0DqjAnSvwcgIzd07bt1l/ay8QLUvaMem6k
7i4HutIgkLYIBNIWgUDaIvbgK5nk+Iaj+f6V8hpj+x4q2WY/JWKq1tUH1/4FoLh/rWHSFWcO9jpt
C93jbd78Qp/1i/jKqqNJMqYVLqN5p3HxyNt9YiRIBh9axbnW4noLLqvd2te5VYVYPHZl11zXQVHR
7xWIXa1tLWrL+GMAi+stFFjt1uJRaPTcNfrnGr1eC1kLqkmgebR48K81cx/V7f6gbRGtZ3IAt652
65Ehjp6zxLuu9Opfi9hHtFVUmPfF4iTHoP1cKv1h7uyRhWxF2ro+XT2bh2bXQ8mVYMQD+Yl9okER
6tQYCVmMtPX26g9mK8GqMqWC2tTuCC4RB1IbI5WpA6mYxYLY17S1uJxKZn9bsJ+ZnXJN7rGmQgaP
Xfkli+gzE9ZVECS33+p48K81txTfyPYgdt/6tlvxr0X4DFzftrhdgqzd99iFPgnEx9wIpC0CgbRF
IJC2CKQtAoG0RSCQtgikLQKBtEUgkLYIpC0CgbRFIJC2CKQtAoG0RSCQtggE0haBtEUgkLYIRKm0
jcTVUJiHcqIc0RoRxHArC8XjcUG4t5Ue1Zx6SAERxbBbdS0h87leuCXslNcm3FSvobSrXMRehPEH
57nGbi3UI7PhuHyeyTXCezuf5uEhaMmmocAvNZcHzkDMJe0OS8Eh1xQ5pvAPQguVRuwXbXuPNZTL
qkxcm30TvqumzkGOqbPWkCBEcrJSvpcfo4IYhcAA3M9Ym4uITTRXLiQKoRhVpgExnBOoHqRFI0El
r6wyY2HxGZ6SyotCNKXkDch5lXRVjtKwSJDIOtUkV5EXZoq7SaRto08JIThMo54J0QIpWmc4Rw+i
8EgKhmlaKIkM2PW0TV7RQm/xw5P6g/ve0xfe1J7IEGCH670zjd2NjEQN8EMW09QVCXVFc4oWrO+O
fIFROZVN967AnT3vHOiJrslpz1+T8zbK8jYm+/93ntI2GF7saoflnneiPQdymjZl6aoc5RnRHU7J
IZNcBfPsOqRwdz0sz6290XeKnn26oS8DbV0RKhfau37SMN4Od3e//UbvXciAXU/b5WYtxNVay7mU
lvbdj/beopqNdyQXWaAffn/9DCNSQ3+Y8zgDk5fhTrWECBO9LPKm6AHYhPNw48aZjJJ0e0zO2yWf
Th2iGTgHYTIDWXpy4/qZVb1dPF2Ro8n+uRwyyVWQYdchTdJctNAnIM9EzNKyWZicHVqlh+AErNLz
w+esJRG7BHWmd5l2mDKEap96Rot44pnnpjZ4/NDiJMw9QRMWLh8+ND6VaYcrV/LcRqi/+ZNPtI9s
KGXqbv7kX9Jg0/uuNNxw81TjZN+hh6OrLK0dPmnMy07bb55iKVdvfu45eGPDlFdNV+TIwu8CLpv+
b86r5md1PNF+ZYO8761f8UJcxF0sBaDmlheegzc3/vOT/a98+sAqUqAcaJ/aORNgJx5j1qItayrU
K68/N3P2vok0DSwEu1uVpJQusIadAazAlddYyswvjvWvGKUb82o1nBkaWqN5Xz5vzqvLkTEiyzbL
TVBzxSSePjXgzdf1qATwQnVyLR9/+xfn+1aQcXtgAsw8dzQ0NMRsRhoRElpfpc9cBQujIqNp6P6F
P6TkpIHLI4y9EISOo3ouETq/Qw8Pwm0dbELt/trH4WPQCQrdeF7BUC1lIj0/mouHad66lDEvhyJH
RhY625SJOl1uDcy06PnbOmkL6uC2cT2K1jkTD9FaxlvjEVry+RRvPmIv0NYJDYHFuy8taqehk0xL
LY21RS42sPPmQM8wMyCPpY/rueYvpoOUjL2JOxj7FpNLkQvfgDMjNyn2Ksu7ZKjiqZEjMH3peITa
zTTvIWNeDkWOjPWLy1+XQwa5UuITAT3/19MX5iGcWDxnsJGPpW+5+FOYPn96cWwBFm8fOHzxADJg
V8K/FRfF4NSBey7gO8++wN5ZcTGSOxi58FO8o4hdpW0RqG13obZFIJC2CATSFoG0RSAqi3rsAkTF
oE3UR1HbIva3tlW3VFQ3DJXPLHDeTdScRdnQzOmwVTg3xrniUnfHKdK0ohcgmZO1/E57ACrbCdoz
g9rppECqHqf2h3Neaa/vtGIyEizXSmBL+yOZNzt32fq8VBBw27LXVjFIW2qvt8txG1G2vd/5/3bW
gltmfcPsQqlanNIfLnlL3ARrb9q2ljEvmca3zhW1B/0a6EVZr+2jWtabRhyHdNH8LpcgmbMRb+Uc
xe+kHdf+1lu2OvPw3Xpn1nvWRho/iXl8Vwqeq6rw3SwwSmxNNmxMTKyqgfjVH5XA73n7SrZUrntU
X8CAlGzyTcpU0ReS8p/xmWjvUiJVhE/+3EuJeGGWZMov7z7sUsawE7e6AXEhC8SinQpdZIX6eWfa
tsqezmC0Fe0dIpV453f5PqLOzFJNUsm6q2ohNhKrVOLGQd7rkvcdW/dAP2/dtiUu1p2pQ9zffvzo
N08y/VS2BZSshXhS2YxsR7taIv5d6m6Bx3lbyZmhkmwl8H9A9NtVpYvx10RwYRYhYB6/pbRC8pIq
7VybdkdoW2fbVrEObEaC27NLkm0Mc7FK2FzS1iaHizTNfDlFhDCrQJt54YVIwcxOveOWqg4fL3l3
KKLlElROf1vUA772YUlavMK3Yhf72yJry/PI2ClCdt8r2XbeHxA+dSLBW+GHtkUgkLYIRCWMBATC
Dn0tjGgZpaK2RexybVv484s53g+f2mIvxx7cbbfkbVls3hYsnq32dOLZ39bcULA54Bb3tzWXQH/b
Is6qxJaz3D61BanlQbbqk1tef1ubZ6tjx3j0tzU3FOwOuEX9bc0l0N/WUZcSxZVW7RAHP9HKTLuQ
Uigo+TBmCHh5CJUkEoq1lTgWtP7Qg1TqHtgeGDrc/W3r3Ips616bPcC4C6JJYQCoB9gF7kX+uKkX
daUpndIS2SrL7L+XqMoNsVTq/pVsyZcRVV+4TUQyHorfEx9JXXV7TXJ9xpiuWncOcPe3La6+jHU6
+xlYHHX1TNJ+87ctXZ9XdHxX+X44N4C4mcoFvb+tQtw8aon7O4PFUXefONoWoq2X3xFWWtlu/2le
canuhqv7r3V2aifsMNRaRj0x61vJTftW3kSottnsZ8OkkmVL+5q1Lrat6ccg+hPMYD85+dRKPk7c
kmqLdstl84klhtUaSEHbViKOwgv72xapVoId5nAb9UVqMX9bieyjMbxT5kK2r0f3ur9tfZFHF3H6
AS9ih9vne97ftpBPAmG/k9IOiIpMVxT+XLd9KVVCKtMYqq+LRDOpsoirCyFVENtGwe30ci11p/7g
+oIwt7K0uP6NwL/7H9ee8Nu2RSC2Y9vmWtY21uetsa1C4O1MrDxGQqpBFAYj2p7fyrZ6Lfp20cMR
sCTGQpBsEIRHcpCLM0CT8BTA14eV/PcKgw1JljcYq0DXpSKiEM1BS0QQI+XbuVy5PngmKARbrIkR
2g25vCA2pGi+QZ5P7sd8jnZFI0CD44U3yL0Xjit9ybtOj1fOIvKZ0rN6LhbHrjFniGsNi0K4RZWh
Z6yqXUAeEeuWp6+9Y2MtzF6dXm0VI89s2WIwGAmHlxeu//IDX1xX9b68dW7PEU3/v6EH5cTU2NXs
906kArCQXbv1/PTUFDyQOL8x8ztP8zwzx966+ujxL+Vo3siHf/KE7910ePmfWo4tZvO5JoHWWi6p
yvVlMq+887UNs9TcgR7aDeTkfKDrkbWnBx79Ac3H2zEn9tHQ9Fc2kt++bpc4861u1nu5hl65h6em
pq7fkFxT4/m+xpSINcrZ2q3J12jP0lx//eKY0oBo98KP/2V2XY+r2TiQ+s3JdUXGlL53cpWMhJm/
qq35P6UhUWFsc8Z+XFle+pu/6EuFom89sS1t+xlYh9DQKtekfLg2BUNJge+6m6d6jG1LGufjPKRo
U+jInoU1SE3SPwflN4ZnA3n4NWX/0oP9oVhqiO9qWzdx1P+u+wyEJiALmdzs67BRNqnK9bWMhA5l
LTv03qNkmJyEAQjBMZaP4hxcnqChjUN5OOX05vAReZ/2e/SNU1PXEyEtXsF71Uu4AZS9LVN3j4S1
Rs0N8O3e1bh0du4GthOrWUZVkBtuDNXeePnqO80A82yv+ULHC2+98fq7QvlYcuu0rYVjGiE5Nv+x
N77Gdt1tHDwb6WrM8uDza8u931EyZOE98CDbGTdPGZ8RInRs5R5MZS/LqUHQ9naegJz//ZWXW0Ix
Xsa9dNXrezDMr89kP1yRq43F4Dw8wA689pvkUG1rbW5t0kHifVfl0vpmsO39wVktXs11TQlswMpD
EdZ9R/tYLg4RWjKczXrcQ+8bvWqVUXnKNlGL6fbpa/Osp7z+m722MPlu4euNLVuj7dIo9D5mtAqn
g9DNA11Mk8hb2K/URqPwrNajzZScoU52u2qWG7pvgVDk+FGxXWxiqf1gMOwqQFsB/j7EVVDmNITL
JlW5vv6J+cXuL5iTlpvly1RGJiiDRgmFFoOt4lFm61vwsNwty9oGwamuxJQeb85FkVju7f4Tmms1
8YIa9eboHacTb7K4TjXuy+N9N1llVByH8w0181squfkfSlI1BtoGro2PQvddekTsBPxMfrdi+kOZ
EfzTzcvqneJ36avJaDZRA+nzAfZkXFj70OpcNsopPqLvUB6rxFbiUvIPWkbo9cw09b+cKptU5fro
YMjAt5wyJOTDCJ+XMYQW1i6vTn04/aniVYTyYgG2pbOB++CbAP/cJ55Q40jfK1/ov4nF/Y0aF7sM
61U3EGYX09n80bZDLbIN4O1f86GbXm1YX16c3RptIbZw7WWqQROqbkyllORaFlQ6Ed4U9dkzSszA
ci6dr1XPATrrA32zG7L2u03TJ5Xos8DyWrqmDugr4Bekckrl15fQWGmbQmSdMwh1Wh8NQirHs3YI
sYlAvngVrYafALjfpt8yfNEUmG27zqyhnffL65i0uLpxa/uR2mbFDih0/I0b2346t7o8ENi6bRuM
x2I/pP1QAzOymdH2KrUMmM4UYLyDPi0TwHh827hWop49C8XW2MkQhB9q6WQvbZCRYHSGSw0Jn0vF
4vxxfQAC/vdXSJyJ9c9Dc355oKxS+fWJ0BGCP3fKIELnOPyYXmBHJ/D32QSMv4t2GTX9X4NE7sEi
E55xZmtNFkgOCWMdrGc3ufUhT20FYDjDuP5ZNS4oznTSO7RjMLuQXs8G//ogKParw7ElcNPR/Jsr
iwNbsWsMtL0+lhY+n3wRpMQnZJLVffDCz+GpkSMwfenx9EuLEE4cgfDo4u9qJf6C2pCR2sX0R1MQ
+e7S+89PU3uiLgBiG3+Bnv27cwfTVB7FeiW0QqSmbeXlEGT77ynnvKVyfUsvpRuTvU4Z5s4vn05K
8EIyvXyMP6ank6fT5+m9aYFDzNYvXsU6FLpzDYGBlUvTjNwxzSZZTA42jS1qcfTe1bUtX1rcWWo3
EHo4S97dfvhdDs+XG29592x2WdqyJb6tr2Spw8KSp4xNmZkYIDwiDu7+VK3XV7cpwZ8mF6ovdXR9
bWOOz9fSh2GgXvjVtp+92/u4G1td8fY6/s2PIxtLmBKRJ4AdlX9ozouAmuwOoi2n7j+fjKxBQKyd
KIv+Qp8ERCVoW2bgYkqIXQikLQJpi0AgbREIpC0CaYtAVA2Gr1fKh3z7vrmStx+l+wXLCrA+VIC/
TN7FtN2hi0jZVoD1Y1jgOhC730iQJElZ3oSHLNGgJ9A8jjnLr2sRCBdta9Y+xLrUn/FEDfM8xNeF
xJG1iBJfyZzWxZSM9CRIMMQO0bY2u9LhRLKzGWmL2Bm0Na9zSwppVnytQewUI8GmViXDErgSFNC+
CESFta36wOf7BOkLYhvtAGLdKct3I4HsyqVzET4B/W0RZQD62yIQSFsE0haBQNoiEEhbBNIWgdgd
tJUMf80hj5DsZRTPMG1bPsnuKmaIkawRWqy9lCEkSU4OaHqc2gjJ3MBCrVE83BA7E2Vd5MhhP2Pz
R18C9m1RDVncXWsl4s5afX9bF7n6hu2Kv5qxwc6t4f/j1+pdZiRYPW6NLrWSpKg/3ePWmE3Pr1KJ
mNSXVHy3etMAMMlzp3FpI0pX70jNvaNt7R63epD9DxaPW12zEXV7ZKvfjbrXt2R00CEu1JJMG3dr
jhCGQsSFwJKz1jfuIcpkGXYWdm0NugbtFtpK3pSVceNu+60ljk9XYj4WZIRlO3utOlLIqLbS2VGg
5Nwqp4vgnsXoq7AbaKvdWg+vZRJ4I3xZTORtliAGKpYg0TJ8EDv9lYwUJwTxzhuHey9thZ8eChXM
QkoqJRGcSNh9MwkFfm8uOZuVxGA8GoNOGouUzFZvhUhpo2fL6h2xA2lr8rjVDEA5qDxqzU6qhjN1
LotYE1w5I1l+G2GKKPpkd52m0sXoLQdS7PflWoPlckjonYkt+dsWsfjKYxB6lVJqbbgsgg+otL9t
yZ8bpKIP1QpzosSvAsjYPW3bbt0OLBMvSNkz6rmRursc6EqDQNoiEEhbBAJpi9iDr2SS4xuO5lNY
0hcCYnNxsU6CSsRUrbVWAPPnDsm48K7k+FplmDtWpp3ZAWcO9jhtC81nbvPmF/q6X9hXVqG10Sl3
G/61iD1sJJh/DGDxt5WMP0Gwrnbr8MsERYjFY1d2zXUdFGVhGtJ1X2hbi9oyKiuL6y0UWO3WTEKT
567RP9fo9VrIWrB5tHjyrzWxF9XtvqBtEYVFzJQw/yTBI0OIExOJd7OkiH9tuWwbxG6iraLCvK/o
JjkG7edS6dxyTkQ2Im3dSOHd5cT8ExnJlWDEA/mJfaJBIt7KoLLd70aCV8d+IllpZlepJkG6ZWxL
JuAcWaghpbqnI/Ysbc3uqdrNd/WwBbNTrukVylTI4LErv2sRfWbC+stay5yrLse7f62EE7d7Frtv
fdut+NcifAaub1vcLkHW7nvsQp8E4mNuBNIWgUDaIhBIWwTSFoFA2iIQSFsE0haBQNoiEEhbBNIW
gUDaIhBIWwTSFoFA2iIQSFsEAmmLQNoiEEhbBKJU2kbiaijMQzlRjcgNyqF4PC4I97bSo5pTDykg
ohh2ivcAT2VaQtuXxJJT4hb7zEW2vV1b6QKEFxh/cJ5r7NZCPfKdOK7dk7waGoKWbBoK/FJzeeAM
xLbWGk+//7zDSzYPWToC2bJ2pb1dQ8ivCmjbe6yhnHZfk8Y7PAc5pkhaQ4IQyclK+V5+jApiFAID
cL/C2lReFKIprnTov1RU5PkfEWkuGvGMGM7RSFqGZcmEgjGWKxcShVBMU1exsPiMWU6A/qGHSFCp
j2ViclOPCGKeZXomFCQsbzIsBMIZ3j5ZZjxOImIGkqFgE4v93+qByWUCwmGeLSKIoWFaLtgUj8ux
igylHcqF8EsVhUZ6gY9QwclQvBVycruU+OGIQONZ3pZwgF0mwj/aJq9oobf44cmwGnFn2Pg0hAA7
XO+daexuZLe7AX7IYpq6IqGuaE7XMm2D4cWudrVYe9dP0jR/43j4bBcr9nCkp55GRiJdbfTshoa+
Fc6HVDbdu6LVtTHZ/0mzHEX+89eU+mj4zyLdVNJ4Q3iQSfp0Qx8n613zays9xCRzM9z/MMR7f7TJ
ry7QOHg2wpsyv8giGp9fW+79DtzZ86N1XtP8FV0Gb4eOxq6zkeNNtM7IG713CbRN34Ewa5cSf3f3
2zSed1zPOwd6osgzH2m73KyFuLprOZdSzlvDKYPBdkeS3+V++P31M4wMDf1hzuMMTF6GOw0C74TJ
DGh6Ogu3B4ZW6GEyyiOnJ0CEVZicoJIAXpgFTqbMTdEDcohj6hDkLXJk3B7T6zs+ySVNTMIaK6JK
uvRIFDYUmX/M42jSs9ANx6bZo6D3tS44NknL0Qy8/Su/F43S9CBE5aUYMs26DN4OHVmITtL6aZ2H
hjJv02r/GARD/CYcPneGj53zcOOGHEKUEeZVaeKaomShhucHlIjIXEgJ0UMsXXs1Ro9kpR86z6Ti
kID6NEsT+4cgPrKm5xRO0qMcQf8p8TzXcI5HjqzZsjQdGwu/V22GEm2Xw2UZ6osnsjyTIpdneuE/
qZKajt33pfdqBZVD63JGOMlLqldN3p/8l4/AUGBAb64iw1wyruTRSor5N26pXWUnSnym8SSMhiTe
Wf2QCO/5Tad30qo0Jx6Lc3sNoPu0GmJqKtQrrz83c/a+CcbXhWB3q5KUMgmshTNDQ2swQq0OdnMh
peU6xSyRFNTQ/3gWHStw5TV7I41yDFDqSzHBXJLRijytSVqBjxpkjsr5c39Ey6ZShgJpeJNNLtRB
KmeXwUAboOSvYyVroFM+D5x890nBGB96+xfnZZsnNfOLY/0rqB59p60+azM0NMTsNRqhhBQsjIqM
pqH7F/6Q3iIauDzCtW0QOo6CcVZJgKO5eBgGoZXRNAHjrfSM5hqn1AE41UkfsiJ0zMSNM0cPwm0d
1rkjs5xOlTtafaSTHoJMUth0KdkOVeatHXpsBsaZnbz+V1TueActp/fFbeNyer1dhiynpU1tES/5
fehkrf8xnIDXeLuU+PD9deu8a2io9nH4GPKsgtrWFaGTTH8sjbVFLjaw8+ZAzzCz/46lj19aNOSb
vnQ8Qu3gsZrrjFzT508vji3C1KX0aZ6rdnlsHaaPpW+5+FNDmd7EHZyVCVc5Z0ZuUuxetb6nl8fm
mdy2sReNk9CdbRuqzN8waNX1C4+zq15/h8p9PP2S3uDQ6OLvsqfIha8Splj5CE2oMmQ5y4LaotPp
Swu0zuW2sSUIjsDoId4uJX7x9sWGiwdYxsXkUuTCN5Bnvtq2lbSGCs9qtl5fLZOkkiGEL098dizt
vUAKDve9MrevaVRp27ZqtBXyBWczIyHPPBDza2Vt2fAHNyAQnvVeQMzXhlOAtN0PtEUgbSts2yIQ
u/CVDIFA2iIQSFsE0haBQNoiEOWA0U3cvtUd2FK1M2XTMqeDL/AgW9vgrMTdcQqLVqW65lK2VwPL
DpZSga0AJbBtd6kcWSm9Jr1fLTttOiQZ74G0Q3ZaWWJ/oj7T1r71qBHElpM4H/xhrQfZ6m2Uyipa
keqaSzLVrR14f7iKte2ZKekpDtvIE1t9tiTLvvT7SNs66FIiM5moHaLtxViU2GUGKYWCkg9jxn1f
X8n8OPJQvWGn14KZicNzzlzCsE9mpRjj2OC/dc5bB6VqEbIF2hKmHyTjyJUUveFd5VUVNtVUPqlF
+1kito53LWgb/oXpa9oBtmTbqRIKxOUr2ZJfA6q+cMuU3nTqVOcnJvGZk9UcEyXdAHn3Ycn1ueTx
atSB6LrTsHEz+P3zob7e+4Ngv6PEXacJuG4UT0obkVvd4b368O1HdLXOQ5wQT2pghylbf6r3JtUh
VwnNkSRnVVHKFe2n3YVrLU82Yta3kpv23Ycmgo+ymJpw71DJk6R9tSd2vbtdZjkoJq46SciDSoRy
kHx8QfBRNvEk2VsuyfxCRpxtW7W/SKGa+JuwsZdN2S09b82711HM31ab1UHbtnJzIdt/3lT6flXa
37a+yLOMWL/RIKrG2+pYNLtoJsH0moqUreh0RTlmDfb8LUNXGgTSFoFA2iIQSFvEXnwlkzxY8/rn
ykp73Hr5Sra1RhTJryYXdkR2cJIt6nng5Fjr5HZrdcoFkxew7m+rRVTd39Y3R1unmYRSXKwr7XEr
ldqkksZDkenSQo7IFv9Xo/scKcJahzJqS0wnkr0PiF3NGCZ+9qe/rfrpRTIcrDrJ9Yb4xFoPd8Kn
j2iFG2CIJ1uTXLSkS9Xm4ebzd6EivW/1ty3d0ba07qsvpF+ISXV4fE77Sp7qwcPvFEp07Cq5aicP
cXc7o6L9b/1KtuTzPau3DikCTk8dr9amRKr7HdjyVC2XpiGeapYr170F3P1tHSRvsduMZoX6K4x9
8CW+3nFYb9G43BmfZ3TXn7JpGg9EINZnFfEwiksa5IU9d3fWJ81oJWlbkHx+PQLLr2zJjmmNtC1O
OigOiezg3q8gaksxwaVdwdoyv0X791JeorOsk1OuZA3tk9+l1Ds/Ze0ayxrp6HFbXW/PLbqcFslf
kjuuZKje3d/WVsap5W5OuU5utxLZGXegYsD1bXcktut2u9f9bfHj7g7l7Q41bHawkYCo/mzIlpJK
yrMnX8kQCKQtAoG0Rexz4EwCYttYkg8V3Mjd5m8LxPRh3+3bmFR4RVgfPHG9+9uWPP3jySvW7QJs
yd79bW0fvVz8bSXNk9ZtmVs9Zketb1uZmQRifx/dwgSgP5643v1tS57+kUq4nOLJ3v1tbd+4XPxt
lRApXEKO2dfr2xbUJ5JJCehcIX4t1CnfDs/+tqWub1skfxEfFVsy2ULFXpvsuDAuKaB5ttvr3rLV
lZSbVIa2Fn2ieTVVdLVbHxcJ8O8SivROyVSXHEpIWx2tZeyaJb87sjBtrdaTrSkmZao8zSTlP+Mz
USrq0lAdomxLqpvBKIE1WfLqb1uWplmuWdoPPgnOtq3ilgFGW9FOPKnEO7/Lfe3cnGOJahtJxOHN
wOeLtjsykn3nJu7ycNDNN8suAm7MrVq/VXOBW3v+cj+2i054VKvfozvVlUZyZqj862Yir4tLJLKH
WVv4h7vVX2hW8cbdj/62zratmyen249fquaJ688auEW8eN0WmvXgb2ujuYu/rblqF3/byr5DVBvl
/EqGi+BWoivR3xbK6pOArC2rjq9e6V37Sra9l1qEn32J/raAHmAIpC0CgbRFIJC2iL1KW0mSSnk1
VbKbDz69x7o2zaGZkh+iJU/ZyjABIBXsdanw0iv78nNDaY4DLh61/rDWS9O2yFpPV00qwQlvnY9T
NiZtK2kr+sqKRWJbwYKiY4waVfK08HjF4ffWf/5PTOsOuLznVfVr6HtJjjXeGsl0h7w+PfaQtlXH
stG1FpwWuS34k5yqudb7vOhgBT+nqL9RsC81TvSxqdya6vpB75BXMtNIJW5cwHX//Fa3xcwD/daQ
/Wg61Ns6RvJgPe4MnbQ3eUtcOp0U+A1mqTdpDxoJpbwNOP4mcI9St3oX5eLvbDQo9tsrW631CSWR
Imq2iGep0yqsiO2aCVJBHSrZdOy++uWu+hxyeB7JnqMWz08nx1of7ybZdaK33BzJ8HN/S/9KDnfG
tBnZfnC5xVVpEGUArm+LQCBtEUhbBAJpi0AgbRH7Brh3A6KcqNBSt2baSrY1gMyzhOZY00qMfvuE
eZmM3GpLqrW+rfs+z07r25ql2VulL0NC9tf6tqb1VQHst9+4kqrFz9Znf1Qvbk1bbUm11rd1KlNg
fVuQCrZKMtyjfbW+rfJNRukquUeU7lLCWtoWlNb2UNrPrEtqibf1bYskk21dU2EhTkuKEfslS37f
gwIj/G/VgOelbknZaFtEKUhFXOR2jgNNaS0hO6Qd22snKcGYKn8btK9kFVrq1p22xPqMI66DT9ox
ZPRl6BSxFNVkybjOqsf1bW07lrt5MhG3OMlux+3bhUI9PRkUHw63Fez2DoqsGEtsq8kRdUFr/9e3
tdW+PyYs6j31jBezTvJ/3WyPeaqjbew2VPGfJ21f2e40VGiTpwL+tkYbQYIqWwjVNBE8JUsESu6P
cpgIpbV2T2pbZ09Nbyu7+s1aD+8a/qxvW+Qy1RVmtX2DiGGWtfAEql5GDRkvwGHFXBNfjb7OuL4t
YofPheD6toA+CTuWt1UsvQuAtN2Zkxek5Bdkj8V9Ry4q1udnkLaI3YNkNLi8/PbsQrA+P+xnPXUh
7GvEttE+Rf+k7v6vT80sQ4ZFrKw+eWBj5JkKaNtUgygMRpKalR3nh5awlmE4ApbEWAiSDYLwSA5y
cQZoEp4C+Loy0IbvFQYbkixvMOZzt0Voe1JyE3INghhNlUVqA7tKEhTuZReUE+OO1ebygtiQov0w
yPpB6cd8jnZFI5VQ7MKHI4Ig97nSgxThuNLHcVUW6O14JigEW1TdJvc96NcuHxQ5FbZr7m09fm3e
EDG7cLtvOtegbQ8vL1z/5Qe+uK4OIGAjCHqOTKkZ3tCDcmJq7Gr2eydSAVjIrt16fnpqCh5InN+Y
+Z2neZ6ZY29dffT4l3I0b+TDP3nCxx5rre2m7Xn60NjrtAnkzmfOHP+Dmu1LnfkWkxp7/9zCW9+j
3Ih1w5TFijvQQ6PIyflA1yNrTw88+gPaD7wf58Q+Gpr+ykby29eLVPI36+mZsT9j1Fu7NfkabT4d
dr1yRe0wBF8ekGWB2o5M5pV3vrYhExm+d+KfWvI8Vbl2RcZUu7WpfuNKcPPqP61Ac0Y+VY8h6cno
xttf9VXbfgbWITS0yjUpH65NwVBSoGGAvChEQWTBXEQQQ+oQ6siehTVITdI/B+VXhWcDefg1UU49
2B+KpYZW+OCYOOpnp72XD7VNENghAwOT8NtlkPqRTfY3OywF1tKUTVlbhnv43zWYnIQBCMEx1g8U
5+DyBA1tHMrDqaImWGYtIAJn4Q0QkKUaR9xvy7L0drSMhA5lV5TUNQhNQNZw7aqMymK4oXbz6hw0
A8w3M86ajr9auNEHnVtrDB4LmeRv/mNvnHbZEDQOno10NWZ58Pm15d7vKBmy8B54EOgDOU8ZnxEi
9BGRezCVvSynBuE1VdIE5Pzst7Fr7O86pMVIil4GbdD5Mki97yonb21YDFOJT4bt7x9X2N88xGK0
vgfYIc8ibpJDta21ubVJD/WM0z6k2ICVhyK0m5KLhrTzmlSlHesPhnk/c/C+B+XaBZq6yWTMV5az
0frbr8yzOl3/UWshEJ3xi7ZLo9D7mG7bAkwHoZsHupgmWeXBldpoFJ5VMmzQERWEUCfr2Jrlhu5b
IBQ5flRsF5tYaj8YDDtfaZuWK0qMhLtvovqm8+/LIvVhLnWifz7SczO0nLOby8vN8mUqI5NTWA+F
FoOt4lFm6xe5778NvXLzl3u7/4RKNSrMk7pUuR39E/OL3V8AVTF0dsqp9NojPTdBPhHt1VIrg3+z
6SVXfuOcX7QNXBsfhe679IjYCfiZ3LNszCuG959uXlbvFO+xryaj2UQNpM8H2NNsYe1Dq3PZKKf4
iKYLKH9r/O/AdPbEJFU7b46l/yhRTrkZ9qxYfdQtWalrhP2pMYQW1i6vTn04/alirD118uWPy80P
3AfftKTqUpV20EMGvqWkfjV5nfW9fu3p7Ox9WmplMLe83nGkRbYJXP61Hnk1k/64X7SF2MK1l6kG
Tai6MZVSkmtZUOEGvClqBWooMQPLuXS+Vj0H6KwP9M1usDMBbtMmKSrYj7F0dmVTKJu4hDw+TzwW
51a+HTWscwahTuujQUjleFd0CLGJQL6w+Nzd8IrkfDsUWSmZtko7EgYey31fZ29QhZFKz/7G4WZm
z3KbwHxsCb76q/RAuU1uQz8F47HYD6GeXvaMPMPS9iq1DJjOFGC8gz6REsB4fNu4VqKePQvF1tjJ
EIQfaulkL22QkWB0hksNCZ9LxeLcJDxQiVeFkDjDmhAWcj8bKB9tRTj6z9SIHxoaYqa9Y4bOcfgx
vcCOTuDvswkYfxd/Q8q+Boncg4XFNz+wPCdPKIaEsQ4QbYOG9rzAkpV2iNARgj9XJiB53wd5YXEm
xOw1ofVVm4xKqIrOTPao0CyfqLY1Pb7ryLs3VgZ8mP000Pb6WFr4fPJFkBKfkElW98ELP4enRo7A
9KXH0y8tQjhxBMKji7+rlfgLCEOkdjH90RREvrv0/vPT9JlXFwCxjb9Az/7duYNpKo+/MVTgh+0N
dW3Ll6bhH+rCj79cPvW+dOn44LH1Qk/J88unkxK8kEwvy/mmk6fT55megUPM1i8sPjtxjzLL2hAY
WKHNN0OVpbVj6aV0Y7KX2W1s2ljue5Za19Z4aYrKWLzbJqMyCEir19pvMMZQzubSc/7Uti0PsNRh
YclTxqbMTAwQpSEO7m5VM0czWy3qT1uV+nItmXfYM2T+XUJozsf6tue4GFtd8ZQv+M2PIw1LNk/y
8oyt45Pl+YECJQWoyVaHtmxEHRRACM/6Wx/62yLKS9uKAD3AELsQSFsE0haBQNoiEEhbBNIWgaga
DF+vlE/j5uVSzSFnVOTXzT7+/l/Cve53MW139KJnPm7bLRHcKXgvGAl8l3O+7Ilpv3MlGvQEmscx
p08gu0osojLa1qx9iHUFbeOJYclbh5x+PcqRXwgvr2ROO0FLRnoWW/+2rI9yH5cjRRth92tbsL2l
2U8kO5t9pi0SC+GRtuZ9Lgqu/rurX2tQ2e4pI8GmViXDqrcSFNC+yFpEhbUt0XYnM61vT+xrr5rt
Tl9vvo8VSDhxu+uA/raIMgD9bREIpC0CaYtAIG0RCKQtAmmLQOxc2HY4L8HP1gaHvTq1OWAlg7qt
pz2LIWQRIn+sIy6F1M0WbY21yZUsW30Wao0E6M64S2i7bRAnIptdb4jti5qeRfMrcxwQbnLZgRTM
ovmqqZ5txgY7t4b/j6zdZUaC1ePW6FIrSbLTrcHj1phNz69SiajFFE9dUoT55gwmeQUGSGmPBV06
UnPPaFu7x60e5JtpWjxudc1G1O2RrX43qv0gGRWqw3OdWGLl6oha1uGhTux8LDwwJAKG/XHdW4OM
3iW0lbw9/o2Or05b9Do9XS3bfxOvtrGxOmJjuLHhxFWu7s8gObfKsU7mWYyuCruBttqm2VJxJkvg
jfDbs40L5XVzV3czsE2OQV6a4jyKEDv2lcwDIYh3wjnce6lkmnorVDALKamURCSkx66bSSgwDyY5
m5XEYDwag04ai5TMVrC4SpauryWPQxCxS2lr8rjVDEA5qDxqzf6vhjPDtBR4cpNVsshPcSAWlrk8
2fWsrtNUNrl6RCEGG+aOCdq2OxVb8reVyHaSy1PJlmvDZRF8QKX9bUv+3CB5egOqIEr8KoCM3dO2
7dbtwDLxgpQ9o54bqbvLga40CKQtAoG0RSCQtog9+EomOb7hqPOwpX0hIDYXF+skqERM1br6sei+
svrMcDH/WtVh0fIJGLEXaVtoPnObN7/Q130nX1mDZ6HmW2aMKexfa/CatPjXIvawkSAZfGgV51qL
6y24rHZrX+dWFWLx2JVdc10HheHz8BaGDRJ1P2lbi9oyKiuL6y0UWO3WzBqT567RP9fo9Wq3Fhx9
b4gDJx0tDIuXD7J4X9DWlQD2OLNvLfE8j0+ctKNLWdkmNg+Hwv61WuPwu8J+oq1U6l2XHIP2c2kr
z3Sunknx4eT21EDsE9qS4q9obiyy/YKxhPXGt+KDuyW/XcReNRK8OvYTyfbOJBXUppLtF+USKURq
iRTUyEhYpK3ZJiTmJQ7cPWzB7JRrco81FTJ47HK5yu8apUKctTTGk3+tWwRiz2D3rW+7Ff9ahM/A
9W2L2yXI2n2PXeiTQHzMjUDaIhBIWwQCaYtA2iIQSFsEAmmLQNoiEEhbBAJpi0DaIhBIWwQCaYtA
2iIQSFsEAmmLQCBtEUhbBAJpi0AUh/mXu5Fu9ads4R4WyjX084jcPewvC8YBRmDw0mwc1Jx6SAFZ
gboVh3hPiCu1DLkVb1lZ2YJAxN6lba6xWwv1yBw5Lp+vQ3JZzTUELdl0IS4sD5yBGGyXLW7F7yhR
MJJ2rxsJ91hDuaxyfgMEDPnmIAfxOLSGBCGS4/nEe/kxKohRCAzA/TGm5uL0/2dCQQIpGh9mRSJB
Ho6mIBkWAuEMDEcEIZSEVF4UaGQuLOo/WIwH4hGm/+PkEUHMp2jphhA9F5j+5OFWWjbYotbREg6w
OhS58TgJC01NojgsN4NExIxznYhdT9vkFS30Fj88GVbON2Hloci89pyWSXy9d6axu5GbEvBDFtPU
FQl1RXNGDffphr4MtHVFoj0H6Nnz16C9KxLpaoO75tdWegjc3f32G713QdtgeLGrHep7wht6awZG
u2cg1/2ezfGG8GAbjZi9Sv+sydJpeFlce6PvulrHnT3vHOiJqnJpiydPHtuc7r9baX+4/2HnOhG7
nrbLzVooxul5TtVG+US0t/sLihqM35FcZIF++P31M8zQbOgPcx5nYPIy3GkSPzVLKZ+FydmhVXp2
ewxWYXKClsxceiQKGzTt8LkzlHMwmaG5RJicNpQNwVehGY6vwsQkYytkYnoaDWdqo5+AvFrHebhx
g0pS5NLIQwDzh2iC2oxnnetE7ErUhYxn7TBlCNU+9YwSkdtYeea5/7bB44cWJ2HuCZqwcPnwofGp
TDtcuZLnNkL9zZ98on1kQylDD+3wSWi/eeoueuAR9FB383PPwU83XviPP4jccMvU8q/6X/n0gdWr
LPKNDZrvCbkwL5v49MULT1/5y6+wxOnNdlkIbxgPk/e99asbblbraJzsO/RwdFWRyyPhTZagN0NJ
+89PGutEBpQF7VM7ZwLsxGNxPnWgoEY5pkK98vpzM2fvm0jTwEKwu1VJSjkJTEDKIOTM0NAanIYr
rzGF+vYvzvet0DI8MsHK64iJJ+86GYzxEjm71DS8+bp+lpr5xbH+FVWuI5S0j5vqROx6I0E1ArSX
8KEhZknSiJDQ+ip9hitYGBUZTUP3L/wh53Lo8ghjLwSh46ieSweNn4krWl1Uw9kONs12f906FSHA
0Vw8zNLaTBbGcO/IlFw6rEWOqGOgFg6M63nD99c+Dh9T5bpAqfP5lF4nYo/Q1gkNgcW7L+l2Z+gk
M2mXxtoiFxvYeXOgZ5jR7Fj6+KVFe2kaf8vFn8rhaTm8kGhjz+fF2xcbLh6A6UvHI9RenhfTdcZy
sYdBiMHUpXTb2Ita5FMjRxSiJiLn9LyLyaXIhW+och0R6VTqHDis14nYlajBNbIQ2weuuIhAIG0R
SFsEAmmLQCBtEUhbBGLnoh67AFExLGmhKGpbxL7Wtvat7sCWqp0pm5Y5HcoMpVnFZWsbnJV1DyhV
qlsDJGuy1hnEde92oyxldzYlhpWyiXLaf9Da5aZmSnt9p5V6a5+6bp9EbDmJ86HcrDVWWBDq/Ze2
VEMRqe4NsOz4btzH3c5a28VIlt4lTtvIS24i9LymZhIJ9hFt7bqUyEwmag9pezEWJXb5dK1Ugnz5
rklbraGAVLIVTe31YkxCSMEOVUSQ7TbFPxTozToPmUjJtCVMP0gmhSH3hgSeVV65YdjLl3hibcmj
h3iSWugueaa0/WIUFhY2gYwDi2yxmVW4Y4VeybbZ1vrCFSv95aSPpMoOeK+bV/upRdyeMWZlqe8s
LLmVsV0Mcdk+u9A1u76E7LNXsh195WQHtMCJKMTZTtHeDR3JZWUl2Ya2t0iWgEj7lLYFX82qo2y3
PyNQealejGzJSb5V2RbJVMII2CuotYxVYta3kpv2lXbwO0FFXzS2p9oIIWDTEVbWKpk89bW0L1jr
YtvKTxrzQTfbeO/woG7HyZ0v+TbaiVRlReLWAEsX/P/tXVtsHFcZ/n3Z2R3vxt4zuw5xBKSJ0xZR
iYf0krpOQLVbUKiq8gB94FKlQqIPoCKkqg+lohTR0oRUCkKC0gAFQkv70AoqQgtRXFFnE2qEKyVV
JajjpGmadWp7j5PY3p0dXzhz2bnP7qx3dr2X/4ucOXvuc+Y7//nP2X/nJ0ZGNVykjME8S+XaMCo7
YepUKMDlAXjUVHfoDqqiUr9uoKTp5Wh9CfVgTgpq/bxq/euGzhLrIjF9g4NoFP286VWFztKbd6Rs
fRyYkEBqacYtGQKBtEUgqgP8wTmiUgRmRYvSFtEyWzLtcFY/9HJV7n2ciFXHFtfHFtt0Yhpg1SVv
gFqTi9rbejVss8N1M7u1PQ9vy91Ws7clzv3oGs5jqmOLS303HLC9bckboOa2S9jbejXssMN1Mbsl
xUuY+9Gi9rZFxQ21CAGDK2SNhoM+50LpJ0H8Zy2j6nKPAckaGvbbZbN0drfcDXbw/fWqo7z8pDa0
tYkb3aqppta3VTy0JFWbUCVGh5TbBepSgq51tgY3NFeqNGn80tauPTk6YhGm2mpGtX/mNdH5vGr0
XXk1bcBKKYzUkr+ovW2gXbPdM22F74fcdVvNPATMuqKTeLTMJ9/ghg3utrMFXdRh51rM3rYK8lBv
h7SCAUmnj8XB0O6sRkieu591G7f1MLiljt+a0Sot27760RrweW5L3RlKVS1BtdMlxuNqQtZ6MdBp
Mbs+t+9qudsa0tZdt7ValFrUVeLOZRdb3FrottWx97XejidrdMNXvRfe9rZek83ShosFr3NW1IW9
bXftDReD/HIXjXJrMZS+RrnZ7W3bkbX1ydt1LN08um1Zm1pEAJpqRcNM6uxZjMa4zpgQoKtYtABD
VFdJkDbmxWk5kGiPdE4KdSdtEQg7ZnsikckL02p4+oOzySjJBEzbTCzMDUfH9AmkutVLGi7nRqNg
SxR4GItx3EMSSEMyIM79CuBno1r+PdxwbEzOGxFqMESZaJjrliAZ5cLGXVQM7f7guYjsT92GKBsG
aZULxzIs37CSTx3HVYkNRQ9AzPPGx6IcF5NM/dbqUQZ3SPHDrt5FoX49P0Mvu8euXmtcVH0ksSG1
gjpA8iGu91x6xkLjC5Nte3oqfzomn7ub5+euvnv7j5a0j5rr3Fs/rrtTfd8IqomZtz4U/3RLJgRz
Yv66Y+fOnoX7UseW03c/q+RJ77jw4SM3/lhieaP3Ht1X9VHaPH86ueOyuCrFOdZqULVq95fNnrp0
cNlaq7ThVjYMZNds6KaH8s/ufuTPLJ/Sj5nwbSx07sDy2G+uetX7x1tPb9wxKxn91upRBncEXlxa
SL/1hJysxRv5ZWEj9YRvHPyPKU7tC6Sf2ckuZw3fyTWCw+du5ofxW/41EplVPyWypuvpuZ8Tie4L
Sto+DEvAj+QUSapM13iEH+MUr7urTB7IbkmHQGLznNekKfSLRyAPGdkB+SZ1q/D70Cp8SvNfummQ
FzIji8rkmNhW/aF7GPgJECErTf8PgnMBrd1f8jjfJy5ak76gZThzBnYDDztUR+zwOkxOsNBy3yrc
wXvWuwz8jJpf67dWj4ZsPhQGyVS/kZ9hPj99Hp43x6l9ga+t1IOYzcT3JHMXTjLhmpC56rymO9oi
3WPB0LYdduiEVLDyj4GhvOx1t2f4SPSmHlEJvpafHzisZRDh07BX9oG7yhif5aJsbkl7M+KkmhoB
3WvzBEjVH6xVtScM47pb68pRuL+9Xcr9Wdb5D9RmBQGOwX3yRWn9E2qovbddyp/xrPenMJpUKaf1
W6vHwDhr26jfyK9gz10nz5vj1L7APR+uv2rQE7n77AtsqOTR8v5Lv38tF0sGQNsrJ2DgMbNWeC4C
O5XATbIkySnBxfbubvi9LjESjJz8dvlxtc3Hdm4BPnrjtvDWcFxOHQSTYlcD2nLwFx5kaZO9C4Lz
Aa3d3+DE7OWdj1uT5hPqbWozE7RJo4X4y5He8DZZ13fFwInHPtO2ZOr3oP3Q6IswYKrfyK/g+W8M
bDHHqX2B7wrrL2vnVk76lDPtQUjb0MXxE7Dzc0aEcAu8qY6gPOG1E8EfrEzqIyw/pafHusVUGywc
C8kr41z+K7kZsVuhuO6LnNUUoPjzBB17IHmc3U86Pvh2cEeE2v2xyZCFZ9wypNTLceU40RSay0/m
zt678KBHvbffduTUKjH1O2Vj7R273r7fVL+RXx3Re9hoK3H15jRmpi0vbu1LgKYPeP1t2pqTrswE
cQAmzF18m0nQVEE2ZjJacrscVLEA58N6gTZGzNC8tFCYNvJT294Zum16WZUi1+vKTi3GKzSfX2jr
ALYFfJwGWatyfymdlXa0yYMzDB36GA1DRlKy9nPCRGjV6zhT1ktFU7+1egrJd8Ipaq7fyG88OiWO
q79jr9BcbqY/0qvpAwnntXPLteJcXzC6bWRIEF6FTjZOaVXnuOYdphnIMpOD8X62WqZA5vH143qJ
TnktDPcKu3jo+lZyu7xpgyyFE2mlVp57NCMMKcv1BghVf7D4cFoYnIXE6vzuQGtV7i8M/Tzsd8sQ
hu3j8Dd2g/3bQdnPpmB8o0Im8b+QkvZ6HeFANskKsfxav7V6NCTum59RDxq1eCO/MrS977AES1x9
QcgsLl37h42g6bKma4K7Jpdfu5x1HIBlZ8WOs2NvHLo6fWrqY/IhyqXnLpw49OtfHJTSD09OTF+G
7smDUvdk7uXNhROWZ0/tDcWXstL3X4T4eHbnsal9MPrCMkQP8LKWsHg69G1p6o1DLG/+uku5qo9U
XDq4NMM0vcHtW7duDewASLs/MbMYmXr0kP3chw3D/PsrL0xd2jf6ZC7/pTc7WEz6ocP59xY6ICk9
BRvavvlX93pPPBkSp+bk/Fq/tXoKp4sx5S5YUIsv5E/JKxlZWTz80RVTHcaBpXJZ/wMwZR/0+kpn
353vWvZr8cO/fUJ8uuL2KvpyN7OZu+Lv2WfTAiB8Ygi8vyrtvZqrsIbqdNm7vcz43flVRdL2cuGP
Alp1K7NJEHKL/rbjv7wf2VjGkYjppMuGKD/jp4I2sW5oq2zkJXGV+/sNwYkuNKVBVJ+2gQNNaRAN
CKQtAmmLQCBtEQikLQJpi0CsG0yGGDYX8b78vvpKrxCGa/oqtUPx55sNTNs6fUsX1ScTrd60wB/L
N76SQCnVXsaihGzRYCSwPK45A5e1VRXqyNiGlrZW6UPsb9C2vLja/K5bEsTLwkuTCgUiwt+WzM0P
PXV9OXCDSy2cEo0vbR16pcsH6mQzLraI+qCt9Q22pJhkrfq2ppq1o7BtKiXBIVap+S22UET6ooqA
qLG0Jfr7WS1vsDXrATadQPUo1KgPn+LBbcMB7W0RAQDtbREIpC0CaYtAIG0RCKQtAmmLQNQvzOe2
hgdo8+cy4OKr0/DRpWZw+vE1nZraXKmb++Fw8OVw9u3oLLXbDlObZ89ivdEvaNVY77StGMSNyFbT
G6ejQiOLzZW6O0kNdpmSCLgXKcwWUwQx5/PsjXGhBFnbKEqC3eLWbFJLqWp0a7K4NWcz8heoRArF
NEtdUozrxB5pqQ/WtBBQN0FcqJ24zj5kagNKW6fFrVUAgc3i1pBspOAe2W53U9AfqMVpupNOxHQp
6B0FQwhTIQ9fnu712iYGJYby4NIbuzqCwrbeaUv9Lf9mT7vOZ0pcl1XiJU3NzLBMDmdzRRx6Oulc
jlZD3PRz1fu1YmCMwreuaau78qalmUzBH+ErZNFaleqA9HPivtFE1OWWjJQmBPHPG5eHbl2WfZKC
+mhqTSymRVcAiixpnJOEIudg1F2tJCbl0Rz02PX4Vh5pGTJ1bVKR+JpqiDqnrcXiVl+61aBmg2s1
sDV90k9o7QnerCycpxotGKelFpNf974SrwTbby5MEd6kLGQyHTgT1G3rDmuyty0hioKRVL5VB1J+
vShLA0at7W3L/rqBllyKa8yJMr8OQMY2tW67du0xIF6QwDMauZG6DQ40pUEgbREIpC0CgbRFNOGW
jLrucHTbvzJtruwmLvbTT0oszfqwwQXr91ZF7GvtNrOAX882L22LnWdW+NSLfa1f3FbWsC0zp/kq
Y7mg1WzTKwnUZEOrGdfaTG/B4223zvfcFiqxWeyqprmek4IEOG2Qrs0tbW1iyyylbKa3UORtt1aK
WSx3zfa5ZqvXYtqCQwPwYV/rzl4Ut81N2xKSili5YH3brU9quBpbeVlnU6cGU559LdoUtARtNRHm
/4Vu1DXo/EzL15sLljuVLPy4IWsJ2pLSWzQvFlH7jwrLeN+4uw1uGWUQra4k+LXoJ5S4rume0tT+
o3YPglKbmylP60RfpxiIFqCt1exVf+yeFrZgNcq1mMdaCpksdpV6td81upzCetnggi/7WmsZh90t
ovHReO+3XSP/kLbVBL7ftrRegqxteTSgTQKpWSEE0haBQNoikLYIBNIWgUDaIhBIWwTSFoFA2iIQ
SFsE0haBQNoiEEhbBNIWgUDaIhBIWwTSFocAgbRFIJC2CATStmVBq1z25Rr3AWmLQGmLQCBtEQhX
tOEvsVGvbRQQpG2LUZdUtywlte0DKgkI1G0RCKQtAoFbMkSzoBOHoAU2ZMU8tvkqV2o/VWq7pb2N
u4xXCGruOTx6irRtjWMEb49tfsqVOkSj4CedlvV2bJcOo26LKOflqYHI2rKnGioJiGoSnAQ2P1wV
FKQtomI5WLuZUqRzqCQgGlC+I21R2DYgkLbI2rrsWvFk/LqhFeipq4qWY1BaajU2eXRbj3PbIifM
SFsEKgkIBNIWgUDaIpC2CMS6Ab8la0YMyf+V573ZcPac7XnwgFt88O3K2VNzvFEuKywPP7Ibaduq
qMThePflA2uuaaTsbmbj0UyhXPLmV/hX3kj3oZLQ0khGwmEB9kgg7YEMH+7KqHKN/Q31RGCU4yJJ
JR9Lk89BpWgoJsHQ7rtAinFRSc61R8mc1T5FYKyL48dYkEQ4gZXrCsucW3O7Mvjogh7OneSBj2xC
3ba1MX9UnPsypDbCxhNwOCJGPmkkdVyE4Vj+6Lzy4SU+vcwuifPSdIIJvhFI0PxrCTnX80p67xSX
UMvcHMlHbmbB5YsxVvSly+IMqaBddc4M6sGvTrL/Jh9A2rascjski7fcbuAn4EgepBC8egYmdhoZ
JgQIic/dkFM+fG9CmGUXMQG8qESIIfisqOZS1nLhTE79FJmAMxEWPCdkdrFyIeDvqKBdezmlOeF3
Pu4PvyVrStaquqLUK60MjGT6RD6rRHF55cL+5IsUl9rOKXoki1ciWfB43hoqZA6LhU8QkvQENdua
21Wza9EM4bSseWzKo7RtafSsvH6Fia9Q/Cm2Y89Apk1dlbXU0MLUka0qCTJKZGpkZESlzHE9pJUo
lJFrMSiTsmYru10FQkoPhrax/7aJqCS0Nr4+e4Osk4Z2PA6wn4ft+xmLhMw1Wup3RoXBFfXIqx/k
yPAskC5VSZDgzS6jHgL9YY1YPPQbC/x+CQS+gnYV1i7M6eH3cqMwmutF2rY2Bjb0yc/3o9QECye4
3ABAdGFTh5b64p3hnstK6N/5sJxvdguXiyoRS3HuJ1GTQOTys9qJVSIsGjaFA3Fu8Z8VtCurtAtz
BvH7jn6ee/LoDOq2iOA05XoC0hZRCly+7rqESgKiFOqPtUhbRCMCaYtA2iIQSFsEAmmLQNoiEEhb
BAJpi2hq/B+ZI/brKK1BMAAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-08-09 12:33:23 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-003.11" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Deferiprone and DFO in combination versus DFO alone, outcome: 3.11 Adverse events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwEAAAMQCAMAAABIS5kZAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-03-21 14:59:48 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-03-21 14:59:48 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-03-21 14:21:58 +0000" MODIFIED_BY="[Empty name]">Search strategies for review update (March 2013)</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-21 14:59:48 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>CENTRAL (<I>The Cochrane Library</I>)</B>
<BR/>#1       IRON CHELATING AGENTS explode all trees (MeSH)<BR/>#2       CHELATION THERAPY single term (MeSH)<BR/>#3       deferiprone OR L1* OR kelfer* OR DMHP* or ferriprox* OR cp20 OR dmohpo OR hdmpp NEXT cpd OR hdpp<BR/>#4       exjade* or deferasirox* or (icl NEXT 670) or icl670* or (cgp NEXT 72670) or cgp72670<BR/>#5       deferoxamine* or deferoximine* or deferrioxamine* or desferioximine* or desferrioxamine* or desferroxamine* or desferal* or desferral* or DFO or  desferin* or desferol* or dfom<BR/>#6       (iron NEAR/5 (chelat* or reduc*))<BR/>#7       #1 OR #2 OR #3 OR #4 OR #5 OR #6<BR/>#8       THALASSEMIA explode all trees (MeSH)<BR/>#9       IRON OVERLOAD explode all trees (MeSH)<BR/>#10     thalassemi* OR thalassaemi*<BR/>#11     cooley* anemia OR cooley* anaemia<BR/>#12     hemoglobin NEAR disease OR haemoglobin NEAR disease<BR/>#13     mediterranean anemia* OR mediterranean anaemia*<BR/>#14     erythroblastic anemia* OR erythroblastic anaemia*<BR/>#15     iron NEAR overload*<BR/>#16     hemochromatosis or haemochromatosis OR hemosiderosis OR haemosiderosis<BR/>#17     #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16<BR/>#18     #7 AND #17</P>
<P>
<B>PubMed (epublications only)</B>
<BR/>(deferiprone[ti] OR L1[ti] OR ferriprox[ti] OR deferoxamine[ti] OR deferoximine[ti] OR deferrioxamine[ti] OR desferioxamine[ti] OR desferrioxamine[ti] OR iron chelat*[ti] OR iron overload[ti]) AND (random* or trial or study or group or groups or cohort* or allocat* or assign*) AND (publisher[sb] NOT pubstatusnihms)</P>
<P>
<B>MEDLINE (Ovid)</B>
<BR/>1.      exp IRON CHELATING AGENTS/<BR/>2.      CHELATION THERAPY/<BR/>3.      (deferoxamine* or deferoximine* or deferrioxamine* or desferioximine* or desferrioxamine* or desferroxamine* or desferal* or desferral* or desferin* or desferol* or DFO or dfom).mp.<BR/>4.      (deferiprone or L1* or kelfer or DMHP or ferriprox or cp20 or dmohpo or (hdmpp adj cpd) or hdpp).mp.<BR/>5.      (exjade* or deferasirox* or (icl adj 670*) or icl670* or (cgp adj "72670")).mp.<BR/>6.      (iron adj5 (chelat* or reduc*)).tw.<BR/>7.      or/1-6<BR/>8.      exp THALASSEMIA/<BR/>9.      exp IRON OVERLOAD/<BR/>10.    (thalassemi* or thalassaemi*).tw.<BR/>11.    (cooley* and (anemi* or anaemi*)).tw.<BR/>12.    ((hemoglobin or haemoglobin) adj3 disease).tw.<BR/>13.    (iron adj3 overload*).tw.<BR/>14.    ((mediterranean or erythroblastic) adj (anemi* or anaemi*)).tw.<BR/>15.    (hemochromatosis or haemochromatosis or hemosiderosis or haemosiderosis).tw.<BR/>16.    or/7-15<BR/>17.    6 and 16<BR/>
</P>
<P>
<B>Embase (Ovid)</B>
<BR/>1.      IRON CHELATING AGENT/<BR/>2.      CHELATION THERAPY/    <BR/>3.      DEFEROXAMINE/<BR/>4.      DEFEROXAMINE MESYLATE/ <BR/>5.      DEFERIPRONE/   <BR/>6.      DEFERASIROX/<BR/>7.      (deferoxamine* or deferoximine* or deferrioxamine* or desferioximine* or desferrioxamine* or desferroxamine* or desferal* or desferral* or desferin* or desferol* or DFO or dfom).mp.<BR/>8.      (exjade* or deferasirox* or (icl adj 670*) or icl670* or (cgp adj 72670).mp.<BR/>9.      (deferiprone OR L1 OR kelfer OR DMHP OR ferriprox* OR cp20 OR dmohpo OR (hdmpp adj cpd) OR hdpp OR deferrum OR deferum).mp.<BR/>10.    (iron adj5 (chelat* or reduc*)).tw.<BR/>11.    or/1-10<BR/>12.    exp THALASSEMIA/<BR/>13.    IRON OVERLOAD/<BR/>14.    (thalassemi* or thalassaemi*).tw.<BR/>15     (cooley* and (anemi* or anaemi*)).tw.<BR/>16.    ((hemoglobin or haemoglobin) adj3 disease).tw.<BR/>17.    (iron adj3 overload*).tw.<BR/>18.    ((mediterranean or erythroblastic) adj (anemi* or anaemi*)).tw.<BR/>19.    (hemochromatosis or haemochromatosis or hemosiderosis or haemosiderosis).tw.<BR/>20.    or/11-19<BR/>21.    11 and 20<BR/>
<BR/>
<B>Transfusion Evidence Library, KoreaMed, IndMed, PakMediNet, WHO ICTRP, Hong Kong Trials Register &amp; ClinicalTrials.gov</B>
<BR/>defer* OR desfer* OR DFO OR ferriprox OR exjade OR icl 670 or icl670 OR chelat*</P>
<P>
<B>LILACS &amp; ISRCTN REGISTER</B>
<BR/>(deferiprone OR L1 OR kelfer OR DMHP or ferriprox or deferoxamine or deferoximine or deferrioxamine or desferioximine or desferrioxamine) AND (thalassemia OR thalassaemia OR thalassemic OR thalassaemic OR anemia OR anaemia) OR (desferroxamine or desferal or desferral or DFO or dfom or desferol or desferin or exjade or deferasirox or &#8220;icl 670&#8221; or icl670 or &#8220;cgp 72670&#8221;) AND (thalassemia OR thalassaemia OR thalassemic OR thalassaemic OR anemia OR anaemia)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-03-21 14:56:44 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-03-21 13:50:59 +0000" MODIFIED_BY="[Empty name]">Search strategies for original review (June 2006)</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-21 14:56:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>CENTRAL (<I>The Cochrane Library</I>) &amp; UK National Research Register</B>
<BR/>#1      IRON CHELATING AGENTS explode all trees (MeSH)<BR/>#2      CHELATION THERAPY single term (MeSH)<BR/>#3      deferiprone<BR/>#4      L1* OR kelfer* OR DMHP* or ferriprox* OR cp20 OR dmohpo OR hdmpp  <BR/>          NEXT cpd OR hdpp<BR/>#5      #1 OR #2 OR #3 OR #4<BR/>#6      THALASSEMIA explode all trees (MeSH)<BR/>#7      thalassemia* OR thalassaemia* OR thalassemic* OR thalassaemic*<BR/>#8      cooley* anemia OR cooley* anaemia<BR/>#9      hemoglobin NEAR disease OR haemoglobin NEAR disease<BR/>#10    mediterranean anemia* OR mediterranean anaemia*<BR/>#11    erythroblastic anemia* OR erythroblastic anaemia*<BR/>#12    #6 OR #7 OR #8 OR #9 OR #10 OR #11<BR/>#13    #5 AND #12 </P>
<P>
<B>MEDLINE (Ovid)</B>
<BR/>1.      exp IRON CHELATING AGENTS/<BR/>2.      CHELATION THERAPY/<BR/>3.      DEFERIPRONE.mp.<BR/>4.      30652-11-0.RN.<BR/>5.       (L1 OR kelfer OR DMHP OR ferrirprox OR cp20 OR dmohpo OR (hdmpp adj cpd) OR hdpp).ti,ab.       <BR/>6.      or/1-5<BR/>7.      exp THALASSEMIA/<BR/>8.      (THALASSEMIA$ OR THALASSAEMIA$ OR THALASSEMIC$ OR THALASSAEMIC$).ti,ab.<BR/>9.      (COOLEY$ ANEMIA$ OR COOLEY$ ANAEMIA$1).ti,ab.<BR/>10.     (HEMOGLOBIN H DISEASE OR HAEMOGLOBIN H DISEASE).ti,ab.<BR/>11.     (HEMOGLOBIN F DISEASE OR HAEMOGLOBIN F DISEASE).ti,ab.<BR/>12.     (MEDITERRANEAN ANEMIA$ OR MEDITERRANEAN ANAEMIA$).ti,ab.<BR/>13.     (ERYTHROBLASTIC ANEMIA$ OR ERYTHROBLASTIC ANAEMIA$).ti,ab.<BR/>14.     or/7-13<BR/>15.     6 AND 14</P>
<P>
<B>Embase (Ovid)</B>
<BR/>1.      DEFERIPRONE/<BR/>2.      CHELATION THERAPY/<BR/>3.      DEFERIPRONE.mp.<BR/>4.      30652-11-0.RN.<BR/>5.       (L1 OR kelfer OR DMHP OR ferriprox$ OR cp20 OR dmohpo OR (hdmpp adj cpd) OR hdpp).ti,ab.<BR/>6.      or/1-5<BR/>7.      exp THALASSEMIA/<BR/>8.      (THALASSEMIA$ OR THALASSAEMIA$ OR THALASSEMIC$ OR THALASSAEMIC$).ti,ab.<BR/>9.      (COOLEY$ ANEMIA$ OR COOLEY$ ANAEMIA$1).ti,ab.<BR/>10.     (HEMOGLOBIN H DISEASE OR HAEMOGLOBIN H DISEASE).ti,ab.<BR/>11.     (HEMOGLOBIN F DISEASE OR HAEMOGLOBIN F DISEASE).ti,ab.<BR/>12.     (MEDITERRANEAN ANEMIA$ OR MEDITERRANEAN ANAEMIA$).ti,ab.<BR/>13.     (ERYTHROBLASTIC ANEMIA$ OR ERYTHROBLASTIC ANAEMIA$).ti,ab.<BR/>14.     or/7-13<BR/>15.     6 AND 14<BR/>
</P>
<P>
<B>Biological Abstracts, Cambridge Scientific Abstracts, ISI Web of Knowledge, Zetoc, ClinicalTrials.gov &amp; Current Controlled Trials</B>
<BR/>(deferiprone OR L1 OR kelfer OR DMHP or ferriprox) AND (thalassemia OR thalassaemia OR thalassemic OR thalassaemic OR anemia OR anaemia OR hemoglobin disease OR haemoglobin disease)</P>
<P>
<B>NHSBT SRI Handsearched RCT Procite Database</B>
<BR/>#4=defer OR #4=L1 OR #4=kelfer OR #4=DMHP or #4=ferriprox or #4=dfo or #4=exjade* or #4=icl670 or #4="icl 670" or #4="cgp 72670" or #4=dfom</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;40 papers comprising 17 independent studies included in qualitative/ quantitative synthesis&lt;/p&gt;&lt;p&gt;(17 primary trial studies;&lt;br&gt;23 secondary references of included studies)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;100 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;893 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;893 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;2974 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;793 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;60 full-text articles excluded&lt;/p&gt;&lt;p&gt;(20 references comprising 13 studies awaiting classification;&lt;br&gt;40 excluded studies)&lt;br&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>